clopidogrel profile

Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	60606
CHEMBL ID	1771
CHEBI ID	37941
SCHEMBL ID	4769
MeSH ID	M0155432

Synonym
AC-19024
BIDD:GT0284
HY-15283
AB00053786-07
BRD-K27721098-065-02-9
KBIO1_000787
DIVK1C_000787
sr-25990
methyl (2s)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)ethanoate
113665-84-2
SPECTRUM_000105
clopidogrel
methyl (2s)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate
CHEBI:37941 ,
D07729
clopidogrel (usp/inn)
clopidogrel (tn)
MLS001304711
(+)-clopidogrel
DB00758
BSPBIO_003211
methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)acetate
methyl (+)-(s)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4h)-acetate
clopidogrel [inn:ban]
hsdb 7430
thieno(3,2-c)pyridine-5(4h)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (s)-
KBIOGR_000689
KBIO2_005681
KBIO3_002431
KBIO2_000545
KBIOSS_000545
KBIO2_003113
NINDS_000787
SPECTRUM4_000175
SPBIO_000463
SPECTRUM2_000512
SPECTRUM3_001606
IDI1_000787
NCGC00163329-02
MLS001165708
smr000550475
MLS001195633
HMS2090O21
(s)-methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate
methyl (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate
cge ,
HMS502H09
r-130964
zyllt
sr 25990
r 130964
clopidogrel acino
nsc-758613
CHEMBL1771
clopidogrel hexal
bdbm50318910
cpd000550475
nsc748298
nsc-748298
HMS3259B08
STK580572
BBL010770
methyl (2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate
HMS2234N16
AKOS005504280
a74586sno7 ,
clopidogrel winthrop
thrombo
(+)-(s)-clopidogrel
clopidogrel 1a pharma
(s)-clopidogrel
unii-a74586sno7
clopidogrel teva (hydrogen sulphate)
nsc 758613
bdbm50397662
NCGC00163329-04
clopidogrel [inn]
clopidogrel [mi]
(s)-methyl .alpha.-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)-.alpha.-(o-chlorophenyl)acetate
clopidogrel [hsdb]
clopidogrel [vandf]
clopidogrel [ema epar]
clopidogrel [who-dd]
CS-0656
plavix®
gtpl7150
methyl (2s)-2-(2-chlorophenyl)-2-{4h,5h,6h,7h-thieno[3,2-c]pyridin-5-yl}acetate
CCG-221243
NC00703
SCHEMBL4769
AB00053786-08
(+)-(s)-(2-chlorophenyl) (6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetic acid methyl ester
methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate
(s)-(+)-methyl (2-chlorophenyl)-(6,7-dihydro-4h-thieno[3,2-c]pyrid-5-yl)acetate
(+)-(s)-2-(2-chlorophenyl)-(6,7-dihydro-4h-thieno[3,2-c]pyrid-5-yl)acetic acid methyl ester
methyl (+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetate
methyl-(s)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridine-5-yl)-acetate
(s)-(+)-methyl (2-chlorophenyl)(6,7-dihydro-4h-thieno[3,2-c]pyrid-5-yl)acetate
methyl (s)-(+)-alpha-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4h)-acetate
(+) clopidogrel
MLS006011891
thieno[3,2-c]pyridine-5(4h)-acetic acid, .alpha.-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (.alpha.s)-
AB00053786_10
AB00053786_09
DTXSID6022848 ,
methyl (+)-(s)-alpha-(o-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4h)-acetate
N11780
SBI-0052755.P002
HMS3715J08
'methyl (2s)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)ethanoate'
Q410237
DS-13362
mfcd05662337
thiaminelaurylsulphate
BRD-K27721098-065-05-2
AMY8913
thieno[3,2-c]pyridine-5(4h)-acetic acid, alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (alphas)-
methyl (2s)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate sulfate
EN300-7388859
(s)-methyl2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate
(s)-methyl alpha-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)-alpha-(o-chlorophenyl)acetate
dtxcid202848
(+)-methyl-alpha-5-
b01ac04
methyl (+)-(s)-alpha-(o-chlorophenyl)-6,7dihydrothieno
methyl (2s)-(2-chlorophenyl)(6,7-dihydrothieno(3,2-c)pyridin-5(4h)-yl)acetate
(alphas)-alpha-(2-chlorophenyl)-6,7-dihydrothieno

Excerpt	Reference	Relevance
" These results indicate that clopidogrel is more effective and safer than aspirin in reducing adverse cardiovascular events in patients with atherosclerosis."	( Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Creager, MA, 1998)	0.3
" The incidence of early permanent discontinuations of the study drug due to adverse events was almost identical in both treatment groups (11."	( Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999)	0.3
" The primary end point consisted of major peripheral or bleeding complications, neutropenia, thrombocytopenia, or early discontinuation of study drug as the result of a noncardiac adverse event during the study-drug treatment period."	( Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLAS Bertrand, ME; Gershlick, AH; Rupprecht, HJ; Urban, P, 2000)	0.31
" Closure of the femoral access site after carotid stenting using a Perclose closure device is safe and effective even in patients receiving an aggressive anticoagulation and antiplatelet therapy."	( Safety and efficacy of the Perclose suture-mediated closure device following carotid artery stenting under clopidogrel platelet blockade. Borisch, I; Feuerbach, S; Finkenzeller, T; Hamer, O; Lenhart, M; Link, J; Paetzel, C; Toepel, I; Zorger, N, 2004)	0.32
" Primary endpoints were a composite of death and non-fatal myocardial infarction (MI) (efficacy endpoint) as well as a composite of major adverse side effects (safety endpoint) as considered in every single study."	( Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis. Bracchetti, D; Casella, G; Fontanelli, A; Galvani, M; Ottani, F; Pavesi, PC; Rubboli, A; Sangiorgio, P, 2003)	0.32
"Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT."	( A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. Benhameid, O; Endo, M; Shennib, H, 2003)	0.32
"Low-dose aspirin (acetylsalicylic acid) has been shown to be as effective as high-dose aspirin in the prevention of stroke, with fewer adverse bleeding events."	( Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Weinberger, J, 2005)	0.33
"To report procedure-related complications and neurological adverse events of unprotected over-the-wire (OTW) and protected rapid exchange (RX) carotid artery stenting (CAS) in a single-center patient series during an 8-year period."	( Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series. Ahmadi, A; Amighi, J; Boltuch, J; Dick, P; Minar, E; Mlekusch, W; Sabeti, S; Schillinger, M; Schlager, O, 2005)	0.33
" No group differences in mortality or adverse cardiac events were observed at 6 months."	( Early administration of clopidogrel is safe after off-pump coronary artery bypass surgery. Cooper, WA; Craver, JM; Guyton, RA; Halkos, ME; Lattouf, OM; Petersen, R; Puskas, JD, 2006)	0.33
" An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations."	( Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006)	0.33
"The use of clopidogrel in addition to standard therapy for AMI is safe and effective."	( [Effectiveness and safety of clopidogrel bisulfate in complex therapy of patients with acute coronary syndrome with ST segment elevation]. Giliarov, MIu; Malova, EV; Novikova, NA; Sulimov, VA; Syrkin, AL, 2006)	0.33
"We performed a systematic review to define the relative and absolute risk of clinically relevant adverse events with the antiplatelet agents, aspirin and clopidogrel."	( Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Laine, L; McQuaid, KR, 2006)	0.33
" However, clopidogrel therapy may be accompanied by rare life-threatening adverse events."	( Non-bleeding side effects of clopidogrel: have large multi-center clinical trials underestimated their incidence? Almsherqi, ZA; McLachlan, CS; Sharef, SM, 2007)	0.34
" GP IIb/IIIa inhibitors and clopidogrel, separately, have been shown to decrease adverse outcomes in patients with non-ST-elevation acute coronary syndromes, but the need for combination therapy is uncertain."	( Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006)	0.33
" Among the thienopyridines, clopidogrel is considered to be a safer alternative to ticlopidine due to its decreased incidence of hematologic adverse effects."	( Hematologic adverse effects of clopidogrel. Arora, R; Balamuthusamy, S, )	0.13
"0001), and major adverse cardiac events (8."	( Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). Holmes, DR; Kuntz, RE; Leon, MB; Mishkel, G; Moses, JW; Popma, JJ; Raizner, AE; Satler, LF; Teirstein, PS; Wang, P; Weisz, G; Wilensky, RL, 2007)	0.34
"Clopidogrel has a favourable side effect profile, in which the most serious complications are related to bleeding diathesis."	( Noncardiogenic pulmonary edema associated with clopidogrel: a serious but unexpected side effect of clopidogrel. Akyol, A; Eksik, A; Erdinler, IC; Ucer, E; Yazici, S, 2007)	0.34
"We compared the rates of major adverse cardiovascular events (MACE) as well as the rates of bleeding in medically managed patients randomized to ENOX versus UFH in the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) trial, stratified by concomitant clopidogrel use."	( Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. Antman, EM; Braunwald, E; Dalby, A; Duris, T; Gao, R; Lopez-Sendon, J; Morrow, DA; Murphy, SA; Pfisterer, M; Sabatine, MS, 2007)	0.34
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."	( Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)	0.34
"The CCT appears to be relatively safe compared with other regimens."	( Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute. Bergeron, S; Brulotte, S; Lemieux, A; Magne, J; Nguyen, CM; Poirier, P; Sénéchal, M, 2007)	0.34
" One major adverse clinical event (0."	( Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. Davis, KE; Denardo, SJ; Tcheng, JE, 2007)	0.34
" No mortality or extrathoracic bleeding occurred in either group, and there were no differences in the incidence of adverse myocardial events or hospital length of stay."	( Clopidogrel is safe early after on- and off-pump coronary artery bypass surgery. Bourke, ME; Chan, V; Kulik, A; Mesana, TG; Ressler, L; Ruel, M, )	0.13
"Loading with 375 mg of clopidogrel and 325 mg of aspirin appears to be safe when administered up to 36 hours after stroke and transient ischemic attack onset in this pilot study."	( LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. Albright, KC; Allison, TA; Grotta, JC; Meyer, DM, )	0.13
" In conclusion, clopidogrel resinate was proved to be an efficient and safe polymeric salt as a candidate for a new clopidogrel salt."	( The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. Ahn, KB; Ahn, SK; Choi, MH; Im, DS; Ki, MH; Kim, BS; Shin, HJ, 2008)	0.35
"Mild and moderate chronic kidney disease (CKD) is associated with decreased survival and increased adverse events after a percutaneous coronary intervention (PCI)."	( The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Berger, PB; Best, PJ; Brennan, DM; Califf, RM; Dasgupta, A; Steinhubl, SR; Szczech, LA; Topol, EJ, 2008)	0.35
"Clopidogrel pretreatment before PCI is beneficial and safe regardless of whether a GPI is used at the time of PCI."	( Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Cannon, CP; Fox, KA; Hamdalla, HN; Mehta, SR; Sabatine, MS; Steinhubl, SR; Topol, EJ, 2008)	0.35
" The indication, dosage, duration of therapy, and adverse events were examined."	( Safety and efficacy of clopidogrel in children with heart disease. Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L, 2008)	0.35
"Clopidogrel therapy in a pediatric population appears to be relatively safe and effective; however, randomized, controlled prospective studies are needed to determine the true efficacy and safety of clopidogrel in children."	( Safety and efficacy of clopidogrel in children with heart disease. Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L, 2008)	0.35
" The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0."	( A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008)	0.35
"Long term triple antiplatelet therapy was asociated with a significant increase in adverse events and bleeding rates, and their severity, and a trend to increased discontinuations."	( A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008)	0.35
" CONCLUSION , This data shows that tenecteplase is safe and effective in Indian patients with STEMI and conforms to the international ASSENT-2 trial data."	( Efficacy and safety of tenecteplase in Indian patients with st-segment elevation myocardial infarction. Jayanthi, K; Prabhakar, D; Ramachandran, P; Sathyamurthy, I; Srinivasan, KN; Vaidiyanathan, D, )	0.13
"It has been hypothesized that persistent presence of polymer may compromise the safety of drug-eluting stents, and that therefore biodegradable polymer coatings might reduce late adverse events."	( Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009)	0.35
"This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting."	( Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009)	0.35
" For antiplatelet agents, the most important risk is excess bleeding, especially as emerging evidence suggests that excess bleeding is associated with adverse long-term outcomes; thus prevention and management of excess bleeding is critically important."	( Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. Spinler, SA, 2009)	0.35
" In view of recent data demonstrating adverse outcomes in patients discontinuing clopidogrel, this study is useful in optimally managing this group of patients."	( Safety of carotid endarterectomy in patients concurrently on clopidogrel. Chapital, AB; Fleming, MD; Fowl, RJ; Money, SR; Scott, P; Stone, WM, )	0.13
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."	( Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)	0.35
"We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)."	( Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010)	0.36
" A low postoperative dose of aprotinin in patients receiving clopidogrel is safe and has comparable effects regarding postoperative bleeding complications as a high dose."	( Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study. Istad, R; Ringdal, MA; Tangen, G; Tølløfsrud, S; Øvrum, E; Øystese, R, 2010)	0.36
" In the Japanese population, however, the impact of clopidogrel on the occurrence of early adverse events is unknown."	( Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation. Hayashi, F; Iijima, R; Nakamura, M; Sugi, K, 2010)	0.36
" Primary end point was the combined incidence of major adverse coronary events and major bleedings."	( Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A, 2010)	0.36
"Results of our cohort study suggest that use of DES associated with a treatment with clopidogrel only may be safe and significantly reduce the need for new revascularization in patients requiring chronic anticoagulation."	( Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A, 2010)	0.36
" Logistic regression showed that only the incomplete revascularization was the independent risk factor of adverse events (odds ratio (OR)=2."	( Safety and effectiveness of percutaneous coronary intervention (PCI) in elderly patients. a 5-year consecutive study of 201 cases with PCI. Chen, Q; Ke, D; Li, G; Liu, Y; Wu, Q; Yang, Y, )	0.13
"The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months."	( Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)	0.36
" The incidence of major adverse cardiac events was collected at 4 years."	( Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)	0.36
" Secondly, the efficacy and safety disparity of clopidogrel, statins and irinotecan each among races and genetic variants are discussed to illustrate that pharmacogenetic knowledge is important for the interpretation and prediction of drug interaction-induced adverse events, whereas drug interaction -induced adverse events are equally informative for identifying genes-based mechanisms involved."	( Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. Bai, JP, 2010)	0.36
"We observed a clustering of adverse events in the 0 to 90 days after stopping clopidogrel."	( Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. Clarke, CL; Go, AS; Ho, PM; Magid, DJ; Peterson, ED; Rumsfeld, JS; Sedrakyan, A; Shetterly, SM; Tsai, TT; Wang, TY, 2010)	0.36
" Despite the widespread usage and favorable safety profile, much attention has focused recently on potential adverse events associated with use."	( Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents. Johnson, DA, 2010)	0.36
"Tirofiban is safe and effective in patients with ACS."	( Safety evaluation of tirofiban. Tebaldi, M; Valgimigli, M, 2010)	0.36
"Proton pump (H(+)/K(+)-adenosine triphosphatase) inhibitors (PPIs) are widely used to treat patients with acid-related disorders because they are generally perceived to be safe and effective."	( Safety of proton pump inhibitor exposure. Metz, DC; Yang, YX, 2010)	0.36
" However, the incidence of adverse ischemic events post-PCI appeared to be higher in patients receiving bivalirudin without adequate pretreatment with clopidogrel."	( Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010)	0.36
"In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications."	( Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010)	0.36
" Acute or chronic use can cause bleeding, a major adverse effect, which can lead to drug discontinuation or noncompliance with therapy."	( The safety of clopidogrel. Kleiman, NS; Mangalpally, KK, 2011)	0.37
" Thrombotic thrombocytopenic purpura, a rare but important adverse event, has also been reviewed."	( The safety of clopidogrel. Kleiman, NS; Mangalpally, KK, 2011)	0.37
"Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin is a well-established antithrombotic strategy, with hemorrhage being the chief adverse event (AE) of concern."	( National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010)	0.36
"To estimate the numbers and rates of emergency department (ED) visits for hemorrhage-related AEs (hemorrhage or evaluation for potential hemorrhage) from DAT in the United States and put them in the context of those from warfarin, we analyzed AEs from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project, 2006-2008, and outpatient prescribing from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, 2006-2007."	( National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010)	0.36
" It is concluded that MEGX test widens opportunities for personalization and safe pharmacotherapy."	( [Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity]. Kukes, IV; Paukov, SV; Ruvinov, IuV; Sivkov, AS, 2010)	0.36
" In 199 patients treated with DAT alone (control group) and 103 patients treated with rabeprazole plus DAT (rabeprazole group), we examined the incidences of GI bleeding and major adverse cardiac events (MACE) including stent thrombosis."	( [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. Chubachi, H; Ikee, R; Miyasaka, Y; Saito, S; Yasu, T, 2010)	0.36
" The secondary end point assessed by three of these studies was major adverse cardiac events (MACEs: cardiovascular death, myocardial infarction and thromboembolic complications)."	( Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. Arora, R; Bedi, U; Khosla, S; Molnar, J; Singh, M; Singh, PP, 2011)	0.37
"To evaluate the safety (primary outcome, defined as any bleeding complication or thrombocytopenia) and adverse outcomes (secondary outcomes, defined as death from cardiovascular causes, myocardial infarction or stroke) of clopidogrel therapy in patients aged ≥75 years with stable or unstable coronary artery disease undergoing PCI, and to compare these outcomes with those in younger controls."	( Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011)	0.37
" The rate of the first adverse (secondary) outcome of the composite of death from cardiovascular causes, myocardial infarction or stroke was higher in older patients (12."	( Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011)	0.37
"034), and major adverse cardiac events (2."	( Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. Cheng, JW; Dorsch, MP; Goldberg, T; Mohammad, RA, 2010)	0.36
" At 1-year follow-up, major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), acute coronary syndrome leading to hospitalization and nonfatal stroke, were recorded."	( Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Capodanno, D; Cicorella, N; Gavazzi, A; Guagliumi, G; Lettieri, C; Lortkipanidze, N; Musumeci, G; Nijaradze, T; Romano, M; Rosiello, R; Rossini, R; Sirbu, V; Tarantini, G; Valsecchi, O, 2011)	0.37
"0), and major adverse cardiac events (2."	( Safety and efficacy of clopidogrel reloading in patients on chronic clopidogrel therapy who present with an acute coronary syndrome and undergo percutaneous coronary intervention. Ben-Dor, I; Gaglia, MA; Gonzalez, M; Mahmoudi, M; Maluenda, G; Pichard, AD; Sardi, G; Satler, LF; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z, 2011)	0.37
"Within a regional STEMI system of care, half-dose fibrinolysis combined with immediate transfer for PCI may be a safe and effective option for STEMI patients with expected delays due to long-distance transfer."	( Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Dirks, TG; Duval, S; Garberich, RF; Harris, JL; Henry, TD; Larson, DM; Madison, JD; Sharkey, SW; Stokman, PJ; Westin, RK, 2012)	0.38
"Even very short-term dual antiplatelet therapy seems safe after coronary stenting with Genous in de novo coronary artery lesions located in secondary branch vessels."	( Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial. Biondi-Zoccai, G; Bramucci, E; Colombo, A; Ferlini, M; Grinfeld, L; Iadanza, A; Morice, MC; Petronio, AS; Pierli, C; Sangiorgi, GM, 2011)	0.37
" However, a randomized controlled trial that compared clopidogrel alone with the combination of clopidogrel and omeprazole found no increase in adverse cardiovascular outcomes and a reduction in the rate of adverse gastrointestinal outcomes attributable to omeprazole."	( Recent safety concerns with proton pump inhibitors. Chen, J; Howden, CW; Leontiadis, GI; Yuan, YC, 2012)	0.38
"High platelet reactivity (HPR) under treatment with clopidogrel or aspirin is associated with adverse outcome."	( Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Christ, G; Delle-Karth, G; Drucker, C; Huber, K; Jilma, B; Maurer, G; Neunteufl, T; Siller-Matula, JM; Tolios, A, 2013)	0.39
" The rates of the composite of cardiac adverse events (acute coronary syndrome, stent thrombosis, stroke, death and revascularization) were recorded during 12-month follow-up."	( Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Christ, G; Delle-Karth, G; Drucker, C; Huber, K; Jilma, B; Maurer, G; Neunteufl, T; Siller-Matula, JM; Tolios, A, 2013)	0.39
"The composite endpoint of cardiovascular adverse events occurred more often in patients with high platelet reactivity (HPR) to both agonists ADP and AA (37."	( Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Christ, G; Delle-Karth, G; Drucker, C; Huber, K; Jilma, B; Maurer, G; Neunteufl, T; Siller-Matula, JM; Tolios, A, 2013)	0.39
"Dual low responsiveness to clopidogrel and aspirin is a strong predictor of cardiac adverse events, especially in patients with diabetes mellitus, which underlines the need for personalized antiplatelet treatment."	( Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Christ, G; Delle-Karth, G; Drucker, C; Huber, K; Jilma, B; Maurer, G; Neunteufl, T; Siller-Matula, JM; Tolios, A, 2013)	0.39
" The drug is associated with rare adverse effects such as thrombotic thrombocytopenia purpura, acute hepatotoxicity, and neutropenia."	( Prasugrel as a safe alternative for clopidogrel-induced polyarthralgias. Coulter, CJ; Montandon, SV, 2012)	0.38
" Therefore, it remains unclear how to best manipulate PARs for safe antithrombotic activity."	( Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Hamilton, JR; Jackson, SP; Lee, H; Mountford, JK; Sturgeon, SA, 2012)	0.38
"Our results indicate that PAR antagonists used in combination with aspirin provide a potent yet safe antithrombotic strategy in mice and provide insights into the safety and efficacy of using PAR antagonists for the prevention of acute coronary syndromes in humans."	( Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Hamilton, JR; Jackson, SP; Lee, H; Mountford, JK; Sturgeon, SA, 2012)	0.38
"We analyzed data from 31 627 patients treated with intravenous alteplase enrolled in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register."	( Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N, 2012)	0.38
"To clarify the frequency of Japanese patients who are resistant to antiplatelet agents, and then clarify correlations between resistance and thromboembolic adverse events in neurointervention."	( [Resistance to antiplatelet agents assessed by a point-of-care platelet function test and thromboembolic adverse events in neurointervention]. Asai, T; Haraguchi, K; Izumi, T; Matsubara, N; Miyachi, S; Naito, T; Wakabayashi, T; Yamanouchi, T, 2012)	0.38
" Thromboembolic adverse events occurred in 7 patients."	( [Resistance to antiplatelet agents assessed by a point-of-care platelet function test and thromboembolic adverse events in neurointervention]. Asai, T; Haraguchi, K; Izumi, T; Matsubara, N; Miyachi, S; Naito, T; Wakabayashi, T; Yamanouchi, T, 2012)	0.38
" In conclusion, both non-metabolized clopidogrel and ticlopidine as well as metabolites of these compounds are toxic towards myeloid progenitor cells."	( Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites. Brecht, K; Donzelli, M; Krähenbühl, S; Maseneni, S; Taegtmeyer, AB, 2012)	0.38
"In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation."	( Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013)	0.39
", drug-associated adverse events, including the proportional reporting ratio, the reporting odds ratio, the information component given by a Bayesian confidence propagation neural network, and the empirical Bayes geometric mean."	( Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012)	0.38
", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, 736 adverse events were listed as warfarin-associated adverse events, and 147 of the 736 were bleeding complications, including haemorrhage and haematoma."	( Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012)	0.38
"Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation."	( Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)	0.39
" The primary outcome was the rate of major adverse cardiac events (MACE), defined as a composite of cardiac death, non-fatal myocardial infarction (MI), and target lesion revascularization (TLR)."	( Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)	0.39
" Other common adverse effects of ticagrelor such as dyspnea and ventricular pauses appear to be mild and self-limited."	( Safety profile and bleeding risk of ticagrelor compared with clopidogrel. Lincoff, AM; May, CH, 2012)	0.38
" Proton pump inhibitors cause few adverse effects with short-term use; however, long-term use has been scrutinized for appropriateness, drug-drug interactions, and the potential for adverse effects (e."	( Reducing adverse effects of proton pump inhibitors. Ament, PW; Dicola, DB; James, ME, 2012)	0.38
" The primary endpoint was the incidence of bleeding adverse events."	( Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. Minematsu, K; Tanahashi, N; Uchiyama, S, 2012)	0.38
" No significant difference between the groups was detected in the incidence of bleeding adverse events, which was 14."	( Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. Minematsu, K; Tanahashi, N; Uchiyama, S, 2012)	0.38
" The CP-load group experienced more in-hospital major adverse cardiac events (5."	( Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R, 2013)	0.39
"OH 44195: The insertion of small-bore chest tube in patients receiving clopidogrel can be safe if performed by experienced operators and by using US guidance along with lateral insertion site, which has the lowest risk of lacerating the intercostal arteries."	( Safety of ultrasound-guided small-bore chest tube insertion in patients on clopidogrel. Boujaoude, Z; Dammert, P; Pratter, M, 2013)	0.39
" Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up."	( Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z, 2013)	0.39
" We will examine the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) in patients undergoing percutaneous coronary intervention with DES for the treatment of coronary lesions."	( Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013)	0.39
" In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization."	( Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013)	0.39
"TAT could significantly reduce the rates of MACEs and cardiac death in comparison to DAT, but more attention should be paid to adverse side effects of the drugs."	( Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis. Fu, ZX; Li, J; Tang, HQ; Zhang, Y, 2013)	0.39
"Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA."	( Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M, 2014)	0.4
" Hepatotoxicity is a rare but potentially serious adverse reaction associated with clopidogrel."	( Hepatocellular toxicity of clopidogrel: mechanisms and risk factors. Bouitbir, J; Brecht, K; Krähenbühl, S; Lindinger, PW; Maseneni, S; Zahno, A, 2013)	0.39
" No patient experienced any adverse effects in the postoperative period related to the use of ticagrelor."	( Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. Dixon, T; Freeman, WD; Hanel, RA; Johns, G; Miller, DA; Navarro, R; Nordeen, JD; Sapin, M; Taussky, P; Tawk, RG, 2014)	0.4
" All of our patients showed immediate platelet inhibition after a loading dose of 180 mg of ticagrelor, with no adverse effects."	( Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. Dixon, T; Freeman, WD; Hanel, RA; Johns, G; Miller, DA; Navarro, R; Nordeen, JD; Sapin, M; Taussky, P; Tawk, RG, 2014)	0.4
"The data generated from this large single-center experience in AF patients treated with DES revealed that dual therapy with OAC plus clopidogrel for 6-12 months followed by monotherapy with OAC appears both safe and effective at long-term follow-up."	( Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Abdel-Wahab, M; Akin, I; El-Mawardy, M; Geist, V; Richardt, G; Seivani, Y; Sulimov, DS; Toelg, R, 2013)	0.39
" However, no data are available regarding its impact on adverse clinical outcomes in patients undergoing percutaneous coronary intervention (PCI)."	( Comparison of clinical efficacy and safety of clopidogrel resinate with clopidogrel bisulfate in patients undergoing percutaneous coronary intervention. Chang, K; Cho, JS; Chung, WS; Her, SH; Jeong, SH; Kim, CJ; Kim, PJ; Park, MW; Seung, KB; Yim, HW, 2013)	0.39
" We compared cumulative adverse outcomes during a 1-year follow-up after PCI in the overall population and in the PS-matched cohort."	( Comparison of clinical efficacy and safety of clopidogrel resinate with clopidogrel bisulfate in patients undergoing percutaneous coronary intervention. Chang, K; Cho, JS; Chung, WS; Her, SH; Jeong, SH; Kim, CJ; Kim, PJ; Park, MW; Seung, KB; Yim, HW, 2013)	0.39
"In this large real-world PCI population, CR was as effective and as safe as CB in preventing adverse clinical outcomes."	( Comparison of clinical efficacy and safety of clopidogrel resinate with clopidogrel bisulfate in patients undergoing percutaneous coronary intervention. Chang, K; Cho, JS; Chung, WS; Her, SH; Jeong, SH; Kim, CJ; Kim, PJ; Park, MW; Seung, KB; Yim, HW, 2013)	0.39
" The present study was aimed to assess the safety aspect of DLBS1033 in a preclinical setting, which included observation on toxic signs after acute and repeated administrations, and the drug's effect on prenatal development and drug interaction."	( Toxicity studies of a bioactive protein with antithrombotic-thrombolytic activity, DLBS1033. Adnyana, IK; Anggadireja, K; Sigit, JI; Sukandar, EY; Tjandrawinata, RR, 2014)	0.4
" However, the comparative risks of gastrointestinal (GI) adverse events during DAPT are not clear."	( Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL, 2013)	0.39
" The safety profile was evaluated by using adverse events (AEs), which were assessed by physical examination, vital signs, ECGs, clinical laboratory tests, and interviews."	( The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, si Huh, W; Jung, JA; Kim, JR; Kim, MJ; Kim, TE; Ko, JW; Lee, SY; Park, KM, 2013)	0.39
" The prevalence of adverse events was assessed at each visit through a direct interview."	( Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013)	0.39
" There was no significant difference in the drug-related adverse events between the two groups (12."	( Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013)	0.39
" The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events."	( Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014)	0.4
" Perioperative mortality, morbidity and the incidence of adverse events were balanced between the groups without statistical significance."	( [Effectiveness and safety of tranexamic acid in patients receiving on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation]. Li, LH; Shi, J; Wang, GY; Wang, YF; Xue, QH; Yuan, S, 2013)	0.39
" We analysed adverse events (AEs) consistent with either pulmonary infection or sepsis, and subsequent mortality, in 18,421 PLATO patients treated with ticagrelor or clopidogrel."	( Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J, 2014)	0.4
" However, the adverse event rate after the substitution to clopidogrel remains undetermined."	( Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014)	0.4
" The primary end point of this study was adverse events of interest, including clinically significant reduced blood cell counts, hepatic dysfunction, bleeding, and other serious side effects."	( Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014)	0.4
"The adverse event rates after the substitution of ticlopidine for clopidogrel is similar to the adverse event rates of patients who were initially treated with clopidogrel."	( Safety evaluation of substituting clopidogrel for ticlopidine in Japanese patients with ischemic stroke--Hiroshima ticlopidine, clopidogrel safe exchange trial. Aoki, S; Hosomi, N; Ito, H; Kataoka, S; Kohriyama, T; Matsumoto, M; Mihara, C; Mukai, T; Nezu, T; Noda, K; Nomura, E; Ohtsuki, T; Ota, T; Takamatsu, K; Takeda, I; Torii, T; Yamada, A; Yokoyama, T, 2014)	0.4
" Major adverse cardiovascular events, comprising all-cause death, nonfatal infarction, nonfatal stroke, and ischaemia-driven target vessel revascularization, was the primary efficacy end point."	( Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register. Asanin, M; Brdar, N; Djuricic, N; Krljanac, G; Lasica, R; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L, 2014)	0.4
"Antiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end-stage renal disease undergoing dialysis."	( Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014)	0.4
" Five adverse events (3."	( Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation. Cho, YK; Hur, SH; Jung, BC; Kim, H; Kim, KB; Kim, KS; Kim, W; Kim, YN; Lee, BR; Lee, JB; Lee, JH; Nam, CW; Park, HS; Park, JS; Yang, DH; Yoon, HJ, 2014)	0.4
" Other adverse events observed in patients treated with this platelet inhibitor are discussed, including hematological complications, and cutaneous and hepatic idiosyncratic reactions."	( Efficacy and safety of prasugrel in acute coronary syndrome patients. Delzor, F; Nanau, RM; Neuman, MG, 2014)	0.4
" The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke."	( Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)	0.4
" Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events."	( Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015)	0.42
" Prasugrel is at least as effective and safe as clopidogrel in patients with ACS undergoing early invasive management."	( Efficacy and Safety of Prasugrel Compared With Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Brener, SJ; Lella, LK; Wang, A, )	0.13
"This meta-analysis demonstrates that short-term combination of clopidogrel and aspirin is effective and safe for stroke prevention in high vascular risk patients."	( Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014)	0.4
"7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs."	( Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015)	0.42
"Early surgery appears safe for patients with hip fracture though there may be a small increase in the rate of blood transfusion."	( Is early hip fracture surgery safe for patients on clopidogrel? Systematic review, meta-analysis and meta-regression. Doleman, B; Moppett, IK, 2015)	0.42
" Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database."	( Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. Abe, J; Hara, H; Kinosada, Y; Miyamura, N; Nakamura, M; Nishibata, Y; Sekiya, Y; Suzuki, H; Suzuki, Y; Tsuchiya, T; Umetsu, R; Uranishi, H, 2015)	0.42
"No treatment emergent adverse events in the 300/75 mg and 600/150 mg regimen were observed in EMs, IMs, and PMs."	( A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects. Hasegawa, S; Kajiwara, M; Kobayashi, M, 2015)	0.42
"Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality."	( Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015)	0.42
"The aim of our study was to triage clinical and laboratory predictors of major adverse clinical events (MACE) following coronary stenting."	( Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015)	0.42
"The primary efficacy endpoints were all-cause death and major adverse cardiovascular events (MACEs)."	( Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. Ding, SL; Fang, D; Fang, Q; Gan, XD; Li, KY; Peng, S; Wan, J; Wei, BZ, 2015)	0.42
" Rates of adverse events were similar between the two groups."	( Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in stroke patients: multicenter, randomized, open-label, phase 4, non-inferiority clinical trial. Kang, K; Kim, BK; Kim, HJ; Koh, SH; Lee, SJ, 2016)	0.43
" Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities."	( Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. Bundhun, PK; Chen, MH; Qin, T, 2015)	0.42
"Four studies including 1005 patients reporting the adverse clinical outcomes and six studies including 519 patients reporting the platelet activities, with a total of 1524 patients have been analyzed in this meta-analysis."	( Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. Bundhun, PK; Chen, MH; Qin, T, 2015)	0.42
" No significant difference in stent thrombosis and bleeding risks between these 2 groups shows TAPT to be almost as safe as DAPT in these diabetic patients."	( Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. Bundhun, PK; Chen, MH; Qin, T, 2015)	0.42
" Outcome measures were overall bleeding, major bleeding, and major adverse cardiac events (MACE)."	( Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies. Cavallari, I; De Luca, L; Patti, G; Ricottini, E, 2016)	0.43
"To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack."	( [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015)	0.42
" Operating early on patients on clopidogrel is safe and does not appear to confer any clinically significant bleeding risk."	( Clopidogrel and hip fractures, is it safe? A systematic review and meta-analysis. Della Torre, PK; Shatwell, MA; Soo, CG; Yolland, TJ, 2016)	0.43
"There was no major adverse cardiac event (MACE) and pouch infection were observed among 3 groups in perioperation."	( [Safety of implantation permanent pacemaker at different times in patients with dual antiplatelet therapy]. Cong, H; Li, X; Li, Z; Wang, Z; Zhang, F; Zhang, L, 2016)	0.43
"We consecutively enrolled 375 patients with IS after they received clopidogrel therapy, and venous blood samples were subjected to genotyping allelic variants of genes modulating clopidogrel absorption (ATP binding cassette subfamily B1, ABCB1), metabolic activation (cytochrome P450[CYP] 3A and CYP2C19), and biologic activity (platelet membrane receptor [ P2Y12, P2Y1)], and glycoprotein IIIa [ GPIIIa]) and statistically analyzing their interactions with clopidogrel sensitivity (CS) and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up."	( Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2017)	0.46
" Single locus analysis showed that only the CYP2C19*2(rs4244285) variant was independently associated with CS and risk of adverse events after adjusting covariates."	( Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2017)	0.46
"Sensitivity of patients with IS to clopidogrel and clopidogrel-induced adverse clinical events may be multifactorial but is not determined by single gene polymorphisms."	( Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2017)	0.46
" Adverse events (AEs) and abnormalities in blood, urine, liver, and kidney function were monitored."	( Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. Hu, H; Huang, Y; Kong, Y; Li, C; Li, Y; Nao, J; Song, Y; Tan, L; Zhang, J; Zhang, W, 2016)	0.43
" Vinpocetine could be an effective and safe component of treatment regimen for acute cerebral infarction."	( Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. Hu, H; Huang, Y; Kong, Y; Li, C; Li, Y; Nao, J; Song, Y; Tan, L; Zhang, J; Zhang, W, 2016)	0.43
" The secondary endpoints were 6-month major adverse cardiac events (MACE), which included cardiac death, nonfatal myocardial infarction, or ischemic symptoms driven target vessel revascularization."	( Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016)	0.43
" Major adverse cardiac events occurred in 4 (8."	( Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016)	0.43
" The primary efficacy endpoint was major adverse cardiac events (MACE), defined as the composite of cardiac death, myocardial infarction, or stent thrombosis."	( Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Abizaid, A; Bhatt, DL; Chieffo, A; Colombo, A; Costa, RA; Feres, F; Genereux, P; Gilard, M; Giustino, G; Hong, MK; Jang, Y; Kim, BK; Kim, HS; Leon, MB; Morice, MC; Palmerini, T; Park, KW; Redfors, B; Sardella, G; Sawaya, F; Stone, GW; Valgimigli, M, 2016)	0.43
"We wished to explore the relationship between CYP3A5 polymorphisms and adverse events in patients undergoing clopidogrel therapy."	( Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis. Wang, CH; Wang, YQ; Zhang, JH, 2016)	0.43
" The primary outcome was major adverse cardiovascular events (MACE)."	( Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis. Wang, CH; Wang, YQ; Zhang, JH, 2016)	0.43
"No significant correlation was found between CYP3A5 polymorphisms and adverse events due to clopidogrel therapy."	( Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis. Wang, CH; Wang, YQ; Zhang, JH, 2016)	0.43
"Using data on 11 955 acute myocardial infarction (MI) patients treated with percutaneous coronary intervention at 233 hospitals and enrolled in the TRANSLATE-ACS study, we compared whether discharge PPI use altered the association of 1-year adjusted risks of major adverse cardiovascular events (MACE; death, MI, stroke, or unplanned revascularization) and Global Use of Strategies To Open Occluded Arteries (GUSTO) moderate/severe bleeding between prasugrel- and clopidogrel-treated patients."	( Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M, 2016)	0.43
"Exploratory analyses of adverse event reports (AERs) from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database (2004-2012 periods) were conducted."	( Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events. Hansen, RA; Rahman, MM; Scalese, MJ, 2017)	0.46
" We took into consideration adverse events including death from any cause, major stroke within 30 days, and death between 30 days and 1 year later from any stroke."	( The Feasibility and Safety of Separate Carotid Artery Stenting Using the Restrict Protective Method for Bilateral Carotid Stenosis. Bishnori, I; Goto, S; Ishikawa, K; Kato, Y; Ohshima, T; Yamamoto, T, 2017)	0.46
" We observed no adverse events, restenosis, or recurrent symptoms during follow-up."	( The Feasibility and Safety of Separate Carotid Artery Stenting Using the Restrict Protective Method for Bilateral Carotid Stenosis. Bishnori, I; Goto, S; Ishikawa, K; Kato, Y; Ohshima, T; Yamamoto, T, 2017)	0.46
" Outcomes were evaluated for major adverse cardiovascular events (MACE) and bleeding at 1 year."	( Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System. Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K, 2017)	0.46
"Thromboembolic and hemorrhagic complications are among the most feared adverse events in the endovascular treatment of aneurysms, and this is particularly the case for flow diverter devices."	( A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures. Adeeb, N; Griessenauer, CJ; Gupta, R; Moore, JM; Ogilvy, CS; Patel, AS; Shallwani, H; Siddiqui, A; Thomas, AJ; Youn, R, 2017)	0.46
"Ticagrelor is a safe and effective agent for prevention of thromboembolic complications following flow diverter deployment when compared to clopidogrel."	( A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures. Adeeb, N; Griessenauer, CJ; Gupta, R; Moore, JM; Ogilvy, CS; Patel, AS; Shallwani, H; Siddiqui, A; Thomas, AJ; Youn, R, 2017)	0.46
"In a cohort receiving PED, a 600-mg loading dose of clopidogrel should be safe and efficacious in those off the standard protocol or showing <30% platelet inhibition before treatment."	( Safety and Efficacy of a 600-mg Loading Dose of Clopidogrel 24 Hours Before Pipeline Embolization Device Treatment. Atallah, E; Bekelis, K; Chalouhi, N; Hasan, D; Jabbour, P; Rosenwasser, RH; Saad, H; Smith, M; Tjoumakaris, S; Zarzour, H, 2017)	0.46
"The US Food and Drug Administration Adverse Event Reporting System (FAERS) is a global passive surveillance database that relies on voluntary reporting by health care professionals and consumers as well as required mandatory reporting by pharmaceutical manufacturers."	( Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS). Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Litvinov, O; Marciniak, TA; Serebruany, VL, )	0.13
"From the FAERS database we extracted and examined adverse event cases coreported with oral P2Y12 platelet inhibitors."	( Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS). Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Litvinov, O; Marciniak, TA; Serebruany, VL, )	0.13
"Overall, 2015 annual adverse events were more commonly coreported with clopidogrel (n = 13,234) with known source filers (n = 12,818, or 96."	( Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS). Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Litvinov, O; Marciniak, TA; Serebruany, VL, )	0.13
" Patients filed most adverse events for clopidogrel and prasugrel, while physicians originated most ticagrelor complaints."	( Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS). Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Litvinov, O; Marciniak, TA; Serebruany, VL, )	0.13
" The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up."	( The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. Cheng, JH; Feng, ZW; Hu, ZH; Li, XY; Lv, QZ; Shi, HT; Wang, QB; Wang, Z; Wu, HY; Xie, XQ; Xu, Q; Xue, Y, 2018)	0.48
"The present study indicated that long-term oral low-dose aspirin was safe for patients with both TBAD and coronary heart disease who underwent EVAR."	( Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN, 2017)	0.46
" Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months."	( SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017)	0.46
" The primary outcome measured was the composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), or ischaemia-driven target lesion revascularisation at the 12-month follow-up."	( Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy. Cho, DK; Choi, S; Hong, BK; Hong, MK; Jang, Y; Jeon, DW; Kang, TS; Kang, WC; Kim, BK; Kim, BO; Kim, JS; Kim, S; Kim, YH; Kwon, HM; Lee, BK; Lee, OH; Min, PK; Shin, DH; Woo, SI; Yoon, YW, 2018)	0.48
"We sought to investigate whether double antiplatelet therapy (DAPT) is safe in patients after LAAC."	( Dual antiplatelet therapy is safe and efficient after left atrial appendage closure. Czub, P; Fojt, A; Grygier, M; Hendzel, P; Kapłon-Cieślicka, A; Karolczak, N; Kochman, J; Lodziński, P; Maksym, J; Marchel, M; Mazurek, T; Opolski, G; Piątkowski, R; Wilimski, R, 2018)	0.48
"LAAC followed by DAPT seems to be a safe and efficient alternative for stroke prevention in patients with NVAF who have contraindications to anticoagulation therapy."	( Dual antiplatelet therapy is safe and efficient after left atrial appendage closure. Czub, P; Fojt, A; Grygier, M; Hendzel, P; Kapłon-Cieślicka, A; Karolczak, N; Kochman, J; Lodziński, P; Maksym, J; Marchel, M; Mazurek, T; Opolski, G; Piątkowski, R; Wilimski, R, 2018)	0.48
"This study was aimed to investigate the correlation between CYP2C19 and ABCB1 polymorphisms and the recurrence of ischemic cardiovascular adverse events in patients with coronary artery disease treated with clopidogrel."	( CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. Fang, W; Gan, Q; Han, W; Hou, X; Liu, Y, 2018)	0.48
" One-year follow-up visit was carried out to record the incidence of cardiovascular adverse events after drug-eluting stent implantation was inset."	( CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. Fang, W; Gan, Q; Han, W; Hou, X; Liu, Y, 2018)	0.48
"Follow-up visit results suggested that the patients with high on-treatment platelet reactivity (HPR) had a higher recurrence rate of cardiovascular adverse events after PCI operation and clopidogrel treatment."	( CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. Fang, W; Gan, Q; Han, W; Hou, X; Liu, Y, 2018)	0.48
"CYP2C19*3 polymorphism could be an important predictive factor of HPR and ischemic cardiovascular adverse events after clopidogrel treatment."	( CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. Fang, W; Gan, Q; Han, W; Hou, X; Liu, Y, 2018)	0.48
" As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies."	( Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. Liu, X; Zhang, JJ, 2018)	0.48
" Efficacy outcomes included ischemic stroke, stent thrombosis, major adverse cardiovascular event (MACE), all-cause mortality and myocardial infarction (MI); safety outcome was major bleeding."	( Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. Huang, J; Liu, L; Tang, X; Zhang, X, 2018)	0.48
" The aim of this study was to evaluate the degree of on-treatment platelet reactivity, and its association with ischaemic and haemorrhagic adverse events at follow up in PAD patients undergoing percutaneous transluminal angioplasty (PTA)."	( On-Treatment Platelet Reactivity is a Predictor of Adverse Events in Peripheral Artery Disease Patients Undergoing Percutaneous Angioplasty. Antoniucci, D; Basili, S; Elmahdy, MF; Giusti, B; Gori, AM; Grifoni, E; Marcucci, R; Migliorini, A; Paniccia, R; Pratesi, C; Pulli, R; Valenti, R; Violi, F, 2018)	0.48
"TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis."	( The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019)	0.51
"We assessed primary causative adverse events (PCAE) after BC and GC in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)."	( Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. Agewall, S; Atar, D; Geudelin, B; Hall, TS; Hyun Kim, M; Lomakin, N; Marciniak, TA; Serebruany, VL, 2019)	0.51
" However, the overall adverse event profile suggests potentially better safety of BC over GC formulations."	( Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. Agewall, S; Atar, D; Geudelin, B; Hall, TS; Hyun Kim, M; Lomakin, N; Marciniak, TA; Serebruany, VL, 2019)	0.51
" We analyzed the occurrence of major adverse cardiovascular events and periprocedural myocardial infarction."	( Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention. Abellán-Huerta, J; Jurado-Román, A; López-Lluva, MT; Lozano-Ruiz Poveda, F; Piqueras-Flores, J; Sánchez-Pérez, I, 2019)	0.51
" At the end of follow-up, major adverse cardiovascular event rate was not different between groups."	( Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention. Abellán-Huerta, J; Jurado-Román, A; López-Lluva, MT; Lozano-Ruiz Poveda, F; Piqueras-Flores, J; Sánchez-Pérez, I, 2019)	0.51
"To describe and evaluate the bleeding-related adverse events associated with use of P2Y12 inhibitors utilizing data from the FDA Adverse Event Reporting System (FAERS) database."	( Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system. Abou-Ali, A; Fahmy, AI; Mekkawy, MA, 2019)	0.51
"We identified 2,252, 2,450, and 549 adverse event reports attributed to clopidogrel, ticagrelor, and prasugrel use, respectively."	( Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system. Abou-Ali, A; Fahmy, AI; Mekkawy, MA, 2019)	0.51
" Secondary outcomes were adverse bleeding events (safety outcome)."	( Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis. Bilotta, F; Campo, G; Parodi, G; Pavasini, R; Serenelli, M; Tonet, E; Vitali, F, 2019)	0.51
" Compared with nonsmokers within the first year of follow-up, the reductions of stroke and major adverse cardiovascular event rate were 18% ( P=0."	( Effectiveness and Safety of Platelet ADP -P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta-Analysis. Chen, S; Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhou, S, 2019)	0.51
"Clopidogrel combined with low-dose aspirin is safe and effective in antithrombotic therapy for children with KD complicated by CAA."	( [Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms]. Chen, TT; Guo, YH; Li, Y; Liu, YL; Lu, YH; Shi, K; Wang, XM, 2019)	0.51
" This practice, especially in complex PCI, could be affected by a higher rate of peri-procedural adverse events."	( Safe and Effective Management of Antiplatelet Therapy in a Clopidogrel-Naive Patient Undergoing "Ad Hoc" Complex Coronary Intervention: A Case Report. Colombo, A; Marchese, A; Resta, F; Tito, A, 2020)	0.56
"Patients who are at increased risk for MI can be maintained on DAPT up to the time of CABG because surgery is safe when patients are offered PPT."	( Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe? Charif, F; El Zein, A; Hamdan, R; Issa, M; Jassar, Y; Saab, M; Younes, M; Youness, G, 2019)	0.51
" Aspirin alone appears to be safe for use in those patients."	( Clopidogrel plus Aspirin Use is Associated with Worse Long-Term Outcomes, but Aspirin Use Alone is Safe in Patients with Vasospastic Angina: Results from the VA-Korea Registry, A Prospective Multi-Center Cohort. Baek, SH; Cho, SS; Gwon, HC; Han, SH; Her, SH; Jo, SH; Kim, SE; Lee, BK; Lee, KY; Lee, MH; Park, KH; Rha, SW; Seo, WW; Suh, JW; Yang, TH, 2019)	0.51
" In conclusion, treatment with low-dose IC TNK appears safe and well tolerated during PPCI."	( Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49). Bainey, KR; Devireddy, C; Gibson, CM; Gopalakrishnan, L; Grip, L; Guo, J; Kazziha, S; Kumar, V; Marshall, JJ; Mavromatis, K; Pinto, D; Singh, P; Stouffer, GA, 2020)	0.56
"Although the number of adverse events (AEs) increased with vicagrel dose, none were considered serious, suggesting that vicagrel is safe and well-tolerated."	( Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor. Chen, H; Chen, W; Gong, Y; Lai, X; Li, H; Li, X; Li, Y; Liu, C; Liu, X; Liu, Y; Sheng, L; Sun, H; Xu, H; Yang, J; Yang, M; Yuan, F, 2020)	0.56
" The primary efficacy endpoint was major adverse cardiovascular events (MACE) defined by each study, and the safety endpoint was TIMI non-CABG major bleeding."	( Efficacy and Safety of Potent Oral P2Y Han, Y; Jiang, Z; Li, Y; Li, Z; Ma, S; Song, H; Yu, P, 2020)	0.56
" However, an increased risk of ticagrelor-related adverse events prompted the evaluation of low-dose regimens."	( Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR). Cang, H; He, M; Li, J; Li, Y; Liu, G; Mu, H; Shi, J; Sun, D; Wang, J; Wang, W; Xu, M; Zhang, C; Zhang, H; Zhang, Z; Zhao, C; Zhao, S, 2021)	0.62
" Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-dose clopidogrel, or single-dose enoxaparin, consistent with clinically relevant dose regimens, was safe and well tolerated with no serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, bleeding-related TEAEs, and no significant changes in coagulation parameters."	( Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020)	0.56
" The primary endpoint was major adverse cardiovascular events (MACE), including cardiovascular (CV) death, all-cause death, myocardial infarction (MI), stent thrombosis and stroke."	( Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis. Gwak, HS; Lee, N; Seong, JM; Yoon, HY, 2020)	0.56
"Compared with ASA, DAPT showed a non-significant impact on long-term survival and demonstrated to be a safe option."	( Early dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass surgery: survival and safety outcomes. Amorim, MJ; Barros, AS; Cerqueira, RJ; Ferreira, AF; Leite-Moreira, AF; Lourenço, AP; Moreira, R; Pinho, P; Rocha-Gomes, JN; Saraiva, FA, 2020)	0.56
" The endpoints were major adverse cardiac events (MACEs), death, stroke, myocardial infarction (MI), stent thrombosis, and bleeding events."	( Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. Li, D; Li, X; Shen, S; Wu, H; Xiang, X, 2020)	0.56
" The primary endpoint for efficacy was the rate of major adverse cardiac events (MACEs)."	( Efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis. Chen, Q; Li, D; Lu, C; Wang, C; Wang, S; Wang, Y; Wang, Z; Xu, T; Xuan, H; Zhang, H; Zhang, Y, 2020)	0.56
" The aim of this study is to investigate the efficacy and safety of switching from ticagrelor to clopidogrel in AMI patients with no adverse event during the first month after the index PCI with newer-generation DES."	( A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALO Ahn, Y; Chang, K; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Kim, CJ; Kim, HY; Kim, MC; Park, CS; Park, MW; Seung, KB; Yoo, KD, 2021)	0.62
"TALOS-AMI is a multicentre, randomised, open-label study enrolling 2,590 AMI patients with no adverse events during the first month after the index PCI."	( A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALO Ahn, Y; Chang, K; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Kim, CJ; Kim, HY; Kim, MC; Park, CS; Park, MW; Seung, KB; Yoo, KD, 2021)	0.62
" Efficacy (major adverse cardiovascular events, acute or chronic limb ischaemia, vascular amputation, peripheral revascularisation) and safety (all-cause mortality and overall bleeding) outcomes were evaluated via Bayesian network meta-analyses."	( Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Cimminiello, C; De Carlo, M; Di Minno, G; Fazeli, MS; Sayre, T; Siliman, G, 2021)	0.62
"98) significantly reduced major adverse cardiovascular events risk compared with aspirin."	( Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Cimminiello, C; De Carlo, M; Di Minno, G; Fazeli, MS; Sayre, T; Siliman, G, 2021)	0.62
"This updated network meta-analysis confirms that clopidogrel significantly decreases the risk of major adverse cardiovascular events compared with aspirin, without increasing bleeding risk."	( Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Cimminiello, C; De Carlo, M; Di Minno, G; Fazeli, MS; Sayre, T; Siliman, G, 2021)	0.62
" Major adverse cardiovascular and cerebrovascular events (MACCEs) and bleeding events according to ticagrelor or clopidogrel use were compared."	( Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Gao, R; Guo, T; Li, J; Li, Y; Qiao, S; Qiu, H; Tang, Y; Wang, Y; Xu, B; Yan, L; Yang, Y; Zheng, J, 2021)	0.62
" On the other hand, the difference between ticagrelor and clopidogrel for net adverse clinical events was significant (4."	( Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Gao, R; Guo, T; Li, J; Li, Y; Qiao, S; Qiu, H; Tang, Y; Wang, Y; Xu, B; Yan, L; Yang, Y; Zheng, J, 2021)	0.62
"In the VOYAGER PAD trial, rivaroxaban plus aspirin reduced the risk of adverse cardiovascular and limb events with an early benefit for acute limb ischemia regardless of clopidogrel use."	( Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Anand, SS; Bauersachs, R; Berkowitz, SD; Bonaca, MP; Brackin, T; Brasil, D; Capell, WH; Debus, ES; Haskell, L; Hess, CN; Hiatt, WR; Jaeger, N; Madaric, J; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR; Sillesen, H; Szalay, D, 2020)	0.56
" However, there were no significant differences in the adverse drug reactions between the two groups."	( Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke. Chen, M; Dai, X; Deng, X; Fu, S; Gong, Q; He, W; Huang, L; Li, C; Luo, Q; Qiu, T; Wang, J; Wang, M; Xiao, H, 2021)	0.62
"Genetic variations of enzymes that affect the pharmacokinetics and hence effects of medications differ between ethnicities, resulting in variation in the risk of adverse drug reactions (ADR) between different populations."	( The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in Japan. Aoki, Y; Chandler, RE; Lönnstedt, IM; Wakao, R, 2021)	0.62
"Prasugrel/ticagrelor, compared to clopidogrel, reduces risk of major adverse cardiovascular event (MACE) in Hong Kong ACS population."	( Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study. Lam, ASM; Lee, VWY; Yan, BPY, 2021)	0.62
" The primary effectiveness endpoint was a major adverse cardiovascular event (MACE), and the primary safety endpoint was a major bleeding event."	( Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan. Hsieh, KP; Hwang, SJ; Li, YS; Wang, SH; Yang, YH, 2022)	0.72
" Intravenous (IV) tirofiban alone or combined with DAPT was shown to be safe and effectively improved clinical outcome in progressive ischemic stroke patients."	( Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients. Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y, 2021)	0.62
"Our study suggested that tirofiban use appears to be safe as monotherapy in AIS treatment compared with common dual antiplatelet therapy, however, no improvement in functional outcomes was found."	( Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke. Chen, C; Hu, W; Liu, D; Liu, J; Liu, T; Luo, W; Song, J; Tao, C; Yuan, X; Zhang, C; Zhu, Y, 2021)	0.62
"To assess the efficacy and safety of low-dose prasugrel compared to clopidogrel based on the occurrence of major adverse cardiac events (MACEs) and major bleeding in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI)."	( Efficacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis. Kengkla, K; Kumtep, W; Saokaew, S; Senthong, V; Ungsriwong, S; Wongsalap, Y, 2022)	0.72
" The primary endpoint was net adverse clinical event, defined as the primary efficacy endpoint of death, myocardial infarction, or cerebrovascular accident and the primary safety endpoint of any bleeding event."	( Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Flahive, J; Fraielli, K; Gill, K; Servati, N, 2021)	0.62
"This small cohort study suggests, in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention, the net adverse clinical event rate does not differ between clopidogrel and potent P2Y12 inhibitors in the setting of triple antithrombotic therapy."	( Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Flahive, J; Fraielli, K; Gill, K; Servati, N, 2021)	0.62
"Early hip fracture surgery is safe for elderly patients within 5 days of clopidogrel withdrawal, without increased perioperative blood loss, transfusion requirement, complications, and mortality compared with patients not taking antiplatelet drugs."	( Safety of early surgery for geriatric hip fracture patients taking clopidogrel: a retrospective case-control study of 120 patients in China. Li, B; Wang, G; Wu, XB; Yang, MH; Yao, DC; Zhang, P; Zhang, WC; Zhou, Y; Zhu, SW, 2021)	0.62
" CONCLUSIONS Continuing anticoagulation or antiplatelet was safe in not increasing bleeding complications or perioperative transfusion requirements."	( Is Continuing Anticoagulation or Antiplatelet Therapy Safe Prior to Kidney Transplantation? Alonso-Escalante, JC; Machado, L; Tabar, KR; Thai, N; Tindall, R; Uemura, T, 2021)	0.62
"This study indicated that compared with patients without clopidogrel administration, elderly patients with hip fractures who receive clopidogrel as long-term anti-platelet therapy are relatively safe for surgery in less than 5-7 days after discontinuation of clopidogrel."	( Evaluation of Clopidogrel Safety in Geriatric Patients with Hip Fracture: A Retrospective Study. Chong, H; Wang, G; Wu, X; Yang, M; Zhang, W; Zheng, S; Zheng, Y; Zhou, Y, 2021)	0.62
"To establish the safety and efficacy of different dual antiplatelet therapy (DAPT) combinations in patients with acute coronary syndrome (ACS) according to their baseline ischaemic and bleeding risk estimated with a machine learning derived model [machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE) score]."	( Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study. Abu-Assi, E; Bruno, F; Cerrato, E; Chieffo, A; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; De Filippo, O; Dominguez-Rodriguez, A; Elia, E; Gallone, G; Henriques, JPS; Iannaccone, M; Kinnaird, T; Leonardi, S; Liebetrau, C; Manzano-Fernández, S; Omedè, P; Patti, G; Piroli, F; Raposeiras-Roubin, S; Wańha, W, 2022)	0.72
" Thus, if those patients needed operative treatment for BPH, they may be at high risk of hemorrhage or its related adverse effects with the usage of anti-thrombotic drugs during the peri-operative time."	( Safety of not withholding clopidogrel therapy during the immediate several days pre- and post-trans-urethral resection of prostate (TURP): a retrospective cohort study. Abdulhamid, AK; Khalaf, RJ, 2022)	0.72
"The continuation of usage of anti-thrombotic therapy (clopidogrel) during peri-operative period in patients with TURP for BPH is a safe practice."	( Safety of not withholding clopidogrel therapy during the immediate several days pre- and post-trans-urethral resection of prostate (TURP): a retrospective cohort study. Abdulhamid, AK; Khalaf, RJ, 2022)	0.72
" The primary outcome endpoint was evaluated based on the adverse cardiac and cerebrovascular events within 12 months."	( Safety and Efficacy Evaluation of Antithrombotic Therapy with Rivaroxaban and Clopidogrel After PCI in Chinese Patients. Bai, L; Cui, XR; Fu, LZ; Yang, XH; Zhang, JD; Zhou, YQ, )	0.13
"00%) main adverse cardiac and cerebrovascular events occurred during the 12 months of follow-up, including 5 (9."	( Safety and Efficacy Evaluation of Antithrombotic Therapy with Rivaroxaban and Clopidogrel After PCI in Chinese Patients. Bai, L; Cui, XR; Fu, LZ; Yang, XH; Zhang, JD; Zhou, YQ, )	0.13
" Cilostazol therapy significantly increased the risk of adverse events of headache (odds ratio, 12."	( Efficacy and Safety of Cilostazol for Atherosclerosis: A Meta-analysis of Randomized Controlled Trials. Huang, T; Wan, H; Wu, Q; Wu, T; Yang, P; Zhang, H, 2022)	0.72
" Net adverse clinical events were identified as the composite end point, which was defined as a composite of cardiovascular death, myocardial infarction, revascularization, stroke, and bleeding at 12 months after acute coronary syndromes."	( Efficacy and Safety of De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Clinical Trials. Bai, N; Ma, Y; Niu, Y; Shang, YS; Wang, ZL; Zhong, PY, 2022)	0.72
" Safety endpoints included adverse events (AEs) and Bleeding Academic Research Consortium-defined any bleeding."	( Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention. Gong, Y; Han, Y; Jiang, H; Kang, Y; Lai, X; Li, J; Li, Y; Liu, B; Liu, Y; Ma, S; Qi, Z; Ren, L; Sun, H; Tang, C; Tang, Y; Zhao, X; Zheng, M, 2022)	0.72
" Safety endpoints included bleeding events and adverse events (AEs)."	( Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III). Kamouchi, M; Kimura, K; Kitazono, T; Koyama, N; Matsumaru, Y; Matsuo, H; Nakamura, M; Tsutsumi, J; Umemura, K, 2023)	0.91
"OACs plus single antiplatelet therapy and dual antiplatelet therapy alone are both safe and efficacious management strategies after CVSS stent placement."	( Safety and efficacy comparison between OACs plus single antiplatelet and dual antiplatelet therapy in patients with cerebral venous sinus stenosis poststenting. Bai, C; Chen, Z; Ding, Y; Ilagan, R; Ji, X; Meng, R; Wu, X, 2022)	0.72
" Major adverse cardiovascular events and bleeding events were assessed by using Mantel-Haenszel-pooled risk ratio and 95% con- fidence interval."	( Efficacy and Safety of Ticagrelor in East Asian Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials. Lin, J; Qin, Q; Xie, C; Zhu, J, 2022)	0.72
" The effectiveness outcome was major adverse cardiovascular events (MACE) defined as a composite of recurrent myocardial infarction, repeat revascularization, stroke, or cardiovascular death at 12 months."	( Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study. Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C, 2022)	0.72
" Many randomized, double-blind, placebo-controlled, multicenter clinical trials suggest that NBP is a safe and effective treatment for ischemic stroke."	( Efficacy and safety of butylphthalide in secondary prevention of stroke: study protocol for a multicenter, real world trial based on Internet. Lv, J; Xie, Z; Zhao, D; Zhao, G, 2022)	0.72
"), and adverse events of patients in groups."	( Efficacy and safety of butylphthalide in secondary prevention of stroke: study protocol for a multicenter, real world trial based on Internet. Lv, J; Xie, Z; Zhao, D; Zhao, G, 2022)	0.72
" Effectiveness endpoints were evaluated by the major adverse cardiovascular events, encompassing all-cause death, non-fatal myocardial infarction, and clinically driven revascularization."	( Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B, 2022)	0.72
"Ticagrelor was associated with a lower incidence of major adverse cardiovascular events than clopidogrel at 12 months in elderly Chinese patients with coronary artery disease, without a significant increase of Bleeding Academic Research Consortium bleeding events."	( Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B, 2022)	0.72
"The first 3 months after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) is a high-risk period for adverse events, including ischemic and bleeding events, which decrease greatly with time."	( Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. Li, X; Lin, Y; Peng, W; Zhang, Y, 2023)	0.91
" Major adverse cardiovascular and cerebrovascular events (MACCE) were considered the primary end point, and major bleeding was considered the secondary end point."	( Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. Li, X; Lin, Y; Peng, W; Zhang, Y, 2023)	0.91
" The primary comprehensive endpoint was a major adverse cardiovascular event (MACE) composite of cardiovascular death, stroke, or myocardial infarction, while the secondary endpoints were cardiovascular death, all-cause stroke, ischemic stroke, myocardial infarction, and all-cause death."	( Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J, 2023)	0.91
" The secondary endpoint is a composite of major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, cardiac death, nonfatal myocardial infarction, stent thrombosis, ischemia-driven target vessel revascularization, and stroke."	( Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T, 2023)	0.91
" Our meta-analysis aimed to demonstrate whether intensified antithrombotic regimens with ticagrelor plus aspirin have more beneficial effects and fewer adverse events compared to those of clopidogrel plus aspirin in East Asian patients with ACS undergoing PCI."	( Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023)	0.91
" The primary endpoint was bleeding events, and the secondary endpoints were major adverse cardiovascular and cerebrovascular events (MACCEs, including cardiovascular death, nonfatal myocardial infarction [MI], and stroke), all-cause death, and definite/probable/possible stent thrombosis."	( Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023)	0.91
"This real-world study suggests that cilostazol is effective and safe for noncardioembolic ischemic stroke and may be associated with better effectiveness in hypertensive patients compared to clopidogrel."	( Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. Je, NK; Lee, YJ, 2023)	0.91
" Outcomes included major adverse cardiovascular events, all cause death, major bleeding and myocardial infarction."	( Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. Liu, C; Ma, L, 2023)	0.91
" In head-to-head comparison, no significant difference was observed between all antithrombotic treatment strategies with respect to primary endpoint of major adverse cardiovascular events."	( Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. Liu, C; Ma, L, 2023)	0.91

Excerpt	Reference	Relevance
" These data and those of previous studies indicate that a dose of 300 to 400 mg produces a rapid onset of the pharmacodynamic action of clopidogrel, with levels of inhibition close to steady-state reached within 2 hours."	( Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Bachmann, F; Cariou, R; Geudelin, B; Hauert, J; Savcic, M; Wyld, PJ, 1999)	0.3
"In order to obtain a global assessment of circulating clopidogrel-related products and of the excretion of the drug, the pharmacokinetic behavior and the excretion balance of 14C radioactivity following the administration of a single dose of 75 mg of 14C-labeled clopidogrel were compared in 6 clopidogrel-free healthy male subjects (Period I) and after 7 days of once daily therapy with the unlabeled drug in these subjects (at steady state) (Period II)."	( Pharmacokinetic profile of 14C-labeled clopidogrel. Broekhuysen, J; Deroubaix, X; Lins, R; Necciari, J, 1999)	0.3
"The potential influence of clopidogrel on the pharmacokinetics of theophylline was evaluated in 15 healthy male subjects during the pharmacokinetic steady state of theophylline, after single and multiple doses."	( Clopidogrel does not affect the pharmacokinetics of theophylline. Caplain, H; Necciari, J; Thebault, JJ, 1999)	0.3
" Pharmacokinetic analysis of clopidogrel was limited due to low plasma concentrations arising from rapid hydrolysis to SR 26334."	( Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. Much, DR; Necciari, J; Nichola, P; Slugg, PH; Smith, WB; Vargas, R, 2000)	0.31
" In preparation for such a study, we have performed a pharmacodynamic study of the platelet inhibitory effects of clopidogrel in patients on maintenance hemodialysis."	( A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. Fiore, L; Hasbargen, JA; Kaufman, JS; O'Connor, TZ; Perdriset, G, 2000)	0.31
" Pharmacokinetic analysis of this new product showed it to have a more consistent and reproducible absorption compared with immediate-release dipyridamole."	( Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. Lenz, T; Wilson, A, 2003)	0.32
" The lesser long-term pharmacodynamic potency of aspirin relative to clopidogrel raises the prospect of the need for more effective antiplatelet agents or a synergistic combination therapy for stroke prevention in the future."	( Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Chang, HW; Chang, YY; Chen, MC; Chen, SS; Chen, WH; Kao, YF; Lai, SL; Lan, MY; Liu, JS; Yip, HK, 2004)	0.32
" To evaluate possible pharmacokinetic determinants of this response variability, we developed a sensitive and specific liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for quantification of unmodified inactive clopidogrel, its inactive carboxyl metabolite, and its active thiol metabolite in plasma."	( Pharmacokinetics of clopidogrel after administration of a high loading dose. Gorchakova, O; Harlfinger, S; Kastrati, A; Lazar, A; Schömig, A; Schömig, E; Taubert, D; von Beckerath, N, 2004)	0.32
" The method was successfully applied to the pharmacokinetic study of the two different polymorphs of clopidogrel bisulfate in Wistar rat."	( Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. Barot, D; Lohray, VB; Mohan, PR; Sharma, K; Singh, SS, 2005)	0.33
" Pharmacokinetic parameters for these groups were calculated and compared with one another."	( Interaction study of aspirin or clopidogrel on pharmacokinetics of donepezil hydrochloride in rats by HPLC-fluorescence detection. Aboul-Enein, HY; Nakashima, K; Nishiwaki, J; Ohwaki, Y; Wada, M; Yamane, T, 2007)	0.34
" Ketoconazole decreased R-138727 and clopidogrel active metabolite Cmax (maximum plasma concentration) 34-61% after prasugrel and clopidogrel dosing."	( Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Brandt, JT; Darstein, C; Ernest, CS; Farid, NA; Jakubowski, JA; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2007)	0.34
" The developed assay method was applied to a pharmacokinetic study in human volunteers after oral administration of clopidogrel at a dose of 150 mg."	( Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. Shin, BS; Yoo, SD, 2007)	0.34
" The pharmacodynamic response to clopidogrel is more variable than the response to prasugrel, but the reasons for variation in response to clopidogrel are not well characterized."	( Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Brandt, JT; Close, SL; Ernest, CS; Farid, NA; Iturria, SJ; Lachno, DR; Payne, CD; Salazar, D; Winters, KJ, 2007)	0.34
"Genotyping was performed for CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4 and CYP3A5 on samples from healthy subjects participating in studies evaluating pharmacokinetic and pharmacodynamic responses to prasugrel (60 mg, n = 71) or clopidogrel (300 mg, n = 74)."	( Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Brandt, JT; Close, SL; Ernest, CS; Farid, NA; Iturria, SJ; Lachno, DR; Payne, CD; Salazar, D; Winters, KJ, 2007)	0.34
" Decreased exposure to its active metabolite is associated with a diminished pharmacodynamic response to clopidogrel."	( Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Brandt, JT; Close, SL; Ernest, CS; Farid, NA; Iturria, SJ; Lachno, DR; Payne, CD; Salazar, D; Winters, KJ, 2007)	0.34
" The therapeutic usefulness of clopidogrel has been limited by documented inter-individual heterogeneity in platelet inhibition, which may be attributable to known clopidogrel pharmacokinetic variability."	( Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. Al-Zumyli, R; Arafat, T; Bulatova, NR; Yousef, AM, 2008)	0.35
" Clopidogrel carboxylate plasma levels were measured and non-compartmental analysis was used to determine peak plasma concentration (C(max)), time to peak plasma concentration (T(max)), elimination half-life (t(1/2e)), and area under the curve (AUC(0-->infinity))."	( Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. Al-Zumyli, R; Arafat, T; Bulatova, NR; Yousef, AM, 2008)	0.35
" Pharmacokinetic parameter estimates (AUC(0-t last), C(max), and t(max)) and inhibition of platelet aggregation (IPA) by light transmission aggregometry were assessed at multiple time points after the LD and final MD."	( Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Ernest, CS; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.35
" The lack of a clinically meaningful effect of high-dose atorvastatin on the pharmacodynamic response to prasugrel after the loading or maintenance dose indicates that no dosage adjustment should be necessary in patients receiving these drugs concomitantly."	( Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.35
" The involvement of the phenomenon with CYP2C19 led some to believe that it was a pharmacokinetic issue."	( Clopidogrel resistance: pharmacokinetic or pharmacogenetic? Ford, NF, 2009)	0.35
" We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel."	( Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ, 2009)	0.35
" For prasugrel, there was no statistically significant difference in active metabolite exposure or pharmacodynamic response between CYP2C19 EM and RM."	( Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ, 2009)	0.35
" For pharmacokinetic analysis, blood was drawn at 0, 20, 40, 60, 90, 120, 180, 240 and 360 min after clopidogrel loading and peak plasma concentrations (C(max)) of the AMC were quantified with liquid chromatography-tandem mass spectrometry (LC-MS/MS)."	( Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. Bouman, HJ; Breet, NJ; Hackeng, CM; Parlak, E; Taubert, D; ten Berg, JM; ten Cate, H; van Werkum, JW, 2010)	0.36
" Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic response may be higher in Asian subjects than in white subjects."	( Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Farid, NA; Jakubowski, JA; Kelly, R; Kothare, P; Li, YG; Natanegara, F; Ni, L; Payne, CD; Richard Lachno, D; Salazar, DE; Small, DS; Teng Loh, M; Tomlin, M; Winters, KJ; Yuen, E, 2010)	0.36
"This study compared the pharmacodynamic response to a single 30-mg dose of prasugrel in healthy Chinese and white subjects and the response to a single 30-mg dose of prasugrel and a single 300-mg dose of clopidogrel in healthy Chinese subjects."	( Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Farid, NA; Jakubowski, JA; Kelly, R; Kothare, P; Li, YG; Natanegara, F; Ni, L; Payne, CD; Richard Lachno, D; Salazar, DE; Small, DS; Teng Loh, M; Tomlin, M; Winters, KJ; Yuen, E, 2010)	0.36
" The 90% confidence intervals (CIs) for the log-transformed ratios for pharmacokinetic parameters (Cmax and AUC) of SR26334 fell within the predefined pharmacokinetic equivalence range of 80 - 125%."	( Pharmacokinetics and the antiplatelet effect of a new clopidogrel formulation, clopidogrel besylate, in healthy subjects. Jeon, SH; Kim, JS; Kim, KA; Lee, GH; Park, JY; Ryu, JH, 2010)	0.36
"To determine pharmacodynamic and pharmacokinetic properties of clopidogrel and the metabolite SR 26334 in dogs."	( Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs. Brainard, BM; Budsberg, SC; Kleine, SA; Papich, MG, 2010)	0.36
"This study is a phase 3, multi-dose, pharmacodynamic comparison of prasugrel versus clopidogrel in Asian patients with ACS undergoing PCI."	( Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Boonbaichaiyapruck, S; Ge, J; Goh, YS; Hong, BK; Hou, CJ; Pinton, P; Zhu, J, 2010)	0.36
"Pharmacogenomic and pharmacokinetic aspects of clopidogrel nonresponsiveness were considered in detail."	( Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Di Girolamo, G; Giorgi, MA; González, CD, 2010)	0.36
" It has been suggested that staggering administration of clopidogrel and omeprazole may overcome this pharmacodynamic (PD) interaction."	( Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Ueno, M, 2010)	0.36
" John's wort (SJW), a CYP2C19 and CYP3A4 inducer, enhances the pharmacodynamic response of clopidogrel."	( The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. Gurbel, PA; Lau, WC; Rubenfire, M; Shields, T; Tantry, US; Welch, TD, 2011)	0.37
"This report is the first to demonstrate the superior pharmacodynamic effect of ticagrelor compared with clopidogrel irrespective of CYP2C19 genotype."	( First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C, 2010)	0.36
" Clopidogrel significantly increased the half-life (242% of control phase) and area under the plasma concentration-time curve from 0 to infinity (AUC(inf)) (227% of control phase) of sibutramine and decreased the apparent oral clearance (31% of control phase) of sibutramine."	( Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. Bae, JW; Jang, CG; Lee, SY, 2011)	0.37
" The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM."	( A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011)	0.37
" This has led to the development of other P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, with different pharmacokinetic characteristics that influence their pharmacodynamics."	( Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD, 2011)	0.37
" However, the pharmacokinetic advantages of both prasugrel and ticagrelor allow clinicians to center patient management by selecting the best drug for the appropriate subject."	( Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD, 2011)	0.37
" The pharmacokinetic profile of the thienopyridine clopidogrel has resulted in highly variable pharmacokinetics and efficacy responses."	( Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel. Achar, S, 2011)	0.37
" The aim of this study was to assess the impact of CCB therapy on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stent placement."	( Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Bernlochner, I; Kastrati, A; Mehilli, J; Morath, T; Neumann, L; Sarafoff, N; Schömig, A; Sibbing, D, 2011)	0.37
" The primary pharmacodynamic end point was adenosine diphosphate-induced platelet aggregation (in AU · min) with multiple electrode platelet aggregometry after loading with 600 mg clopidogrel."	( Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Bernlochner, I; Kastrati, A; Mehilli, J; Morath, T; Neumann, L; Sarafoff, N; Schömig, A; Sibbing, D, 2011)	0.37
" In the present study, we evaluated the possible pharmacokinetic interactions of Danshen extract with docetaxel and clopidogrel in rats."	( Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions. Jang, YP; Kim, HJ; Lee, JH; Lee, YJ; Oh, JH; Shin, YJ, 2011)	0.37
"Safety concerns have recently emerged based on a drug interaction between clopidogrel and proton pump inhibitors leading to reduced pharmacodynamic effects."	( Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, MK; Pham, JP; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	0.37
"Pantoprazole therapy used at high doses is not associated with modulation of the pharmacodynamic effects of clopidogrel, irrespective of timing of drug administration."	( Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, MK; Pham, JP; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)	0.37
"Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling of clopidogrel was developed from pooled data from healthy volunteers (n = 44) and stroke patients (n = 35)."	( Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. Han, S; Hwang, Y; Kang, W; Lee, HW; Lee, J; Lim, MS; Seong, SJ; Sohn, DR; Yim, DS; Yoon, YR, 2012)	0.38
" This article provides an overview on antiplatelet drug response variability, an update on definitions, including the role of pharmacodynamic testing, underlying mechanisms - with emphasis on recent understandings on pharmacogenetics and drug-drug interactions - and current and future perspectives on individualized antiplatelet therapy."	( Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Angiolillo, DJ; Tello-Montoliu, A; Ueno, M, 2011)	0.37
"Prasugrel demonstrated higher active metabolite exposure and more consistent pharmacodynamic response across all three predicted phenotype groups compared with clopidogrel, confirming observations from previous research that CYP2C19 phenotype plays an important role in variability of response to clopidogrel, but has no impact on response to prasugrel."	( Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Close, SL; Farid, NA; Ho, M; Jakubowski, JA; Kelly, RP; Natanegara, F; Shen, L; Small, DS; Walker, JR; Winters, KJ, 2012)	0.38
" Other pharmacokinetic parameters estimated for FA were also altered by the coadministrations, but no statistically significant differences were observed."	( Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. Li, Y; Liu, C; Mi, S; Wang, N; Zhang, Y, 2011)	0.37
" The present first-in-human study assessed the pharmacokinetic and pharmacodynamic effects of PM103 and its safety in 144 healthy human subjects."	( Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Adams, MP; Cooper, WD; Cushing, DJ; Kowey, PR; Machatha, S; Mosher, GL; Souney, PF; Zhang, B, 2012)	0.38
" The pharmacokinetic and pharmacodynamic effects of clopidogrel have been significantly influenced by the enzyme activity of the ABCB1 C3435T and the CYP2C19 system."	( Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy Accordin Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Yoon, SE, 2012)	0.38
" This study aimed to define pharmacodynamic (PD) profiles, including high platelet reactivity (HPR) rates, among elderly patients on maintenance clopidogrel therapy and to assess the PD effects of prasugrel 5 mg/day in elderly with HPR."	( Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Angiolillo, DJ; Calvi, V; Capodanno, D; Capranzano, P; D'Urso, L; Miccichè, E; Tamburino, C, 2011)	0.37
" However, if cilostazol exerts different pharmacodynamic (PD) effects according to levels of on-treatment platelet reactivity remains unknown."	( Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013)	0.39
" If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
"A dose-response effect was observed for all pharmacodynamic parameters tested."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
" Pharmacodynamic end-points were vasodilator-stimulated phosphoprotein P2Y(12) platelet reactivity index, maximal platelet aggregation to 5 and 20 μmol/l adenosine diphosphate, and VerifyNow P2Y12 platelet response units."	( A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Bhatt, DL; Brooks, JK; Frelinger, AL; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J, 2012)	0.38
"Pharmacokinetic and pharmacodynamic responses with omeprazole demonstrated assay sensitivity."	( A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Bhatt, DL; Brooks, JK; Frelinger, AL; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J, 2012)	0.38
" In the ONSET-OFFSET study (parallel group trial) and the RESPOND study (crossover trial), the pharmacodynamic effects of ticagrelor were compared with clopidogrel in patients with coronary artery disease (CAD)."	( Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Bliden, K; Butler, K; Gurbel, PA; Husted, SE; Høimark, L; Storey, RF; Tantry, US; Teng, R; Wei, C, 2012)	0.38
" Expression of the 3435T/T genetic variant encoding the MDR1 gene for the P-glycoprotein efflux transporter results in a significantly reduced maximum drug concentration and area under the plasma concentration-time curve as intestinal absorption of clopidogrel is reduced; and the expression of the mutant *2 allele of CYP2C19 results in similar pharmacokinetic effects as the two cytochrome P450 (CYP)-mediated steps required for the production of the active metabolite of clopidogrel are impaired."	( Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Ferro, A; Floyd, CN; Passacquale, G, 2012)	0.38
" A prospectively designed platelet function substudy was performed in a selected cohort of patients to provide insight into the pharmacodynamic effects of cangrelor, particularly in regard to whether cangrelor therapy may interfere with the inhibitory effects of clopidogrel."	( Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. Angiolillo, DJ; Becker, RC; Bhatt, DL; French, WJ; Harrington, RA; Huber, K; Liu, T; Prats, J; Price, MJ; Saucedo, JF; Schneider, DJ; Shaburishvili, T, 2012)	0.38
"This substudy of the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention patients (INNOVATE-PCI) trial evaluated the pharmacokinetic and pharmacodynamic effects of two dosing regimens of IV followed by oral elinogrel (120 mg IV plus 100 mg oral twice daily; 120 mg IV plus 150 mg oral twice daily) versus standard clopidogrel therapy (300-600 mg oral loading dose plus 75 mg oral maintenance dose) in 56 patients undergoing nonurgent PCI."	( Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (I Angiolillo, DJ; Broderick, S; Buerke, M; Conley, PB; Dabrowski, M; Gurbel, PA; Harrington, RA; Jennings, LK; Kochman, J; McClure, MW; Neumann, FJ; Rao, SV; Saucedo, JF; Stephens, G; Stumpf, J; Trenk, D; Welsh, RC; Wójcik, J, 2012)	0.38
"To evaluate the pharmacokinetic and pharmacodynamic effects of concomitant administration of single loading doses of clopidogrel or multiple doses of clopidogrel with multiple doses of dabigatran etexilate."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.39
"3-131%), as did its pharmacodynamic effects on the inhibition of platelet aggregation."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.39
"When given concomitantly, dabigatran etexilate and clopidogrel at clinically relevant doses did not appear to have significant effects on the pharmacokinetic and pharmacodynamic profiles of either agent."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.39
"As ticagrelor, clopidogrel and cangrelor therapies may be used in the same clinical setting, their potential pharmacodynamic interactions are of interest."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	0.38
" No pharmacodynamic interaction occurred between ticagrelor and cangrelor."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	0.38
"The extent of the pharmacodynamic drug-drug interactions observed between clopidogrel and cangrelor or ticagrelor apparently depends on the level of receptor occupancy when clopidogrel is administered."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	0.38
" The pharmacokinetic (PK) characteristics of clopidogrel have been studied previously in whites or Korean volunteers, but these PK characteristics may not be fully extrapolated to the Chinese people."	( Pharmacokinetics of clopidogrel in healthy Chinese volunteers. Chen, SL; Ding, L; Fan, HW; Tan, J; Wang, GJ; Zou, JJ, 2012)	0.38
" The measured pharmacokinetic parameters did not differ significantly between the clopidogrel besylate and clopidogrel bisulfate groups."	( Comparative pharmacokinetics/pharmacodynamics of clopidogrel besylate and clopidogrel bisulfate in healthy Korean subjects. Cho, JY; Jang, IJ; Kim, BH; Kim, JR; Lim, KS; Shin, HS; Shin, SG; Yoon, SH; Yu, KS, 2012)	0.38
"In this study, we investigated pharmacokinetic drug interactions of clopidogrel with P-gp inhibitors in rats and dogs."	( Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine A in rats and dogs. Lee, JH; Lee, YJ; Oh, JH; Shin, YJ, 2012)	0.38
" At steady-state ticagrelor (50 mg bid, or 200 mg bid), concomitant aspirin (300 mg qd) had no effect on mean maximum plasma concentration (Cmax), median time to Cmax (tmax), or mean area under the plasma concentration-time curve for the dosing interval (AUC0-τ) for ticagrelor and its primary metabolite, AR-C124910XX."	( Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Butler, K; Maya, J; Teng, R, 2013)	0.39
"Healthy subjects (n = 160; ages 20 to 53 years; homozygous CYP2C19 extensive metabolizer genotype; no nicotine for 6 weeks, prescription drugs for 4 weeks, over-the-counter drugs for 2 weeks, and no caffeine or alcohol for 72 h; confined; restricted diet) received clopidogrel 75 mg/day for 9 days, at which time clopidogrel pharmacokinetic and pharmacodynamic endpoints were measured."	( Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet f Barnard, MR; Bhatt, DL; Brooks, JK; Frelinger, AL; Lampa, M; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J, 2013)	0.39
" All identified factors together accounted for only 18% of intersubject variation in pharmacokinetic parameters and 32% to 64% of intersubject variation in PRI, MPA, and PRU."	( Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet f Barnard, MR; Bhatt, DL; Brooks, JK; Frelinger, AL; Lampa, M; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J, 2013)	0.39
"Previous studies involving a loading dose (LD) of 60 mg prasugrel have suggested that active metabolite exposure and pharmacodynamic responses may be higher in persons of Asian ethnicity than in Caucasian subjects."	( Pharmacodynamic comparisons for single loading doses of prasugrel (30 mg) and clopidogrel (600 mg) in healthy Korean volunteers. Jung, DK; Kim, MH; Zhang, HZ, 2013)	0.39
"The goal of this study was to investigate the impact of high-dose atorvastatin on the pharmacodynamic (PD) effects of double-dose clopidogrel in statin-naive patients with stable coronary artery disease (CAD) and high-on-treatment platelet reactivity (HTPR) while on standard-dose clopidogrel before percutaneous coronary intervention (PCI)."	( High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A, 2013)	0.39
" Most pharmacokinetic and pharmacodynamic studies in vivo were conducted using small sample sizes and were single centered, resulting in conflicting data."	( Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo--a systematic review. Chen, J; Chen, SY; Lian, JJ; Luo, TC; Zeng, XQ, 2013)	0.39
" Randomized controlled trials that compared pharmacodynamic impacts of a PPI on the efficacy of clopidogrel in vivo were included."	( Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo--a systematic review. Chen, J; Chen, SY; Lian, JJ; Luo, TC; Zeng, XQ, 2013)	0.39
" A population pharmacokinetic (PK) model was developed using NONMEM(®) to describe the time course of clopidogrel-IM in plasma and to design a sparse-sampling strategy to predict clopidogrel-IM exposures for use in characterizing anti-platelet activity."	( Population pharmacokinetic analysis of clopidogrel in healthy Jordanian subjects with emphasis optimal sampling strategy. Arafat, T; Melhem, M; Reynolds, DK; Van Wart, SA; Xue, B; Yousef, AM, 2013)	0.39
" The validated assay was successfully applied to the quantification of all four thiol metabolites in human plasma in support of a human pharmacokinetic study."	( A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: application to a clinical pharmacokinetic study. Arnold, ME; Furlong, MT; Kadiyala, P; Mariannino, T; Mylott, W; Roongta, V; Savant, I; Scott, L; Yuan, M, 2013)	0.39
"This study assessed pharmacodynamic (PD) response to the reduced prasugrel maintenance dose of 5 mg in very elderly (VE) patients (≥75 years of age)."	( Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. Angiolillo, DJ; Brown, PB; Erlinge, D; Foley, DP; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Luo, J; Moser, BA; Small, DS; Svensson, P; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C, 2013)	0.39
"To assess the impact of smoking on clinical and pharmacodynamic response to clopidogrel."	( The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. Chai, H; Chen, M; Huang, DJ; Li, Q; Liu, W; Luo, XL; Peng, Y; Ren, X; Wang, XQ; Zhang, C; Zhao, ZG, 2014)	0.4
"Smoking appears to positively modify the relative clinical efficacy and pharmacodynamic effects of clopidogrel."	( The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. Chai, H; Chen, M; Huang, DJ; Li, Q; Liu, W; Luo, XL; Peng, Y; Ren, X; Wang, XQ; Zhang, C; Zhao, ZG, 2014)	0.4
"This article is an overview of currently used antithrombotic therapies in the management of ischaemic stroke with special focus on their pharmacokinetic properties and how these properties may influence their clinical utility."	( Pharmacokinetic considerations for antithrombotic therapies in stroke. Apostolakis, S; Lip, GY; Shantsila, E, 2013)	0.39
"This study examined the effects of curcumin on the pharmacokinetic and pharmacodynamic properties of warfarin and clopidogrel in Wistar rats."	( Curcumin alters the pharmacokinetics of warfarin and clopidogrel in Wistar rats but has no effect on anticoagulation or antiplatelet aggregation. Liu, AC; Lou, HX; Zhao, LX, 2013)	0.39
" In patients with high on-treatment platelet reactivity (HTPR) while on standard-dose clopidogrel, high-dose atorvastatin enhances the pharmacodynamic (PD) effects of double-dose clopidogrel."	( Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A, 2014)	0.4
"This study was designed to compare the pharmacokinetic properties and safety profile of a fixed-dose combination formulation of ASA and clopidogrel with concurrent administration of each agent in healthy male Korean volunteers."	( The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, si Huh, W; Jung, JA; Kim, JR; Kim, MJ; Kim, TE; Ko, JW; Lee, SY; Park, KM, 2013)	0.39
" However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation."	( Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014)	0.4
" There was no significant difference in the pharmacodynamic effects of clopidogrel on platelet reactivity from baseline to 6-months follow-up (297 ± 57 vs."	( Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation. Bednar, F; Kocka, V; Linkova, H; Sulzenko, J; Tousek, P; Widimsky, P, 2013)	0.39
" The calculated concentrations were used to determine the pharmacokinetic parameters of the analytes."	( Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Burchardt, P; Danielak, D; Główka, F; Karaźniewicz-Łada, M; Komosa, A; Kruszyna, L; Lesiak, M, 2014)	0.4
" To observe whether antithrombin agents affect the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban, an open-label and parallel study was conducted."	( Pharmacokinetic and pharmacodynamic properties of batifiban coadministered with antithrombin agents in Chinese healthy volunteers. Chen, H; Chen, K; He, XM; Jia, MM; Li, J; Li, SF; Li, WY; Liu, MZ; Wang, YH; Wu, SL; Zhou, Y, 2013)	0.39
" A population pharmacokinetic (PK) model was developed from a randomized, cross-over, drug-interaction study in healthy male Korean subjects (n = 17)."	( Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. Abdelhady, AM; Desta, Z; Jiang, F; Overholser, BR; Shin, JG; Yeo, CW, 2014)	0.4
"Increased body weight is independently associated with impaired clopidogrel pharmacodynamic (PD) response."	( Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014)	0.4
" The AUC0-24 and Cmax of active clopidogrel metabolite decreased with both omeprazole and rabeprazole, and conditions of bioequivalence were not met, except for AUC0-24 with rabeprazole."	( Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Azizi, M; Ducint, D; Funck-Brentano, C; Gaussem, P; Molimard, M; Remones, V; Steichen, O; Szymezak, J, 2013)	0.39
" However, under our experimental conditions and proton-pump inhibitor doses, there was no significant pharmacodynamic interaction between rabeprazole or omeprazole and clopidogrel, despite a significant decrease in the formation of clopidogrel active metabolite."	( Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Azizi, M; Ducint, D; Funck-Brentano, C; Gaussem, P; Molimard, M; Remones, V; Steichen, O; Szymezak, J, 2013)	0.39
" This investigation aimed to evaluate the effect of hypothermia on the pharmacodynamic response of aspirin and clopidogrel in patients (n = 20) with ST elevation myocardial infarction undergoing primary PCI."	( Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. Angiolillo, DJ; Ariza, A; Cequier, A; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Homs, S; Lorente, V; Marcano, AL; Rivera, K; Romaguera, R; Roura, G; Sánchez-Elvira, G; Sánchez-Salado, JC; Sosa, SG; Teruel, L, 2014)	0.4
" We verified if the pharmacodynamic effects of CYP3A4-metabolized statins (atorvastatin) and non-CYP3A4-metabolized statins (pitavastatin) differ in patients with coronary artery disease (CAD) treated with DAPT."	( Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C, 2014)	0.4
"Smokers have a greater relative benefit of clopidogrel therapy compared with nonsmokers, likely attributed to its enhanced pharmacodynamic (PD) effects."	( Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; Darlington, A; Degroat, C; Desai, B; Ferrante, E; Ferreiro, J; Franchi, F; Guzman, LA; Muniz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2014)	0.4
"This article focuses on the pharmacokinetics of prasugrel and recently published pharmacodynamic and clinical studies."	( Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Coons, JC; Harris, J; Schwier, N; Seybert, AL, 2014)	0.4
"Prasugrel exhibits favorable pharmacokinetic and pharmacodynamic properties compared to clopidogrel."	( Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Coons, JC; Harris, J; Schwier, N; Seybert, AL, 2014)	0.4
"In patients referred for PPCI, ticagrelor bolus following clopidogrel resulted in more rapid and profound platelet inhibition, demonstrating a positive pharmacodynamic interaction."	( A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. Blondeau, M; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Marquis, JF; Maze, R; Moudgil, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY, 2014)	0.4
" Pharmacokinetic effects were estimated by measuring active metabolite of clopidogrel, and pharmacodynamic effects by inhibition of adenosine diphosphate (ADP)-induced platelet aggregation."	( Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Andersson, T; Galbraith, H; Nagy, P; Niazi, M; Nylander, S; Ranjan, S; Wallentin, L, 2014)	0.4
" Here, we assessed effects of CYP2C19 metaboliser status on pharmacokinetics (PK) and pharmacodynamic (PD) responses to prasugrel 5-mg and 10-mg and clopidogrel 75-mg using data from two PK/PD studies in stable coronary artery disease (CAD) patients (GENERATIONS and FEATHER)."	( The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Angiolillo, DJ; Bergmeijer, TO; Brown, PB; Duvvuru, S; Erlinge, D; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Moser, BA; Small, D; Sundseth, S; Svensson, P; Tantry, US; ten Berg, JM; Walker, JR; Winters, KJ, 2014)	0.4
" Neither the absolute ADP-induced P2Y12 receptor-activated platelet aggregation, exposure to CAMD nor the pharmacokinetic parameters of proguanil, cycloguanil and 4-CPB exhibited any significant differences among the genotype groups."	( CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. Brosen, K; Damkier, P; el Achwah, AB; Nielsen, F; Pedersen, RS; Stage, TB; Vinholt, PJ, 2014)	0.4
" The serum concentrations of IVA and N-demethyl ivabradine were determined by ultra-performance liquid chromatography-mass spectrometry and pharmacokinetic parameters were calculated using DASver3."	( The effect of clopidogrel on pharmacokinetics of ivabradine and its metabolite in rats. Chen, H; Hu, GX; Huang, CK; Lian, QQ; Shang-Guan, WN; Sun, W; Wang, Z; Wang, ZS; Zhang, XD; Zhu, GH, 2015)	0.42
"The objective was to compare the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ticagrelor with clopidogrel among subjects of Hispanic ethnicity, as the PD and PK effects of antiplatelet agents among Hispanics are not specifically known."	( A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, L; Maya, J; Price, MJ; Teng, R, 2015)	0.42
" This review considers pharmacodynamic and clinical data to guide clinicians when switching between antiplatelet drugs is considered."	( Pharmacodynamic and clinical implications of switching between P2Y12 receptor antagonists: considerations for practice. Bagai, A; Chua, D; Cohen, EA; Fitchett, D; Saw, J; Verma, S; Vijayaraghavan, R; Welsh, R, 2014)	0.4
" The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI."	( A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG, 2014)	0.4
" The covariates including demographic characteristics, laboratory indexes, combined medication, complications and genetic polymorphisms of related enzymes were screened for their influence on the pharmacokinetic and pharmacodynamics parameters."	( [Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome]. Ding, XL; Gao, J; Hang, YF; Jiang, B; Miao, LY; Xie, C; Xue, L, 2014)	0.4
" In the present study, a dynamic physiologically based pharmacokinetic (PBPK) model was developed in Simcyp for clopidogrel and clopi-H4 using a specific sequential metabolite module in four populations with phenotypically different CYP2C19 activity (poor, intermediate, extensive, and ultrarapid metabolizers) receiving a loading dose of 300 mg followed by a maintenance dose of 75 mg."	( Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics. Boulenc, X; Djebli, N; Fabre, D; Fabre, G; Hurbin, F; Sultan, E, 2015)	0.42
" The method was applicable for the quality control of the mentioned drugs in raw material, bulk drug and pharmaceutical formulations as well as in pharmacokinetic studies."	( Liquid Chromatographic Method for Simultaneous Quantitation of Clopidogrel, Aspirin and Atorvastatin in Rat Plasma and Its Application to the Pharmacokinetic Study. Akhalaque Ahmad, RA; Chatpalliwar, VA; Chhajed, SS; Porwal, PK, 2015)	0.42
" Clopidogrel carboxylic acid was used for the pharmacokinetic study of clopidogrel."	( Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. Bai, X; Chen, F; Fang, C; Han, M; Liu, M; Yang, G; Yang, Y; Zhao, J; Zhu, Q, 2015)	0.42
" The ginsenoside Rg, from FDDP was determined by HPLC and its pharmacokinetic parameter were finally compared."	( [Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. Dai, GL; Ju, WZ; Ma, ST; Sun, BT; Tan, HS; Zhao, WZ, 2014)	0.4
"Long term with clopidogrel has effect on the pharmacokinetic character of Rg, from FDDP, this research may provides theoretical support for the FDDP-clopidogrel combination treatment in clinical."	( [Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. Dai, GL; Ju, WZ; Ma, ST; Sun, BT; Tan, HS; Zhao, WZ, 2014)	0.4
" Among the heterozygous CYP2C192 subjects, all pharmacodynamic parameters measured by whole blood impedance aggregometry were significantly different between subjects with different CYP3A53 genotypes."	( The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions. Kanjanawart, S; Nakkam, N; Tassaneeyakul, W; Tiamkao, S; Vannaprasaht, S, 2015)	0.42
" Clopidogrel 75 mg (day 3) had no significant effect on the pharmacokinetic variables of simvastatin or simvastatin acid compared with placebo."	( Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. Backman, JT; Itkonen, MK; Neuvonen, M; Neuvonen, PJ; Niemi, M; Tornio, A, 2015)	0.42
" Pharmacodynamic studies have shown that this interaction is avoided when clopidogrel is given at the end of the cangrelor infusion."	( Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation. Agarwal, Z; Gogo, P; Schneider, DJ; Seecheran, N, 2015)	0.42
"The primary objective of the present study was to evaluate the pharmacokinetic and pharmacodynamic interactions between clopidogrel and cilostazol in relation to the CYP2C19 and CYP3A5 genotypes."	( The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. Ghim, JL; Kim, DH; Kim, EY; Kim, HS; Lim, Y; Oh, M; Shin, JG, 2016)	0.43
" Plasma concentrations of clopidogrel, cilostazol and their active metabolites (clopidogrel thiol metabolite, 3,4-dehydrocilostazol and 4″-trans-hydroxycilostazol), and adenosine diphosphate-induced platelet aggregation were measured for pharmacokinetic and pharmacodynamic assessment."	( The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. Ghim, JL; Kim, DH; Kim, EY; Kim, HS; Lim, Y; Oh, M; Shin, JG, 2016)	0.43
"The aim of the present case report was to describe a novel pharmacokinetic drug–drug interaction between the antiplatelet agent clopidogrel and the antineoplastic agent paclitaxel."	( Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. Backman, J; Bergmann, TK; Brosen, K; Filppula, AM; Launiainen, T; Nielsen, F, 2016)	0.43
" Pharmacodynamic assessments were conducted using three assays (vasodilator-stimulated phosphoprotein, VerifyNow P2Y12, and light transmittance aggregometry, LTA) at baseline, 30 min, 2, 24 h, and 1 week."	( A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Singh, K; Wilson, RE; Zenni, MM, 2016)	0.43
" Pharmacodynamic effect was measured by an impedance method with a Multiplate analyzer."	( Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. Bergus, P; Burchardt, P; Danielak, D; Główka, F; Karaźniewicz-Łada, M; Komosa, A; Wiśniewska, K, 2017)	0.46
" Pharmacokinetic parameters of clopidogrel and its metabolites were not significantly different in carriers of *1G allele, comparing to wt/wt homozygotes."	( Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. Bergus, P; Burchardt, P; Danielak, D; Główka, F; Karaźniewicz-Łada, M; Komosa, A; Wiśniewska, K, 2017)	0.46
"CYP3A4*1G might not be a significant contributor to the variability in pharmacokinetic and pharmacodynamic response to clopidogrel therapy."	( Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. Bergus, P; Burchardt, P; Danielak, D; Główka, F; Karaźniewicz-Łada, M; Komosa, A; Wiśniewska, K, 2017)	0.46
"In this review, we discuss the unique pharmacodynamic properties of several antiplatelet drugs with their possible potential molecular of mechanisms on inhibiting platelet aggregation."	( The pharmacodynamics of antiplatelet compounds in thrombosis treatment. Geraldine, P; Jayakumar, T; Sheu, JR; Yang, CH; Yen, TL, 2016)	0.43
"To complete a systematic review evaluating the currently available evidence regarding the pharmacokinetic and pharmacodynamic activity of orally administered clopidogrel, prasugrel and ticagrelor during the acute phase of a myocardial infarction in relation to mechanical reperfusion with primary percutaneous coronary angioplasty."	( Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review. Cotton, JM; Cox, AR; Khan, N, 2016)	0.43
"Twelve papers were included in our final analysis; seven relating to pharmacodynamic studies, one to a pharmacokinetic study and four to pharmacokinetic/pharmacodynamic studies."	( Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review. Cotton, JM; Cox, AR; Khan, N, 2016)	0.43
" Plasma miR-142 was negatively associated with H4 Cmax (r = -0."	( Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. Chen, JY; He, GD; Li, HP; Li, XX; Lin, HM; Liu, JE; Meng, JX; Tang, L; Tang, QJ; Wang, LY; Wu, H; Zhang, MZ; Zhong, SL; Zhong, WP, 2016)	0.43
"Genetic variants in the pharmacokinetic (PK) mechanism are the main underlying factors affecting the antiplatelet response to clopidogrel."	( Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel. Chen, JY; He, GD; Lei, HP; Li, HP; Li, XX; Lin, HM; Liu, SW; Ma, DL; Mai, LP; Sun, S; Tang, L; Wang, XP; Wu, H; Zhang, B; Zhang, ZW; Zhong, SL; Zhong, WP; Zhou, HK, 2017)	0.46
"Clopidogrel is a key antiplatelet drug that has substantial interpatient variability in pharmacodynamic response."	( Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics. Monte, SV; Norgard, NB, 2017)	0.46
"A number of reports have demonstrated that obesity is a risk factor for a reduced clopidogrel pharmacodynamic response."	( Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics. Monte, SV; Norgard, NB, 2017)	0.46
" This review encompasses the most recent updates on factors influencing pharmacokinetic and pharmacodynamic responses to clopidogrel."	( Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. Chen, XP; Li, MP; Tang, J; Zhang, YJ, 2017)	0.46
"In this single-center, prospective, randomized pharmacodynamic study, 52 ESRD patients on HD were prescribed clopidogrel (300mg loading dose [LD], then 75mg daily), standard-dose ticagrelor (180mg LD, then 90mg twice daily), or low-dose ticagrelor (90mg LD, then 90mg daily) for 14days."	( The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. Ihm, CG; Jeong, KH; Kim, JB; Kim, JS; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS, 2017)	0.46
" This post hoc analysis investigated the pharmacodynamic effects of ticagrelor versus clopidogrel loading dose (LD) in troponin-negative acute coronary syndrome patients with or without DM undergoing percutaneous coronary intervention in the Ad Hoc PCI study."	( Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y, 2017)	0.46
" A physiologically based pharmacokinetic (PBPK) model was developed for dasabuvir to evaluate the DDI potential with clopidogrel, the acyl-β-D glucuronide metabolite of which has been reported as a strong mechanism-based inhibitor of CYP2C8 based on an interaction with repaglinide."	( Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir. Badri, P; Bow, D; Fischer, V; Fu, W; Shebley, M, 2017)	0.46
" In the present study, a joint parent-metabolite population pharmacokinetic model was developed to adequately describe observed concentrations of clopidogrel and its active thiol metabolite (H4)."	( Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. Burchardt, P; Danielak, D; Graczyk-Szuster, A; Główka, F; Karaźniewicz-Łada, M; Komosa, A; Kruszyna, Ł; Lesiak, M, 2017)	0.46
"Searching for pharmacokinetic interaction studies between clopidogrel and omeprazole in humans was performed in PubMed."	( A pharmacokinetic model of drug-drug interaction between clopidogrel and omeprazole at CYP2C19 in humans. Lohitnavy, M; Lohitnavy, O; Morasuk, T; Tangamornsuksan, W; Thiansupornpong, P, 2017)	0.46
"Our clopidogrel-omeprazole pharmacokinetic interaction model with a description of competitive inhibition at CYP2C19 could successfully describe concentration-time courses from the selected datasets."	( A pharmacokinetic model of drug-drug interaction between clopidogrel and omeprazole at CYP2C19 in humans. Lohitnavy, M; Lohitnavy, O; Morasuk, T; Tangamornsuksan, W; Thiansupornpong, P, 2017)	0.46
"The long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in patients undergoing early percutaneous coronary intervention (PCI) after fibrinolytic therapy is unknown."	( Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Pon, Q; Yang, A; Zimmermann, RH, 2018)	0.48
" A sequential, open-label, and two-period pharmacokinetic drug interaction study was designed to compare clopidogrel pharmacokinetic parameters before and after 7 days of administration of Danshen capsules in twenty healthy male volunteers."	( Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Xu, M; Yu, HB; Zhang, LT; Zheng, XT; Zhong, ZF; Zhou, CH, 2018)	0.48
" Thus, this prospective study sought to evaluate the pharmacodynamic effect of clopidogrel monotherapy in patients on phenprocoumon undergoing PCI and assessed clinical outcomes."	( Pharmacodynamic safety of clopidogrel monotherapy in patients under oral anticoagulation with a vitamin K antagonist undergoing coronary stent implantation. Abdelrazek, S; Bömicke, T; Chafai, A; Eltaweel, S; Ferenc, M; Hochholzer, W; Neumann, FJ; Stratz, C; Trenk, D; Valina, C, 2019)	0.51
" Concentrations of clopidogrel and the clopidogrel active metabolite derivative (CAMD) were measured in each blood sample by use of liquid chromatography-tandem mass spectrometry, and pharmacokinetic parameters were determined with a noncompartmental model."	( Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. Knych, HK; Kozikowski, TA; Norris, JW; Tablin, F; Watson, JL, 2019)	0.51
"Although acid suppressants are needed to attenuate gastrointestinal bleeding (GIB) after percutaneous coronary intervention (PCI), pharmacodynamic interaction between clopidogrel and proton pump inhibitor (PPI) can increase the risk of high platelet reactivity (HPR)."	( Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: The randomized, prospective, PROTECT trial. Ahn, JH; Bae, JS; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, KH; Koh, JS; Kwak, CH; Park, JR; Park, Y, 2020)	0.56
"Possible interaction between clopidogrel and CYP3A4-metabolised atorvastatin or non-CYP3A4-metabolised rosuvastatin was investigated based on pharmacokinetic parameters of clopidogrel and its metabolites as well as the platelet reactivity test in patients undergoing coronary angiography/angioplasty."	( Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. Burchardt, P; Dolatowski, F; Gumienna, A; Główka, F; Karaźniewicz-Łada, M; Rzeźniczak, J; Słomczyński, M, 2019)	0.51
" To investigate the pharmacokinetic interaction between FDDP and CBT after oral administration of FDDP, CBT and their combination in rats, a novel LC-MS method with segmented scan modes (multiple reaction monitoring and selected ion monitoring) and polarity (positive and negative ionization) was developed."	( Segmented scan modes and polarity-based LC-MS for pharmacokinetic interaction study between Fufang Danshen Dripping Pill and Clopidogrel Bisulfate Tablet. Du, Y; Guo, MZ; Ji, L; Ji, S; Ma, YS; Shao, X; Su, ZY; Tang, DQ; Wang, YJ; Zhao, L, 2019)	0.51
" In this study, we established an UPLC-MS/MS spectrometry method for the determination of XQ-1H and investigated the pharmacokinetic effect of clopidogrel on XQ-1H in rats subjected to middle cerebral artery occlusion (MCAO)."	( Pharmacokinetics and pharmacodynamics analysis of XQ-1H and its combination therapy with clopidogrel on cerebral ischemic reperfusion injury in rats. Chen, X; Fang, W; Fei, Y; Hou, K; Khadankhuu, B; Li, F; Li, Y; Xu, D, 2020)	0.56
"There were significant differences in the pharmacokinetic parameters of the H4 active metabolite of CLP in the atorvastatin and rosuvastatin group divided according to their CYP2C19 genotype."	( Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin. Burchardt, P; Danielak, D; Główka, F; Karaźniewicz-Łada, M; Krzyżańska, D; Rzeźniczak, J; Słomczyński, M, 2020)	0.56
" The impact of LOF alleles on the pharmacodynamic response to half-dose prasugrel in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI) is unknown."	( Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial). Ann, SH; Cho, YR; Guo, LZ; Jin, C; Jin, E; Kim, MH; Kim, SJ; Lee, MS; Park, JS; Shin, ES, 2020)	0.56
" Clopidogrel has long been the gold standard but has major pharmacological limitations such as a slow onset and long duration of effect, as well as weak platelet inhibition with high inter-individual pharmacokinetic and pharmacodynamic variability."	( Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists. Dingemanse, J; Schilling, U; Ufer, M, 2020)	0.56
" Here we describe the results of 3 studies that evaluated the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects."	( Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020)	0.56
" The pharmacokinetic parameters were derived by a noncompartmental model."	( Pharmacokinetics and Bioequivalence of Clopidogrel Hydrogen Sulfate Tablets in Fed and Fasted Conditions: An Open-Label, Randomized, Semireplicated Crossover Study in Healthy Chinese Volunteers. Chen, X; Gong, S; Hu, C; Hu, X; Li, L; Pei, T; Yang, J; Zhang, L, 2020)	0.56
" The pharmacokinetic profiles of pemafibrate with virtual administrations of P450 inhibitors and/or disease interactions were generated using a physiologically based pharmacokinetic (PBPK) model previously established for co-administration of pemafibrate with OATP1B1 inhibitors."	( Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations. Ogawa, SI; Shimizu, M; Yamazaki, H, 2020)	0.56
"A rapid and sensitive chiral liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the enantioseparation and determination of clopidogrel bisulfate enantiomers in beagle plasma was established and successfully applied to a stereoselective pharmacokinetic study."	( Development and validation of a LC-MS/MS method for the enantioseparation and determination of clopidogrel bisulfate in beagle plasma and its application to a stereoselective pharmacokinetic study. He, J; Liu, W; Tian, Y; Zhang, Y; Zhang, Z, 2021)	0.62
" How CKD status affects the pharmacodynamic (PD) and pharmacokinetic (PK) profiles of different ticagrelor maintenance dose regimens in patients with DM is unknown."	( Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. Abou Jaoude, P; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X, 2022)	0.72
" Plasma concentrations of clopidogrel were measured at different time points in the absence and presence of the concurrent use of tested herbal products and the pharmacokinetic parameters were calculated."	( Clopidogrel-herb Interactions: A Pharmacokinetic and Pharmacodynamic Assessment in a Rat Model. Ahmad, A; Alkharfy, K; Alotaibi, A; Alotaibi, K; Alqahtani, S; Jan, B; Raish, M, 2021)	0.62
" Treatment with black seed also caused an increase in clopidogrel Cmax by 31."	( Clopidogrel-herb Interactions: A Pharmacokinetic and Pharmacodynamic Assessment in a Rat Model. Ahmad, A; Alkharfy, K; Alotaibi, A; Alotaibi, K; Alqahtani, S; Jan, B; Raish, M, 2021)	0.62
"This investigation was a substudy analysis conducted in selected cohorts of patients with stable atherosclerotic disease enrolled from a larger prospective, open-label, parallel-group pharmacodynamic (PD) study."	( Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. Angiolillo, DJ; Bass, TA; Been, L; Franchi, F; Galli, M; Geisler, T; Jaoude, PA; Jennings, LK; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X, 2022)	0.72
" Pharmacokinetic (PK) profiles and the influence of CYP2C19 polymorphisms were explored in subgroup analysis."	( Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention. Gong, Y; Han, Y; Jiang, H; Kang, Y; Lai, X; Li, J; Li, Y; Liu, B; Liu, Y; Ma, S; Qi, Z; Ren, L; Sun, H; Tang, C; Tang, Y; Zhao, X; Zheng, M, 2022)	0.72
" This study aimed to develop a semi-mechanistic population pharmacokinetic (PopPK) model to characterize the pharmacokinetic (PK) profile of M15-2, the active metabolite of vicagrel and clopidogrel, and to evaluate the influence of CYP2C19 polymorphisms and other covariates in healthy subjects and patients with acute coronary syndrome (ACS) after oral administration."	( Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2. Gong, Y; He, Y; Lai, X; Li, YG; Liu, X; Liu, Y; Sun, H; Yan, X; Zhang, EY; Zhang, L, 2022)	0.72
" The effects of SAI on the pharmacokinetic and pharmacodynamic behaviors of clopidogrel were investigated in rats."	( Interaction study of salvianolic acids for injection on pharmacokinetics of clopidogrel in rats using LC-MS/MS. Chu, Y; Ju, A; Li, D; Li, W; Li, X; Li, Y; Wu, Y; Xie, Y; Zheng, D, 2022)	0.72
"This was a prospective, randomised, double-blind, placebo-controlled pharmacodynamic study in patients with ASCVD on clopidogrel treatment and with LDL-C levels ≥70 mg/dL despite a maximally tolerated statin dose."	( Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study. Angiolillo, DJ; Been, L; Franchi, F; Maaliki, N; Ortega-Paz, L; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, M; Zhou, X, 2023)	0.91

Excerpt	Reference	Relevance
"to investigate the effect of clopidogrel combined with aspirin or aspirin alone on fibromyointimal hyperplasia (FIMH) in a bypass model with native vein grafts (NVG) and biocompound grafts (BCG)."	( Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting. Gutersohn, A; Hetzer, R; Mülling, C; Musci, M; Sänger, S; Schaffner, T; Wellnhofer, E; Zurbrügg, HR, 2001)	0.31
"Clopidogrel in combination with aspirin, given before percutaneous coronary intervention, has become the standard for stent thrombosis prevention."	( The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. Dick, SE; Hongo, RH; Ley, J; Yee, RR, 2002)	0.31
"Clopidogrel in combination with aspirin before CABG is associated with higher postoperative bleeding and morbidity."	( The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. Dick, SE; Hongo, RH; Ley, J; Yee, RR, 2002)	0.31
"To review systematically the clinical effectiveness and the cost-effectiveness of clopidogrel used in combination with standard therapy including aspirin, compared with standard therapy alone for the treatment of non-ST-segment elevation acute coronary syndromes (ACS)."	( Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Griffin, S; Hawkins, N; Henderson, R; Jones, L; Main, C; Orton, V; Palmer, S; Riemsma, R; Sculpher, M; Sudlow, C, 2004)	0.32
" The clinical effectiveness and cost-effectiveness of clopidogrel in combination with standard therapy compared with standard therapy alone were synthesised through a narrative review with full tabulation of the results of the included studies."	( Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Griffin, S; Hawkins, N; Henderson, R; Jones, L; Main, C; Orton, V; Palmer, S; Riemsma, R; Sculpher, M; Sudlow, C, 2004)	0.32
"The results of the CURE trial indicate that clopidogrel in combination with aspirin was significantly more effective than placebo combined with aspirin in a wide range of patients with ACS."	( Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Griffin, S; Hawkins, N; Henderson, R; Jones, L; Main, C; Orton, V; Palmer, S; Riemsma, R; Sculpher, M; Sudlow, C, 2004)	0.32
" To date, evidence supporting antiplatelet drug resistance are pharmacokinetic response variability, drug-drug interaction through competitive inhibition a specific enzymatic pathway, genetic variability, and variability in the induction of enzymatic pathway in metabolic activation of prodrugs, like clopidogrel."	( Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Gurbel, PA; Lau, WC, 2006)	0.33
" Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding."	( Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007)	0.34
"A patient admitted for coronary angioplasty received a loading dose of Clopidogrel 600 mg, in combination with an infusion of Tirofiban and one prophylactic dose of Enoxaparin."	( Cerebellar hematoma complicating 600 mg loading dose of clopidogrel in combination with tirofiban. Aoun, N; Azar, R; Kadri, Z; Moussa, R; Sarkis, A, 2008)	0.35
" However, drug-drug interactions may lead to a greatly increased risk of gastrointestinal bleeding when these drugs are combined."	( Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. Brophy, JM; Delaney, JA; Opatrny, L; Suissa, S, 2007)	0.34
"To investigate the effect of removing phlegm and dispelling stasis method (RPDSM) combined with Western medicine for treatment of cerebrovascular stenosis."	( [Removing phlegm and dispelling stasis method combined with Western medicine for treatment of cerebrovascular stenosis]. Gao, L; Liu, Q; Wang, PP, 2008)	0.35
" We evaluated apixaban, a direct and highly selective factor Xa inhibitor, in combination with clinically relevant doses of aspirin and/or clopidogrel for prevention of arterial thrombosis in rabbits."	( Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. Crain, EJ; Watson, CA; Wong, PC, 2008)	0.35
" The current review focuses distinctly on three aspects: (a) an in-depth coverage on the bioanalytical methods for the quantification of clopidogrel and its inactive carboxylic acid metabolite as well as the active metabolite in pre-clinical and clinical samples; (b) an overview of the pharmacokinetic/pharmacodynamic aspects of clopidogrel; and (c) enumerating the key findings from drug-drug interaction studies of clopidogrel with various co-substrates such as lanzoprazole, fluvastatin, atorvastatin, pravastatin, digoxin, ketoconazole, donezepil and theophylline."	( Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies. Mullangi, R; Srinivas, NR, 2009)	0.35
" In situations in which both clopidogrel and a PPI are indicated, pantoprazole should be used since it is the PPI least likely to interact with clopidogrel."	( Drug-drug interaction between clopidogrel and the proton pump inhibitors. Mathews, KD; Norgard, NB; Wall, GC, 2009)	0.35
" This article reviews the metabolism of various PPIs and existing data regarding the drug-drug interaction between PPIs and clopidogrel."	( Drug interaction between clopidogrel and proton pump inhibitors. Cheng-Lai, A; Khalique, SC, )	0.13
"We investigated whether clopidogrel combined with aspirin affects local thrombin formation and platelet activation triggered by vascular injury."	( Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Branicka, A; Stepień, E; Tracz, W; Undas, A; Wołkow, P; Zmudka, K, 2009)	0.35
"Our study shows that clopidogrel combined with aspirin does not reduce thrombin formation following vascular injury, but attenuates platelet sCD40L and P-selectin release."	( Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Branicka, A; Stepień, E; Tracz, W; Undas, A; Wołkow, P; Zmudka, K, 2009)	0.35
" In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)."	( [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009)	0.35
"To evaluate the long-term therapeutic effects of atorvastatin via cytochrome P450 (CYP)3A4 pathway or a non-CYP 3A4 pathway statin, pravastatin, combined with clopidogrel for the patients undergoing coronary stenting."	( [Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial]. Han, YL; Jing, QM; Li, Y; Wang, DM; Wang, SL; Wang, ZL; Zhang, ZL, 2009)	0.35
"The 12 month clinical outcomes were similar between patients receiving atorvastatin 20 mg/d or pravastatin 20 mg/d combined with clopidogrel after coronary stenting."	( [Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial]. Han, YL; Jing, QM; Li, Y; Wang, DM; Wang, SL; Wang, ZL; Zhang, ZL, 2009)	0.35
"The efficacy of Danggui, Honghua alone or combination with clopidogrel was determined in three experimental models."	( Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel. Li, Y; Wang, N, 2010)	0.36
" However, studies have found decreased efficacy of clopidogrel when concurrently administered with a PPI."	( Drug interaction between clopidogrel and proton pump inhibitors. Jackevicius, CA; Liu, TJ, 2010)	0.36
" Moreover, unwanted drug-drug pharmacokinetic interactions influencing CYP2C19 activity and clopidogrel bioactivation such as with proton pump inhibitors remain a matter of intense controversy."	( Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Ancrenaz, V; Besson, M; Daali, Y; Dayer, P; Desmeules, J; Fontana, P; Samer, C, 2010)	0.36
"This study evaluated the risk of upper gastrointestinal bleeding (UGIB) associated with use of low-dose acetylsalicylic acid (ASA) alone and in combination with other gastrotoxic medications."	( Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. García Rodríguez, LA; Hernández-Díaz, S; Johansson, S; Lin, KJ, 2011)	0.37
"Multidrug therapy increases the risk for drug-drug interactions."	( Clopidogrel-drug interactions. Angiolillo, DJ; Bates, ER; Lau, WC, 2011)	0.37
" This review will provide an overview of the mechanisms underlying thienopyridine-associated drug-drug interactions, and highlight the most recent developments in the field and propose guidance for the practitioner."	( Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance. Collet, JP; Hulot, JS; Montalescot, G, 2011)	0.37
" In this article, the authors review the current studies that reported a possible drug-drug interaction between clopidogrel and PPIs, particularly omeprazole."	( Clopidogrel and proton pump inhibitors: is there a significant drug-drug interaction? Azab, AN; Friger, M; Gilutz, H; Shmulevich, E, 2011)	0.37
"An analysis of a case-control study of rhabdomyolysis was conducted to screen for previously unrecognized cytochrome P450 enzyme (CYP) 2C8 inhibitors that may cause other clinically important drug-drug interactions."	( A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Floyd, JS; Heckbert, SR; Kaspera, R; Kwok, PY; Lumley, T; Marciante, KD; Psaty, BM; Tamraz, B; Totah, RA; Weiss, NS; Wiggins, KL, 2012)	0.38
"Our results indicate that PAR antagonists used in combination with aspirin provide a potent yet safe antithrombotic strategy in mice and provide insights into the safety and efficacy of using PAR antagonists for the prevention of acute coronary syndromes in humans."	( Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Hamilton, JR; Jackson, SP; Lee, H; Mountford, JK; Sturgeon, SA, 2012)	0.38
"To compare the effects of clopidogrel combined with dihydropyridine calcium-channel blockers (CCBs) or non-dihydropyridine CCBs on coronary artery disease (CAD) in elderly patients."	( [Effect of clopidogrel combined with calcium-channel blocker on coronary artery disease in elderly patients: a propensity score-based retrospective cohort study]. Cao, J; Fan, L; Gao, Y; Liu, X; Lu, X; Ma, C, 2012)	0.38
"A total of 1021 patients were enrolled, among whom 402 patients were prescribed with clopidogrel and 619 with clopidogrel combined with CCB (dihydropyridine in 547 and non-dihydropyridine in 72)."	( [Effect of clopidogrel combined with calcium-channel blocker on coronary artery disease in elderly patients: a propensity score-based retrospective cohort study]. Cao, J; Fan, L; Gao, Y; Liu, X; Lu, X; Ma, C, 2012)	0.38
"Compared with clopidogrel without CCB, clopidogrel with CCB does not increase the mortality or composite thromboembolic events in elderly CAD patients, but clopidogrel combined with non-dihydropyridine CCB is associated with significantly increased composite thromboembolic events in comparison with dihydropyridine CCB."	( [Effect of clopidogrel combined with calcium-channel blocker on coronary artery disease in elderly patients: a propensity score-based retrospective cohort study]. Cao, J; Fan, L; Gao, Y; Liu, X; Lu, X; Ma, C, 2012)	0.38
" Clopidogrel, an antiplatelet drug, is widely prescribed either alone or in combination with aspirin as dual antiplatelet therapy for the prevention of vascular occlusive events."	( Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Basri, HB; Hasan, MS; Hin, LP; Stanslas, J, 2013)	0.39
"SilverHawk Plaque Excision combined with aggressive pharmacotherapy in this presented high-risk population is associated with promising long-term outcomes that compare favorably with accepted standards of care."	( Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013)	0.39
" This study assessed whether high-dose aspirin: a) provides additional anti-platelet efficacy, assessed in vivo and ex vivo, when combined with P2Y12 inhibition; and/or b) has a negative effect on vascular function."	( High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H, 2013)	0.39
"We sought to compare the effects of clopidogrel combined with warfarin with clopidogrel alone in the prevention of restenosis after endovascular treatment (EVT) of the femoropopliteal artery."	( A prospective randomized controlled clinical trial on clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after endovascular treatment of the femoropopliteal artery. Feng, Y; Guo, M; Li, H; Liang, G; Luo, X; Zhang, C; Zhang, F, 2013)	0.39
"Between June 2008 and May 2009, 88 consecutive patients referred for EVT were randomly divided into a clopidogrel group (42 cases) and a clopidogrel combined with warfarin group (46 cases) before the procedure."	( A prospective randomized controlled clinical trial on clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after endovascular treatment of the femoropopliteal artery. Feng, Y; Guo, M; Li, H; Liang, G; Luo, X; Zhang, C; Zhang, F, 2013)	0.39
" The objective of this study was to evaluate the prevalence and clinical consequences of potential drug-drug interactions of clopidogrel with drugs affecting CYP3A4 activity."	( Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences. Heikkilä, P; Huupponen, R; Laine, K; Tirkkonen, T; Vahlberg, T, 2013)	0.39
" A loading dose of clopidogrel combined with other antithrombotic therapy might be an effective treatment for CWS."	( Loading dose of clopidogrel in combination with other antithrombotic therapy for capsular warning syndrome. Ando, Y; Inatomi, Y; Kawano, H; Nakajima, M; Yonehara, T, )	0.13
"Clopidogrel and ticlopidine, sometimes in combination with ASA, are associated with a low risk of bleeding during renal transplantation and does not seem to be a contraindication for renal transplant surgery."	( Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study. Abramowicz, D; Benahmed, A; Broeders, N; Donckier, V; Ghisdal, L; Hoang, AD; Kianda, M; Le Moine, A; Lemy, A; Madhoun, P; Massart, A; Mikhalski, D; Racapé, J; Sadis, C; Wissing, M, 2014)	0.4
"Based on real world research the circumstances of the clinical use of usual drugs combined with salvianolate injection are surveyed."	( [Analysis of salvianolate injection combined with usual drugs in treatment of coronary heart disease in real world]. Chang, YP; Hu, J; Xie, YM; Zeng, XB; Zhang, H; Zhuang, Y, 2013)	0.39
"In 1 605 patients with coronary heart disease (CHD), salvianolate injection was most frequently (51%) combined with clopidogrel and isosorbide dinitrate."	( [Analysis of salvianolate injection combined with usual drugs in treatment of coronary heart disease in real world]. Chang, YP; Hu, J; Xie, YM; Zeng, XB; Zhang, H; Zhuang, Y, 2013)	0.39
"In the real world, salvianolate injection combined with usual treatment was found to be more effective than other treatment combinations."	( [Analysis of salvianolate injection combined with usual drugs in treatment of coronary heart disease in real world]. Chang, YP; Hu, J; Xie, YM; Zeng, XB; Zhang, H; Zhuang, Y, 2013)	0.39
"Patients in nursing homes are often treated with many drugs concurrently (polypharmacy), which increases the risk of drug-drug interactions."	( [Drug-drug interactions in nursing home patients]. Slørdal, L; Spigset, O; Staurset, HB; Søraas, IA, 2014)	0.4
"The incidence of serious drug-drug interactions among nursing home patients in Trondheim Municipality is low."	( [Drug-drug interactions in nursing home patients]. Slørdal, L; Spigset, O; Staurset, HB; Søraas, IA, 2014)	0.4
"The treatment with Valsartan combined with Clopidogrel and Leflunomide can reduce the urinary proteins loss and renal function deterioration for IgA nephropathy patients and cause minimal adverse reactions."	( Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy. Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z, 2015)	0.42
" Mechanisms through which polypharmacy may increase adverse health outcomes include decreased adherence, increased drug side effects, higher use of potentially inappropriate medications, and more frequent drug-drug interactions."	( Appropriate prescribing and important drug interactions in older adults. Paauw, DS; Wallace, J, 2015)	0.42
" Accordingly, potential drug-drug interactions associated with the concomitant use of these agents present an area of concern."	( Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin. Markowitz, JS; Wang, X; Zhu, HJ, 2015)	0.42
" Importantly, these drug-drug interactions have prognostic implications, since patients with high on-treatment platelet reactivity associated with reduced clopidogrel metabolism have an increased risk of ischemia."	( Drug-drug interactions between clopidogrel and novel cardiovascular drugs. Angiolillo, DJ; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Rollini, F, 2015)	0.42
" The purpose of this study was to compare the efficacy and safety of clopidogrel combined with aspirin (CA) versus sarpogrelate combined with aspirin (SA) treatment in carotid endarterectomy (CEA) patients."	( Effects of Sarpogrelate Combined with Aspirin in Patients Undergoing Carotid Endarterectomy in China: A Single-Center Retrospective Study. Gu, Y; Guo, J; Guo, L; Qi, L; Tong, Z; Wang, Z; Yu, H; Zhang, J, 2016)	0.43
" The objective of this study was to determine the efficacy and safety of endoscopy combined with the administration of antiplatelet and/or anticoagulant agents to stimulate bleeding in order to define a source."	( Pharmacologic provocation combined with endoscopy in refractory cases of GI bleeding. Adler, DG; Jex, KT; Nicaud, MJ; Raines, DL, 2017)	0.46
"Provocative testing combined with endoscopy can be justified as an option in the diagnostic algorithm of complex cases of GI bleeding when intermittent bleeding related to a vascular lesion, such as an angioectasia or Dieulafoy, is suspected."	( Pharmacologic provocation combined with endoscopy in refractory cases of GI bleeding. Adler, DG; Jex, KT; Nicaud, MJ; Raines, DL, 2017)	0.46
" The objective of the present study was to identify the mechanism of clopidogrel-mediated drug-drug interactions (DDIs) on the pharmacokinetics of OATP1B1 and/or CYP2C8 substrates in vivo."	( Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. Ieiri, I; Irie, S; Kim, SJ; Kimura, M; Kusuhara, H; Maeda, K; Sugiyama, Y; Yoshikado, T, 2016)	0.43
"Uncertainty regarding clopidogrel effectiveness attenuation because of a drug-drug interaction with proton pump inhibitors (PPI) has led to conflicting guidelines on concomitant therapy."	( Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. Guzauskas, GF; Serbin, MA; Veenstra, DL, 2016)	0.43
"The risk and benefit of GP-IIb/IIIa Inhibition (GPI) in combination with recent antiplatelet regimens in acute coronary syndromes (ACS) remain unassessed."	( Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials. Agueznai, M; Ardouin, P; Beygui, F; Blanchart, K; Collet, JP; Lemaître, A; Milliez, P; Montalescot, G; Roule, V; Sabatier, R, 2017)	0.46
" CYP2C19 genotyping combined with platelet reactivity is an independent and additive predictor of 1-year MACE in Chinese patients undergoing stenting with clopidogrel treatment, which is better than either test alone."	( CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention. Chen, J; Chen, JL; Gao, RL; Gao, Z; Han, YL; He, C; Qiao, SB; Tang, XF; Wang, J; Wu, Y; Xu, B; Yang, YJ; Yao, Y; Yuan, JQ; Zhang, JH, 2016)	0.43
"Dasabuvir, a nonnucleoside NS5B polymerase inhibitor, is a sensitive substrate of cytochrome P450 (CYP) 2C8 with a potential for drug-drug interaction (DDI) with clopidogrel."	( Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir. Badri, P; Bow, D; Fischer, V; Fu, W; Shebley, M, 2017)	0.46
" This commentary outlines the US Food and Drug Administration (FDA) interdisciplinary review team's scientific perspective to address the potential for a significant drug-drug interaction (DDI) between clopidogrel and VIEKIRA PAK."	( Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug-Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective. Arya, V; Mishra, P; Reynolds, KS; Younis, IR; Zhao, P, 2017)	0.46
"The study aimed to investigate the impact of clopidogrel combined with proton pump inhibitors (PPI) pantoprazole treatment on the prognosis of patients with transient ischemic attack (TIA)."	( Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack. Lu, M, 2017)	0.46
" This study aimed to investigate the influences of dual-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor on the platelet activity and MACE events of patients with CYP2C19*2 gene function deficiency and poor clopidogrel response after PCI."	( Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI). Chen, S; Geng, Y; Gu, J; Hao, Q; Qi, P; Wang, H; Wang, L; Zhang, Y, 2017)	0.46
"We aimed to develop a mathematical model describing a drug-drug interaction between clopidogrel and omeprazole in humans."	( A pharmacokinetic model of drug-drug interaction between clopidogrel and omeprazole at CYP2C19 in humans. Lohitnavy, M; Lohitnavy, O; Morasuk, T; Tangamornsuksan, W; Thiansupornpong, P, 2017)	0.46
"To investigate temporal trends in the use of non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in combination with aspirin and/or clopidogrel in patients with atrial fibrillation (AF) following acute myocardial infarction (MI) and/or percutaneous coronary intervention (PCI)."	( Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. Berger, JS; Bjerring Olesen, J; Gerds, TA; Gislason, GH; Hansen, ML; Lamberts, M; Langtved Pallisgaard, J; Nissen Bonde, A; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018)	0.48
"From 2011 to 2016, the use of NOAC in combination with antiplatelet(s) increased in patients with AF following MI/PCI and exceeded the use of VKA in combination with antiplatelet(s) by 2016."	( Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. Berger, JS; Bjerring Olesen, J; Gerds, TA; Gislason, GH; Hansen, ML; Lamberts, M; Langtved Pallisgaard, J; Nissen Bonde, A; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018)	0.48
" Three months later, he was noted to have elevated creatine kinase (CK), thought to be related to a potential drug-drug interaction between ticagrelor and atorvastatin."	( Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin. Beavers, JC, 2019)	0.51
"A probable drug-drug interaction occurred with concomitant ticagrelor and atorvastatin."	( Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin. Beavers, JC, 2019)	0.51
"56%) was the most common triple Western medicine therapy, often combined with antibiotics and blood stasis drugs in use."	( [Drug combination characteristics of Shenxiong glucose injection in treating ischemic cerebrovascular disease in real world]. Jia, PP; Liu, H; Wang, GQ; Xie, YM; Zhang, Y; Zhuang, Y, 2017)	0.46
"Previous studies have found that Panax quinquefolius saponins (PQS) combined with dual antiplatelet therapy (DAPT) of aspirin and clopidogrel enhances antithrombotic effects while reducing gastric mucosal injury induced by DAPT."	( Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction. Kou, N; Miao, Y; Qu, H; Shi, DZ; Wang, MM; Xue, M; Yang, B; Yang, L; Zang, MX, 2018)	0.48
"The case-crossover design may be useful for evaluating the clinical impact of drug-drug interactions in electronic healthcare data; however, experience with the design in this context is limited."	( The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation. Bykov, K; Gagne, JJ; Glynn, RJ; Mittleman, MA; Schneeweiss, S, 2019)	0.51
"The three-parameter model assumes a common drug-drug interaction effect, whereas the saturated model is useful for identifying potential effect heterogeneity or differential confounding across strata."	( The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation. Bykov, K; Gagne, JJ; Glynn, RJ; Mittleman, MA; Schneeweiss, S, 2019)	0.51
"Few population-based studies have examined bleeding associated with clopidogrel drug-drug interactions (DDIs)."	( Clopidogrel Drug Interactions and Serious Bleeding: Generating Real-World Evidence via Automated High-Throughput Pharmacoepidemiologic Screening. Bilker, WB; Brensinger, CM; Cohen, JB; Hennessy, S; Leonard, CE; Nam, YH; Pham Nguyen, TP; Soprano, SE; Zhou, M, 2019)	0.51
"To study the clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease (KD) complicated by coronary artery aneurysm (CAA)."	( [Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms]. Chen, TT; Guo, YH; Li, Y; Liu, YL; Lu, YH; Shi, K; Wang, XM, 2019)	0.51
"Clopidogrel combined with low-dose aspirin is safe and effective in antithrombotic therapy for children with KD complicated by CAA."	( [Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms]. Chen, TT; Guo, YH; Li, Y; Liu, YL; Lu, YH; Shi, K; Wang, XM, 2019)	0.51
"Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the only option for complete revascularization in some patients with diffuse coronary artery disease."	( Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H, 2020)	0.56
" Polypharmacy increases the probability of drug-drug interactions (DDIs)."	( Clopidogrel drug interactions: a review of the evidence and clinical implications. Angiolillo, DJ; Franchi, F; Lee, CH, 2020)	0.56
" Here, we confirmed the protective effect and mechanism of XST combined with DAPT (XST+ASA+CLP) on cerebral ischemia/reperfusion injury, exploring their better pharmacological action for clinical patients."	( Xuesaitong injection (lyophilized) combined with aspirin and clopidogrel protect against focal cerebral ischemic/reperfusion injury in rats by suppressing oxidative stress and inflammation and regulating the NOX2/IL-6/STAT3 pathway. Dong, DX; Meng, XB; Qu, MW; Sun, GB; Sun, XB; Zhao, LY; Zhu, T, 2021)	0.62
"Tirofiban can be used to treat patients with acute ischemic stroke (AIS), this study was to evaluate the efficacy and safety of tirofiban combined with heparin in the treatment of mild to moderate AIS."	( Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke. Chen, M; Dai, X; Deng, X; Fu, S; Gong, Q; He, W; Huang, L; Li, C; Luo, Q; Qiu, T; Wang, J; Wang, M; Xiao, H, 2021)	0.62
"Our objective was to systematically evaluate the efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention and to provide an evidence basis for clinical treatment decision-making."	( Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis. Duan, R; Han, YY; Li, ZX, 2021)	0.62
" Our findings showed that antiplatelet therapies (aspirin/clopidogrel cocktail and atopaxar) combined with anastrozole failed to prevent hypercoagulation and induced evidence of a partial EMT."	( Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation. Augustine, TN; Xulu, KR, 2021)	0.62
"This study assessed the efficacy and safety of tirofiban in combination with dual-antiplatelet therapy (DAPT) in progressive ischemic stroke."	( Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients. Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y, 2021)	0.62
"To investigate the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris (UA)."	( Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up. Deng, L; Jia, HZ; Li, MC; Zhu, W, 2021)	0.62
" Many drug-drug interactions (DDIs) are caused by perpetrator drugs inhibiting or inducing cytochrome P450 (CYP) enzymes, resulting in alterations of the plasma concentrations of a victim drug."	( Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel. Backman, JT; Filppula, AM; Tornio, A, 2022)	0.72
"Ischemic stroke combined with hypertension can increase risks of stroke recurrence and death."	( The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis. Fang, W; Guo, X; Jiang, H; Jin, X; Liu, Y; Sun, P; Yu, J, 2021)	0.62
"Clopidogrel bisulfate tablets combined with olmesartan medoxomil has prominent clinical effects in the treatment of ischemic stroke patients with hypertension, evidently improving the prognosis."	( The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis. Fang, W; Guo, X; Jiang, H; Jin, X; Liu, Y; Sun, P; Yu, J, 2021)	0.62
"This study aimed to explore the clinical study of clopidogrel combined with Huoxue Tongluo prescription in improving transient ischemic attack (TIA) and the effect on MMP-9, Hcy, and CRP."	( Clinical Study of Clopidogrel Combined with Huoxue Tongluo Prescription in Improving Transient Ischemic Attack and the Effect on MMP-9, Hcy, and CRP. Chen, Z; Li, Y; Ma, L; Ma, Y; Meng, X, 2022)	0.72
"Clopidogrel combined with Huoxue Tongluo prescription can significantly improve the therapeutic effect and reduce the levels of MMP-9, Hcy, and CRP in patients with TIA."	( Clinical Study of Clopidogrel Combined with Huoxue Tongluo Prescription in Improving Transient Ischemic Attack and the Effect on MMP-9, Hcy, and CRP. Chen, Z; Li, Y; Ma, L; Ma, Y; Meng, X, 2022)	0.72
"This study aimed to estimate how prevalent potential drug-drug interactions (pDDIs) were in patients with cardiovascular diseases who were hospitalized for more than 24 hours, and to determine the risk factors associated with these pDDIs."	( Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital. Almaghaslah, D; Khaled, A; Makki, S; Nagib, R; Siddiqua, A, 2023)	0.91
"To assess the antiplatelet effect of cilostazol clinically, we compared the effects of cilostazol in combination with clopidogrel on various platelet function tests."	( Differential inhibition of platelet function by cilostazol in combination with clopidogrel. Dahlen, JR; Hosokawa, K; Kitagawa, K; Ohnishi, T; Shirai, Y; Yamazaki, M, 2023)	0.91

Excerpt	Reference	Relevance
"Two open, randomized, crossover bioavailability studies were carried out to assess the influence of concurrent antacid medication and food on the bioavailability of clopidogrel."	( Clopidogrel bioavailability: absence of influence of food or antacids. Dickinson, JP; McEwen, J; Moreland, TE; Necciari, J; Perles, P; Pritchard, G; Strauch, G, 1999)	0.3
" The rate of absorption of extended-release dipyridamole is considerably slower than that of immediate-release dipyridamole, while similar plasma concentrations are maintained to optimise antiplatelet efficacy."	( Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. Lenz, T; Wilson, A, 2003)	0.32
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."	( Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Boosi, R; Kandikere, VN; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M, 2006)	0.33
"Clopidogrel improves endothelial nitric oxide bioavailability and diminishes biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease, suggesting that beyond inhibition of platelet aggregation, adenosine phosphate receptor blockade may also have promising vasoprotective effects."	( Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Baldus, S; Böger, R; Heitzer, T; Karstens, M; Meinertz, T; Ortak, M; Rudolph, V; Schwedhelm, E; Sydow, K; Tschentscher, P, 2006)	0.33
" We tested the hypothesis that the intestinal efflux transporter P-glycoprotein (P-gp) limits the oral bioavailability of clopidogrel and that variance in the MDR1 gene encoding P-gp predicts absorption variability."	( Impact of P-glycoprotein on clopidogrel absorption. Goeser, T; Grimberg, G; Jung, N; Kastrati, A; Lazar, A; Schömig, A; Schömig, E; Taubert, D; von Beckerath, N, 2006)	0.33
"The present study aimed at investigating the effects of concomitant food intake on the bioavailability of a single oral dose of clopidogrel (CAS 113665-84-2)."	( Effect of food on bioavailability of a single oral dose of clopidogrel in healthy male subjects. Kandikere, VN; Mudigonda, K; Nirogi, RV, 2006)	0.33
" In contrast to aspirin, the response to clopidogrel is highly variable and reflects the bioavailability of the active metabolite and not "resistance" of the receptor to inhibition."	( Aspirin and clopidogrel resistance. Fitzgerald, DJ; Maree, A, 2007)	0.34
" It is applied to study the bioavailability of 75 mg clopidogrel mesylate tablets in 16 human subjects with satisfactory results."	( Rapid LC-ESI-MS-MS method for the simultaneous determination of clopidogrel and its carboxylic acid metabolite in human plasma. Kundlik, M; Patel, NK; Shah, H; Shrivastav, PS; Subbaiah, G, )	0.13
" The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs."	( Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. Farid, NA; Fusegawa, K; Hagihara, K; Ikeda, T; Ikenaga, H; Kazui, M; Kurihara, A; Nanba, T; Okazaki, O; Takahashi, M, 2009)	0.35
"A 300 mg loading dose of crushed clopidogrel administered via NG tube provides faster and greater bioavailability than an equal dose taken orally as whole tablets."	( Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. Chesebro, JH; Farkouh, ME; Fuster, V; Zafar, MU, 2009)	0.35
"The aim of the presented comparative study was to evaluate the bioavailability of clopidogrel (CAS 113665-84-2) formulations containing clopidogrel bisulfate (CAS 135046-48-9, CBS) 75 mg based on the parent compound (CBS) and its metabolite SR 26334 - clopidogrel carboxylic acid (CAS 144457-28-3, CCA) determination."	( Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. Bogiel, M; Duda, J; Marzec, A; Pawłowska, M; Sieradzki, E; Tejchman-Małecka, B, 2009)	0.35
"Genetic C3435T polymorphism of the multidrug resistance gene-1 (MDR-1) limits oral bioavailability of clopidogrel and influences prognosis in patients with myocardial infarction."	( Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Filipiak, KJ; Kisiel, B; Kostrzewa, G; Małek, ŁA; Opolski, G; Płoski, R; Serafin, A; Spiewak, M, 2009)	0.35
" The validated method was applied in bioavailability and bioequivalence study."	( Development and validation of high-throughput liquid chromatography-tandem mass spectrometric method for simultaneous quantification of clopidogrel and its metabolite in human plasma. Chandiran, IS; Jayaveera, KN; Naidu, YK; Rao Divi, K; Reddy S, R; Reddy, MP, 2010)	0.36
" If a substrate drug with oral bioavailability is equal to or less than 80%, an intravenous drug interaction study at low dose along with a few key oral drug interaction studies could be useful for achieving this objective with the aid of modeling and simulations."	( Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. Bai, JP, 2010)	0.36
" Prasugrel is more potent than clopidogrel with a better bioavailability and lower pharmacodynamic variability."	( Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Ancrenaz, V; Besson, M; Daali, Y; Dayer, P; Desmeules, J; Fontana, P; Samer, C, 2010)	0.36
"Clopidogrel bisulphate has quite low bioavailability (40-50%)."	( Development of sustained release formulation of an antithrombotic drug and application of Fuzzy logic. Degim, İT; Tan, C, )	0.13
" In conclusion, clopidogrel improved endothelial function and NO bioavailability in heart failure."	( Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure. Bauersachs, J; Fraccarollo, D; Loch, E; Neuser, J; Pförtsch, S; Schäfer, A; Vogt, C, 2011)	0.37
" To improve the solubility of clopidogrel napadisilate, a novel clopidogrel napadisilate-loaded solid dispersion was prepared by the spray-drying technique using HPMC and colloidal silica, and the physicochemical properties, dissolution and bioavailability in beagle dogs were evaluated compared to the clopidogrel bisulphate-loaded commercial product."	( New clopidogrel napadisilate salt and its solid dispersion with improved stability and bioequivalence to the commercial clopidogrel bisulphate salt in beagle dogs. Choi, HG; Kim, KS; Kim, YI; Shanmugam, S; Suh, KH; Woo, JS; Yong, CS, 2011)	0.37
"FA was rapidly absorbed with a low bioavailability after a single oral administration."	( Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. Li, Y; Liu, C; Mi, S; Wang, N; Zhang, Y, 2011)	0.37
" Genetic polymorphisms are thought to affect conversion of the prodrug to the active metabolite, and the FDA has recently added a black-box warning to clopidogrel to highlight the effects of these polymorphisms on drug bioavailability and to inform prescribers about the availability of genetic testing."	( Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. Johari, V; Rodgers, GM; Saunders, PJ; Smock, KJ, 2011)	0.37
"The bioavailability of clopidogrel bisulfate (CAS 135046-48-9) form I was compared with that of clopidogrel bisulfate form II in 12 male Sprague-Dawley rats."	( Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. Che, WJ; Ou-Yang, PK; Tan, XH; Wei, P; Zhang, ZJ; Zou, QG, 2011)	0.37
" Some patients do not respond to the drug; this condition can be due to patient-related factors (poor compliance, genetic factors, cardiovascular risk profile) or to drug-related factors (reduced bioavailability or absorption, drug-drug interactions)."	( Responsiveness to P2Y12 receptor inhibitors. Esposito, G, 2011)	0.37
"The ABCB1 C3435T polymorphism limits oral bioavailability of clopidogrel and may influence prognosis of patients treated with clopidogrel."	( ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. Li, J; Luo, M; Sheng, W; Sun, X; Xu, X, 2012)	0.38
"The present study was performed to compare the bioavailability of two clopidogrel 75 mg film-coated tablet formulations (test formulation and reference formulation)."	( Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers. Handayani, LR; Santoso, ID; Setiawati, A; Setiawati, E; Tjandrawinata, RR; Yunaidi, DA, 2011)	0.37
" Preliminary pharmacokinetic study results showed that the bioavailability of clopidogrel thiolactone generated from 9a was 6-fold higher than that generated from clopidogrel, implying a much lower clinically effective dose for 9a in comparison with clopidogrel."	( Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent. Gong, Y; Jiao, B; Lv, F; Qi, X; Shan, J; Sun, H; Yuan, F; Zhang, B; Zheng, W; Zhu, Y, 2012)	0.38
" Similarly, clopidogrel bioavailability remained unchanged by chronic administration of dabigatran etexilate (part 3: ratio test/reference for AUC(0-24) was 103%; 90% CI 80."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.39
"The bioavailability of clopidogrel in critically ill patients after cardiopulmonary resuscitation is significantly impaired compared with stable patients."	( Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Čundrle, I; Hlinomaz, O; Opatřilová, R; Pavlík, M; Součková, L; Šrámek, V; Suk, P; Zvoníček, V, 2013)	0.39
" When possible, the use of alternative drugs with more uniform and predictable bioavailability and with favorable profiles in terms of risk/benefit and cost/benefit ratios should be preferred."	( Diagnosis and management of high platelet reactivity on treatment with clopidogrel. Cattaneo, M, 2012)	0.38
" Following the oral administration of clopidogrel with or without the P-gp inhibitors, quercetin (250 mg/kg), telmisartan (8 mg/kg), and cyclosporine A (10 mg/kg), in rats and dogs, the plasma concentration-time profiles of clopidogrel carboxylic acid, a surrogate marker for the bioavailability of clopidogrel, were determined."	( Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine A in rats and dogs. Lee, JH; Lee, YJ; Oh, JH; Shin, YJ, 2012)	0.38
" Clopidogrel resistance is likely to develop as a result of a decreased bioavailability of the active metabolite, due to genetic variation or concomitant drug treatment."	( Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part II: Potential causes and laboratory tests. Sas, K; Sztriha, LK; Vadász, D; Vécsei, L, 2013)	0.39
" In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats."	( Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist. Abell, LM; Bostwick, JS; Bouthillier, G; Chang, M; Gao, Q; Hiebert, S; Hua, J; Huang, CS; L'Heureux, A; Lam, PY; Liu, E; Lloyd, J; Ma, B; McDonnell, PA; Pi, Z; Price, LA; Qiao, JX; Rehfuss, R; Ruel, R; Schnur, DM; Schumacher, WA; Spronk, SA; Steinbacher, TE; Thibeault, C; Wang, TC; Wexler, RR; Wu, Q; Zheng, J, 2013)	0.39
" However, unlike other medications, subtle differences in clopidogrel bioavailability may lead to acute consequences including stent thrombosis (ST)."	( Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel. Baber, U; Badimon, JJ; Hulot, JS; Kini, A; Kovacic, JC; Krishnan, P; Li, JR; Mehran, R; Moreno, P; Sharma, SK; Sweeny, J, 2014)	0.4
" The C3435T polymorphism in this gene affects the bioavailability of clopidogrel, however, its effects on clinical outcomes are inconclusive."	( Genetic and nongenetic factors influencing the response to clopidogrel. Bontardelli, F; Merlini, PA; Notarangelo, MF, 2013)	0.39
" SAR studies were conducted to improve PK and potency, resulting in the identification of compound 3e, a potent, orally bioavailable P2Y1 antagonist with a suitable PK profile in preclinical species."	( Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet Bostwick, JS; Chacko, SA; Chen, BC; Chen, XQ; Clark, CG; Hiebert, S; Hua, J; Huang, CS; Jeon, YT; Lam, PY; Levesque, PC; Li, D; Li, L; Liu, Y; Malley, M; Mathur, A; Price, LA; Qiao, JX; Rehfuss, R; Ruel, R; Schumacher, WA; Seiffert, DA; Shen, H; Stewart, AB; Sun, D; Thibeault, C; Wang, TC; Wang, Y; Wexler, RR; Wong, HS; Wu, DR; Yang, W; Zhu, J, 2014)	0.4
" These findings indicate low-dose aspirin coadministration may decrease clopidogrel bioavailability but does not decrease its efficacy."	( Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity. Cho, JY; Chu, K; Hong, KS; Jang, IJ; Ji, SC; Jung, KH; Lee, H; Lee, S; Lim, KS; Oh, J; Shin, D; Shin, KH; Yoon, SH; Yu, KS, 2014)	0.4
"Two randomized, single dose, 2-period, 2-sequence crossover studies were conducted to evaluate the comparative bioavailability of two clopidogrel formulations under fasting and fed conditions."	( Comparative bioavailability of two oral formulations of clopidogrel: determination of clopidogrel and its carboxylic acid metabolite (SR26334) under fasting and fed conditions in healthy subjects. Breznik, M; Brvar, N; Cvitkovič Marčič, L; Grabnar, I; Lachance, S; Lévesque, A; Mateovič-Rojnik, T; Merslavič, M, 2014)	0.4
"The intention of this study was to compare the physicochemical properties, stability and bioavailability of a clopidogrel napadisilate (CN)-loaded solid dispersion (SD) and solid self-microemulsifying drug delivery system (solid SMEDDS)."	( Comparison of a solid SMEDDS and solid dispersion for enhanced stability and bioavailability of clopidogrel napadisilate. Balakrishnan, P; Choi, HG; Kim, DS; Kim, DW; Kim, JO; Kwon, MS; Lee, BJ; Park, JH; Park, YJ; Yong, CS; Yousaf, AM, 2014)	0.4
" Its dissolution profiles and oral bioavailability in rats were also compared with that of CNM and clopidogrel bisulfate (CB)."	( Clopidogrel Napadisilate Monohydrate Loaded Surface-Modified Solid Dispersion: Physicochemical Characterization and in Vivo Evaluation. Cho, KH; Choi, HG; Kim, DW; Kim, JO; Kim, YH; Kwon, MS; Yong, CS, 2015)	0.42
" Since the bioavailability of 30d was low in rat and dog, we developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug (ACT-281959, 45)."	( 4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in Caroff, E; Gnerre, C; Hess, P; Hilpert, K; Hubler, F; Meyer, E; Renneberg, D; Rey, M; Riederer, MA; Steiner, B; Treiber, A, 2015)	0.42
"ESSENTIALS: The reliability of platelet tests as markers of the variable bioavailability of clopidogrel is not yet defined."	( Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. Beltrame, F; Benati, M; Calabria, S; Cattaneo, M; Danese, E; Fava, C; Gelati, M; Gottardo, R; Guidi, GC; Minuz, P; Tagliaro, F; Tavella, D, 2016)	0.43
" VASP-P could be useful in studies aimed at investigating relations between CAM bioavailability and clinical events."	( Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. Beltrame, F; Benati, M; Calabria, S; Cattaneo, M; Danese, E; Fava, C; Gelati, M; Gottardo, R; Guidi, GC; Minuz, P; Tagliaro, F; Tavella, D, 2016)	0.43
" It has poor oral bioavailability due to poor dissolution and possible premature degradation in the intestine."	( Enhancement of Dissolution Rate and Intestinal Stability of Clopidogrel Hydrogen Sulfate. Bali, DE; El Maghraby, GM; Osman, MA, 2016)	0.43
" The relative bioavailability of the formulation was 101."	( Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. Di, XH; Jiang, N; Song, LX; Xu, J; Xu, L; Xu, XT; Yang, YG; Zhang, M; Zhao, GT, 2015)	0.42
"Prasugrel exhibits beneficial mid-term effects on endothelial nitric oxide bioavailability and inflammatory markers."	( Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A randomized controlled trial. Baldus, S; Friedrichs, K; Fuchs, A; Hellmich, M; Klinke, A; Mollenhauer, M; Rudolph, TK; Rudolph, V; Schlichting, A; Schwedhelm, E, 2017)	0.46
"In the present investigation, oral dissolving/dispersible/disintegrating tablets (ODTs) of clopidogrel were designed with a view to enhance the bioavailability and patient compliance by two different methods, namely, direct compression and effervescent methods using directly compressible excipient and treated agar (TAG)."	( Effect of directly compressible excipient and treated agar on drug release of clopidogrel oral disintegrating tablets. Kumar Reddy, BK; Nirosha, M; Sai Kiran, BS; Venkateswarlu, K, 2017)	0.46
" Although generally well tolerated, its efficacy varies among individuals, with the main hypothesis that its bioavailability relies on its bioconversion to the active compound, which, in turn, depends on the genetic background and/or interactions with other drugs."	( CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel. Garay-Sánchez, P; Martínez-Quintana, E; Medina-Gil, JM; Riaño, M; Rodríguez-González, F; Saavedra, P; Tugores, A, 2018)	0.48
"This study demonstrates that the bioavailability of these 4 generic clopidogrel products authorised in Serbia is very similar."	( Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia. García-Arieta, A; Miljković, B; Pejčić, Z; Vučićević, K, 2019)	0.51
"Clopidogrel bisulfate (CB) is a golden antiplatelet treatment, yet its benefits are limited by its low bioavailability (<50%) caused by poor intestinal solubility and absorption."	( Stabilizing excipients for engineered clopidogrel bisulfate procubosome derived in situ cubosomes for enhanced intestinal dissolution: Stability and bioavailability considerations. Abdelmalak, NS; Badawi, A; El-Laithy, HM; Elsayyad, NME, 2019)	0.51
"Clopidogrel (CLOP) is an antiplatelet drug with poor solubility in intestinal fluid, which limits its bioavailability after oral administration."	( Probing the effect of various lipids and polymer blends on clopidogrel encapsulated floating microcarriers. Ali, A; Asghar, S; Hussain, T; Irfan, M; Irshad, S; Khalid, I; Khalid, SH; Khan, AN; Khan, IU; Sabir, N; Shahzad, Y; Yousaf, AM, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"Variability in P-glycoprotein (P-gp) efflux transporting activity was supposed to be involved in altered intestinal absorption and bioavailability of clopidogrel in patients; however, reliable evidence is still lacking."	( P-glycoprotein deficiency enhances metabolic activation of and platelet response to clopidogrel through marked up-regulation of Cyp3a11 in mice: Direct evidence for the interplay between P-glycoprotein and Cyp3a. Ge, PX; Ji, JZ; Jiang, LP; Li, YF; Mi, QY; Tai, T; Xie, HG; Zhu, T, 2021)	0.62
" The therapeutic effects of drug molecules are majorly dependent on the bioavailability and, in essence, on the solubility of the used drug molecules."	( Exploration on the drug solubility enhancement in aqueous medium with the help of endo-functionalized molecular tubes: a computational approach. Paul, R; Paul, S, 2021)	0.62
"The therapeutic efficacy of clopidogrel as an antiplatelet drug varies among individuals, being the mainstream hypothesis that its bioavailability depends on the individual genetic background and/or interactions with other drugs."	( Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022)	0.72
"Despite being a first-line clinical drug, thienopyridines have many unsatisfactory aspects, including the low bioavailability of clopidogrel(CLP) and the high bleeding risk of prasugrel."	( Evaluation of efficacy and safety after replacement of methyl hydrogen with deuterium at methyl formate of Clopidogrel. Cai, D; Cao, X; Chen, C; Chen, L; Gao, M; Gu, J; Li, X; Liu, S; Liu, Y; Miao, Y; Niu, J; Sun, Y; Wu, T; Xu, Z, 2022)	0.72
"The study aimed to increase the intestinal solubility and absorption of orally bioavailable clopidogrel-bisulfate (CPB) by complexing with hydroxypropyl-β-cyclodextrin (HCD) to form a binary inclusion complex that was stabilized by Tween 80 (T80) resulting into mixed inclusion complex."	( Preparation and Characterization of Clopidogrel Bisulfate-hydroxypropyl-β-Cyclodextrin Mixed Inclusion Complex for Improved Intestinal Solubility and Anti-Thrombotic Efficacy. Chaudhary, S; Rana, V; Sharma, R; Singh, A, 2023)	0.91

Excerpt	Relevance	Reference
" From a dose-response showing that the administration of increasing doses of tissue thromboplastin resulted in a subsequent progressive increase of thrombus weight, two concentrations of tissue thromboplastin were chosen: a high dose (550 microL/kg, IV) where thrombus formation was optimal and a concentration (7 microL/kg, IV) where tissue thromboplastin-hypercoagulability was intermediate."	( Importance of platelets in experimental venous thrombosis in the rat. Bernat, A; Herbert, JM; Maffrand, JP, 1992)	0.28
" Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine."	( Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999)	0.3
" This review article examines research on both monotherapy and combination antiplatelet therapy for secondary stroke prevention, with an emphasis on lessons learned about dosage schedules, treatment protocols, and side-effect profiles."	( Antiplatelet therapy for secondary stroke prevention. Forbes, CD, 1999)	0.3
" In both studies, the inhibition of platelet aggregation induced by 5 microM of ADP was measured before dosing (baseline), then at regular intervals during and after treatment."	( Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Cariou, R; Kieffer, G; Lowe, GD; Nimmo, WS; Thebault, JJ, 1999)	0.3
" Bleeding time and platelet aggregation induced by 5 microM of ADP were measured before treatment (baseline) and at regular intervals after dosing during treatment."	( Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. Dickinson, JP; Houle, JM; Kieffer, G; Kindermans, M; Necciari, J; Pierce, CH; Serre-Lacroix, E, 1999)	0.3
" Platelet aggregation induced by 5 microM of ADP was measured in plasma samples taken at screening, 2 hours after dosing on day 1 to day 9; 2, 5, and 24 hours after dosing on day 10; and on alternate days until day 24."	( Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Denninger, MH; Necciari, J; Serre-Lacroix, E; Sissmann, J, 1999)	0.3
" Tests of hemostasis (ADP-induced platelet aggregation and bleeding time) were carried out 2 hours after clopidogrel dosing on days 5, 7, 9, 11, and 14."	( Clopidogrel does not affect the pharmacokinetics of theophylline. Caplain, H; Necciari, J; Thebault, JJ, 1999)	0.3
" Therefore, no dosage adjustment of clopidogrel is required in patients with Child-Pugh Class A or B cirrhosis."	( Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. Much, DR; Necciari, J; Nichola, P; Slugg, PH; Smith, WB; Vargas, R, 2000)	0.31
" Despite the growing use of GP IIb/IIIa antagonists, much information remains unknown as to the proper dosing and the effects these agents have on other elements of the hemostatic and vascular systems."	( Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents. Frelinger III, AL; Furman, MI; Michelson, AD, 2000)	0.31
" Because of better side-effect profile and simpler dosing regime, clopidogrel has largely replaced ticlopidine."	( Isolated profound thrombocytopenia associated with clopidogrel. Elmi, F; Peacock, T; Schiavone, J, 2000)	0.31
"To review the efficacy and dosage of aspirin in stroke prevention, and to review the benefits and risks of the newer strategies, compared with aspirin."	( Newer antiplatelet therapies in stroke prevention. Davis, SM; Donnan, GA, 2001)	0.31
" It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease."	( [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. Scheen, AJ, 2001)	0.31
" We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk."	( Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001)	0.31
"5 mg/kg intravenous (IV), and eptifibatide using the ESPIRIT dosing (180 g/kg bolus IV, immediately followed by a 2 g/kg/minute continuous IV infusion, and then a second 180 g/kg bolus IV ten minutes after the first bolus)."	( Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. Bertolet, BD; Gupta, A; Miller, L, 2002)	0.31
"A stability indicating, reversed-phase high-performance liquid chromatographic method was developed and validated for the determination of clopidogrel in pharmaceutical dosage forms."	( A validated LC method for the determination of clopidogrel in pharmaceutical preparations. Mitakos, A; Panderi, I, 2002)	0.31
" This may have implications regarding the need for separate heparin dosing algorithms for patients undergoing PCI in the setting of different GPIIb-IIIa inhibitors."	( Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention. Ball, SA; Dauerman, HL; Desourdy, MA; Furman, MI; Goldberg, RJ, 2002)	0.31
" This rabbit model with a high dosage of clopidogrel and aspirin, and a short-time exposure of the heart valve leaflets to rabbit blood under laminar flow, should be further evaluated with respect to whether it can give information about antithrombotic regimens in patients after mechanical heart valve replacement."	( Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Bickel, C; Buerke, M; Hauroeder, B; Hundt, F; Meyer, J; Peetz, D; Rupprecht, HJ; Schlitt, A; Victor, A, 2002)	0.31
"Better tolerability, reduced toxicity (particularly hematologic), and the convenience of once-daily dosing have resulted in the replacement of ticlopidine with clopidogrel."	( Clopidogrel-associated leukopenia. Kockler, DR; McCarthy, MW, 2003)	0.32
" We sought to establish an optimal clopidogrel dosing regimen for sustained platelet inhibition in stented patients."	( Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Alford, AB; Bell, CR; Cummings, CC; Gurbel, PA; Meister, AF; Serebruany, VL, 2003)	0.32
" Therefore, despite improved outcomes, further studies are required to determine the optimal duration and dosage regimen of such combination therapy to maximize its risk-benefit ratio."	( Clopidogrel in the management of ischemic heart disease. Bhatt, R; Cavusoglu, E; Cheng, J; Eng, C; Kunamneni, PB; Marmur, JD, )	0.13
" Intravenous glycoprotein IIb/IIIa inhibitors effectively prevent periprocedural thrombotic complications, but their short duration of action and parenteral dosing don't allow for long-term protection."	( What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? Berger, P; Steinhubl, S, 2003)	0.32
" On the other hand, ASA has even to be applied at a dosage that almost completely inhibits thromboxane synthesis in order to act on platelet aggregation at all."	( [Platelet aggregation disorders]. Patscheke, H, 2003)	0.32
" Moreover, ximelagatran has rapid onset and offset of action, fixed oral dosing without the need for anticoagulation monitoring, low potential for food and drug interactions, and a therapeutic margin wider than that of warfarin."	( New possibilities in anticoagulant management of atrial fibrillation. Waldo, AL, 2004)	0.32
" If the international normalized ratio (INR) was kept > 2 for a long period, by means of frequent check-ups and effective dosage adjustment, the chance of death, recurrent myocardial infarction or stroke was 30-50% lower than when acetylsalicylic acid only was used."	( [Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives]. Brouwer, A; Verheugt, FW; Waskowsky, WM, 2005)	0.33
" Specifically, there was no difference in the tirofiban dose-response curves with either platelet agonist for any of the three time points (before, and three and six hours after, clopidogrel administration)."	( Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study. Berger, PB; DiBattiste, PM; Lennon, R; Lubbe, D; Orford, JL; Talreja, D, 2004)	0.32
" The objective of this study was to conduct a detailed time-resolved analysis of the effects of the GPIIb/IIIa inhibitor tirofiban with concomitant clopidogrel in ACS patients undergoing percutaneous coronary intervention (PCI) to improve the dosing regimen of these two commonly used antiplatelet drugs."	( Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Badar, J; Covic, L; Jacques, S; Kimmelstiel, C; Kuliopulos, A; Waxman, S; Weintraub, A, 2005)	0.33
"This study shows that the currently utilized tirofiban dosage is suboptimal and suggests that patients may benefit from a higher dose regimen."	( Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Badar, J; Covic, L; Jacques, S; Kimmelstiel, C; Kuliopulos, A; Waxman, S; Weintraub, A, 2005)	0.33
"We determined the effect of clopidogrel dosing on the incidence of nonresponsiveness (NR) and high post-treatment platelet aggregation (post-PA)."	( The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. Bliden, KP; Gurbel, PA; Hayes, KM; Herzog, WR; Tantry, US; Yoho, JA, 2005)	0.33
" Higher dosing strategies and methods to confirm platelet inhibition should be further investigated in order to optimally use clopidogrel in patients undergoing stenting."	( The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. Bliden, KP; Gurbel, PA; Hayes, KM; Herzog, WR; Tantry, US; Yoho, JA, 2005)	0.33
" Patients were randomized to either standard dosing with clopidogrel or 1 of 3 prasugrel regimens."	( Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Antman, EM; Behounek, BD; Braunwald, E; Carney, RJ; Lazzam, C; McCabe, CH; McKay, RG; Murphy, SA; Weerakkody, G; Winters, KJ; Wiviott, SD, 2005)	0.33
"To review a pediatric experience with the antiplatelet agent clopidogrel and suggest a dosage regimen."	( Clopidogrel use in children. Avner, M; Benson, LN; Finkelstein, Y; Koren, G; Nurmohamed, L, 2005)	0.33
" In addition, AYPGKF- and thrombin-induced TXA2 generation was significantly reduced in platelets from mice dosed with clopidogrel, confirming the results obtained with the human platelets."	( P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. Garcia, A; Kim, S; Kunapuli, SP; Prabhakar, J; Shankar, H, 2006)	0.33
" AZD6140 (100 and 200 mg bid, 400 mg qd) rapidly and nearly completely inhibited ADP-induced platelet aggregation after initial dosing (day 1) and at day 28."	( Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M, 2006)	0.33
" Changes in total thrombus area (TTA) under low shear rate (LSR; 212 s(-1)) and high shear rate (HSR; 1690 s(-1)) conditions were measured, using the ex vivo Badimon perfusion chamber model pre-dose and 2 and 5 hours after dosing on Day 6, and capillary bleeding times (CBT) were determined."	( Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Badimon, JJ; Bylock, A; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Kalies, I; Nyström, P; Sarich, TC; Wåhlander, K, 2006)	0.33
" It was shown that standard dosing of tirofiban is insufficient for optimal platelet inhibition."	( Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. Akbulut, T; Akgoz, H; Bilsel, T; Ciloglu, F; Dayi, SU; Ergelen, M; Sayar, N; Terzi, S; Yesilcimen, K, 2006)	0.33
" Multiple mechanisms likely contribute to clopidogrel variability of response, including inappropriate dosing or underdosing of clopidogrel, drug-drug interactions, and genetic polymorphisms."	( Variability of response to clopidogrel: possible mechanisms and clinical implications. Frishman, WH; Lerner, RG; Nawarskas, J; Nguyen, T, )	0.13
" In the triple therapy group, the international normalized ratio or aspirin dosage did not influence the bleeding risk."	( Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. Bergman, G; Chou, E; Hong, MK; Khurram, Z; Minutello, R; Naidu, S; Parikh, M; Wong, SC, 2006)	0.33
"At the dosing regimens chosen in the JUMBO trial, it seems that prasugrel is a more potent antiplatelet agent than clopidogrel."	( Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Lowry, DR; Malinin, AI; Meilman, H; Midei, MG; Serebruany, VL, 2006)	0.33
" Thirteen patients required a higher dosage of aspirin and/or an additional anti-platelet agent to achieve therapeutic adequacy."	( Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders. Gemmell, R; Hartwell, T; Manoharan, A, 2006)	0.33
" This study examined the degree of PI after a high-dose load of clopidogrel compared with standard dosing and the time course of functional recovery after the discontinuation of daily therapy."	( Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Cannon, CP; Coleman, JL; Price, MJ; Steinhubl, SR; Teirstein, PS; Wong, GB, 2006)	0.33
" A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition."	( A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG, 2006)	0.33
"This double-blind, placebo-controlled trial was designed to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y(12) ADP receptor antagonist compared with clopidogrel, during multiple oral dosing in healthy subjects."	( A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Asai, F; Brandt, JT; Freestone, S; Hirota, T; Jakubowski, JA; Matsushima, N; Naganuma, H; Winters, KJ, 2007)	0.34
" Whether platelet inhibition can be enhanced by increasing clopidogrel maintenance dosage in T2DM patients is unknown."	( Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Angiolillo, DJ; Bass, TA; Bernardo, E; Charlton, RK; Costa, MA; Desai, B; Guzman, LA; Shoemaker, SB; Yuan, H; Zenni, MM, 2007)	0.34
"Although appropriate anticoagulation is essential to maximize the efficacy and safety of primary PCI, the optimal dosing of enoxaparin in this setting is unclear."	( A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. Armstrong, PW; Buller, CE; Gordon, P; O'Neill, B; Welsh, RC; Westerhout, CM, 2007)	0.34
" Recent studies have left clinicians with many questions regarding the role and dosing regimens of clopidogrel in STEMI, PCI, and primary or secondary prevention."	( Contemporary issues in clopidogrel therapy: new evidence shaping clinical practice. Emmons, KL; Taylor, NR, 2007)	0.34
"Clopidogrel is an established alternative to ticlopidine in addition to aspirin after coronary stenting because of its safety, but its optimal initial dosing is unclear."	( Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression. Abbate, A; Agostoni, P; Biondi-Zoccai, GG; Lotrionte, M; Moretti, C; Sangiorgi, G; Sheiban, I; Valgimigli, M, 2007)	0.34
" Within the limitations of the study, prasugrel was found to be well tolerated when dosed as LD followed by MD in the presence of ASA and provided greater platelet inhibition than ASA alone."	( Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. Brandt, JT; Farid, NA; Jakubowski, JA; Lachno, DR; Li, YG; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ, 2007)	0.34
" However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation."	( Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007)	0.34
" Failure to reduce the dose of a GP IIb/IIIa for patients with renal insufficiency resulting in excessive dosing of GP IIb/IIIa inhibitors increases the risk of major bleeding and is particularly common among the elderly, women, and patients with renal insufficiency."	( Managing acute coronary syndrome: evidence-based approaches. Spinler, SA, 2007)	0.34
" Dosing of aspirin in the first 24 hours was as follows: 17."	( Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007)	0.34
" The model identified a clopidogrel poor responder as a subject who failed to achieve and maintain an IPA >or= 25% (or DeltaMPA >or= 20%) with 5 microM ADP at 4-5 and 24 hours after dosing or who failed to achieve and maintain an IPA >or= 20% (or DeltaMPA >or= 15%) with 20 microM ADP at 4-5 and 24 hours after dosing."	( Clopidogrel poor responders: an objective definition based on Bayesian classification. Brandt, JT; Jakubowski, JA; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ, 2007)	0.34
" Elderly patients (> or = 75 years of age) received a novel enoxaparin dosing regimen and when compared with UFH, benefited from a lower relative bleeding risk than younger patients without compromising efficacy in preventing death or MI."	( ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. Gabriel, RS; White, HD, 2007)	0.34
"In the majority of potentially adverse clopidogrel exposures reported to poison control centers the doses are twice the recommended dosage or less."	( Pattern of clopidogrel exposures reported to Texas poison centers during 1998-2004. Forrester, MB, 2007)	0.34
" For aspirin, the median dosage per week was 1300 mg and median ARU was 410."	( Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. Flaherty, CA; Lee, VH; Lopes, DK; Prabhakaran, S; Wells, KR, 2008)	0.35
"Antiplatelet and antithrombotic activity of multiple oral dosing of prasugrel were evaluated in several animal species."	( Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Asai, F; Hashimoto, M; Isobe, T; Jakubowski, JA; Niitsu, Y; Ogawa, T; Otsuguro, K; Sugidachi, A, 2008)	0.35
" Prasugrel is orally more potent and acts more rapidly than clopidogrel, allowing lower oral dosing despite of similar in vitro activity of the active metabolites."	( [Prasugrel, a new thienopyridine]. Huber, K; Schrör, K, 2007)	0.34
" Despite the unambiguous clinical benefit associated with clopidogrel, accumulating experience with this drug has also led to identification of some of its drawbacks, which are related to inadequate platelet inhibition with standard dosage regimens as well as to its irreversible antiplatelet effects."	( ADP receptor antagonism: what's in the pipeline? Angiolillo, DJ, 2007)	0.34
"Platelet inhibition as measured by vasodilator-stimulated phosphoprotein (VASP) and light transmission aggregometry (LTA) have shown concordance following dosing of clopidogrel."	( A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.35
" Investigation of alternative clopidogrel dosing regimens to reduce ischaemic events in high-risk patients identified by this assay is warranted."	( Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Endemann, S; Ernst, A; Gollapudi, RR; Levisay, JP; Price, MJ; Sawhney, NS; Schatz, RA; Stinis, CT; Teirstein, PS; Valencia, R, 2008)	0.35
" One hundred sixty-one patients on 100 mg of aspirin co-medication underwent elective coronary stenting and were given an initial dosage of 600 mg clopidogrel, followed by 75 mg clopidogrel daily."	( How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Engelhardt, A; Lask, S; Mügge, A; Neubauer, H, 2008)	0.35
" The specific dosing and its clinical usefulness of each medication are considered."	( [Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations]. Keltai, M, 2008)	0.35
" Hyporesponsive patients might benefit from different dosing strategies or additional antiplatelet therapies."	( Investigating the mechanisms of hyporesponse to antiplatelet approaches. Angiolillo, D; Bates, E; Berger, PB; Bhatt, D; Braunwald, E; Cannon, CP; Furman, MI; Gurbel, P; Michelson, AD; Peterson, E; Wiviott, S, 2008)	0.35
" In recent years, clopidogrel dosing strategies among such patients have evolved considerably, with newer approaches involving loading doses prior to PCI and increases in the time interval and loading dosage in an effort to overcome variable responsiveness/hyporesponsiveness to platelet inhibition."	( Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Angiolillo, D; Bates, E; Berger, PB; Bhatt, D; Braunwald, E; Cannon, CP; Furman, MI; Gurbel, P; Michelson, AD; Peterson, E; Wiviott, S, 2008)	0.35
" Since prasugrel is still under investigation, an official recommended dosage regimen has yet to be determined."	( Prasugrel: a novel antiplatelet agent. Haber, SL; Riley, AB; Tafreshi, MJ, 2008)	0.35
" Future studies with prasugrel should determine its optimal dosage regimen to minimize bleeding risks and evaluate its outcomes in ACS and safety profile in special patient populations."	( Prasugrel: a novel antiplatelet agent. Haber, SL; Riley, AB; Tafreshi, MJ, 2008)	0.35
" Clopidogrel at 3 mg kg(-1) was dosed orally once daily for three days, with the last dose given 2 h before injury."	( Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. Crain, EJ; Watson, CA; Wong, PC, 2008)	0.35
" A total of 119 patients undergoing PCI were blindly randomized in 2:1 fashion to receive clopidogrel loading 600 mg on the table immediately before PCI and 75 mg 2 times/day for 1 month (high-dose group) versus standard dosing (300 mg loading and 75 mg/day; low-dose group)."	( Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents. Abuzahra, M; Bobek, J; Caldera, A; Dokainish, H; Gonzalez, R; Hartley, WB; Lakkis, N; Pillai, M, 2008)	0.35
" Decision to increase clopidogrel dosage may vary on the basis of the assay used, thus highlighting the need for unambiguous guidelines with respect to assay selection, as platelet function assays are not interchangeable."	( Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E, 2008)	0.35
" Currently, efficiency, dosing and indications of established antiplatelet substances are being re-evaluated, whilst new, so far unrecognized molecular targets for inhibition of platelet activity come up front."	( Antiplatelet drugs in cardiological practice: established strategies and new developments. Klauss, V; Krötz, F; Sohn, HY, 2008)	0.35
" The ExTRACT-TIMI 25 trial employed a novel dosing regimen for enoxaparin adjusted for age and renal function, which was designed to minimize bleeding risk while maintaining the beneficial effects of enoxaparin."	( ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. Giugliano, RP; Thomas, D, 2009)	0.35
" These results indicate that further studies are needed to determine the optimal dosing and timing of antiplatelet therapies for patients undergoing primary PCI."	( Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). Alexander, D; Gibler, WB; Mann, N; Ohman, EM; Ou, FS; Peterson, ED; Roe, MT, 2008)	0.35
" The drug was given as monotherapy for 10 days, and after a 6-day run-in period with atorvastatin 80 mg/day, the same dosage of atorvastatin was continued with the respective thienopyridine for 10 days."	( Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.35
"Blood samples were collected before and at various time points after dosing on days 1 and 11 for determination of plasma concentrations of metabolites and for measurement of platelet aggregation induced by adenosine 5'-diphosphate 20 microM and vasodilator-stimulated phosphoprotein (VASP)."	( Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.35
" The lack of a clinically meaningful effect of high-dose atorvastatin on the pharmacodynamic response to prasugrel after the loading or maintenance dose indicates that no dosage adjustment should be necessary in patients receiving these drugs concomitantly."	( Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008)	0.35
"The CURRENT-OASIS 7 trial will help to define optimal dosing regimens for clopidogrel and ASA in patients with ST and non-ST-segment-elevation ACS treated with an early invasive strategy."	( Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008)	0.35
" In view of all this it is not surprising that in the past years the indications, application and dosage of anticoagulant and platelet aggregation inhibitor drugs have changed."	( [Current issues of anticoagulation therapy in the course of dental treatment and oral surgery]. Barabás, JB; Horváth, C; Joób-Fancsaly, A; Kalmár, G; Koppány, F, 2008)	0.35
" If planned immediate PCI after thrombolytic therapy is not indicated, PCI immediately after high dosage of glycoprotein IIb/IIIa-Inhibitors in combination with a high dose of clopidogrel may give good results."	( [Acute intervention for ST-elevation myocardial infarction]. Heintzen, MP, 2008)	0.35
"Despite a lack of clear recommendations to guide decision-making, reductions in enoxaparin sodium dosage in the elderly and in patients with mild and moderate renal dysfunction are common in patients with acute coronary syndrome."	( Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study. Beckerman, P; Ben-Artzi, M; Ben-Yehuda, A; Haber, G; Levin, A; Muszkat, M; Varon, D, 2009)	0.35
" Recent data have demonstrated limitations with the currently approved dosing regimen of clopidogrel (loading dose, 300 mg; maintenance dose, 75 mg daily) in a significant number of patients during the first few hours-days of treatment (Gurbel et al, Circulation."	( Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. Giugliano, RP; Thomas, D, 2009)	0.35
" The proposed methods have been successfully applied to the analysis of CLP in pharmaceutical dosage forms without interference from other dosage form additives and the results were statistically compared with the official method."	( Spectrophotometric and spectrodensitometric determination of Clopidogrel Bisulfate with kinetic study of its alkaline degradation. Abbas, SS; Abdelkawy, M; Abdelrahman, MM; Zaazaa, HE, 2009)	0.35
" The dose-response effect as studied by platelet aggregometry showed that the required molar concentration to block the interactive effect in the case of YH was less than that of MRS2179."	( Platelet responsiveness to yohimbine hydrochloride and MRS2179 in the context of the interaction between collagen and epinephrine in acute coronary syndrome. Chakrabarti, P; Chaudhuri, U; Dasgupta, AK; Deb, S; Guha, P; Guha, S; Lahiri, P; Roy, S; Sardar, P, )	0.13
" However, these studies are limited by varying antiplatelet drug dosing regimens, heterogeneous laboratory assessments for ex vivo platelet function, and wide interindividual variation in platelet responses."	( Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Fuster, V; Gorog, DA; Sweeny, JM, 2009)	0.35
" A clopidogrel maintenance dosage of 150 mg daily for 1 week resulted in greater platelet inhibition than 75 mg daily (50 +/- 28% vs."	( The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. Armstrong, G; Dahl, ML; El-Jack, S; Farrell, H; Gladding, P; Gunes, A; Kay, P; Ormiston, J; Ruygrok, P; Scott, D; Stewart, J; Webster, M; Zeng, I, 2008)	0.35
" A maintenance dosage of 150 mg daily produces greater platelet inhibition than 75 mg daily."	( The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. Armstrong, G; Dahl, ML; El-Jack, S; Farrell, H; Gladding, P; Gunes, A; Kay, P; Ormiston, J; Ruygrok, P; Scott, D; Stewart, J; Webster, M; Zeng, I, 2008)	0.35
"Recurrent ischemic events occurred even during routine use of 75 mg clopidogrel in addition to aspirin, that indicated a potentially insufficient maintenance dosage of clopidogrel."	( A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation. Han, YL; Jing, QM; Li, Y; Ma, YY; Wang, B; Wang, DM; Wang, G; Wang, SL; Wang, ZL; Xu, K, 2009)	0.35
" It is quickly absorbed and exhibits a rapid antiplatelet effect, with higher and more consistent levels of inhibition of platelet aggregation (IPA) being maintained across the dosing interval than with clopidogrel."	( Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Husted, S; van Giezen, JJ, 2009)	0.35
"The study was conducted as a monocentric, open, randomized, single-dose, two-period crossover trial in 48 healthy volunteers with a duration of hospitalization of approximately 24 h after dosing on day 1 and with a real wash-out period of 7 days."	( Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. Emritte, N; Erenmemisoglu, A; Koytchev, R; Richter, W; Tuncay, E; Van der Meer, MJ, 2009)	0.35
" When patients were further stratified into 4 groups according to the timing and dosage of clopidogrel loading, the incidence of the primary outcome was 16% and 27% in those receiving 600 and 300 mg before and 28% and 39% in those receiving 600 and 300 mg after PPCI, respectively (p for trend <0."	( Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Behar, S; Beinart, R; Boyko, V; Fefer, P; Hammerman, H; Hod, H; Matetzky, S; Segev, A, 2009)	0.35
" This study evaluated the effect on platelet aggregation of four different dosing regimens of clopidogrel given before elective PCI in a randomized, prospective, double-blind, and placebo-controlled design."	( Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial. Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E; Turgeon, J, 2009)	0.35
" HCPR as measured with the novel INNOVANCE P2Y cartridge was associated with clinical determinants such as BMI, female gender, impaired LVEF (left ventricular ejection fraction), renal failure and dosing of clopidogrel."	( The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Berg, JM; Bouman, HJ; Elsenberg, EH; Hackeng, CM; van de Wal, RM; van Werkum, JW; Verheugt, FW; Zomer, AC, 2009)	0.35
" Thus, two major paradoxes in cardiovascular medicine today are: 1) despite the overwhelming evidence that platelet reactivity strongly influences the development of potentially catastrophic events including myocardial infarction and stent thrombosis in the PCI patient, no measurement is made in clinical practice to assess the presence of blood vulnerability (platelet reactivity) and 2) despite the overwhelming evidence that the effect of dual antiplatelet therapy with aspirin and P2Y12 receptor blockers is variable, the guidelines largely recommend a uniform, "one size fits all" dosing of these agents in the PCI patient without any confirmation of an adequate antiplatelet effect."	( Platelet monitoring for PCI: is it really necessary? Gurbel, PA; Tantry, US, 2009)	0.35
" Personalizing clopidogrel dosing using pharmacogenomics may be an effective method of optimizing treatment."	( Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. Baak, R; Bvaldivia, B; Gladding, P; Ormiston, J; Ruygrok, P; Stewart, J; Voss, J; Webster, M; White, C; White, H, 2009)	0.35
" (2) Clopidogrel may be under dosed in obese patients."	( Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010)	0.36
" The improved efficacy of multiple-drug therapy is associated with an increased risk of bleeding, which raises the issue of the dosing of these drugs."	( Antiplatelet agents. Spectre, G; Varon, D, 2009)	0.35
" The improved efficacy of multiple drug therapy is associated with an increased risk of bleeding, which raises the issue of the dosing of these drugs."	( Frontiers in platelet inhibition. Shai, E; Spectre, G; Varon, D, 2009)	0.35
"A novel stability-indicating normal phase liquid chromatographic (NP-LC) method was developed for the determination of purity of clopidogrel drug substance and drug products in bulk samples and pharmaceutical dosage forms in the presence of its impurities and degradation products."	( A validated stability-indicating normal phase LC method for clopidogrel bisulfate and its impurities in bulk drug and pharmaceutical dosage form. Durga Rao, D; Kalyanaraman, L; Sait, SS; Venkata Rao, P, 2010)	0.36
" Some recent studies have suggested that a higher clopidogrel maintenance dosage could enhance ex vivo platelet inhibition and thereby overcome resistance to clopidogrel."	( High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S, 2010)	0.36
"To investigate whether a higher clopidogrel maintenance dosage is associated with a reduced risk of stent thrombosis after percutaneous coronary intervention (PCI) in clopidogrel-resistant patients and to evaluate the frequency of hemorrhagic accidents that could be associated with a high clopidogrel maintenance dosage."	( High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S, 2010)	0.36
" All patients received a clopidogrel loading dose of 300 mg, then 32 patients received a clopidogrel maintenance dosage of 75 mg/day (patients admitted between 2004 and 2005) and 20 patients received 150 mg/day (patients admitted in 2006)."	( High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S, 2010)	0.36
"Our data suggest that a high maintenance dosage of clopidogrel (150 mg/day) is associated with a reduced risk of definite stent thrombosis and MACE compared with a maintenance dosage of 75 mg/day."	( High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S, 2010)	0.36
" Optimal dosing strategy as determined by ticagrelor's pharmacokinetic and pharmacodynamic profile is a loading dose of 180 mg followed by 90 mg by mouth twice daily."	( Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Anderson, SD; Epstein, BJ; Shah, NK; Yim, J, 2010)	0.36
" Twenty-four hours after a 300 mg loading dose of clopidogrel, one group received a dosage of 75 mg/day of clopidogrel and a placebo for 14 days, followed 3 weeks later by the same protocol but with coadministration of 75 mg/day clopidogrel and 20 mg/day omeprazole instead."	( Effects of omeprazole on the antiplatelet activity of clopidogrel. Jeong, JW; Kim, NH; Oh, SK; Park, HY; Rhee, SJ; Yoo, NJ; Yun, KH, 2010)	0.36
" While there is some established evidence for an induction strategy and design of chemical structure, the proposed dosing input strategy is speculative in nature."	( Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play? Srinivas, NR, )	0.13
" In a research study using an earlier four-color version of the assay, it was demonstrated that warfarin dosing can be influenced by a cytochrome P450 (CYP) 4F2 variant."	( DMET microarray technology for pharmacogenomics-based personalized medicine. Burmester, JK; Mansfield, E; Sedova, M; Shapero, MH, 2010)	0.36
" After a washout period of > 2 weeks, the subjects underwent a platelet aggregation test before and after dosing with 75 mg of clopidogrel for 7 days."	( [13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel. Furuta, T; Iwaki, T; Umemura, K, 2010)	0.36
" The large clinical trials COAG and EU-PACT will define the extent to which pharmacogenetic dosing affects the safety and efficacy of warfarin and coumarin derivatives."	( Implementing genotype-guided antithrombotic therapy. Duconge, J; Ruaño, G; Seip, RL, 2010)	0.36
" We review the recent data on efficacy and safety of dosing strategies for antiplatelet therapy in PCI."	( Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A, 2010)	0.36
" East and Southeast Asian patients (N = 715) with moderate- to high-risk ACS undergoing PCI will be randomized to one of three prasugrel dosing regimens (60 mg LD/10 mg MD; 30 mg LD/7."	( Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Boonbaichaiyapruck, S; Ge, J; Goh, YS; Hong, BK; Hou, CJ; Pinton, P; Zhu, J, 2010)	0.36
"This study assesses the optimal dosing schedule for ticagrelor in healthy volunteers and compares the degree of IPA with clopidogrel."	( Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Butler, K; Teng, R, 2010)	0.36
"Multiple dosing provided predictable pharmacokinetics of ticagrelor and its metabolite over the dose range of 50-600 mg once daily and 50-300 mg twice daily with C(max) and AUC(0,t) increasing approximately dose-proportionally."	( Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Butler, K; Teng, R, 2010)	0.36
" This article provides an overview of ADP P2Y₁₂ receptor-inhibiting strategies, including high clopidogrel dosing regimens and novel agents under advanced clinical development."	( Platelet P2Y₁₂ receptor inhibition: an update on clinical drug development. Angiolillo, DJ; Vivas, D, 2010)	0.36
" Additionally, it provides an overview of tirofiban's pharmacology and summary of the clinical efficacy and safety data of two dosing regimens."	( Safety evaluation of tirofiban. Tebaldi, M; Valgimigli, M, 2010)	0.36
" * We tested whether the separate dosing of a PPI and clopidogrel decreased the risk of attenuation of clopidogrel efficacy."	( Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Furuta, T; Iwaki, T; Umemura, K, 2010)	0.36
" A less than 30% inhibition of platelet aggregation (IPA) during clopidogrel dosing was defined as a 'low responder'."	( Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Furuta, T; Iwaki, T; Umemura, K, 2010)	0.36
" Morning and evening dosing of omeprazole were both associated with lower IPA in DMs."	( Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Furuta, T; Iwaki, T; Umemura, K, 2010)	0.36
" Multiple gastroduodenal biopsies were performed during 2 esophagogastroduodenoscopy in subjects dosed with aspirin enteric-coated 81 mg once daily or clopidogrel 75 mg once daily."	( Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel?: a prospective, randomized study involving 630 biopsies. Aisenberg, J; Bamji, ND; Bodian, CA; Cohen, LB; Desai, JC; Dikman, AE; Harpaz, N; Kornacki, S; Miller, KM; Sanyal, S; von Althann, C; Whitson, MJ, 2011)	0.37
" Regarding the postoperative course, significant results could be demonstrated for: adrenaline dosage (0."	( Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG. Adamczak, M; Boulesteix, AL; Eifert, S; Kilian, E; Lamm, P; Mair, H; Reichart, B, 2010)	0.36
" However, evidence-based guidelines for dosing have not been established for either agent."	( Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010)	0.36
"Four randomized, placebo-controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between clopidogrel (300-mg loading dose/75-mg/day maintenance dose) and the proton-pump inhibitor (PPI) omeprazole (80 mg) when they are administered simultaneously (study 1); whether the interaction, if any, can be mitigated by administering clopidogrel and omeprazole 12 h apart (study 2) or by increasing clopidogrel to 600-mg loading/150-mg/day maintenance dosing (study 3); and whether the interaction applies equally to the PPI pantoprazole (80 mg) (study 4)."	( Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Angiolillo, DJ; Bergougnan, L; Cheng, S; Dubar, M; Gibson, CM; Hurbin, F; LaCreta, FP; Nicolas, O; Ollier, C; Perrin, L, 2011)	0.37
" Until further reliable controlled data are available, this potential, but currently unproven, clinical interaction can be minimized by widely separating the dosing of clopidogrel and PPI."	( NSAID-induced gastrointestinal and cardiovascular injury. Chan, FK; Ng, SC, 2010)	0.36
"Absorption is a critical component of the pharmacokinetics for solid dosage forms administered orally."	( Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke. Conrado, DJ; Derendorf, H; Gonzalez, D, 2010)	0.36
" Alternative dosing regimens might enhance platelet inhibition."	( Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. Barker, CM; Kandzari, DE; Murray, SS; Price, MJ; Teirstein, PS; Topol, EJ, 2010)	0.36
" If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended."	( [Dilemma between gastroprotection and cardiovascular prevention]. Kandulski, A; Malfertheiner, P; Venerito, M, 2010)	0.36
" Management is currently limited to dosing alteration and introduction of other antiplatelet agents."	( Resistance to aspirin and clopidogrel therapy. Alam, S; Assaad, S; Beresian, J; Bitar, A; Charafeddine, K; Khoury, M; Musallam, KM; Taher, AT, 2011)	0.37
" It was aimed to increase its bioavailability by designing a controlled release dosage form of clopidogrel, which is different from available current dosage forms in the market."	( Development of sustained release formulation of an antithrombotic drug and application of Fuzzy logic. Degim, İT; Tan, C, )	0.13
" The serum thromboxane levels in mice (n = 3) dosed with clopidogrel and prasugrel were decreased by 83."	( Antagonism of P2Y₁₂ reduces physiological thromboxane levels. Bhavaraju, K; Gartner, TK; Georgakis, A; Jin, J; Kunapuli, SP; Nurden, A; Nurden, P; Tomiyama, Y, 2010)	0.36
" The present article reviews data on the clinical impact of enhanced P2Y12 inhibition with either higher clopidogrel dosing or new oral antiplatelet agents, including prasugrel and ticagrelor, in the setting of STEMI, focusing on results in the setting of primary PCI."	( Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C, 2010)	0.36
" One hour after the last dosing of clopidogrel, all subjects received 15-mg of sibutramine."	( Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. Bae, JW; Jang, CG; Lee, SY, 2011)	0.37
"A rapid, simple, and easy method for the simultaneous determination of clopidogrel and aspirin from bulk material and dosage formulations in the presence of meloxicam as internal standard has been developed."	( Simultaneous determination of clopidogrel and aspirin by RP-HPLC from bulk material and dosage formulations using multivariate calibration technique. Ali, KA; Arayne, MS; Nawaz, M; Sultana, N, 2011)	0.37
" 75-mg daily maintenance dosage of clopidogrel on clinical and laboratory end-points in patients undergoing PCI."	( Clopidogrel 150 vs. 75 mg day(-1) in patients undergoing percutaneous coronary intervention: a meta-analysis. Chen, YG; Hao, PP; Li, RJ; Wang, JL; Yang, JM; Zhang, MX; Zhang, Y, 2011)	0.37
"As compared with the currently recommended 75-mg day(-1) maintenance dosage of clopidogrel, the 150-mg day(-1) dosage can reduce major adverse cardiac and/or cerebrovascular events but may increase the risk of minor bleeding."	( Clopidogrel 150 vs. 75 mg day(-1) in patients undergoing percutaneous coronary intervention: a meta-analysis. Chen, YG; Hao, PP; Li, RJ; Wang, JL; Yang, JM; Zhang, MX; Zhang, Y, 2011)	0.37
" Until further data is available, some clinical strategies can be recommended: (1) individual gastrointestinal risk assessment, with PPIs administration only to patients on dual anti-platelet therapy with additional GI risk factors; (2) preferential use of PPIs that have shown less interference with clopidogrel efficacy; (3) wide separation of PPI and clopidogrel dosing to minimize the risk of interaction (PPI may be given before breakfast and clopidogrel at bedtime); (4) or alternative use of histamine-2-receptor antagonist therapy, in patients at low GI risk."	( [Clopidogrel--proton pump inhibitors drug interaction: implications to clinical practice]. Albuquerque, A; Fontes-Carvalho, R, 2010)	0.36
"The aim of this work was a preliminary study of the "in-process" amorphization of clopidogrel hydrogensulfate (CLP) as model drug during the production of tablets as dosage form."	( Formulation of tablets containing an 'in-process' amorphized active pharmaceutical ingredient. Jójárt-Laczkovich, O; Szabó-Révész, P, 2011)	0.37
" In order to achieve the desired results and, as with all medications, PPIs should always be used appropriately taking care never to exceed correct dosage and duration."	( Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections. Ferraccioli, GF; Gremese, E; Laria, A; Zoli, A, 2011)	0.37
" However, it needs to be shown that the higher dosage is associated with a beneficial clinical outcome in these patients."	( A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S, 2012)	0.38
" We examined potential associations between high on treatment platelet reactivity and the risk of ST and assessed the effects of increased antiplatelet dosage on platelet inhibition."	( High on treatment platelet reactivity and stent thrombosis. French, JK; Juergens, CP; Parikh, D; Rajendran, S; Shugman, I, 2011)	0.37
" Further study is required to determine optimal dosing and proper patient selection with prasugrel treatment."	( Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. Martin, MT; Nutescu, EA; Spinler, SA, 2011)	0.37
" Blood samples were collected before dosing and at 0, 2, 4, 7, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180 and 210 min after drug administration to determine the plasma drug concentration of FA."	( Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. Li, Y; Liu, C; Mi, S; Wang, N; Zhang, Y, 2011)	0.37
"A double-blind crossover study was conducted in four CYP2C19 genotype-defined metabolizer groups to assess whether increase in clopidogrel dosing can overcome reduced pharmacodynamic response in CYP2C19 poor metabolizers (PMs)."	( Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Bergougnan, L; Bhatt, DL; Dubar, M; Farenc, C; Hurbin, F; Lacreta, F; Pearson, K; Perrin, L; Simon, T; Vicaut, E, 2011)	0.37
" Doubling clopidogrel dosage to 150 mg restored the basal response."	( Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Cerboni, P; Doyen, D; Ferrari, E; Moceri, P, 2011)	0.37
" The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing."	( Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011)	0.37
" A "one size fits all" approach to clopidogrel dosing is probably flawed."	( Clopidogrel "resistance": where are we now? Hobson, AR; Qureshi, Z, 2013)	0.39
" PM103 is an intravenous formulation of clopidogrel being developed as an alternative to oral clopidogrel to provide for dosing flexibility in the emergent clinical setting."	( Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Adams, MP; Cooper, WD; Cushing, DJ; Kowey, PR; Machatha, S; Mosher, GL; Souney, PF; Zhang, B, 2012)	0.38
"All patients received 325 mg of aspirin and a loading dose of 600 mg of clopidogrel followed by a maintenance dosage of 325 mg/d of aspirin and 75 mg/d of clopidogrel for at least 6 months."	( High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011)	0.37
"In HD patients exhibiting HTPR following standard clopidogrel treatment, prasugrel 10 mg day(-1) is significantly more efficient than doubling the clopidogrel dosage in achieving adequate platelet inhibition."	( Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Alexopoulos, D; Davlouros, P; Fourtounas, C; Goumenos, D; Kassimis, G; Komninakis, D; Panagiotou, A; Xanthopoulou, I, 2011)	0.37
" Adjusted dosing according to weight may help achieve adequate therapeutic platelet inhibition and reactivity while decreasing thromboembolic complications."	( Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. Alexander, MJ; Choulakian, A; Drazin, D; Kornbluth, P; Nuño, M, 2011)	0.37
" Blood samples were drawn just before the first clopidogrel intake on day 1, and after the last dosing (day 7)."	( Effect of clopidogrel on circulating biomarkers of angiogenesis and endothelial activation. Azizi, M; Blanchard, A; Bura, A; Gaussem, P; Remones, V; Smadja, DM; Szymezak, J, 2012)	0.38
"Compared with the rational loading dosage, the tailored loading dosage better inhibited platelet aggregation based on a > 50% decrease in adenosine phosphate-mediated platelet aggregation (rational loading dosage vs."	( Use of tailored loading-dose clopidogrel in patients undergoing selected percutaneous coronary intervention based on adenosine diphosphate-mediated platelet aggregation. Chen, X; Ge, CJ; Lü, SZ; Meng, K; Song, XT; Zhu, HG, 2010)	0.36
" Twenty-nine healthy volunteers had platelet studies performed before and 1 week after 75 mg daily dosing of clopidogrel."	( Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. DeLao, T; Guthikonda, S; Ibrahim, H; Kleiman, NS; Nadipalli, S, 2012)	0.38
" Whether this is worth both the risk of non-compliance with twice-a-day dosing in real-life patients lacking the same motivation as their trial-volunteer counterparts, and the 2000-fold difference in incremental cost, is the remaining matter for debate."	( Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. Davies, JE; Francis, DP; Nijjer, SS, 2012)	0.38
" In the management of bleeding ulcer patients with high-risk stigmata of recent hemorrhage, resuming antiplatelet agents at 3-5 days after the last dosing is a reasonable strategy."	( New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. Hsu, PI, 2012)	0.38
"This study sought to assess the presence of a dose-response effect of cigarette smoking and its impact on high on-treatment platelet reactivity (HPR) in patients with diabetes mellitus treated with clopidogrel."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
" If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
"A dose-response effect was observed for all pharmacodynamic parameters tested."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
"Cigarette smoking is associated with a dose-response effect on clopidogrel-induced antiplatelet effects and lower rates of HPR in diabetes mellitus patients."	( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012)	0.38
"Testing platelet function makes clopidogrel dosing safer, and simplifies therapy adjustments in long-term treatment."	( Prophylactic use of clopidogrel in paediatric cardiac patients. Grohmann, J; Hanke, CA; Nakamura, L; Stiller, B; Zieger, B, 2012)	0.38
" In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively)."	( Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Bliden, K; Butler, K; Gurbel, PA; Husted, SE; Høimark, L; Storey, RF; Tantry, US; Teng, R; Wei, C, 2012)	0.38
" However, the reversible binding of ticagrelor to the P2Y(12) receptor requires a twice-daily dosing regimen."	( Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Ferro, A; Floyd, CN; Passacquale, G, 2012)	0.38
"In patients undergoing elective PCI, using bivalirudin as a bolus only dosing may be as effective and less costly when compared with bolus followed by an infusion for the duration of the intervention."	( Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. Ghosn, S; Sheikh-Taha, M, 2012)	0.38
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."	( Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. Halperin, JL; Varughese, CJ, 2012)	0.38
"This substudy of the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention patients (INNOVATE-PCI) trial evaluated the pharmacokinetic and pharmacodynamic effects of two dosing regimens of IV followed by oral elinogrel (120 mg IV plus 100 mg oral twice daily; 120 mg IV plus 150 mg oral twice daily) versus standard clopidogrel therapy (300-600 mg oral loading dose plus 75 mg oral maintenance dose) in 56 patients undergoing nonurgent PCI."	( Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (I Angiolillo, DJ; Broderick, S; Buerke, M; Conley, PB; Dabrowski, M; Gurbel, PA; Harrington, RA; Jennings, LK; Kochman, J; McClure, MW; Neumann, FJ; Rao, SV; Saucedo, JF; Stephens, G; Stumpf, J; Trenk, D; Welsh, RC; Wójcik, J, 2012)	0.38
"Compared with clopidogrel, the combination of IV and oral elinogrel achieves more rapid and enhanced antiplatelet effects that were sustained through the transition to oral elinogrel in the peri-PCI period, but these were not significant during chronic dosing in this pilot investigation."	( Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (I Angiolillo, DJ; Broderick, S; Buerke, M; Conley, PB; Dabrowski, M; Gurbel, PA; Harrington, RA; Jennings, LK; Kochman, J; McClure, MW; Neumann, FJ; Rao, SV; Saucedo, JF; Stephens, G; Stumpf, J; Trenk, D; Welsh, RC; Wójcik, J, 2012)	0.38
" To assist in estimating therapeutic warfarin doses, the warfarin label provides a pharmacogenomic dosing table and various warfarin pharmacogenomic dosing algorithms are available."	( Clinical pharmacogenomics of warfarin and clopidogrel. Shin, J, 2012)	0.38
" Twenty-week-old mice (n = 10-12) were ovariectomized or sham treated and dosed orally with clopidogrel (1 mg/kg) or vehicle (NaCl) daily for 4 weeks."	( Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. Arnett, TR; Brandao-Burch, A; Hajjawi, M; Jorgensen, NR; Orriss, IR; Patel, JJ; Schwarz, P; Syberg, S, 2012)	0.38
" Therefore the optimal dosage and duration of clopidogrel therapy is of utmost importance."	( Clinical use of clopidogrel. Byrne, RA; Sarafoff, N; Sibbing, D, 2012)	0.38
" Therefore, several new antiplatelet treatment strategies have been developed in order to optimize platelet inhibition: a) modification of dosing of commonly used agents; b) use of new agents; and c) addition of a third antiplatelet drug (triple therapy)."	( Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. Angiolillo, DJ; Ferreiro, JL, 2012)	0.38
"Six trials and one meta-analysis were identified; aspirin dosage was identified as a potential confounder."	( Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention. Dewilde, S; Hawkins, N, 2012)	0.38
" Steady-state dosing of clopidogrel 75 mg qd and dabigatran etexilate 150 mg bid (part 2) demonstrated minor effects on dabigatran pharmacokinetics (AUC(τ,ss) ratio test/reference: 91."	( Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Baumann, S; Friedman, J; Fritsch, H; Härtter, S; Schepers, C; Sennewald, R, 2013)	0.39
"Six male dogs all received 7 different dosing regimens separated by 1-5week washout periods: cangrelor (1μg/kg/min, intravenous infusion); ticagrelor (0."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	0.38
" With clopidogrel dosed 3hours after ticagrelor, IPA was reduced after washout of ticagrelor to 38% at 24hrs vs."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	0.38
"Regardless of dose, adjusted odds ratios associating clopidogrel use with the study endpoint were statistically significant and followed a dose-response pattern."	( Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. Grove, EL; Jørgensen, NR; Schwarz, P; Vestergaard, P; Würtz, M, 2013)	0.39
" The dosage of anti-platelet drugs, combination with any other drugs, clinical characters in baseline of all enrolled patients were analyzed."	( [Clinical application of VerifyNow-P2Y12 assay in evaluation of platelet inhibition efficacy of clopidogrel]. Chen, XM; Cui, HB; DU, WP; Feng, MJ; Hu, YW; Lin, SY; Pan, WM; Wang, SH; Wang, SQ; Wang, Y; Yang, R; Ye, HH; Zhou, HL, 2012)	0.38
" In consideration for prescribing DAPT (drug, dosage and duration) the clinician will have to weigh the potential benefits (reduction in death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke) and risks (severe or life-threatening bleeding) for each and every patient."	( Dual antiplatelet therapy for primary and secondary prevention. Dhruvakumar, S; Gerula, C; Kaluski, E; Klapholz, M; Maher, J; Mathur, AP; Mazza, V; Waller, AH, 2012)	0.38
" There was a nonsignificant decrease in thromboembolic complications in patients whose clopidogrel dosage was tailored to the assay."	( Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. Bennet, H; Berenstein, A; Brockington, C; Chong, J; Ewing, SL; Fifi, JT; Leesch, W; Narang, J, 2013)	0.39
" The comparator was standard dosage of clopidogrel."	( Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A, 2013)	0.39
" Regulatory agencies as well as major cardiac societies suggest the use of other anti-platelet medications or alternative dosing strategies for clopidogrel in patients with reduced effectiveness of clopidogrel."	( High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. Hochholzer, W; Kristensen, SD; Neumann, FJ; Trenk, D, 2013)	0.39
" At steady-state ticagrelor (50 mg bid, or 200 mg bid), concomitant aspirin (300 mg qd) had no effect on mean maximum plasma concentration (Cmax), median time to Cmax (tmax), or mean area under the plasma concentration-time curve for the dosing interval (AUC0-τ) for ticagrelor and its primary metabolite, AR-C124910XX."	( Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Butler, K; Maya, J; Teng, R, 2013)	0.39
" Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation."	( Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014)	0.4
" Additionally, CES1 genetic variants have the potential to serve as a biomarker to predict clopidogrel response and individualize clopidogrel dosing regimens in clinical practice."	( Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. Angiolillo, DJ; Brinda, BJ; Gawronski, BE; Markowitz, JS; Wang, X; Zhu, HJ, 2013)	0.39
" Larger studies are urgently needed to validate a clinically useful threshold to define clopidogrel hyper-response and to examine the clinical effects of antiplatelet dosage adjustment."	( Clopidogrel hyper-response and bleeding risk in neurointerventional procedures. Churilov, L; Dowling, R; Goh, C; Mitchell, P; Yan, B, 2013)	0.39
" Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)."	( Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013)	0.39
" Moreover, inappropriate statin dosing restrictions (underdosing of simvastatin and lovastatin) were deliberately utilized in PLATO, potentially contributing to the beneficial effect of ticagrelor."	( Exploring the ticagrelor-statin interplay in the PLATO trial. Dinicolantonio, JJ; Serebruany, VL, 2013)	0.39
" Dosage was maintained as 75mg clopidogrel daily, 250mg ticlopidine twice daily, and 250mg ticlopidine plus 80mg Gingko Biloba extract twice daily."	( Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia. Hong, JM; Joo, IS; Lee, JS; Lim, YA; Shin, DH, 2013)	0.39
" A review of data regarding aspirin use for secondary prevention of events in ACS demonstrated that low aspirin doses (75 to 160 mg/day) are consistently favored for short- and long-term use because of the lack of a dose-response relationship between increasing aspirin dose and improved efficacy, and a higher incidence of gastrointestinal bleeding with increasing aspirin dose."	( Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. Berger, JS, 2013)	0.39
" In study 2, 35 healthy subjects were treated with LDA 100 mg (regimen A), and then 20 randomly selected subjects were dosed clopidogrel 75 mg (regimen C), LDA/clopidogrel (regimen AC), or LDA/clopidogrel/rabeprazole 10 mg for 7 days."	( Antiplatelet drugs are a risk factor for esophageal mucosal injury. Furuta, T; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2013)	0.39
" A combined formulation of ASA and clopidogrel has been developed to provide dosing convenience and improve adherence."	( The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, si Huh, W; Jung, JA; Kim, JR; Kim, MJ; Kim, TE; Ko, JW; Lee, SY; Park, KM, 2013)	0.39
" Serial blood samples were collected immediately before and after dosing for 24 hours."	( The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, si Huh, W; Jung, JA; Kim, JR; Kim, MJ; Kim, TE; Ko, JW; Lee, SY; Park, KM, 2013)	0.39
" Dans certaines situations de risque par contre, une adaption du dosage est conseillée pour minimiser les effets secondaires négatifs: Chez les patients de plus de 75 ans, et/ou d'un poids corporel de moins de 60 kg, une réduction du dosage de prasugrel est conseillée en raison d'un risque élevé d'hémorragie."	( [Thrombocyte aggregation inhibitors: what are the risks?]. Curkovic, I; Egbring, M; Kullak-Ublick, GA, 2013)	0.39
" For warfarin, no significant sex difference was seen regarding bleeding event reports, suggesting individualised dosing being an important factor."	( Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment. Holm, L; Loikas, D; Malmström, RE; Mejyr, S; Rydberg, DM; Schenck-Gustafsson, K; von Euler, M; Wettermark, B, 2014)	0.4
" In this situation, a number of alternatives to conventional dosing of clopidogrel have been investigated, including increasing the dosage of clopidogrel, switching from clopidogrel to either prasugrel or ticagrelor, or adding cilostazol to clopidogrel therapy."	( Treatment options for patients with poor clopidogrel response. Nawarskas, JJ; Roberts, DI, )	0.13
"Optimal aspirin dosing after acute coronary syndromes remains uncertain."	( Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014)	0.4
" To observe whether antithrombin agents affect the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban, an open-label and parallel study was conducted."	( Pharmacokinetic and pharmacodynamic properties of batifiban coadministered with antithrombin agents in Chinese healthy volunteers. Chen, H; Chen, K; He, XM; Jia, MM; Li, J; Li, SF; Li, WY; Liu, MZ; Wang, YH; Wu, SL; Zhou, Y, 2013)	0.39
" The developed model may serve as the foundation for further exploration of pharmacogenetic-based dosing of EFV."	( Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. Abdelhady, AM; Desta, Z; Jiang, F; Overholser, BR; Shin, JG; Yeo, CW, 2014)	0.4
" In conclusion, in non-diabetic obese patients with CAD, standard prasugrel dosing achieved more potent PD effects than high-dose clopidogrel in the acute phase of treatment, but this was not sustained during maintenance phase treatment."	( Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014)	0.4
" Electronically compiled multidrug dosing histories allowed the concomitant intake of high-dose lipophilic statins to be identified as a risk factor of impaired response to clopidogrel and revealed that exposure to further potential drug-drug interactions (DDIs) was too low for analysis."	( Antiplatelet resistance in outpatients with monitored adherence. Arnet, I; Hersberger, KE; Romanens, M; Tsakiris, DA; Walter, PN, 2014)	0.4
" To overcome the problem some authors have suggested to increase the dosage of the drug, to use other drugs, to genotype patients, and not to use proton pomp inhibitors in patients on double antiplatelet therapy."	( What's new about clopidogrel. Biasucci, LM; Camaioni, C; Cialdella, P; Gustapane, M, 2013)	0.39
"Warfarin is among the ten drugs most commonly involved in adverse drug reactions, has a narrow therapeutic index and complex dosage regimen, exhibits enormous variability dose-response and high risk drug-drug interactions."	( Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital. Guidoni, CM; Obreli-Neto, PR; Pereira, LR, 2014)	0.4
" pylori-positive and 10-negative subjects) with 100 mg aspirin plus 75 mg clopidogrel (AC) once-daily dosing and AC plus 20 mg famotidine twice-daily dosing (ACH)."	( Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine. Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2014)	0.4
" Clopidogrel dosing regimens have evolved over time, enabling us to evaluate platelet reactivity in real-life ACS patients undergoing percutaneous coronary intervention and treated with three different clopidogrel doses."	( Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice. Beigel, R; Fefer, P; Gannot, S; Hod, H; Matetzky, S; Rosenberg, N; Savion, N; Shechter, M; Varon, D, 2015)	0.42
" The grade of gastric mucosal injuries was evaluated by esophagogastroduodenoscopy before and after dosing (on day 0 and day 14), and the grade of gastric mucosal injury was assessed according to the modified Lanza score."	( A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Fukui, H; Hida, N; Hori, K; Miwa, H; Nakamura, S; Ogawa, T; Ohda, Y; Okugawa, T; Oshima, T; Tomita, T; Tozawa, K; Watari, J, 2014)	0.4
" The developed methods were applied for simultaneous analysis of aspirin, atorvastatin and clopedogrel in capsule dosage forms and results were in good concordance with alternative liquid chromatography."	( Comparative study of three modified numerical spectrophotometric methods: an application on pharmaceutical ternary mixture of aspirin, atorvastatin and clopedogrel. Hegazy, ND; Issa, MM; Nejem, RM; Shanab, AA; Stefan-van Staden, RI, 2014)	0.4
" After discontinuation of the CCBs, angiotensin receptor blockers were newly administered to the patients or dosed up for control of blood pressure."	( Antiplatelet effect of clopidogrel can be reduced by calcium-channel blockers. Kim, JY; Kim, YD; Lee, KY; Seo, KD; Yoon, YW, 2014)	0.4
"This is the largest population-scale genetic epidemiology study that provides a high-resolution map of variants associated with clopidogrel response that could be potentially valuable to clinicians to rationally plan appropriate dosage for therapy in resource poor conditions based on population level allele frequencies."	( Pharmacogenetic landscape of clopidogrel in north Indians suggest distinct interpopulation differences in allele frequencies. Basu, A; Bharadwaj, D; Giri, AK; Khan, NM; Scaria, V; Tandon, N, 2014)	0.4
"Twice daily dosing is often perceived as inferior to once daily dosing due to a higher likelihood of missing a dose."	( Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B, 2014)	0.4
"Drug dosing histories of 5014 patients prescribed cardiovascular medications (primarily antihypertensive medicines) were extracted from an electronically compiled dosing history database."	( Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B, 2014)	0.4
" This modelling and simulation study suggests a therapeutic benefit of ticagrelor over clopidogrel when taking into account the most common dosing omissions."	( Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B, 2014)	0.4
" Medication use was compared between transfer and direct-arrival patients to determine if these therapies were delayed or dosed in excess."	( The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. Alexander, KP; Li, S; Magid, DJ; Peterson, ED; Roe, MT; Ting, HH; Wang, TY, 2014)	0.4
"ST-segment elevation myocardial infarction patients transferred for primary PCI in community practice are at risk for delayed and excessively dosed antithrombotic therapy, highlighting the need for continued quality improvement to maximize the appropriate use of these important adjunctive therapies."	( The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. Alexander, KP; Li, S; Magid, DJ; Peterson, ED; Roe, MT; Ting, HH; Wang, TY, 2014)	0.4
" Even a 12-hour separation of dosing does not appear to prevent drug interactions between omeprazole and clopidogrel."	( Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Chilton, R; Johnson, DA; Liker, HR, 2014)	0.4
" At the end of the dosing interval on day 28, mean final-extent IPA was 10."	( Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Emanuelsson, H; Hiasa, Y; Teng, R, 2014)	0.4
" A loading dosage of aspirin (500 mg) and/or clopidogrel (300 mg) was given 24 hours before the procedure to patients naïve to antiplatelet agents, whereas the usual dosage (aspirin 100 mg and clopidogrel 75 mg) was continued for patients who had previously been taking these agents for more than a week."	( Association between silent embolic cerebral infarction and continuous increase of P2Y12 reaction units after neurovascular stenting. Jung, JM; Kang, DW; Kim, BJ; Kim, JS; Kwon, JY; Kwon, SU; Lee, DH, 2014)	0.4
" One of the most widely studied drugs with regard to genomics-guided dosing options is the oral anticoagulant, warfarin."	( Is personalized medicine a dream or a reality? Kim, RB; Morse, BL, 2015)	0.42
" PD assessments included vasodilator-stimulated phosphoprotein, light transmission aggregometry, and VerifyNow P2Y12 ex vivo, before and after dosing and following in vitro incubation with escalating concentrations (1, 3, and 10 μM) of clopidogrel's active metabolite (Clop-AM)."	( Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Jakubowski, JA; Moser, BA; Rollini, F; Sugidachi, A; Tello-Montoliu, A; Ueno, M, 2014)	0.4
" The PRASugrel For Japanese PatIenTs with Coronary Artery Diseases Undergoing Elective PCI (PRASFIT-Elective) study investigated the efficacy and safety of different prasugrel dosing regimens in Japanese patients undergoing elective PCI."	( Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)	0.4
"These results support the risk-benefit profile of an adjusted dosing regimen of prasugrel in Japanese patients undergoing PCI."	( Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014)	0.4
" In this paper, we have described a rapid and convenient method of verification which polymorph of HSCL is present in its final solid dosage form."	( Solid-state NMR as an effective method of polymorphic analysis: solid dosage forms of clopidogrel hydrogensulfate. Kolodziejski, W; Mazurek, A; Pindelska, E; Pisklak, DM; Szeleszczuk, L, 2015)	0.42
"The study involved 209 non-cardiogenic ischemic stroke patients who were administered oral clopidogrel at a dosage of 75 mg/day for at least 1 week."	( Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients. Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Sehara, Y; Tanahashi, N, 2014)	0.4
" CYP2C19 was the covariate in the final pharmacokinetic model, and the model was to design a prior dosage regimen."	( [Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome]. Ding, XL; Gao, J; Hang, YF; Jiang, B; Miao, LY; Xie, C; Xue, L, 2014)	0.4
"This study aimed to validate a loading and maintenance clopidogrel dosing scheme for the inhibition of platelet function, measured by whole blood impedance aggregometry in healthy adult horses."	( Inhibition of platelet function with clopidogrel, as measured with a novel whole blood impedance aggregometer in horses. Failing, K; Moritz, A; Roscher, KA, 2015)	0.42
"Evaluate the impact of salt and counterion identity on performance of solid immediate release dosage forms of miconazole and clopidogrel, respectively, in fasted upper gastrointestinal lumen using in-vitro methodologies."	( In-vitro evaluation of performance of solid immediate release dosage forms of weak bases in upper gastrointestinal lumen: experience with miconazole and clopidogrel salts. Dimopoulou, M; Mourouti, CS; Reppas, C; Symillides, M; Vertzoni, M, 2016)	0.43
"Miconazole data indicate that salts may adversely affect performance of immediate release dosage forms of weak bases."	( In-vitro evaluation of performance of solid immediate release dosage forms of weak bases in upper gastrointestinal lumen: experience with miconazole and clopidogrel salts. Dimopoulou, M; Mourouti, CS; Reppas, C; Symillides, M; Vertzoni, M, 2016)	0.43
" Point-of-care genetic testing for CYP2C192, ABCB1 TT and CYP2C1917 was performed with carriers of either the CYP2C19*2 allele or ABCB1 TT genotype randomly assigned to a strategy of prasugrel 10 mg daily or an augmented dosing strategy of clopidogrel (150 mg daily for 6 days then 75 mg daily)."	( A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Bernick, J; Dick, AJ; Froeschl, M; Glover, C; Gollob, MH; Hibbert, B; Labinaz, M; Le May, MR; Marquis, JF; McPherson, R; Roberts, JD; So, DY; Tran, L; Wells, GA, 2016)	0.43
" Investigators have therefore sought to "escalate" clopidogrel dosing to overcome HTPR to reduce ischemic/thrombotic events."	( Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors. Howell, LA; Polasek, M; Rossi, JS; Stouffer, GA, 2015)	0.42
" We sought to evaluate platelet reactivity during loading and maintenance dosing of ticagrelor versus clopidogrel, and the pharmacokinetic profile of ticagrelor and its metabolite AR-C124910XX, in black patients with stable CAD taking low-dose aspirin (acetylsalicylic acid)."	( Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R, 2015)	0.42
" All patients received low-molecular-weight heparin in prophylactic dosage starting 24 hours after aneurysm treatment."	( Ventriculostomy-Related Hemorrhage After Treatment of Acutely Ruptured Aneurysms: The Influence of Anticoagulation and Antiplatelet Treatment. Bruder, M; El-Fiki, A; Güresir, E; Konczalla, J; Lescher, S; Schuss, P; Seifert, V; Vatter, H, 2015)	0.42
" Study results suggest that there is no benefit to dosing clopidogrel twice daily when compared to either prasugrel or once daily clopidogrel dosing."	( Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population. Khatri, S; Pierce, T, 2015)	0.42
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, dosage and administration, cost, and place in therapy of vorapaxar in the secondary prevention of atherosclerotic events are reviewed."	( Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)	0.42
" All of the incorrect interpretations were for patients with test results indicating a dosing or drug change (6/19; 32%)."	( Community pharmacists' experience with pharmacogenetic testing. Haga, SB; Mills, R; Moaddeb, J, )	0.13
" Therefore, clopidogrel napadisilate is a useful alternative option for the dosing of ischemic stroke patient populations."	( Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in stroke patients: multicenter, randomized, open-label, phase 4, non-inferiority clinical trial. Kang, K; Kim, BK; Kim, HJ; Koh, SH; Lee, SJ, 2016)	0.43
"Clopidogrel (Plavix®), is a widely used antiplatelet agent, which shows high inter-individual variability in treatment response in patients following the standard dosing regimen."	( Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults. Horenstein, RB; Jiang, XL; Lesko, LJ; Lewis, JP; Peletier, LA; Samant, S; Schmidt, S; Shuldiner, AR; Yerges-Armstrong, LM, 2016)	0.43
" A sigmoid dose-response curve defined the relations between CAMCmax and PRI after 3 to 24 h (IC50 , 459."	( Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. Beltrame, F; Benati, M; Calabria, S; Cattaneo, M; Danese, E; Fava, C; Gelati, M; Gottardo, R; Guidi, GC; Minuz, P; Tagliaro, F; Tavella, D, 2016)	0.43
" Therefore, the ABCB1 C3435T genotyping should be one of the parameters taken into account when deciding about the dosing regimen of clopidogrel."	( P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. Apostolovic, SR; Jankovic, SM; Jevtovic-Stoimenov, T; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zivkovic, VS; Zvezdanovic, JB, 2016)	0.43
" The use of novel and more potent drug or high clopidogrel maintenance dosing before stent implantation may be beneficial treatment options for antiplatelet therapy in CYP2C19*2 carriers."	( Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement. Avcilar, T; Cetin, SE; Emre, A; Erdem, A; Guney, AI; Isbir, T; Kaspar, EC; Kirac, D; Terzi, S; Yazici, S; Yesilcimen, K, 2016)	0.43
"The deformation behavior of particles under pressure dominates the mechanical properties of solid dosage forms."	( Visualization and quantification of deformation behavior of clopidogrel bisulfate polymorphs during tableting. Gui, SY; Guo, T; Li, HY; Li, Y; Nangia, A; Wu, L; Xiao, TQ; Yin, XZ; York, P; Zhang, JW, 2016)	0.43
"Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups."	( Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016)	0.43
" Platelet activation markers were measured by flow cytometry on unstimulated or stimulated (adenosine diphosphate (ADP) 20 μM) platelets, before and after each dosing period."	( Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients. Borna, C; Brown, P; Erlinge, D; Gidlöf, O; Jakubowski, JA; Lood, C; Truedsson, L; Wagner, H; Winters, K; Zhou, C, 2016)	0.43
" A study of the ability of the compounds to inhibit ADP-induced platelet aggregation in fresh rat whole blood collected 2 h after oral dosing of rats with the compounds (7."	( Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration. Fawcett, JP; Gu, J; Liu, M; Meng, X; Su, C; Wang, H; Xu, X; Yang, Y; Yang, Z; Zhao, X, 2016)	0.43
" The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations."	( The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. Bolek, T; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016)	0.43
"The dosing regimen of prasugrel adjusted for Japanese patients was compared with that of clopidogrel by analyzing the pharmacokinetics and pharmacodynamics in 40 healthy Japanese subjects in a randomized, single-blind crossover study."	( The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers. Iwaki, T; Umemura, K, 2016)	0.43
"High interindividual variability in clinical outcomes following clopidogrel's standard dosing regimen continues to be a challenge even two decades after its approval."	( Identifying clinically relevant sources of variability: The clopidogrel challenge. Horenstein, RB; Jiang, XL; Lesko, LJ; Lewis, JP; Peletier, LA; Samant, S; Schmidt, S; Shuldiner, AR, 2017)	0.46
" A fixed-dose combination (FDC) capsule (HCP0911) has been developed to provide dosing convenience and improve adherence."	( Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. Ahn, JH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, K; Koh, JS; Kwak, CH; Park, HW; Park, JR; Park, Y; Tantry, US, 2017)	0.46
" Dosage should be individualized in these populations."	( Effect of obesity and serum leptin level on clopidogrel resistance. Çiftçi, C; Doğan, A; Görmüş, U; Kahraman, S; Özdemir, E; Usta, E, 2016)	0.43
" Newer P2Y12 antagonists with faster onset and greater inhibition of platelet activity have improved cardiovascular outcomes but have created uncertainty with the appropriate dosing when switching between agents."	( In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M, 2017)	0.46
"The antiplatelet drug clopidogrel is widely used for prophylaxis of arterial thromboses in cats in a standard dosage of 18."	( Influence of a low dosage of clopidogrel on platelet function in cats as measured by the platelet function analyser PFA-100 and the multiplate analyser. Mischke, R; Teuber, M, 2016)	0.43
" These prerequisites resulted in working out a recommended algorithm of individual dosing of clopidogrel (based on the analysis of case histories of patients with atherosclerosis of lower limb arteries by the level of platelet aggregation to a series of inducers) and correction of the dose of the drug based on the results of molecular-genetic testing of the cytochrome CYPC19 gene."	( [Algorithm for selection of individual therapy with clopidogrel in vascular surgical practice]. Lifshits, GI; Seredina, TA; Shevela, AI; Slepukhina, AA; Zelenskaya, EM, )	0.13
"Various strategies are emerging for dosing antiplatelet therapies in preparation for pipeline stent embolization in adults."	( Optimal pediatric dosing of anti-platelet agents for pipeline stent embolization -a case report and review of the literature. Cobb, MIH; Fernando Gonzalez, L; Hauck, EF; Smith, TP; Zomorodi, AR, 2017)	0.46
" The clopidogrel dosage was adjusted to double the maintenance dose for the ineffective patients."	( Impact of the CYP2C19 Gene Polymorphism on Clopidogrel Personalized Drug Regimen and the Clinical Outcomes. Chen, K; Guo, X; Li, P; Liu, H; Liu, X; Zhang, R, 2016)	0.43
"For percutaneous coronary intervention in postoperative patients, research data is still lacking regarding clopidogrel dosage on the basis of different CYP2C19 genotypes."	( Impact of the CYP2C19 Gene Polymorphism on Clopidogrel Personalized Drug Regimen and the Clinical Outcomes. Chen, K; Guo, X; Li, P; Liu, H; Liu, X; Zhang, R, 2016)	0.43
" However, a substantial number of patients do not respond to clopidogrel despite a standardized dosage regimen, and this is directly associated with poor prognosis."	( Effects of four novel genetic polymorphisms on clopidogrel efficacy in Chinese acute coronary syndromes patients. Cao, S; Chen, BL; Fan, L; Liu, M; Liu, ZQ; Xiao, FY; Zhang, W; Zhou, G; Zhou, HH, 2017)	0.46
"The optimal dosing of novel oral P2Y12 receptor platelet inhibitors such as prasugrel or ticagrelor is unclear and especially challenging in East Asians."	( A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Bang, J; Jin, C; Kim, MH; Serebruany, V, )	0.13
" There was no difference in primary outcome between the loading dosage group 16."	( Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Tan, Z; Wang, W; Xiao, W; Xu, A; Yang, W; Zeng, J; Zhao, Y, 2017)	0.46
" This suggests that clopidogrel dosing in patients with acute coronary syndromes should be personalized, taking into consideration both ischemic and bleeding risk."	( Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017)	0.46
" The dosage of clopidogrel therapy should be adjusted based on its polymorphisms."	( [Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation]. Chen, J; Ding, N; Li, G; Peng, L; Shao, Y; Wang, Y; Xu, Z; Zhang, C, 2017)	0.46
" The genetic variants of vitamin K expoxide reductase might account for the universally lower warfarin dosage used in Chinese population."	( Integrative Medicine on Optimizing Clopidogrel and Aspirin Therapy. Chen, H, 2019)	0.51
" Decreased trend of negative outcomes could be observed in patients with double dosage of clopidogrel, but the difference was not significant."	( Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. Chen, J; Gao, R; Huang, X; Qiao, S; Tang, YD; Wang, W; Wu, Y; Xu, B; Yan, H; Yang, M; Yang, Y; Zhang, K, 2018)	0.48
"This was a prospective, randomized, open-label study conducted in patients on maintenance dosing (MD) of aspirin (81 mg/d) and clopidogrel (75 mg/d)."	( Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study. Agarwal, M; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Kureti, M; Moon, JY; Nagaraju, D; Nawaz, A; Rivas Rios, J; Rivas, A; Rollini, F; Shaikh, Z; Soffer, D; Suryadevara, S; Wali, M; Zenni, MM, 2018)	0.48
" As a result, a substantial number of patients (20-30%) with ACS show an inadequate response to clopidogrel despite a standardized dosing regimen."	( Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful? Bella, J; Krim, N; Zeb, I, 2018)	0.48
"Long-term evidence shows an increased risk of cardiovascular events in the morning hours and recent studies in aspirin-treated patients have shown increased platelet reactivity at the end of the dosing interval."	( Twenty-four-hour time dependency of clopidogrel effects in patients with acute coronary syndromes: The CiCAD-Study. Egger, F; Freynhofer, MK; Gruber, SC; Huber, K; Hübl, W; Weiss, TW; Willheim, M, 2019)	0.51
" Dosing starts at 10 mg dose and with 60 min intervals between doses, this now becomes a 4 h desensitization protocol."	( Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol. Bulva, J; Simon, RA, 2019)	0.51
" For emergent reversal of P2Y12 inhibitors, test method can affect platelet dosing recommendations, as different methods may give different results."	( Laboratory Monitoring of Platelet P2Y12 Receptor Inhibitors and Reversal of Antiplatelet Agents. Ahmed, T; Senzel, L; Spitzer, ED, 2019)	0.51
" There were two treatment phases during which cats received either Plavix or generic clopidogrel at a dosage of 18."	( Comparison of metabolomics and platelet aggregometry between Plavix and generic clopidogrel in cats: a pilot study. Court, MH; Hogan, DF; Lee, PM; Malkawi, M; Moore, GE; Woolcock, AD, 2019)	0.51
"Long-term evidence supports a clustering of cardiovascular events in the early morning and smaller mechanistic studies in aspirin-treated patients have shown increased platelet reactivity at the end of the dosing interval."	( Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study. Aradi, D; Dézsi, DA; Freynhofer, MK; Geisler, T; Gross, L; Haller, PM; Hein-Rothweiler, R; Huber, K; Huczek, Z; Massberg, S; Orban, M; Sibbing, D; Toth-Gayor, GG; Trenk, D, 2019)	0.51
" 63 patients were divided into four groups with different dosage regimen and the serum samples were collected for the analysis."	( Interaction of clopidogrel and fufang danshen dripping pills assay in coronary heart disease based on non-target metabolomics. Chang, H; Guo, MZ; Ji, S; Tang, DQ; Wang, TY; Yang, J, 2019)	0.51
"In order to mimic the standard dosing regimen for DAPT in human, various Sprague-Dawley rats treatment groups were received a bolus oral dose of DAPT on day 1 followed by DAPT for consecutive 13 days in absence and presence of orally co-administered four TCM herbs (Danshen, Gegen, Danggui and Chuanxiong) at their low and high doses."	( Impact of the Chinese herbal medicines on dual antiplatelet therapy with clopidogrel and aspirin: Pharmacokinetics and pharmacodynamics outcomes and related mechanisms in rats. Lee, P; Luo, X; Mok, C; Qian, C; Wu, C; Xiao, M; Yang, M; Zhang, Y; Zuo, Z, 2019)	0.51
" Dosing for neuroendovascular conditions is often extrapolated from the cardiac literature, although outcomes in cardiac patients may not be relevant to neurologic patients, making prophylactic treatment recommendations challenging for these patients."	( Periprocedural Neuroendovascular Antiplatelet Strategies for Thrombosis Prevention in Clopidogrel-Hyporesponsive Patients. Barra, ME; Berger, K; Brophy, GM; Tesoro, EP, 2019)	0.51
" Since patients with different genetic variations respond quite differently to clopidogrel therapy, the related genetic testing plays a vital role in its dosage and genetic testing related to clopidogrel therapy is currently considered as routine test worldwide."	( Comparison between MassARRAY and pyrosequencing for CYP2C19 and ABCB1 gene variants of clopidogrel efficiency genotyping. Dai, S; Jiang, Y; Li, Y; Liu, J; Pan, J; Xu, Z, 2019)	0.51
" Modified dosing strategies were shown to increase the final PRU values and to decrease the percentage of platelet inhibition (137."	( Dose adjustment of clopidogrel in hyper-responder patients with unruptured intracranial aneurysms treated with stents. Cayuela, A; de Albóniga-Chindurza, A; García-Lozano, JR; González, A; Luque Vega, MI; Ortega-Quintanilla, J; Zapata-Arriaza, E, 2020)	0.56
" Integrating pharmacogenomics into clinical practice to assist in drug selection and dosing has the potential to improve the outcomes of treatment, reduce the risk of drug-induced morbidity and death, and be cost-effective."	( Pharmacogenomics: An evolving clinical tool for precision medicine. Eng, C; Erwin, AL; Hicks, JK; Hockings, JK; Mason, NT; Pasternak, AL, 2020)	0.56
" Here we describe the results of 3 studies that evaluated the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects."	( Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020)	0.56
"To allow for tailored dosing and overcome swallowing difficulties, compounded liquid medication is often required in pediatric patients."	( Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4. Anagnostou, K; Cunha, CN; da Silva, SL; Dijkers, E; Ferreira, AO; Polonini, H, )	0.13
" PK modelling and simulation were conducted to support dosing recommendations."	( Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. Axelsen, LN; Bruderer, S; Perez Ruixo, JJ; Poggesi, I; Rasschaert, F, 2021)	0.62
"This review aimed to evaluate the clinical success of clopidogrel dosing based on CYP2C19 genotype and to identify the relevant additional factors that may be useful for consideration by the clinician when dosing individuals with clopidogrel."	( Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration. Chetty, M; Manchandani, P; Ravenstijn, P, 2021)	0.62
"Our results demonstrated the impact of clopidogrel on the pharmacokinetics of selexipag and its active metabolite and suggested that selexipag should be carefully prescribed with clopidogrel with dose adjustment or reducing the dosing frequency in Japanese clinical settings."	( Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers. Hakamata, A; Inui, N; Kamiya, C; Katayama, N; Namiki, N; Odagiri, K; Tanaka, S; Tatsumi, K; Uchida, S; Watanabe, H, 2021)	0.62
"Patients bearing polymorphisms termed CYP2C19 loss of function (LoF) alleles and ABCB1-C3435T may do not properly respond to standard dosage of clopidogrel and have an increased risk of thrombosis."	( The need of a multicomponent guiding approach to personalize clopidogrel treatment. Amelia, F; Carmine, S; Giancarlo, A; Giovanna, N; Graziamaria, C; Maria, C; Martina, T; Teresa, I; Valentina, M; Valeria, C, 2021)	0.62
" Of which, there were 2 cases which changed the dosage of clopidogrel to 75 mg BID, 14 cases who changed clopidogrel to ticagrelor."	( Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI. Gao, M; Hou, YL; Jia, XM; Ma, LP; Ren, MY; Wang, JR; Zhang, M; Zhang, P; Zhang, Y, 2020)	0.56
" To improve adherence to DAPT, the FDC (fixed dose combination) of Acetylsalicylic acid (ASA) and clopidogrel was developed into a single pill instead of two separate pills thus facilitating the dosage and administration of the therapy and increasing compliance."	( Adherence and persistence analysis in patients treated with double antiplatelet therapy (DAPT) at two years in real life. Costantini, A; Romagnoli, A; Santoleri, F, 2021)	0.62
" Compared with a standard clopidogrel-based dual antiplatelet therapy (DAPT) regimen, an intensified dosing strategy appears to offer no additional benefit with a signal of possible harm."	( Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Boden, W; Bossard, M; Budaj, A; Di Pasquale, G; Faxon, D; Flather, M; Gao, P; Granger, CB; Joyner, C; Kastrati, A; Mehta, SR; Moccetti, T; Pais, P; Steg, G; Tanguay, JF; Valentin, V; Yusuf, S, 2021)	0.62
" Patients received alternative drug dosing or antiplatelet agents other than clopidogrel only if this was prescribed for another diagnosis or they had a preexisting contraindication."	( Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting. Hess, NR; Kilic, A; Sultan, I; Thoma, F; Wang, Y, 2021)	0.62
" Clopidogrel hyper-responsive patients received reduced dosing according to the values of follow-up PRUs before and 7, 14, 30, and 90 days after the procedure."	( Active management of the target P2Y12 reaction unit range in patients undergoing stent-assisted coil embolization for unruptured cerebral aneurysms. Furuta, T; Kotsugi, M; Myouchin, K; Nakagawa, I; Nakase, H; Nakase, K; Park, HS; Yamada, S; Yokoyama, S, 2021)	0.62
" This modified dosage regimen has been established in studies conducted in Japan; however, the efficacy and safety of switching from clopidogrel to prasugrel DAPT among Taiwanese patients remain to be explored."	( Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy. Cheng, LC; Chu, PH; Huang, CL; Kuo, FY; Lan, WR; Lee, CH; Lee, WL; Lin, WS; Liu, PY; Lo, PH; Lu, TM; Nikolajsen, C; Rafael, V; Su, CH; Tsukiyama, S; Wang, YC; Yang, WC; Yin, WH, 2022)	0.72
" The impact of proactive regulatory action, such as recommended dosing and therapeutic drug monitoring (TDM), was also observable within the global database."	( The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in Japan. Aoki, Y; Chandler, RE; Lönnstedt, IM; Wakao, R, 2021)	0.62
" A decreased MACCE rate was also observed in patients administered the double dosage of clopidogrel, but the bleeding risk was increased compared with the control group."	( Efficacy and safety of ticagrelor versus clopidogrel with different dosages in acute coronary syndrome patients with high GRACE and CRUSADE scores. Lan, Y; Xiao, P; Xie, F, )	0.13
"Liquisolid compact is a novel dosage form in which a liquid medication (liquid drug, drug solution/dispersion in non-volatile solvent/solvent system) is converted to a dry, free flowing powder and compressed."	( Evaluation of the effect of carrier material on modification of release characteristics of poor water soluble drug from liquisolid compacts. Ali, B; Alyami, HS; Badshah, M; Khan, A; Naz, A; Ullah, M; Wahab, A, 2021)	0.62
"Obesity attenuated metabolic activation of clopidogrel and increased counts of circulating reticulated and mature platelets, leading to impaired platelet responsiveness to the drug in mice, suggesting that clopidogrel dosage may need to be adjusted adequately in overweight or obese patients."	( Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice. Ge, PX; Ji, JZ; Jiang, LP; Li, YF; Mi, QY; Tai, T; Xie, HG; Zhu, T, 2022)	0.72
" We investigated whether alternate-day dosing of vonoprazan might avoid this interaction with clopidogrel while providing sufficient gastric acid inhibition."	( Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel : Influence of alternate-day dosing of vonoprazan. Furuta, T; Hamaya, Y; Higuchi, T; Iwaizumi, M; Kagami, T; Osawa, S; Sugimoto, K; Takahashi, S; Tamura, S; Tani, S; Uotani, T; Yamade, M, 2022)	0.72
"In the present work, we report a method based on micellar liquid chromatography coupled with ultraviolet detection (MLC/UV), for the simultaneous quantification of combined anti-platelet therapy namely, clopidogrel bisulfate (CPS), aspirin (ASP), together with salicylic acid (SA), in their pharmaceutical dosage form."	( Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations. Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS, 2022)	0.72
"The MLC/UV method was successfully applied to the quantitative analysis of CPS, ASP together with SA-as a main degradation product of ASP-in their pharmaceutical dosage form."	( Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations. Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS, 2022)	0.72
"The developed method was successfully applied for the determination of clopidogrel bisulfate (CPS), aspirin (ASP), together with salicylic acid (SA), in their pharmaceutical dosage form."	( Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations. Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS, 2022)	0.72
" We therefore titrate clopidogrel dosing to maintain a moderate level of platelet inhibition using the VerifyNow P2Y12 assay."	( Excessive platelet inhibition following Pipeline embolization of intracranial aneurysms. Anders, M; Beitelshees, AL; Caffes, N; Cannarsa, G; Cherian, J; Gandhi, D; Jindal, G; Khunte, M; Malhotra, A; Miller, TR; Rock, P; Simard, JM, 2023)	0.91
" Advantages in both PK and pharmacogenetics suggest that vicagrel may reduce the complexity of currently recommended CYP2C19-based dosage adjustment for clopidogrel."	( Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2. Gong, Y; He, Y; Lai, X; Li, YG; Liu, X; Liu, Y; Sun, H; Yan, X; Zhang, EY; Zhang, L, 2022)	0.72
" Clopidogrel was the most difficult medication to consistently administer, and twice a day dosing was the highest frequency of medication administration most owners could achieve."	( A multicenter prospective evaluation of owner medication adherence for feline cardiovascular disease in the referral setting. Allen, JW; Chapel, EH; Murphy, LA; Nakamura, RK; O'Malley, B; Russell, NJ; Schrope, DP; Sloan, CQ; Wang, ML; Zimmerman, SA, 2022)	0.72
" We aimed to evaluate the dose-response relationship of milvexian in participants treated with dual antiplatelets."	( Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. Amarenco, P; Bereczki, D; Czlonkowska, A; Diener, HC; Donovan, M; Endres, M; Gailani, D; Hankey, GJ; Kahl, A; Kasner, SE; Li, D; Lutsep, HL; Molina, CA; Ntaios, G; Perera, V; Sharma, M; Shuaib, A; Toyoda, K; Tsivgoulis, G, 2022)	0.72
"The AXIOMATIC-SSP trial will evaluate the dose-response of milvexian for ischemic stroke occurrence in participants with ischemic stroke or TIA."	( Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. Amarenco, P; Bereczki, D; Czlonkowska, A; Diener, HC; Donovan, M; Endres, M; Gailani, D; Hankey, GJ; Kahl, A; Kasner, SE; Li, D; Lutsep, HL; Molina, CA; Ntaios, G; Perera, V; Sharma, M; Shuaib, A; Toyoda, K; Tsivgoulis, G, 2022)	0.72
" In addition, PGx-guided dosing guidelines are now available for multiple CVD drugs, including clopidogrel, warfarin, and statins."	( Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates. Al-Mahayri, ZN; Al-Maskari, F; Ali, BR; AlKaabi, J; Alqasrawi, MN; Altoum, SM; AlZaabi, A; Badawi, S; George, L; Hamza, D; Jamil, G; Khasawneh, LQ; Ouda, H; Patrinos, GP, 2022)	0.72
" Regarding warfarin, only 20% of the participants exhibited reference alleles at VKORC1-1639G > A, CYP2C92, and CYP2C93, leaving 80% with alternative genotypes at any of the two genes that can be integrated into the warfarin dosing algorithms and can be used whenever the patient receives a warfarin prescription."	( Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates. Al-Mahayri, ZN; Al-Maskari, F; Ali, BR; AlKaabi, J; Alqasrawi, MN; Altoum, SM; AlZaabi, A; Badawi, S; George, L; Hamza, D; Jamil, G; Khasawneh, LQ; Ouda, H; Patrinos, GP, 2022)	0.72
"10]), compared with never use, and there was no evidence of a dose-response relation."	( Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study. Cairat, M; Dossus, L; Fournier, A; Hicks, B; Olesen, M; Pottegård, A, 2023)	0.91

Role	Description
platelet aggregation inhibitor	A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
anticoagulant	An agent that prevents blood clotting.
P2Y12 receptor antagonist	An antagonist at the P2Y12 receptor
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
thienopyridine	Any organic heterobicyclic compound whose skeleton results from the formal ortho-fusion of any bond of a pyridine with any bond of a thiophene.
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
methyl ester	Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Clopidogrel Action Pathway	9	8
Clopidogrel Metabolism Pathway	9	8

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	35.1973	0.0013	10.1577	42.8575	AID1259253; AID1259256
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	19.9526	0.2818	9.7212	35.4813	AID2326
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	89.1251	3.5481	19.5427	44.6684	AID743266
geminin	Homo sapiens (human)	Potency	25.1189	0.0046	11.3741	33.4983	AID624297
Rap guanine nucleotide exchange factor 4	Homo sapiens (human)	Potency	79.4328	3.9811	46.7448	112.2020	AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 2C8	Homo sapiens (human)	Ki	14.3000	0.0018	0.3873	3.3000	AID705605
Cytochrome P450 2B6	Homo sapiens (human)	Ki	1.1000	0.0004	1.4160	10.0000	AID589245
Sodium-dependent serotonin transporter	Homo sapiens (human)	IC50 (µMol)	0.5620	0.0001	0.8645	8.7096	AID625222
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	0.2990	0.0000	0.7048	8.1930	AID625222
Cytochrome P450 2C19	Homo sapiens (human)	Ki	14.3000	0.0001	0.8300	10.0000	AID705605
P2Y purinoceptor 12	Homo sapiens (human)	IC50 (µMol)	2.4000	0.0004	1.0489	10.0000	AID1850679
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid hydroxylation	Cytochrome P450 2C8	Homo sapiens (human)
organic acid metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C8	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C8	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C8	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C8	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C8	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C8	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
cholesterol biosynthetic process	Liver carboxylesterase 1	Homo sapiens (human)
cholesterol metabolic process	Liver carboxylesterase 1	Homo sapiens (human)
response to toxic substance	Liver carboxylesterase 1	Homo sapiens (human)
positive regulation of cholesterol efflux	Liver carboxylesterase 1	Homo sapiens (human)
negative regulation of cholesterol storage	Liver carboxylesterase 1	Homo sapiens (human)
epithelial cell differentiation	Liver carboxylesterase 1	Homo sapiens (human)
cholesterol homeostasis	Liver carboxylesterase 1	Homo sapiens (human)
reverse cholesterol transport	Liver carboxylesterase 1	Homo sapiens (human)
medium-chain fatty acid metabolic process	Liver carboxylesterase 1	Homo sapiens (human)
regulation of bile acid biosynthetic process	Liver carboxylesterase 1	Homo sapiens (human)
cellular response to cholesterol	Liver carboxylesterase 1	Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulus	Liver carboxylesterase 1	Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transport	Liver carboxylesterase 1	Homo sapiens (human)
positive regulation of cholesterol metabolic process	Liver carboxylesterase 1	Homo sapiens (human)
regulation of bile acid secretion	Liver carboxylesterase 1	Homo sapiens (human)
lipid catabolic process	Liver carboxylesterase 1	Homo sapiens (human)
monoamine transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to hypoxia	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to nutrient	Sodium-dependent serotonin transporter	Homo sapiens (human)
memory	Sodium-dependent serotonin transporter	Homo sapiens (human)
circadian rhythm	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to toxic substance	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of gene expression	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of serotonin secretion	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to estradiol	Sodium-dependent serotonin transporter	Homo sapiens (human)
social behavior	Sodium-dependent serotonin transporter	Homo sapiens (human)
vasoconstriction	Sodium-dependent serotonin transporter	Homo sapiens (human)
sperm ejaculation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of neuron differentiation	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of cell cycle	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of organ growth	Sodium-dependent serotonin transporter	Homo sapiens (human)
behavioral response to cocaine	Sodium-dependent serotonin transporter	Homo sapiens (human)
enteric nervous system development	Sodium-dependent serotonin transporter	Homo sapiens (human)
brain morphogenesis	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin uptake	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane depolarization	Sodium-dependent serotonin transporter	Homo sapiens (human)
platelet aggregation	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to retinoic acid	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to cGMP	Sodium-dependent serotonin transporter	Homo sapiens (human)
regulation of thalamus size	Sodium-dependent serotonin transporter	Homo sapiens (human)
conditioned place preference	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
adaptive immune response	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
calcium-ion regulated exocytosis	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
regulation of exocytosis	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
insulin secretion	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
positive regulation of insulin secretion	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
regulation of synaptic vesicle cycle	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
Ras protein signal transduction	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
regulation of insulin secretion	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
monoatomic ion transport	P2Y purinoceptor 12	Homo sapiens (human)
substrate-dependent cell migration, cell extension	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
hemostasis	P2Y purinoceptor 12	Homo sapiens (human)
calcium-mediated signaling	P2Y purinoceptor 12	Homo sapiens (human)
cerebral cortex radial glia-guided migration	P2Y purinoceptor 12	Homo sapiens (human)
cell projection organization	P2Y purinoceptor 12	Homo sapiens (human)
lamellipodium assembly	P2Y purinoceptor 12	Homo sapiens (human)
platelet activation	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of integrin activation by cell surface receptor linked signal transduction	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of monoatomic ion transport	P2Y purinoceptor 12	Homo sapiens (human)
response to axon injury	P2Y purinoceptor 12	Homo sapiens (human)
regulation of chemotaxis	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of chemotaxis	P2Y purinoceptor 12	Homo sapiens (human)
establishment of localization in cell	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	P2Y purinoceptor 12	Homo sapiens (human)
platelet aggregation	P2Y purinoceptor 12	Homo sapiens (human)
cellular response to ATP	P2Y purinoceptor 12	Homo sapiens (human)
visual system development	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of ruffle assembly	P2Y purinoceptor 12	Homo sapiens (human)
regulation of microglial cell migration	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of microglial cell migration	P2Y purinoceptor 12	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 2C8	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C8	Homo sapiens (human)
protein binding	Cytochrome P450 2C8	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C8	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 2C8	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C8	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C8	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 2C8	Homo sapiens (human)
heme binding	Cytochrome P450 2C8	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C8	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
sterol esterase activity	Liver carboxylesterase 1	Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activity	Liver carboxylesterase 1	Homo sapiens (human)
carboxylesterase activity	Liver carboxylesterase 1	Homo sapiens (human)
carboxylic ester hydrolase activity	Liver carboxylesterase 1	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
protein binding	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
cAMP binding	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
protein-macromolecule adaptor activity	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
small GTPase binding	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
G protein-coupled adenosine receptor activity	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled ADP receptor activity	P2Y purinoceptor 12	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activity	P2Y purinoceptor 12	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Cytochrome P450 2C8	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C8	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C8	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C8	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C8	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Liver carboxylesterase 1	Homo sapiens (human)
endoplasmic reticulum	Liver carboxylesterase 1	Homo sapiens (human)
endoplasmic reticulum lumen	Liver carboxylesterase 1	Homo sapiens (human)
lipid droplet	Liver carboxylesterase 1	Homo sapiens (human)
cytosol	Liver carboxylesterase 1	Homo sapiens (human)
lipid droplet	Liver carboxylesterase 1	Homo sapiens (human)
endoplasmic reticulum	Liver carboxylesterase 1	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
cytosol	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
membrane	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
hippocampal mossy fiber to CA3 synapse	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
plasma membrane	P2Y purinoceptor 12	Homo sapiens (human)
cell surface	P2Y purinoceptor 12	Homo sapiens (human)
membrane	P2Y purinoceptor 12	Homo sapiens (human)
cell projection membrane	P2Y purinoceptor 12	Homo sapiens (human)
cell body membrane	P2Y purinoceptor 12	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1493927	Antagonist activity at P2Y12 in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation at 10 uM pretreated for 30 mins followed by collagen addition measured after 5 mins by light transmission aggregometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1217728	Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID700805	Drug metabolism in human liver microsomes assessed as CYP2D6-mediated (2S)-methyl 2-(2-chlorophenyl)-2-(3-hydroxy-2,3,6,7-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1186087	Ex vivo inhibition of platelet aggregation in po dosed Sprague-Dawley rat after 2 hrs	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
AID700809	Drug metabolism in human liver microsomes assessed as CYP1A2-mediated (2S)-methyl 2-(2-chlorophenyl)-2-(3-hydroxy-2,3,6,7-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1339045	Toxicity in Swiss albino mouse assessed as bleeding time at 70 umol/kg, po
AID1217712	Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1068712	Displacement of UDP-[14C]GlcNAc from TarO (unknown origin) after 2.5 hrs by scintillation counting analysis	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites.
AID1656368	Drug metabolism in human plasma assessed as acid metabolite formation at 75 mg, po after 1 hr using radiolabelled compound	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Designing around Structural Alerts in Drug Discovery.
AID1212912	Inhibition of CYP2B6 variant in human liver microsomes harboring CYP2B66/6 genotype assessed as 8-hydroxyefavirenz formation using efavirenz as substrate after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1217711	Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID667509	Drug metabolism in rat liver microsomes assessed as NADPH-dependent active metabolite glutathione adducts 2 formation at 20 uM after 30 mins by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
AID1277732	Toxicity in Swiss albino mouse assessed as bleeding time at 70 umol/kg, po administered as single dose measured up to 24 hrs (Rvb = 3.5 +/- 0.3 mins)	2016	European journal of medicinal chemistry, Mar-03, Volume: 110	Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.
AID1062236	Antithrombotic activity in FeCl2-induced Sprague-Dawley rat carotid artery thrombosis model assessed as reduction of thrombus weight at 20 mg/kg, po after 60 mins relative to vehicle-treated control	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.
AID1493931	Antagonist activity at P2Y12 in human platelet rich plasma assessed as inhibition of ADP-induced CD62P expression pretreated for 30 mins followed by ADP addition measured after 5 mins by flow cytometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1656369	Protein binding in human platelets using radiolabelled compound	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Designing around Structural Alerts in Drug Discovery.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1339042	Anti-thrombotic activity in Swiss albino mouse assessed as protection against collagen/epinephrine-induced pulmonary thromboembolism at 70 umol/kg, po administered 60 mins prior to thrombotic challenge measured 5 hrs post dose
AID1179966	Antithrombotic activity in rabbit model of electrically-induced carotid artery thrombosis assessed as reduction in thrombus formation dosed 30 mins before electrical stimulation	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.
AID700802	Drug metabolism in human liver microsomes assessed as decrease in CYP3A4/5-mediated (S)-5-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-6,7-dihydrothieno[3,2-c]pyridin-5-ium formation at 20 uM in presence of ketoconazole	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1892492	Antithrombotic activity in po dosed cynomolgus monkey electrolytic mediated carotid arterial thrombosis model assessed as reduction in weight of carotid artery thrombus	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
AID1151460	Antithrombotic activity in pentobarbital anesthetized rat assessed as reduction in FeCl2-induced thrombus weight at 10 mg/kg, po administered 1 hr prior to FeCl2 challenge	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID700811	Prodrug activation in human liver microsomes assessed as CYP2D6-mediated 2-oxo-clopidogrel formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1143853	Prolongation of bleeding time in mouse at 70 uM/kg, po administered as single dose by tail excision method relative to control	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation.
AID700813	Prodrug activation in human liver microsomes assessed as CYP2B6-mediated 2-oxo-clopidogrel formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1871460	Lipophilicity, logP of compound
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1064263	Antiplatelet activity against New Zealand white rabbit platelets assessed as inhibition of ADP-induced platelet aggregation preincubated at 30 uM for 2 mins before challenge measured after 2 mins by spectrophotometry	2014	Journal of natural products, Jan-24, Volume: 77, Issue:1	Lignans from the aerial parts of Saururus chinensis: isolation, structural characterization, and their effects on platelet aggregation.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID667508	Drug metabolism in rat liver microsomes assessed as NADPH-dependent active metabolite glutathione adducts 4 formation at 20 uM after 30 mins by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1727519	Antithrombotic activity in cynomolgus monkey model of electrolytic carotid artery thrombosis assessed as increase in bleeding time in provoked kidney at 0.3 mg/kg, PO administered once daily for 3 days measured at 2 hrs post last dose	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID705605	Time dependent inhibition of CYP2C19	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1339041	Anti-thrombotic activity in Swiss albino mouse assessed as protection against collagen/epinephrine-induced pulmonary thromboembolism at 70 umol/kg, po administered 60 mins prior to thrombotic challenge measured up to 5 hrs post dose
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1277741	Antithrombotic activity in Swiss albino mouse assessed as protection against collagen-epinephrine induced pulmonary thromboembolism at 70 umol/kg, po after 4 hrs	2016	European journal of medicinal chemistry, Mar-03, Volume: 110	Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.
AID589247	Mechanism based inhibition of human cytochrome P450 2C19	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1217708	Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID667515	Half life in Sprague-Dawley rat assessed as clopidogrel thioacetate level at 24 umol/kg, po	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1727522	Antithrombotic activity in cynomolgus monkey model of electrolytic carotid artery thrombosis assessed as increase in mesenteric bleeding time at 1 mg/kg, PO administered once daily for 3 days measured at 2 hrs post last dose	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
AID766345	Therapeutic index, ratio of ED50 for antithrombotic activity in Beagle dog modified Folts model to dose required to increase in bleeding time by 3.5 fold in Beagle dog modified Folts model	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.
AID1217710	Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217727	Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1517825	Antithrombotic activity in Wistar rat plasma assessed as wet weight of thrombus at 22 umol/kg, po measured after 1 hr (Rvb = 0.403 +/- 0.183 g)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of novel, potent, isosteviol-based antithrombotic agents.
AID1068713	Ratio of MIC for community acquired methicillin-resistant Staphylococcus aureus USA300 in presence of targocil to MIC for community acquired methicillin-resistant Staphylococcus aureus USA300 by checkerboard broth microdilution assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites.
AID1217709	Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID456232	Activity at human recombinant CES1 expressed in baculovirus-infected Spodoptera frugiperda Sf21 cells assessed as substrate hydrolysis by fluorescence assay	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations.
AID1217707	Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1450602	In vivo drug metabolism in human assessed as CYP2C8-mediated 2-oxoclopidogrel formation	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID705583	Time dependent inhibition of CYP2B6 in human liver microsomes	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID1143852	Antithrombotic activity in mouse assessed as protection against collagen-epinephrine-induced pulmonary thromboembolism at 70 uM/kg, po administered 60 mins prior to thrombotic challenge measured for up to 5 hrs post-drug dose	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation.
AID1517826	Antithrombotic activity in Wistar rat plasma assessed as dry weight of thrombus at 22 umol/kg, po measured after 1 hr (Rvb = 0.120 +/- 0.045 g)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of novel, potent, isosteviol-based antithrombotic agents.
AID1151458	Toxicity in rat assessed as prolongation of cuticle bleeding time at 10 mg/kg, po relative to control	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet
AID700810	Prodrug activation in human liver microsomes assessed as CYP3A4/5-mediated 2-oxo-clopidogrel formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1217704	Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID635594	Antiplatelet activity against New Zealand white rabbit platelets assessed as inhibition of ADP-induced platelet aggregation at 9.6 ug/mL treated 2 mins before ADP challenge measured after 4 mins by turbidimetric analysis	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Structure-activity relationships of chalcone analogs as potential inhibitors of ADP- and collagen-induced platelet aggregation.
AID1068714	Ratio of MIC for community acquired methicillin-resistant Staphylococcus aureus USA300 in presence of cefuroxime to MIC for community acquired methicillin-resistant Staphylococcus aureus USA300 by checkerboard broth microdilution assay	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID635595	Antiplatelet activity against New Zealand white rabbit platelets assessed as inhibition of collagen-induced platelet aggregation at 9.6 ug/mL treated 2 mins before collagen challenge measured after 4 mins by turbidimetric analysis	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Structure-activity relationships of chalcone analogs as potential inhibitors of ADP- and collagen-induced platelet aggregation.
AID705590	Inhibition of CYP2B6 in human assessed as decrease of hydroxybupropion metabolite systemic exposure	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID700800	Prodrug activation in human liver microsomes assessed as increase in Cytochrome P450-mediated (2S)-methyl 2-(2-chlorophenyl)-2-(3-hydroxy-2,3,6,7-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate formation at 20 uM in presence of ketoconazole	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1892498	Antithrombotic activity in cynomolgus monkey assessed as prolongation of kidney bleeding time at 3 mg/kg	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID667510	Drug metabolism in rat liver microsomes assessed as NADPH-dependent active metabolite glutathione adducts 3 formation at 20 uM after 30 mins by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
AID1151457	Toxicity in rat assessed as prolongation of mesentric bleeding time at 10 mg/kg, po relative to control	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet
AID1493932	Antagonist activity at P2Y12 in human platelet rich plasma assessed as inhibition of ADP-induced PAC1 expression pretreated for 30 mins followed by ADP addition measured after 5 mins by flow cytometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1450601	In vivo drug metabolism in human assessed as CYP2C8-mediated 2-(1-((S)-1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-mercaptopiperidin-3-ylidene)acetic acid formation	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID1277719	Antithrombotic activity in Swiss albino mouse assessed as protection against collagen-epinephrine induced pulmonary thromboembolism at 70 umol/kg, po after 1 hr	2016	European journal of medicinal chemistry, Mar-03, Volume: 110	Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.
AID1441772	Drug metabolism assessed as CES1 (unknown origin)-mediated SR26334 formation	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds.
AID1727523	Antithrombotic activity in cynomolgus monkey model of electrolytic carotid artery thrombosis assessed as increase in provoked kidney bleeding time at 1 mg/kg, PO administered once daily for 3 days measured at 2 hrs post last dose	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
AID589245	Mechanism based inhibition of human cytochrome P450 2B6 using recombinant CYP2B6	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1892497	Antithrombotic activity in cynomolgus monkey assessed as prolongation of kidney bleeding time at 1 mg/kg	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
AID1727535	Antithrombotic activity in cynomolgus monkey model of electrolytic carotid artery thrombosis assessed as increase in bleeding time in provoked kidney at 0.3 mg/kg, PO administered once daily for 3 days measured at 2 hrs post last dose relative to control	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
AID1212911	Inhibition of CYP2B6 variant in human liver microsomes harboring CYP2B61/1 genotype assessed as 8-hydroxyefavirenz formation using efavirenz as substrate after 15 mins by LC/MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
AID1493928	Antagonist activity at P2Y12 in human whole blood assessed as inhibition of ADP-induced platelet-aggregation at 10 uM pretreated for 30 mins followed by ADP addition measured after 5 mins by FITC staining-based flow cytometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin.
AID1331279	Antiplatelet aggregatory activity against New Zealand white rabbit platelets at 150 uM preincubated for 2 to 3 mins followed by ADP-addition measured after 4 mins by turbidometric method relative to vehicle control	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Bioactive chemical constituents from the root bark of Morus australis.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1727536	Antithrombotic activity in cynomolgus monkey model of electrolytic carotid artery thrombosis assessed as increase in mesentric bleeding time at 0.3 mg/kg, PO administered once daily for 3 days measured at 2 hrs post last dose relative to control	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
AID640615	Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID700801	Prodrug activation in human liver microsomes assessed as increase in Cytochrome P450-mediated 2-oxo-clopidogrel formation at 20 uM in presence of ketoconazole	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1062235	Induction of mesenteric bleeding time in Sprague-Dawley rat at 20 mg/kg, po measured over 10 mins relative to vehicle-treated control	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.
AID667506	Tmax in Sprague-Dawley rat assessed as clopidogrel thioacetate level at 24 umol/kg, po	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
AID589244	Mechanism based inhibition of human cytochrome P450 2B6 using human liver microsomes	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1450603	In vivo drug metabolism in human assessed as carboxylesterase-mediated clopidogrel carboxylic acid formation in blood	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).
AID700807	Drug metabolism in human liver microsomes assessed as CYP2C9-mediated (2S)-methyl 2-(2-chlorophenyl)-2-(3-hydroxy-2,3,6,7-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID705606	Inhibition of CYP2B6 in human assessed as increase of bupropion systemic exposure	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID700803	Drug metabolism in human liver microsomes assessed as CYP3A4/5-mediated (S)-5-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-6,7-dihydrothieno[3,2-c]pyridin-5-ium formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1217706	Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID700815	Prodrug activation in human liver microsomes assessed as CYP1A2-mediated 2-oxo-clopidogrel formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID700812	Prodrug activation in human liver microsomes assessed as CYP2C19-mediated 2-oxo-clopidogrel formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID700806	Drug metabolism in human liver microsomes assessed as CYP2C19-mediated (2S)-methyl 2-(2-chlorophenyl)-2-(3-hydroxy-2,3,6,7-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID667516	AUC (0 to infinity) in Sprague-Dawley rat assessed as clopidogrel thioacetate level at 24 umol/kg, po	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID667507	Cmax in Sprague-Dawley rat assessed as clopidogrel thioacetate level at 24 umol/kg, po	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID700808	Drug metabolism in human liver microsomes assessed as CYP2B6-mediated (2S)-methyl 2-(2-chlorophenyl)-2-(3-hydroxy-2,3,6,7-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1217729	Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID766347	In vivo antithrombotic activity in Beagle dog modified Folts model assessed as increase in blood flow administered as bolus infusion measured after 30 mins	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.
AID1179967	Induction of bleeding time in rabbit model of electrically-induced carotid artery thrombosis at 80% antithrombotic dose administered 30 mins before electrical stimulation (Rvb = 1 +/- 0.05 No_unit)	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.
AID1517827	Antithrombotic activity in Wistar rat plasma assessed as thrombus formation time at 22 umol/kg, po measured after 1 hr (Rvb = 9.4 +/- 8.9 mins)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of novel, potent, isosteviol-based antithrombotic agents.
AID667511	Drug metabolism in rat liver microsomes assessed as NADPH-dependent active metabolite glutathione adducts 1 formation at 20 uM after 30 mins by LC-MS/MS analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
AID1217733	Time dependent inhibition of CYP2B6 (unknown origin) at 0.3 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID667512	Drug metabolism in rat liver microsomes assessed as NADPH-dependent active metabolite glutathione adducts formation at 20 uM after 30 mins by LC-MS/MS analysis in presence of NADPH and GSH	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1517824	Anticoagulant activity in Wistar rat plasma assessed as ADP-induced platelet aggregation at 22 umol/kg, po measured after 1 hr by Born's method (Rvb = 66.8 +/- 15.8 %)	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of novel, potent, isosteviol-based antithrombotic agents.
AID1143851	Antithrombotic activity in mouse assessed as protection against collagen-epinephrine-induced pulmonary thromboembolism at 70 uM/kg, po administered 60 mins prior to thrombotic challenge	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation.
AID1404801	Antiplatelet activity in Wistar rat platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation pretreated for 1 min followed by ADP addition by turbidimetric method	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation.
AID700814	Prodrug activation in human liver microsomes assessed as CYP2C9-mediated 2-oxo-clopidogrel formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1850679	Inhibition of P2Y12 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Strategies for targeting the P2Y
AID1493926	Antagonist activity at P2Y12 in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 10 uM pretreated for 30 mins followed by ADP addition measured after 5 mins by light transmission aggregometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID700804	Drug metabolism in human liver microsomes assessed as CYP3A4/5-mediated (2S)-methyl 2-(2-chlorophenyl)-2-(3-hydroxy-2,3,6,7-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate formation at 50 uM	2012	ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10	Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.
AID1277739	Antithrombotic activity in ferric chloride-induced Swiss albino mouse arterial thrombosis model assessed as prolonged time to occlusion at 70 umol/kg, po (Rvb = 9.5 +/- 0.4 mins)	2016	European journal of medicinal chemistry, Mar-03, Volume: 110	Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (0.05)	18.7374
1990's	170 (1.74)	18.2507
2000's	2971 (30.34)	29.6817
2010's	5379 (54.93)	24.3611
2020's	1268 (12.95)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,918 (18.77%)	5.53%
Reviews	1,795 (17.56%)	6.00%
Case Studies	849 (8.31%)	4.05%
Observational	309 (3.02%)	0.25%
Other	5,350 (52.34%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (707)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Double-Blind Cross-Over Study Comparing the Pharmacodynamic (PD)Response in Subjects With ACS Receiving 14 Days 10-mg Maintenance Dose (MD) Prasugrel vs 14 Days 150-mg MD Clopidogrel After Using a 900-mg Loading Dose (LD) of Clopidogrel to Re [NCT00385944]	Phase 2	56 participants (Actual)	Interventional	2007-03-31	Completed
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention [NCT01603082]	Phase 4	343 participants (Actual)	Interventional	2012-07-31	Completed
A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention [NCT00097591]	Phase 3	13,619 participants (Actual)	Interventional	2004-11-30	Completed
A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus Clopidogrel in Subjects With Acute Coronary Syndrome Who Are Receiving Clopidogrel [NCT00356135]	Phase 2	139 participants (Actual)	Interventional	2006-07-31	Completed
Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19 [NCT03942458]	Phase 1	50 participants (Actual)	Interventional	2019-04-03	Completed
Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month Aft [NCT05577988]	Phase 3	2,468 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
Randomized Double-Blind Placebo-Controlled Study of Pyrazinoylguanidine Hydrochloride (Amiloride) in Subjects With Coronary Artery Disease [NCT01228214]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2011-03-31	Active, not recruiting
A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given With Ome [NCT01129388]	Phase 1	72 participants (Actual)	Interventional	2009-03-31	Completed
The Impact of Aspirin and Clopidogrel on Brain-derived Neurotrophic Factor (BDNF) Concentrations in Human Serum and Plasma [NCT01264640]		25 participants (Anticipated)	Interventional	2010-07-31	Active, not recruiting
Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent [NCT01261832]	Phase 4	951 participants (Anticipated)	Interventional	2011-07-31	Active, not recruiting
A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation [NCT01192724]	Phase 4	630 participants (Actual)	Interventional	2010-03-31	Completed
Study of Policosanol to Improve High on Clopidogrel Platelet Reactivity After Percutaneous Coronary Stent Implantation(Spirit) [NCT01371058]	Phase 4	350 participants (Actual)	Interventional	2011-03-31	Completed
Phase 3 Study of Prasugrel vs High Dose (150 mg) Clopidogrel in Clopidogrel Resistant Patients Post Coronary Angioplasty. [NCT01109784]	Phase 3	70 participants (Anticipated)	Interventional	2010-04-30	Completed
Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial [NCT01113372]	Phase 4	3,119 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized, Double-blind, Double-dummy, Two Period, Two Treatment Cross-over Pharmacodynamic and Pharmacokinetic Study of Clopidogrel Given as 5-day Repeated Oral Doses (300 mg Loading Dose Followed by 75 mg/Day and 600 mg Loading Dose Followed by 150 m [NCT01123824]	Phase 1	40 participants (Actual)	Interventional	2009-04-30	Completed
Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome [NCT04937699]	Phase 4	2,690 participants (Anticipated)	Interventional	2023-03-28	Recruiting
Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [NCT01158846]	Phase 4	800 participants (Anticipated)	Interventional	2010-08-31	Not yet recruiting
Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734]	Phase 4	3,750 participants (Anticipated)	Interventional	2010-06-30	Recruiting
Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events [NCT01186146]	Phase 4	5,000 participants (Actual)	Interventional	2010-08-31	Completed
Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment [NCT01304472]	Phase 3	25 participants (Anticipated)	Interventional	2011-02-28	Completed
Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS [NCT03775746]	Phase 4	150 participants (Anticipated)	Interventional	2019-01-08	Recruiting
Impact of Type 2 Diabetes on Outcomes Associated With Antiplatelet Drugs: A Retrospective Analysis [NCT05053828]		173,464 participants (Actual)	Observational	2021-09-20	Completed
Low-dose Prasgurel Versus Clopidogrel on the Dual Antiplatelet Regimen for Intracranial Stenting or Flow Diverter Treatment for Unruptured Cerebral Aneurysms: a Multi-center Randomized Controlled Trial [NCT05359224]	Phase 4	406 participants (Anticipated)	Interventional	2022-06-13	Recruiting
Use of Recombinant FVIIa to Mitigate Clopidogrel Anti-platelet Therapy-Mediated Bleeding in a Single Centre, Randomized, Placebo-controlled, Double-blind Clinical Trial [NCT01561950]	Phase 1	91 participants (Actual)	Interventional	2008-05-31	Terminated
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh [NCT00391872]	Phase 3	18,624 participants (Actual)	Interventional	2006-10-31	Completed
[NCT01094457]	Phase 4	840 participants (Actual)	Interventional	2009-03-31	Completed
"Prevalence of clOpidogrel resIstaNce in a Selected Population of Patients Undergoing Elective Percutaneous Coronary Intervention at a Tertiary Cardiovascular Center in Trinidad: The POINT Pilot Study" [NCT03667066]		40 participants (Actual)	Observational	2017-09-01	Completed
A Randomized, Placebo-controlled, Two-sequence, Two-period Crossover Study, to Investigate a Potential Food Effect on the Pharmacodynamic and Bioavailability of Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) in Healthy Male [NCT01129271]	Phase 1	72 participants (Actual)	Interventional	2009-04-30	Completed
A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial [NCT03947229]	Phase 4	3,200 participants (Actual)	Interventional	2019-08-14	Active, not recruiting
PREDICT: Scripps Pilot Study on the Effect of High Clopidogrel Maintenance Dosing and Its Relationship to Cytochrome P450 2C19 Polymorphism Status [NCT01118793]		41 participants (Actual)	Observational	2008-12-31	Completed
Phase I Study to Assess the Safety of APD-791 When Co-administered With Aspirin [NCT02034292]	Phase 1	16 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Sponsor Decision)
Prasugrel in Comparison to High Clopidogrel Dose for Inhibition of Platelet Reactivity as Assessed With a Point-of-Care Platelet Function Assay in Patients Undergoing Chronic Hemodialysis Presenting Resistance to the Usual Clopidogrel Dose [NCT01155765]	Phase 3	70 participants (Anticipated)	Interventional	2010-05-31	Completed
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography ( [NCT02833948]	Phase 3	231 participants (Actual)	Interventional	2016-05-31	Completed
Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)and Presenting With High Platelet Reactivity, as Assessed [NCT01338909]	Phase 3	35 participants (Anticipated)	Interventional	2011-04-30	Completed
Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study [NCT02457130]	Phase 4	30 participants (Anticipated)	Interventional	2015-04-30	Recruiting
A Single Dose Study to Evaluate the Effect of BMS-986120 on Thrombus Formation in an Ex Vivo Thrombosis Chamber Model in Healthy Subjects [NCT02439190]	Phase 1	42 participants (Actual)	Interventional	2015-09-30	Completed
The Long Term Effect of Low Dose Aspirin on Uric Acid in Chinese Patients With Coronary Artery Disease（AURORA): A Prospective Cohort Study [NCT03691688]		2,000 participants (Anticipated)	Observational [Patient Registry]	2018-12-01	Recruiting
Impact of Genetic Variation in CES1 on Antiplatelet Therapy [NCT03161678]	Phase 4	89 participants (Actual)	Interventional	2017-08-22	Completed
Registry of Patients Admitted by Acute Coronary Syndrome to University Hospital of Vigo [NCT03664388]		8,000 participants (Anticipated)	Observational	2016-02-01	Recruiting
Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome [NCT02379676]	Phase 4	38 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study) [NCT00799396]	Phase 4	682 participants (Actual)	Interventional	2006-07-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy [NCT00714961]	Phase 3	3,491 participants (Actual)	Interventional	2003-02-28	Completed
A Mechanistic Study in Patients With Non-Dialysis Chronic Kidney Disease to Investigate Altered Platelet Response to Antiplatelet Therapy (CKD-Platelet Study) [NCT03649711]	Phase 3	76 participants (Actual)	Interventional	2018-11-01	Completed
Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial [NCT05320926]		3,744 participants (Anticipated)	Interventional	2022-03-11	Recruiting
Influence of Vorapaxar on Thrombin Generation and Coagulability [NCT03207451]	Phase 4	81 participants (Actual)	Interventional	2016-01-01	Completed
Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction [NCT01381185]	Phase 4	154 participants (Actual)	Interventional	2011-05-31	Completed
A Prospective, Multicenter, Non-randomized, Post-market Clinical Follow-up Study to Confirm Safety and Performance of the Coherex WaveCrest® Left Atrial Appendage Occlusion System in Patients With Non-valvular Atrial Fibrillation [NCT03204695]		27 participants (Actual)	Interventional	2017-05-29	Terminated(stopped due to Study closed due to device design modifications.)
[NCT02037412]	Phase 4	148 participants (Actual)	Interventional	2014-01-31	Terminated(stopped due to The patient registration was not successful.)
Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in Patients With Non ST Elevation Acute Coronary Syndromes [NCT02071966]	Phase 4	55 participants (Anticipated)	Interventional	2012-11-30	Terminated(stopped due to slow enrollment)
The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man [NCT02120092]	Phase 2	89 participants (Actual)	Interventional	2010-10-31	Completed
Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug [NCT05418556]	Phase 4	3,944 participants (Anticipated)	Interventional	2022-10-21	Recruiting
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation [NCT02247128]	Phase 4	1,016 participants (Actual)	Interventional	2014-01-31	Completed
Study of Clopidogrel and Ticagrelor Anti-Platelet Treatment Using an Individualized Strategy Based on Genotyping in Chinese ACS Patients [NCT02048228]	Phase 2/Phase 3	200 participants (Anticipated)	Interventional	2014-10-31	Not yet recruiting
Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®) [NCT02060786]	Phase 4	90 participants (Actual)	Interventional	2010-10-31	Completed
Optimal Dose of Ticagrelor（90 mg qd）and Double Standard-dose Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With Coronary Heart Disease [NCT03614832]	Phase 4	100 participants (Anticipated)	Interventional	2018-05-01	Recruiting
The Early De-escalation Strategy With Ticagrelor 60 mg or 45 mg on Platelet Reactivity and Clinical Outcomes in Korean Patients With Acute Myocardial Infarction [NCT05210595]	Phase 4	120 participants (Anticipated)	Interventional	2022-01-01	Recruiting
[NCT02032290]	Phase 4	88 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
Effectiveness of Clopidogrel Resinate(PRegrel®) in Patients Undergoing Percutaneous Coronary Intervention Compared With ClopiDogrEl Bisulfate(Plavix®) [NCT01349777]	Phase 4	1,056 participants (Actual)	Interventional	2010-03-15	Completed
Evaluation of the Benefit/Risk Ratio of Restarting or Avoiding Antiplatelet Drugs in Patients Who Had a Spontaneous Intracerebral Hemorrhage While Treated With Antithrombotic Drugs : RESTART-FR Study [NCT02966119]	Phase 3	23 participants (Actual)	Interventional	2016-12-07	Terminated(stopped due to Recruitment difficulties)
Clopidogrel Versus Aspirin Monotherapy Beyond Twelve Months After Percutaneous Coronary Intervention in Patients at High Risk for Recurrent Ischemic Events [NCT04418479]	Phase 4	5,000 participants (Anticipated)	Interventional	2020-08-10	Recruiting
Aspirin and a Potent P2Y12 Inhibitor Versus Aspirin and Clopidogrel Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention for Complex Lesion Treatment (SMART-ATTEMPT) [NCT04014803]	Phase 4	3,500 participants (Anticipated)	Interventional	2020-01-13	Recruiting
Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention. [NCT01930773]	Phase 3	150 participants (Anticipated)	Interventional	2013-03-31	Recruiting
An Open-label, Randomized, 4-treatment, 3-period, Crossover Interaction Study, Evaluating the Effect of Esomeprazole 40 mg, Omeprazole 80 mg or Lansoprazole 60 mg on the Pharmacodynamics and the Pharmacokinetics of Clopidogrel in Healthy Volunteers [NCT01147588]	Phase 1	149 participants (Actual)	Interventional	2010-05-31	Completed
Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. A Prospective, Mono-center, Placebo- and Active Treatment-controlled, Randomized, Cross Over Study. [NCT01175200]		82 participants (Actual)	Interventional	2010-09-30	Completed
Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion: a Randomized Control Trial [NCT05671276]	Phase 4	150 participants (Anticipated)	Interventional	2022-02-01	Recruiting
A Randomized, Open-label, Three-period, Multiple Dosing Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacodynamics of Clopidogrel According to CYP2C19 Genotypes in Healthy Male Volunteers [NCT03814642]	Phase 1	25 participants (Actual)	Interventional	2019-01-21	Completed
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis [NCT00153062]	Phase 4	20,332 participants (Actual)	Interventional	2003-08-31	Completed
Effect of Clopidogrel on Allergen Challenge in Asthma [NCT01955512]	Phase 2	24 participants (Anticipated)	Interventional	2013-05-31	Completed
A Single-center, Open-label, Two-treatment, One-sequence, Cross-over Study to Investigate the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite, ACT-333679, in Healthy Male Subjects [NCT03496506]	Phase 1	22 participants (Actual)	Interventional	2018-03-05	Completed
A Randomized Controlled Trial of Dual Antiplatelet Therapy Versus Antiplatelet Monotherapy and Oral Anticoagulation in Patients With Acute Coronary Syndrome and Coronary Artery Ectasia: OVER-TIME [NCT05233124]	Phase 2	60 participants (Anticipated)	Interventional	2021-09-01	Recruiting
Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II [NCT04078737]	Phase 3	6,412 participants (Actual)	Interventional	2019-09-23	Completed
An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI（EARLY-MYO II） [NCT02201667]	Phase 4	444 participants (Anticipated)	Interventional	2014-08-31	Not yet recruiting
Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone Percutaneous Coronary Intervention - a Randomised, Crossover Study. [NCT02469740]	Phase 4	61 participants (Actual)	Interventional	2015-07-31	Completed
Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling [NCT02224131]	Phase 4	1,856 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis [NCT03289520]	Phase 3	877 participants (Actual)	Interventional	2003-01-07	Completed
The Effects of Crushed Ticagrelor Versus Eptifibatide Bolus +Clopidogrel in Troponin-Negative ACS Patients Undergoing Coronary Intervention [NCT02925923]	Phase 2	100 participants (Actual)	Interventional	2016-11-01	Completed
A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. [NCT02459288]	Phase 4	80 participants (Anticipated)	Interventional	2014-01-31	Recruiting
"High on Treatment Platelet Reactivity in the Intensive Care Unit" [NCT02285751]	Phase 2	200 participants (Anticipated)	Interventional	2012-11-30	Recruiting
A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent [NCT02446730]	Phase 4	1,400 participants (Anticipated)	Interventional	2014-09-30	Recruiting
Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered With Aspirin and Clopidogrel [NCT02419820]	Phase 1	104 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to Sponsor Decision)
A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment [NCT02294643]	Phase 3	220 participants (Actual)	Interventional	2009-04-30	Completed
Efficacy and Safety of Low Dose Rivaroxaban in Patients With Anterior Myocardial Infarction [NCT05744804]		150 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
A Randomized, Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986177 (an Oral Antithrombotic) With Single and Dual Antiplatelet Therapy (Aspirin and Clopidogrel) in Healthy Participants [NCT03698513]	Phase 1	113 participants (Actual)	Interventional	2018-10-04	Completed
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation at High Risk of Stroke and Bleeding Compared to Medical Therapy: a Prospective Randomized Clinical Trial [NCT03463317]	Phase 4	1,512 participants (Anticipated)	Interventional	2018-02-28	Recruiting
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention [NCT02334254]	Phase 4	420 participants (Anticipated)	Interventional	2013-08-31	Recruiting
Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement. [NCT02866175]	Phase 3	1,506 participants (Actual)	Interventional	2017-02-24	Completed
[NCT02817789]	Phase 3	50 participants (Actual)	Interventional	2016-05-09	Completed
Study of Two Regimens of TicagrElor Compared to Clopidogrel in Patients Undergoing ELective Percutaneous Coronary Intervention [NCT02327624]	Phase 4	180 participants (Actual)	Interventional	2015-06-30	Completed
Effects of P2Y12 Receptor Inhibitors on Central and Peripheral Chemoreceptors' Sensitivity [NCT05080478]		50 participants (Anticipated)	Observational	2018-11-01	Recruiting
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial [NCT05611242]	Phase 3	404 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Regular Drug Eluting Stent Versus Dedicated Bifurcation Sirolimus-eluting Stent BiOSS LIM in Coronary Bifurcation Treatment - Randomized POLBOS II Study. [NCT02198300]	Phase 4	202 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized, Double-blind, Active-Controlled Trial Comparing the Safety and Efficacy of Aspirin Versus Clopidogrel in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency [NCT04088513]	Phase 4	440 participants (Anticipated)	Interventional	2020-01-22	Recruiting
Relative Bioavailability of Telmisartan and SR26334, the Main Metabolite of Clopidogrel, After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After p.o. Administration of 80 mg Telmisartan and 75 mg Clopidogrel Alone. A Four- [NCT02262650]	Phase 1	24 participants (Actual)	Interventional	2004-04-30	Completed
Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT [NCT02233790]	Phase 4	600 participants (Anticipated)	Interventional	2014-12-31	Not yet recruiting
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry [NCT02264912]		2,016 participants (Actual)	Observational [Patient Registry]	2008-07-31	Completed
Ticagrelor Plus Aspirin vs Clopidogrel Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke: A Randomized, Active Comparator Arm, Outcome Assessor Blind, Controlled, Feasibility Study [NCT04738097]	Phase 3	90 participants (Actual)	Interventional	2021-08-08	Completed
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI) [NCT04695106]	Phase 4	2,230 participants (Anticipated)	Interventional	2021-10-25	Recruiting
Effect of the Genetic Variant 2C19*2 on Clopidogrel Biological Response in Patients With Premature Coronary Artery Disease [NCT00822666]	Phase 3	109 participants (Actual)	Interventional	2008-10-31	Completed
Differential Effect of Ticagrelor vs Prasugrel or Clopidogrel Loading on Fractional Flow Reserve [NCT02108808]	Phase 4	76 participants (Actual)	Interventional	2014-04-30	Completed
Randomized Evaluation of Short-term DUal Anti Platelet Therapy in Patients With Acute Coronary Syndrome Treated With the COMBO Dual-therapy stEnt [NCT02118870]	Phase 4	1,500 participants (Actual)	Interventional	2014-06-10	Completed
Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function For Patients With ST-Segment Elevation Myocardial Infarction Receiving Emergency Percutaneous Coronary Intervention [NCT02123004]	Phase 4	350 participants (Anticipated)	Interventional	2014-04-30	Not yet recruiting
A Randomized, Open-Label, Parallel, Multi-Center, Phase IV Study to Assess the Effect of Ticagrelor vs Clopidogrel on Adenosine-Induced Myocardial Blood Flow in Peripheral Artery Disease (PAD)Patients [NCT02121288]	Phase 4	0 participants (Actual)	Interventional	2014-12-31	Withdrawn
Platelet Function and genoType-Related Long-term progGosis in DES-treated Patients : A Consortium From Multi-centered Registries [NCT04734028]		13,160 participants (Actual)	Observational	2003-07-09	Completed
PANDDA Study: Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients [NCT02302508]	Phase 4	0 participants (Actual)	Interventional	2019-09-01	Withdrawn(stopped due to Funding)
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After Undergoing Percutaneous Coronary Intervention:The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) - 2 Study [NCT04483583]	Phase 4	80 participants (Anticipated)	Interventional	2020-12-08	Recruiting
Combined Effect of Diabetes and cyp2c19 Polymorphism on Clopidogrel VS Ticagrelor Antiplatelet Activity in Patients of Anterior ST Elevation Myocardial Infarction Undergoing Primary PCI [NCT03613857]		1,022 participants (Actual)	Observational [Patient Registry]	2017-04-15	Completed
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure [NCT03088072]	Phase 4	75 participants (Anticipated)	Interventional	2017-03-23	Recruiting
Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy [NCT03072082]	Phase 4	440 participants (Anticipated)	Interventional	2017-06-30	Not yet recruiting
Platelet Reactivity in Patients With End Stage Renal Disease Receiving Clopidogrel Compared With Ticagrelor [NCT02163954]	Phase 3	16 participants (Actual)	Interventional	2013-01-31	Completed
Randomised, Open Label, 3-way Cross Over Phase I Study to Investigate the Impact of Concomitant Use of Multiple Doses of Clopidogrel (75 mg qd After a Loading Dose of 300 mg) With Multiple Doses of Dabigatran Etexilate (150 mg Bid) on the Pharmacokinetic [NCT02171598]	Phase 1	44 participants (Actual)	Interventional	2009-02-28	Completed
Prospective Randomized Clinical Study of the Aorto-femoral Bypass and the Iliac Arteries With Stenting Recanalization Effectiveness in Patients With the Iliac Segment Occlusive Disease [NCT02209350]	Phase 1	202 participants (Actual)	Interventional	2014-08-02	Active, not recruiting
A Randomized, Open Label, Pilot Study to Assess the Pharmacodynamics Using Vefiynow and VASP Assay; and Pharmacokinetics of Ticagrelor vs Clopidogrel in Patients Undergoing PCI With History of Fibrinolysis in 24-48 Hours [NCT02048085]	Phase 4	0 participants (Actual)	Interventional	2014-01-02	Withdrawn(stopped due to unable to get study up and enrolling)
CYP2C19 Genotype-GUided Dual Antiplatelet theRapy in pAtieNts Treated With New Generation Drug Eluting stEnts (the GUARANTEE Study) [NCT03783351]		4,009 participants (Anticipated)	Interventional	2019-05-27	Recruiting
Effect of Lower Loading Dose of Prasugrel Compared With Conventional Loading Dose of Clopidogrel and Prasugrel in Korean Coronary Artery Disease Patients Undergoing Coronary Angiography [NCT02070159]	Phase 3	43 participants (Actual)	Interventional	2011-12-31	Completed
The Efficacy and Safety of Clopidogrel Combined With Rivaroxaban and Aspirin in Patients With Coronary Heart Disease and Gastrointestinal Diseases Undergoing PCI：a Randomized Controlled Study [NCT04805710]	Phase 4	1,020 participants (Anticipated)	Interventional	2021-03-17	Not yet recruiting
A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial [NCT02094963]	Phase 4	800 participants (Actual)	Interventional	2014-07-05	Completed
Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study - ARMYDA-AMULET [NCT05554822]	Phase 3	574 participants (Anticipated)	Interventional	2021-06-14	Recruiting
CSP #571 - Drug-eluting Stents vs. Bare Metal Stents in Saphenous Vein Graft Angioplasty (DIVA) [NCT01121224]	Phase 4	597 participants (Actual)	Interventional	2012-01-11	Completed
Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients [NCT03385538]	Phase 4	103 participants (Actual)	Interventional	2015-11-01	Completed
[NCT02309970]		90 participants (Anticipated)	Observational	2014-12-31	Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study Using Aspirin and Clopidogrel to Assess Reproducibility and Compare Platelet Function Assays [NCT01108588]	Phase 1	15 participants (Anticipated)	Interventional	2010-06-30	Completed
Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel [NCT01328470]	Phase 4	85 participants (Actual)	Interventional	2009-09-30	Completed
A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (600 mg Loading Dose Followed by 150 mg/Day) Alone or Given Concomi [NCT01129414]	Phase 1	72 participants (Actual)	Interventional	2009-06-30	Completed
Single-Dose Food In Vivo Bioequivalence Study of Clopidogrel Bisulfate Tablets (75 mg; Mylan) to Plavix® Tablets (75 mg; Bristol-Myers Squibb/Sanofi) in Healthy Volunteers [NCT00650169]	Phase 1	47 participants (Actual)	Interventional	2004-12-31	Completed
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation [NCT02224066]	Phase 4	65 participants (Actual)	Interventional	2016-01-31	Completed
High PlatElet Inhibition With TicAgrelor to Improve Left Ventricular RemodeLING in Patients With ST-segment ElevAtion Myocardial Infarction: the HEALING-AMI Trial. [NCT02224534]	Phase 4	326 participants (Anticipated)	Interventional	2014-10-31	Recruiting
Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR2285 Tablets Combined With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects [NCT04945616]	Phase 1	52 participants (Actual)	Interventional	2021-07-13	Completed
Phase IV Study of the Effects of Clopidogrel on Soluble CD40 Ligand, Endothelial Function and Blood Pressure [NCT01112137]	Phase 4	46 participants (Actual)	Interventional	2005-01-31	Completed
A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI [NCT00751231]	Phase 2	652 participants (Actual)	Interventional	2008-12-31	Completed
An Open-label, Randomized, Single-center, 2-way Cross-over Interaction Study, Evaluating the Effect of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg on the Pharmacodynamics and the Pharmacokinetics of Clopidogrel on Days 1 and 9 in Healthy Volunteers [NCT01210339]	Phase 1	58 participants (Actual)	Interventional	2010-11-30	Completed
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study [NCT04001894]	Phase 4	50 participants (Actual)	Interventional	2019-07-02	Completed
An Open-label, Two-treatment Crossover Pharmacokinetic Study of Clopidogrel Hydrogen Sulfate in Healthy Male and Female Subjects [NCT01129063]	Phase 1	32 participants (Actual)	Interventional	2009-03-31	Completed
A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomit [NCT01129375]	Phase 1	72 participants (Actual)	Interventional	2009-02-28	Completed
Use of the Smart Nitinol Stent System for the Treatment of Severe Atherosclerotic Carotid Stenosis: Study Protocol for a Retrospective, Non-randomized, Long-term Parallel Controlled Trial [NCT02800174]		103 participants (Actual)	Interventional	2006-06-30	Completed
Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial [NCT05553613]	Phase 3	900 participants (Actual)	Interventional	2022-10-01	Completed
GORE® CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to Evaluate the Safety and Efficacy of Transcatheter Closure of Patent Foramen Ovale for Relief of Migraine Headaches [NCT04100135]		150 participants (Anticipated)	Interventional	2021-02-05	Recruiting
Phase III, Randomized, International, Multicenter, Open Label, With Blinded Adjudication of Outcomes, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Ticagrelor Compared With Clopidogrel in Patients With Acute Coronary Syndrome With S [NCT02298088]	Phase 3	3,799 participants (Actual)	Interventional	2015-08-31	Completed
Comparative Randomized Single-blind Trial of Amiloride in Coronary Heart Disease [NCT01231165]	Phase 2/Phase 3	70 participants (Actual)	Interventional	2009-02-28	Completed
Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation [NCT01141153]	Phase 4	304 participants (Anticipated)	Interventional	2010-06-30	Active, not recruiting
Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly [NCT02317198]	Phase 4	1,011 participants (Actual)	Interventional	2013-06-30	Active, not recruiting
Does the Magnitude of Platelet Inhibition Inversely Correlate With the Number of TCD-detected Microemboli in Asymptomatic Patients Undergoing Carotid Artery Stenting Prior to Cardiac Surgery Who Are Being Pre-treated With 300 mg or 600 mg Loading Dose of [NCT01146301]	Phase 4	0 participants	Interventional	2008-03-31	Completed
Stroke Imaging Package Study of Intracranial Atherosclerosis [NCT03719820]		550 participants (Anticipated)	Observational [Patient Registry]	2018-11-14	Recruiting
Clinical Trial Program of a Medical Instrument Product [NCT01157455]	Phase 4	1,900 participants (Anticipated)	Interventional	2010-05-31	Recruiting
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting [NCT01159639]	Phase 4	200 participants (Actual)	Interventional	2010-06-30	Completed
Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping [NCT01174693]	Phase 4	795 participants (Actual)	Interventional	2010-03-31	Completed
PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents [NCT01103843]		1,000 participants (Anticipated)	Interventional	2010-04-30	Recruiting
Randomized, Factorial Study to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent [NCT01102439]	Phase 4	82 participants (Actual)	Interventional	2010-04-30	Completed
[NCT01584791]	Phase 4	148 participants (Actual)	Interventional	2010-10-31	Completed
Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent [NCT00910299]	Phase 2	423 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Due to the low rate of primary endpoint events experienced in the study to date)
A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomit [NCT01129427]	Phase 1	66 participants (Actual)	Interventional	2009-08-31	Completed
Benefits and Risks Evaluation of Different Anti-platelet Strategies Beyond a 12-month Period Inpatients Receiving Sirolimus Drug-eluting Stent Implantation [NCT01233167]		5,232 participants (Anticipated)	Interventional	2011-08-31	Not yet recruiting
Thrombocytes And IndividuaLization of ORal Antiplatelet Treatment After Percutaneous Coronary Intervention [NCT01135667]	Phase 4	106 participants (Actual)	Interventional	2010-09-30	Completed
Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets [NCT03787927]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2018-12-03	Active, not recruiting
A Prospective, Randomized, Active-controlled, Double-blind, Parallel, Multi-center, Phase IV, Exploratory Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke [NCT05445895]	Phase 4	500 participants (Anticipated)	Interventional	2022-12-16	Recruiting
Prospective Partially Randomized Comparison of Clopidogrel Loading Versus Maintenance Dosing to Prevent Periprocedural Myocardial Infarction After Stenting for a Stable Angina Pectoris [NCT03759067]		511 participants (Actual)	Interventional	2010-10-18	Completed
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass: Prospective, Randomized Controlled Trial [NCT05166538]	Phase 4	204 participants (Anticipated)	Interventional	2022-02-01	Not yet recruiting
Comparison of the Generic and Original Formulation of Clopidogrel Regarding the Potency of Platelet Inhibition in Patients After PCI [NCT01147133]	Phase 4	75 participants (Actual)	Interventional	2009-11-30	Completed
Comparison Between Ticagrelor and Clopidogrel Effect on Endothelial, Platelet and Inflammation Parameters in Patients With Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease Undergoing PCI [NCT02519608]	Phase 2	44 participants (Actual)	Interventional	2015-09-30	Completed
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome. [NCT03357874]	Phase 3	514 participants (Anticipated)	Interventional	2018-10-28	Recruiting
The Standard Versus Prolonged Dual Antiplatelet Therapy After the XINSORB Bioresorbable Scaffold Implantation Trial [NCT04501900]	Phase 4	2,106 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity [NCT01335048]	Phase 4	50 participants (Anticipated)	Interventional	2011-04-30	Completed
Evaluating the Benefit of Additional Platelet Inhibition in Acute Coronary Syndrome Patients With High Platelet Reactivity Undergoing PCI [NCT01339026]	Phase 4	44 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Change in guidelines favouring newer antiplatelet drugs in ACS)
Role of Clopidogrel in Preventing Exacerbations in Patients With Severe COPD: An Open-label Randomized Controlled Trial. [NCT06021990]	Phase 3	162 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Multicenter, Randomized, Non-inferiority Trial to Evaluate the Safety and Efficacy of Rivaroxaban Compared to Warfarin for Thromboprophylaxis in Children With Giant Coronary Aneurysms After Kawasaki Disease [NCT05643651]	Phase 3	332 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia [NCT01012219]	Phase 1	36 participants (Actual)	Interventional	2009-11-30	Completed
Effects of Different Doses of Ticagrelor and Standard-dose Clopidogrel on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease [NCT02889549]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2016-08-31	Recruiting
Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of R-130964, the Active Metabolite of Clopidogrel, in Healthy Subjects [NCT01263093]	Phase 1	47 participants (Actual)	Interventional	2010-12-31	Completed
Multivariate Analysis of Platelet Reactivity Variety in Patients With Coronary Heart Disease After PCI [NCT02888652]		1,500 participants (Actual)	Observational [Patient Registry]	2015-09-30	Completed
COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) [NCT02578537]	Phase 4	60 participants (Anticipated)	Interventional	2015-10-31	Recruiting
MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers [NCT02570581]	Phase 1	16 participants (Actual)	Interventional	2014-06-30	Completed
Ticagrelor Versus Clopidogrel for Platelet Inhibition in Patients Undergoing Neurovascular Stenting for Intracranial Aneurysm [NCT02675205]	Phase 3	100 participants (Actual)	Interventional	2015-12-31	Completed
Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting [NCT04091074]	Phase 1	26 participants (Anticipated)	Interventional	2022-01-01	Not yet recruiting
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study [NCT02567461]	Phase 4	80 participants (Actual)	Interventional	2016-03-31	Completed
The Efficacy of Renal Artery Stent Combined With Standardized Medical Therapy in Patients With Atherosclerotic Renal Artery Stenosis [NCT02594410]	Phase 4	149 participants (Actual)	Interventional	2011-09-30	Completed
Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation [NCT00774475]	Phase 3	442 participants (Anticipated)	Interventional	2008-11-30	Not yet recruiting
Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial) [NCT00781573]		167 participants (Actual)	Interventional	2008-09-11	Completed
A Prospective Randomized Controlled Clinical Trial of Comparing ticagreLor Versus clopidogrEl on mIcrocirculation in Patients With Acute cOronary Syndrome Study [NCT02618733]		120 participants (Actual)	Interventional	2014-12-31	Completed
Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study) [NCT00799045]	Phase 4	220 participants (Actual)	Interventional	2008-10-31	Completed
Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions [NCT00698607]	Phase 4	1,466 participants (Anticipated)	Interventional	2008-06-30	Active, not recruiting
A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of Ticagrelor Compared With Clopidogrel in Patients With Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] [NCT00642811]	Phase 2	98 participants (Actual)	Interventional	2008-05-31	Completed
Clopidogrel Pharmacogenetics Bench to Bedside - A Practical Application [NCT01341600]		18 participants (Actual)	Interventional	2010-07-31	Completed
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within [NCT00623623]	Phase 3	1,899 participants (Actual)	Interventional	2008-03-01	Completed
Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age [NCT00833703]	Phase 3	49 participants (Actual)	Interventional	2009-01-31	Completed
[NCT00857155]		200 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Resistance to Antithrombotic Therapy in Patients Undergoing Angioplasty and Stenting for Cardiovascular Disease - Vienna REACT [NCT00858715]		46 participants (Actual)	Interventional	2008-05-31	Completed
Ticagrelor Versus Clopidogrel for Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction: A Retrospective Study Based on the Angiography-derived Index of Microcirculatory Resistance [NCT05978726]		325 participants (Actual)	Observational	2017-07-01	Completed
Secondary Stroke Prevention In Patients With Patent Foramen Ovale: International PFO Consortium [NCT00859885]		1,500 participants (Anticipated)	Observational	2008-09-08	Recruiting
Chinese People's Liberation Army General Hospital [NCT02798874]		240 participants (Anticipated)	Interventional	2016-05-31	Enrolling by invitation
Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) [NCT02792712]	Phase 4	200 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Safety and Efficacy of Three Different Loading Doses of Clopidogrel, Administered at First Medical Contact in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. The LOAD & GO Trial [NCT00882739]	Phase 4	168 participants (Actual)	Interventional	2009-04-30	Completed
Cognitive Decline and Underlying Mechanisms in Asymptomatic Intracranial Artery Stenosis Patients: A Cohort Study [NCT05504330]		100 participants (Anticipated)	Observational	2022-08-15	Recruiting
A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Cor [NCT00954707]	Phase 4	2,509 participants (Actual)	Interventional	2009-08-31	Active, not recruiting
Influence of Oral Doses of 75 mg Clopidogrel on the Pharmacodynamics and Safety of Fradafiban After Oral Doses of 30 mg Lefradafiban Tid Over 8 Days in Healthy Male Subjects. An Intra-individual, Open Trial. [NCT02265289]	Phase 1	14 participants (Actual)	Interventional	1999-01-31	Completed
Clopidogrel Monotherapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary Interventions: A Safety Assessment, Pilot Study to Reduce Post-Discharge Bleeding [NCT05223335]	Phase 4	121 participants (Actual)	Interventional	2022-03-29	Completed
TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement: the TIRATROP Study, a Randomized Controlled Trial [NCT02505399]	Phase 4	180 participants (Actual)	Interventional	2015-11-30	Completed
The Carotid and Middle Cerebral Artery Occlusion Surgery Study [NCT01758614]	Phase 3	330 participants (Actual)	Interventional	2013-06-06	Completed
A Phase ⅢB, Prospective, Randomized, Open Label, Blinded-endpoint, Multicenter Trial of the Efficacy and Safety of Urokinase Thrombolysis Comparing With Antiplatelet Agents for Patients With Minor Stroke. [NCT04420351]	Phase 3	1,005 participants (Actual)	Interventional	2020-10-04	Completed
XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT) [NCT01106534]	Phase 4	870 participants (Actual)	Interventional	2009-08-31	Completed
Pharmacodynamic Effect of Loading And Maintenance Doses Of Clopidogrel Versus Half Doses of Ticagrelor In Healthy Subjects [NCT02086903]	Phase 3	12 participants (Actual)	Interventional	2014-02-28	Completed
RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders [NCT02093299]		165 participants (Actual)	Observational [Patient Registry]	2012-12-31	Terminated(stopped due to Lack of feasiability)
Effect of Continuous Clopidogrel Dosing Targeted After Platelet Function Testing in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention With High On-treatment Platelet Reactivity [NCT02096419]	Phase 4	87 participants (Actual)	Interventional	2012-02-29	Completed
Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation (The ATEMS-AF Study) [NCT03073850]	Phase 4	48 participants (Actual)	Interventional	2017-02-23	Terminated(stopped due to Majority of enrolled patients have withdrawn.)
An Open-label, Blinded, Randomized Crossover Four Period Single Dose Full Replicative Bioequivalence Study of Two Formulations Clopidogrel Film-coated Tablets 75 mg (Pharmtechnology LLC, Republic of Belarus) and Plavix® Film-coated Tablets 75 mg (Manufact [NCT05934799]	Phase 1	60 participants (Actual)	Interventional	2023-06-16	Completed
Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity [NCT03062462]	Phase 2/Phase 3	80 participants (Anticipated)	Interventional	2017-02-10	Recruiting
Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not? The CAPITAL OPTI-CROSS Study. [NCT02054663]	Phase 4	60 participants (Actual)	Interventional	2013-12-31	Completed
A Randomised, Open-label, Parallel Group, Multi-center Study Using OCT to Comparing the Efficacy and Safety of Ticagrelor With Clopidogrel in the Prevention of Subclinical Thrombus in Patients After Drug-eluting Stent Implantation [NCT02140801]	Phase 4	352 participants (Actual)	Interventional	2014-05-01	Completed
A Prospective Randomised Controlled Trial [NCT02086019]		250 participants (Actual)	Interventional	2014-05-01	Completed
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study [NCT02429271]	Phase 3	336 participants (Actual)	Interventional	2015-08-31	Completed
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study [NCT06165068]	Phase 3	174 participants (Anticipated)	Interventional	2023-12-31	Recruiting
Dual Anti-platelet Therapy in Chronic Obstructive Pulmonary Disease Study [NCT05567562]	Phase 2	30 participants (Anticipated)	Interventional	2023-12-08	Recruiting
Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LT3001 Drug Product and Drug-Drug Interaction in Healthy Adult Subjects [NCT04809818]	Phase 1	64 participants (Anticipated)	Interventional	2021-03-21	Recruiting
Ticlopidine+Ginkgo Biloba Versus Clopidogrel in Clopidogrel Resistant Patients Undergoing Cartoid Artery Stent Placement [NCT02133989]	Phase 3	86 participants (Anticipated)	Interventional	2014-06-30	Recruiting
Multicenter, Randomized, Open Study, Investigator-initiated Trial for Comparison of Eight Weeks Efficacy and Tolerability of Clopirin and Clopidogrel With Aspirin in Korean Patients With Post-Percutaneous Coronary Artery Intervention [NCT02410083]	Phase 4	448 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized Controlled Clinical Trial of PARIS Coronary Thrombosis Risk Score Combined With D-dimer to Guide New Oral Anticoagulant Antithrombotic Therapy in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention [NCT05638867]	Phase 4	3,944 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention [NCT03378934]	Phase 4	64 participants (Anticipated)	Interventional	2018-09-26	Recruiting
Targeting Platelets in Chronic HIV Infection [NCT02578706]	Phase 2	27 participants (Actual)	Interventional	2015-10-31	Completed
Safety and Efficacy of Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After Drug-coated Balloons for Coronary Small Vessel Disease: A Prospective, Randomized, Open-label, Blinded-endpoint Evaluation, Single-center Study [NCT06088433]	Phase 4	292 participants (Anticipated)	Interventional	2023-11-15	Not yet recruiting
Antiplatelet Therapy for Acute Ischemic Stroke Patients With Thrombocytopenia [NCT06053021]		1,200 participants (Anticipated)	Interventional	2023-09-15	Recruiting
Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. [NCT00734123]	Phase 4	2,948 participants (Anticipated)	Interventional	2008-04-30	Recruiting
Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT) [NCT06037889]	Phase 3	516 participants (Anticipated)	Interventional	2023-11-09	Recruiting
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera [NCT00940784]	Phase 2	0 participants (Actual)	Interventional	2009-06-30	Withdrawn(stopped due to Could not get drug)
Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI [NCT00976092]	Phase 4	548 participants (Actual)	Interventional	2009-09-30	Active, not recruiting
Phase II Study of SCH 530348 in Subjects With Acute Coronary Syndrome [NCT00684203]	Phase 2	120 participants (Actual)	Interventional	2006-12-01	Completed
[NCT00776477]	Phase 3	300 participants (Anticipated)	Interventional	2007-12-31	Recruiting
Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting [NCT00776633]	Phase 4	614 participants (Actual)	Interventional	2008-09-30	Active, not recruiting
Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole [NCT01094275]		75 participants (Actual)	Observational [Patient Registry]	2010-01-31	Completed
A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing [NCT00778193]	Phase 4	125 participants (Actual)	Interventional	2007-10-31	Completed
A Double-Blind, Randomized, Multicenter, Dose-Ranging Trial of CS-747 Compared With Clopidogrel in Subjects Undergoing Percutaneous Coronary Intervention [NCT00059215]	Phase 2	905 participants (Actual)	Interventional	2003-04-30	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
ETAMI-Study: Early Thienopyridine Treatment to Improve Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction [NCT01327534]	Phase 3	63 participants (Actual)	Interventional	2011-05-31	Completed
To Determine the Bioequivalence of Clopid® (Clopidogrel) 75 mg Tablet Manufactured by Ferozsons Laboratories Ltd. Pakistan and Plavix® 75 mg Tablet Manufactured by Sanofi Winthrop Industrie France for Sanofi Pakistan After Oral Administration to Healthy A [NCT05186129]	Phase 1	36 participants (Actual)	Interventional	2018-04-06	Completed
Influence of Oral Doses of 75 mg Clopidogrel on the Pharmacodynamics and Safety of Oral Doses of 100 mg Terbogrel Bid Over 8 Days in Healthy Male Subjects. An Intra-individual, Open Trial. [NCT02222987]	Phase 1	14 participants (Actual)	Interventional	1999-02-28	Completed
A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron [NCT02748330]	Phase 4	40 participants (Actual)	Interventional	2016-06-30	Completed
Neurocognitive Impairment Assessment in Symptomatic Carotid Occlusion Recanalized Endovascularly [NCT04219774]	Phase 2	33 participants (Actual)	Interventional	2020-05-01	Active, not recruiting
Enrichment of CES1 Carriers in the Pharmacogenomics Anti-Platelet Intervention Study [NCT03188705]	Phase 4	6 participants (Actual)	Interventional	2019-10-14	Completed
Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST): a Prospective, Random, Double Blinded and Multi-center Study [NCT05193071]	Phase 4	1,022 participants (Anticipated)	Interventional	2022-07-08	Recruiting
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY [NCT00611286]	Phase 4	1,700 participants (Anticipated)	Interventional	2006-12-31	Completed
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb [NCT04229264]	Phase 3	200 participants (Anticipated)	Interventional	2020-01-09	Recruiting
Post-operative Treatment of Diabetic Peripheral Arterial Disease Guided by Platelet Reactivity Unit [NCT02762864]		200 participants (Anticipated)	Interventional	2016-05-31	Enrolling by invitation
Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI [NCT02696330]	Phase 4	150 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Effect of Plavix Treatment on NO Production Measured by Laser Doppler Method Referring to Endothelial Function in Patients With Severe Coronary Heart Disease [NCT00648453]	Phase 4	39 participants (Actual)	Interventional	2002-12-31	Completed
Influence of Platelet Reactivity in Peripheral Arterial Disease Patients Undergoing Percutaneous Angioplasty on Mid-term Outcomes [NCT04165629]		450 participants (Anticipated)	Observational	2020-01-01	Recruiting
The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol in Clopidogrel Non-Responders After Drug-Eluting Stent Implantation [NCT00620646]		80 participants (Anticipated)	Interventional	2008-02-29	Completed
A Phase I, Open-Label, Randomized, Multiple-Dose, Two-Way Crossover Study of the Pharmacodynamics of CGT 2168 Compared With Plavix® [NCT00620802]	Phase 1	60 participants (Actual)	Interventional	2007-11-30	Completed
STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction [NCT02777580]	Phase 4	609 participants (Actual)	Interventional	2017-08-01	Active, not recruiting
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety [NCT00645918]		2,800 participants (Actual)	Interventional	2008-06-30	Completed
A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients [NCT04409834]	Phase 4	390 participants (Actual)	Interventional	2020-08-05	Completed
Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent [NCT00661206]	Phase 4	4,005 participants (Actual)	Interventional	2008-09-30	Active, not recruiting
Effect of Different Dosing Regimens of Clopidogrel Given Before Elective Percutaneous Coronary Intervention on Platelet Function [NCT00693069]	Phase 3	120 participants (Actual)	Interventional	2004-09-30	Completed
30-d Rand, Eval-blind, Controlled, Multi-centre, Parallel, ph III Study to Evaluate Effect of a Low Maint Dose Ticagrelor Regimen vs Standard Dose Clopidogrel on Coronary Flow Reserve in DM Patients With Impaired Microvascular Function Without Prior MI or [NCT04069234]	Phase 3	0 participants (Actual)	Interventional	2019-09-15	Withdrawn(stopped due to Sponsor decided to stop the study due to commercial reasons.)
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting [NCT00827411]	Phase 4	2,500 participants (Actual)	Interventional	2009-01-31	Completed
Resistance to Antiplatelet Agents, Its Etiology and the Possibility of Its Affection [NCT00839345]		0 participants	Expanded Access		Temporarily not available
Safety and Efficacy of Century Clot-Guided Prophylactic Rivaroxaban Therapy for Post ST-Segment Elevation Myocardial Infarction Complicating Left Ventricular Thrombus Compared With Conventional Antiplatelet Therapy [NCT06013020]	Phase 4	374 participants (Anticipated)	Interventional	2023-08-28	Recruiting
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial [NCT03568890]	Phase 4	510 participants (Anticipated)	Interventional	2018-09-01	Recruiting
Aspirin Versus Clopidogrel for Leaflet Thrombosis Prevention in Patients Undergoing Transcatheter Aortic Valve Replacement: ACLO-TAVR Trial [NCT05493657]		230 participants (Anticipated)	Interventional	2023-02-02	Recruiting
Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy. [NCT00335452]	Phase 3	25,086 participants (Actual)	Interventional	2006-06-30	Completed
The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction). [NCT01012544]	Phase 4	187 participants (Actual)	Interventional	2009-04-30	Completed
Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial [NCT00947843]	Phase 4	306 participants (Actual)	Interventional	2013-11-30	Completed
"Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy" [NCT00944333]	Phase 3	1,378 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to STOP due to recent data in literature questioning the need to continue DAP beyond six months in patients with stable coronary artery stenting with DES.)
Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping™ Assay [NCT01023360]	Phase 4	30 participants (Anticipated)	Interventional	2008-05-31	Recruiting
Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke [NCT00979589]	Phase 3	5,100 participants (Actual)	Interventional	2009-12-31	Completed
Study of the Potentiation of the Effects of Clopidogrel by Rifampicin in Healthy Volunteers [NCT00696566]	Phase 1	12 participants (Actual)	Interventional	2007-11-30	Completed
Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis: Study Protocol of a Randomized Controlled Trial [NCT02689037]	Phase 3	394 participants (Anticipated)	Interventional	2016-04-30	Not yet recruiting
Prospective, Randomized, Double-Blind Trial of Abrupt and Tapered Interruption of Long-term Clopidogrel Therapy After Implantation of a Drug-Eluting Stent [NCT00640679]	Phase 4	782 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to Due to slow enrollment the study was stopped prematurely.)
Single-Dose Fasting In Vivo Bioequivalence Study of Clopidogrel Bisulfate Tablets (75 mg; Mylan) to Plavix® Tablets (75 mg; Bristol-Myers Squibb/Sanofi) in Healthy Volunteers [NCT00648947]	Phase 1	46 participants (Actual)	Interventional	2004-12-31	Completed
Blood Loss and Complications of Internal Fixation of Femoral Neck Fractures in Patients Treated With Clopidogrel [NCT00749710]		100 participants (Anticipated)	Interventional	2008-09-30	Not yet recruiting
[NCT02606552]	Phase 4	9 participants (Actual)	Interventional	2016-07-20	Terminated(stopped due to The number of patients registered for the study was low and it was expected to be difficult to derive the study results.)
Anticoagulant Treatments Evaluation During Percutaneous Coronary Angioplasty in Stable Patients [NCT00669149]	Phase 4	99 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to recruitment difficulties)
PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions [NCT00823212]	Phase 3	1,530 participants (Actual)	Interventional	2009-01-31	Completed
GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients With Patent Foramen Ovale (PFO) - The Gore REDUCE Clinical Study [NCT00738894]		664 participants (Actual)	Interventional	2008-12-10	Completed
[NCT00775762]	Phase 3	213 participants (Anticipated)	Interventional	2008-11-30	Not yet recruiting
Comparison of Platelet Reactivity in Patients With Acute Coronary Syndrome Given Patent Clopidogrel Versus Generic Clopidogrel: Randomized Controlled Trial [NCT02628587]	Phase 4	60 participants (Anticipated)	Interventional	2016-02-29	Not yet recruiting
The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation [NCT02626169]	Phase 4	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Pharmaceutical company sponsor withdrew support prior to enrollment of subjects.)
The Effect of Ticagrelor on the Inflammatory Response to Human Endotoxemia [NCT02612480]		40 participants (Actual)	Interventional	2015-10-31	Completed
Pilot Study of Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease (STEMPAD Trial) [NCT00797056]	Early Phase 1	32 participants (Actual)	Interventional	2008-04-30	Completed
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans [NCT02587260]	Phase 4	54 participants (Actual)	Interventional	2015-12-17	Completed
A Comparison of Platelet Inhibition Following Prasugrel or Clopidogrel Administration in Asian Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention [NCT00830960]	Phase 3	720 participants (Actual)	Interventional	2009-02-28	Completed
Apixaban Versus Antiplatelet Drugs or no Antithrombotic Drugs After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation: A Randomised Phase II Clinical Trial [NCT02565693]	Phase 2	101 participants (Actual)	Interventional	2014-09-30	Completed
Randomized Comparison of Adenosin Intracoronary Infusion and Clopidogrel Pretreatment on Myonecrosis Occurence in Elective PCI [NCT00751491]	Phase 3	60 participants (Anticipated)	Interventional	2008-09-30	Recruiting
Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A Randomised Multi-centre Phase II Trial Comparing Ticagrelor Versus Clopidogrel With Outcome Assessment on MRI (PRECISE-MRI) [NCT02677545]	Phase 2	210 participants (Actual)	Interventional	2016-12-31	Completed
A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction [NCT02663713]	Phase 4	20 participants (Actual)	Interventional	2017-01-31	Completed
A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Explore the Drug Interaction of Tegoprazan or RAPA113 and Clopidogrel After Oral Administration in Healthy Male Volunteers [NCT04171687]	Phase 1	36 participants (Actual)	Interventional	2019-10-21	Completed
Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the Infarct-related Artery in STEMI Patients: A Prospective Randomized Trial of Ticagrelor Versus Clopidogrel [NCT02639143]	Phase 4	50 participants (Actual)	Interventional	2015-12-31	Completed
Comparison of Ulcer Healing in Patients Taking Rabeprazole Plus Aspirin Versus Rabeprazole Plus Clopidogrel for Acute Peptic Ulcer [NCT01037491]		200 participants (Anticipated)	Interventional	2009-10-31	Recruiting
Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery. A Prospective Randomized Controlled Study [NCT00724880]	Phase 4	135 participants (Actual)	Interventional	2006-06-30	Completed
A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg/Day Versus Ticlopidine 200 mg/Day in Patients With Peripheral Arterial Disease - With Extended Treatment of Clopidogrel 75 mg/Day for 40 Weeks [NCT00862420]	Phase 3	431 participants (Actual)	Interventional	2009-02-28	Completed
Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine [NCT00732290]	Phase 1	10 participants (Actual)	Interventional	2009-02-28	Completed
SMart Angioplasty Research Team: Comparison Between P2Y12 Inhibitor MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary BiorEsorbable Scaffold II: (SMART-CHOICE II) Trial [NCT03119012]	Phase 4	1,520 participants (Anticipated)	Interventional	2017-04-19	Suspended(stopped due to cannot use bioabsorbable scaffold)
Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) [NCT02642419]	Phase 4	2,200 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Warfarin After Anterior ST-Elevation Myocardial Infarction [NCT00662467]		20 participants (Actual)	Interventional	2006-11-30	Completed
[NCT02831218]		70 participants (Actual)	Interventional	2016-12-31	Terminated(stopped due to This study was merged into HOWTO-BRS study.)
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease [NCT01107912]	Phase 1	155 participants (Actual)	Interventional	2010-03-31	Completed
Validation of Adjunctive Cilostazol According to CYP2C19 Polymorphism: Prospective, Randomized, Single-Center Trial: [NCT00891670]	Phase 3	80 participants (Anticipated)	Interventional	2009-05-31	Not yet recruiting
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed [NCT00699998]	Phase 3	9,326 participants (Actual)	Interventional	2008-06-30	Completed
LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention [NCT04060914]	Phase 4	225 participants (Anticipated)	Interventional	2019-08-30	Not yet recruiting
A Pharmacoepidemiological Study on the Risk of Bleeding in New Users of Low-dose Aspirin (ASA) in The Health Improvement Network (THIN), UK [NCT02550717]		398,158 participants (Actual)	Observational	2015-09-01	Completed
Phase 4 Study of the Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel [NCT00882388]	Phase 4	40 participants (Actual)	Interventional	2005-03-31	Completed
Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI [NCT00697021]	Phase 3	50 participants (Anticipated)	Interventional	2008-06-30	Recruiting
International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt [NCT00396877]	Phase 3	906 participants (Actual)	Interventional	2006-11-30	Completed
The Influence of CYP2C19 Polymorphism on Antiplatelet Effects and Clinical Outcomes in Non-acute Stroke Patients Treated With Clopidogrel: The Contribution of Genetic Analysis to the Efficacy of Clopidogrel (Cognac) Study [NCT02711410]		518 participants (Actual)	Observational	2009-10-31	Completed
Evaluation of an Experimental EX Vivo Thrombosis Chamber Model in Healthy Male Subjects [NCT00935506]	Phase 1	15 participants (Actual)	Interventional	2009-07-31	Completed
Intensified Loading With Prasugrel Versus Standard Loading With Clopidogrel in Invasive-treated Patients With Biomarker-Negative Angina Pectoris [NCT02548611]	Phase 4	795 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to Due to low recruitment)
Recovery of Platelet Function After a Loading Dose of Prasugrel or Clopidogrel in Aspirin-Treated Subjects Presenting With Symptoms of Acute Coronary Syndromes [NCT01107899]	Phase 1	29 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to Terminated due to Enrollment futility)
Recovery of Platelet Function Following Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Subjects With Stable Coronary Disease [NCT01014624]	Phase 4	56 participants (Actual)	Interventional	2010-02-28	Completed
A Randomized Controlled Trial on the Switch From Ticagrelor to Clopidogrel in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention--OPTImal Management of Antithrombotic Agents: OPTIMA-5 [NCT04116931]	Phase 4	80 participants (Anticipated)	Interventional	2020-06-22	Recruiting
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions: an Open-label, Multicenter, Randomized, Non-inferiority Trial [NCT05209412]		370 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Single-center, Prospective, Controlled Study of the Safety and Efficacy of Aspirin and Clopidogrel in Ischemic Cardiovascular and Cerebrovascular Patients Complications With CAA [NCT04654026]		43 participants (Anticipated)	Observational	2021-02-20	Not yet recruiting
EndothelIal progeNitor Cell Capture steNt With 1-mOnth Dual Antiplatelet Therapy Versus eVerolimus-eluting Stent With stAndard 12-month Dual anTIplatelet Therapy in Elderly (≥ 70 Year) With Stable corONary Artery Disease - INNOVATION Trial [NCT01394848]	Phase 4	1 participants (Actual)	Interventional	2011-10-31	Terminated(stopped due to Previous other study including EPC capture stent raised the issue of safety (significant high incidence of instent restenosis))
A Randomized, Open-label, Two-period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Effect of Darexaban (YM150) on Acetyl Salicylic Acid (ASA) and of Darexaban on the Combination of ASA and Clopidogrel at Steady State [NCT01409616]	Phase 1	100 participants (Actual)	Interventional	2009-04-30	Completed
Prasugrel Versus Adjusted High-dose Clopidogrel to TREAT High On-clopidogrel Platelet Reactivity in Acute Coronary Syndrome Patients After PCI [NCT01493999]	Phase 4	147 participants (Actual)	Interventional	2011-09-30	Completed
Comparative Pharmacokinetics After Single Oral Administration of YH14659, a Fixed Dose Combination Versus Coadministration of Separate Constituents in Healthy Male Volunteers [NCT01422109]	Phase 1	44 participants (Actual)	Interventional	2011-07-31	Completed
Randomized, Open-label, 2-Way Crossover, Bioequivalence Study of Clopidogrel 75 mg Tablet With Plavix® 75 mg In Healthy Subjects Under Fed Conditions [NCT01512485]	Phase 1	51 participants (Actual)	Interventional	2006-10-31	Completed
The Effect of an Acute Dose of Ticagrelor or Clopidogrel and of Treatment for 14 Days on Ischemia-reperfusion Induced Endothelial Dysfunction of the Forearm Vasculature in Healthy Male Subjects. [NCT02580149]	Phase 4	24 participants (Actual)	Interventional	2015-10-31	Completed
Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel [NCT00130039]	Phase 4	457 participants (Actual)	Interventional	2005-08-31	Completed
A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disea [NCT00528411]	Phase 2	123 participants (Actual)	Interventional	2007-10-31	Completed
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease [NCT02798913]	Phase 3	300 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study [NCT03729401]	Phase 4	390 participants (Anticipated)	Interventional	2019-08-22	Suspended(stopped due to Testing supplies unavailable.)
Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease [NCT00816166]	Phase 2/Phase 3	125 participants (Actual)	Interventional	2008-10-31	Terminated
A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects [NCT02560688]	Phase 1	22 participants (Actual)	Interventional	2015-12-31	Completed
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial [NCT02601157]	Phase 4	2,173 participants (Actual)	Interventional	2016-01-18	Completed
The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) [NCT02767401]	Phase 4	200 participants (Actual)	Interventional	2015-09-15	Completed
Anticoagulation Using Rivaroxaban on Top of Aspirin in Recent Stroke/Transient Ischemic Attack Patients With Intracranial Atherosclerotic Stenosis (AA-ICAS) [NCT05700266]	Phase 2/Phase 3	1,180 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease. [NCT00642174]	Phase 2	35 participants (Actual)	Interventional	2008-04-30	Completed
A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial [NCT02609698]	Phase 4	906 participants (Anticipated)	Interventional	2015-08-31	Recruiting
TOPAS-1, A Pharmacodynamic Phase II Study of Clopidogrel P2Y12 Platelet Inhibition [NCT00914368]	Phase 2	450 participants (Anticipated)	Interventional	2009-01-31	Completed
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty [NCT00827346]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2009-01-31	Completed
Efficacy and Safety of Clopidogrel for Primary Prevention in Patients With Subclinical Coronary Atherosclerosis Identified on Imaging [NCT05845489]	Phase 4	9,930 participants (Anticipated)	Interventional	2023-03-09	Recruiting
Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients: A Prospective Multicenter Registry (OPERA) [NCT01325935]	Phase 4	1,187 participants (Actual)	Interventional	2011-04-30	Completed
The Safety and Efficacy of Ticagrelor for Coronary Stenting Post Thrombolysis (SETFAST) Trial. [NCT01930591]	Phase 3	140 participants (Actual)	Interventional	2014-05-31	Completed
Reassessment of Anti-Platelet Therapy Using InDividualized Strategies - Modifying Acute CoroNary Syndrome Algorithms Based on Genetic and Demographic Evaluation: The RAPID-MANAGE Study [NCT02044146]	Phase 2/Phase 3	120 participants (Actual)	Interventional	2014-09-30	Completed
Comparison of Clopidogrel vs. Aspirin Monotherapy Beyond Two Year After Drug-eluting Stent Implantation [NCT02044250]	Phase 4	5,530 participants (Actual)	Interventional	2014-02-28	Completed
A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft. [NCT00174759]	Phase 3	1,460 participants (Anticipated)	Interventional	2004-09-30	Completed
An Open-label, Randomized, Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes [NCT02944123]	Phase 3	120 participants (Actual)	Interventional	2016-09-30	Completed
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI [NCT00889044]	Phase 3	30 participants (Anticipated)	Interventional	2009-04-30	Recruiting
COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial [NCT00814268]	Phase 4	358 participants (Actual)	Interventional	2008-12-31	Completed
The Effects of Physical Training, Aspirin, and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease [NCT00189618]	Phase 4	250 participants (Anticipated)	Interventional	2005-05-31	Completed
A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg Once Daily With a 300 mg Loading Dose Versus Ticlopidine 100 mg Twice Daily in Patients With Stable Angina or Old (Healed) Myocardial Infarction to [NCT00821834]	Phase 3	1,003 participants (Actual)	Interventional	2008-12-31	Completed
Retinal Blood Flow and Microthrombi in Type 1 Diabetes [NCT00406991]	Phase 2	100 participants	Interventional	2003-06-30	Completed
Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation [NCT00822536]	Phase 4	1,798 participants (Actual)	Interventional	2009-01-31	Completed
[NCT01032668]	Phase 3	192 participants (Actual)	Interventional	2008-09-30	Completed
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation [NCT00249873]	Phase 3	7,554 participants (Actual)	Interventional	2003-06-30	Completed
ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery(TEG-CABG Trial):Does Intensified Postoperative Antiplatelet Therapy in Preoperatively Identified Hypercoagulable Patients Improve Outcome After CABG [NCT01046942]	Phase 3	250 participants (Anticipated)	Interventional	2008-11-30	Recruiting
The Impact Of Platelet Function Inhibition On Circulating Cancer Cells In Metastatic Breast Cancer Patients [NCT00263211]	Phase 2	48 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to Stopped due to low percentage of patients with detectable CTCs at baseline.)
Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass? [NCT00228423]	Phase 2	113 participants (Actual)	Interventional	2006-05-31	Completed
Protocol H7T-MC-TABL(a) PRasugrel IN Comparison to Clopidogrel for Inhibition of PLatelet Activation and AggrEgation (PRINCIPLE) - TIMI 44 [NCT00357968]	Phase 2	201 participants (Actual)	Interventional	2006-08-31	Completed
Methods to Augment the Efficacy of Aspirin and Clopidogrel in Healthy Subjects (ASA Only) and Patients With Stable Coronary Artery Disease (Taking Clopidogrel Only) or (Taking Clopidogrel & ASA) With an Elevated Platelet Turnover (Reticulated Platelets). [NCT01011257]	Phase 4	0 participants (Actual)	Interventional	2009-09-30	Withdrawn(stopped due to No funding secured.)
CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention [NCT01012193]	Phase 4	134 participants (Actual)	Interventional	2008-01-31	Completed
Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan [NCT01069302]	Phase 4	106 participants (Actual)	Interventional	2010-02-28	Completed
The Effect of Point-of-care Platelet Function Assay Guided Antiplatelet Therapy on the Periprocedural Increase of Cardiac Enzymes. [NCT01475552]	Phase 4	130 participants (Actual)	Interventional	2010-09-30	Completed
Effect of Rotational Atherectomy on Balloon-resistant Calcified Coronary Lesion the During a Long-term Follow-up Study [NCT01887704]		240 participants (Actual)	Interventional	2010-01-31	Completed
ComPArison of the Effect of Ticagrelor Versus Clopidogrel on Myocardial Blood Flow (MBF) and Reserve (MBFR) Measured With Positron Emission TomograpHy (PET) in Patients With Coronary Artery Disease (CAD): The PATH Study [NCT01894789]	Phase 2/Phase 3	36 participants (Actual)	Interventional	2013-03-31	Completed
Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation: Serial FDG PET/CT Imaging Study of Carotid Artery and Ascending Aorta [NCT01905566]	Phase 4	50 participants (Actual)	Interventional	2013-09-30	Completed
Clopidogrel Or Metoprolol in Myocardial Infarction Trial [NCT00222573]	Phase 4	46,000 participants	Interventional	1999-07-31	Completed
Pharmacodynamic Assessment of Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Exhibiting High Platelet Reactivity Post Fibrinolysis [NCT01950416]	Phase 4	56 participants (Actual)	Interventional	2013-03-31	Completed
Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial [NCT01955200]	Phase 4	1,724 participants (Actual)	Interventional	2013-10-05	Completed
Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke : Role of Platelet alpha2-adrenergic Receptors [NCT01955642]		91 participants (Actual)	Observational	2013-09-30	Completed
[NCT01959191]		859 participants (Actual)	Observational	2008-01-31	Completed
Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI [NCT01959451]	Phase 4	2,600 participants (Actual)	Interventional	2013-09-30	Completed
Platelet Reactivity After Ticagrelor Loading Dose Versus Clopidogrel Loading Dose and Reloading With Ticagrelor, in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention (PCI). [NCT01961856]	Phase 3	74 participants (Actual)	Interventional	2013-09-30	Completed
Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome [NCT01994941]	Phase 4	133 participants (Actual)	Interventional	2013-08-31	Completed
Cilostazol Stroke Prevention Study for Antiplatelet Combination [NCT01995370]	Phase 4	1,884 participants (Actual)	Interventional	2013-12-13	Completed
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy [NCT05926271]	Phase 2	200 participants (Anticipated)	Interventional	2023-07-15	Recruiting
Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study [NCT02869009]	Phase 3	3,000 participants (Actual)	Interventional	2016-11-30	Completed
A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabili [NCT02018055]	Phase 4	2,590 participants (Actual)	Interventional	2014-02-14	Completed
The Effect of Prasugrel as Compared to Clopidogrel on Platelet Function Immediately Following the Termination of Intravenous Bivalirudin in Patients Undergoing Percutaneous Coronary and Structural Cardiac Intervention [NCT01789814]	Phase 4	24 participants (Actual)	Interventional	2013-07-31	Completed
The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-treated Subjects With Stable Coronary Artery Disease [NCT01260584]	Phase 4	110 participants (Actual)	Interventional	2010-11-30	Completed
Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in STEMI Patients (TIME Study) [NCT02026219]	Phase 4	76 participants (Actual)	Interventional	2013-10-31	Completed
A Phase 3, Multicenter, Prospective, Randomized, Open Label, Blinded-endpoint (PROBE) Controlled Trial of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for Injection Versus Standard Medical Treatment for Acute Ischemic Stroke Due to [NCT05141305]	Phase 3	516 participants (Anticipated)	Interventional	2022-04-09	Recruiting
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects [NCT00413608]	Phase 1	140 participants (Actual)	Interventional	2007-01-31	Completed
COMParison of the EffecT of mEdication Therapy: Anticoagulation Versus Anti-platelet Versus Migraine Therapy in Alleviating Migraine With Patent Foramen Ovale [NCT05546320]	Phase 4	1,000 participants (Anticipated)	Interventional	2022-10-15	Recruiting
CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH) [NCT00007683]	Phase 3	1,587 participants (Anticipated)	Interventional	1998-10-31	Completed
Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial [NCT06120725]	Phase 3	580 participants (Actual)	Interventional	2021-09-01	Completed
Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence [NCT00562289]	Phase 3	664 participants (Actual)	Interventional	2007-12-31	Completed
Investigation of the Causes of Health Disparities in African Americans With Coronary Artery Disease on Clopidogrel [NCT04619381]		0 participants (Actual)	Observational	2021-03-19	Withdrawn(stopped due to The study funding was dropped with no patients enrolled)
Safety of High-dose Tirofiban in Patient Undergoing Coronary Angioplasty. [NCT00566891]	Phase 4	2,000 participants (Actual)	Interventional	2007-12-31	Completed
[NCT00589862]	Phase 4	0 participants (Actual)	Interventional	2007-10-31	Withdrawn(stopped due to Failure to secure adequate funding)
Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events [NCT00590174]	Phase 4	1,175 participants (Actual)	Interventional	2007-10-31	Completed
TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization [NCT02211066]	Phase 4	59 participants (Actual)	Interventional	2014-10-31	Completed
Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR) [NCT02486367]	Phase 4	60 participants (Actual)	Interventional	2015-06-30	Completed
PHASE IV Study of Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After Percutaneous Aortic Valve Implantation. Multicenter Randomized Clinical Trial [NCT01642134]	Phase 4	124 participants (Actual)	Interventional	2013-04-30	Completed
Phase 3 Study Comparing the Efficacy and Safety of Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention. [NCT01641510]	Phase 3	70 participants (Actual)	Interventional	2013-10-31	Completed
Drug-eluting Stenting Versus Medical Treatment Alone for Patients With Extracranial Vertebral Artery Stenosis: The VISTA Trial [NCT05885932]		472 participants (Anticipated)	Interventional	2023-08-25	Recruiting
The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome [NCT02484924]		5,225 participants (Actual)	Observational	2010-06-30	Completed
Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrel-loaded Patients Undergoing Percutaneous Coronary Intervention [NCT01609647]	Phase 3	76 participants (Actual)	Interventional	2012-09-30	Completed
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease [NCT01107925]	Phase 1	72 participants (Actual)	Interventional	2010-03-31	Completed
Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition After Elective Coronary Stenting [NCT00302913]		120 participants	Interventional	2005-12-31	Completed
Improving Care for Patients With Acute Coronary Syndrome: Acute Coronary Syndrome Sri Lanka Audit Project (ACSSLAP) [NCT02893280]		0 participants (Actual)	Observational	2015-04-30	Withdrawn(stopped due to Due to an incompatibility with the local procedures)
Clopidogrel 600 mg and 300 mg as a Loading Dose Prior to Percutaneous Coronary Intervention And Serum Troponin Level Elevation: A Pilot Study [NCT00716924]	Phase 3	155 participants (Actual)	Interventional	2004-05-31	Completed
A Randomised, Open-label, Single-Centre, Phase I, Crossover Study to Evaluate the Effect of AZD6482, Compared With Clopidogrel, on Bleeding Time in Healthy Volunteers Receiving Low-Dose ASA [NCT00853450]	Phase 1	28 participants (Anticipated)	Interventional	2009-02-28	Completed
Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease [NCT00728156]	Phase 4	90 participants (Actual)	Interventional	2009-08-31	Completed
A Study of Platelet Function Test in the Application of Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms [NCT03989557]	Phase 4	314 participants (Actual)	Interventional	2019-07-01	Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial) [NCT02640794]	Phase 4	222 participants (Actual)	Interventional	2015-01-31	Completed
Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association With Short-term Single Antiplatelet Therapy in Patients With Coronary Artery [NCT02723981]	Phase 4	0 participants (Actual)	Interventional	2016-04-30	Withdrawn(stopped due to Regulatory authority approval for the initial study design could not be obtained)
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study [NCT02617290]	Phase 3	1,900 participants (Actual)	Interventional	2017-01-09	Completed
Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients [NCT02707445]		5,000 participants (Actual)	Interventional	2011-09-30	Completed
A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patie [NCT01118325]	Phase 2	146 participants (Actual)	Interventional	2010-04-30	Completed
Ticagrelor in Remote Ischemic Preconditioning Study [NCT04174261]	Phase 4	245 participants (Actual)	Interventional	2017-01-29	Completed
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial) [NCT04654052]	Phase 4	634 participants (Anticipated)	Interventional	2021-07-02	Recruiting
Clopidogrel Loading for Acute Ischaemia of Recent Onset (CAIRO) [NCT02776540]	Phase 4	188 participants (Actual)	Interventional	2016-06-01	Completed
High On-treatment Platelet Reactivity to Adenosine Diphosphate Identified by Multiple Platelet Function Assay Guide to Modify Anti-platelet Strategy in Patients Undergoing Percutaneous Coronary Intervention [NCT02699008]		477 participants (Actual)	Interventional	2014-01-31	Completed
150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention [NCT00638326]	Phase 3	500 participants (Anticipated)	Interventional	2008-03-31	Terminated(stopped due to Greater differences between randomized patients than previously anticipated)
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S [NCT00977938]	Phase 4	25,682 participants (Actual)	Interventional	2009-10-31	Completed
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus [NCT04305587]	Phase 1	66 participants (Actual)	Interventional	2020-03-16	Completed
Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56 [NCT01235351]	Phase 2	335 participants (Actual)	Interventional	2010-10-31	Completed
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET [NCT01115738]	Phase 2	282 participants (Actual)	Interventional	2010-05-31	Completed
Standard Medical Management in Secondary Prevention of Ischemic Stroke in China. [NCT00664846]		4,000 participants (Anticipated)	Interventional	2008-04-30	Completed
A Prospective Cohort Study of Predictors and Prognostic Factors on the Acute Ischemic Stroke [NCT03122002]		1,200 participants (Actual)	Observational	2018-03-03	Terminated(stopped due to Limited number of participants enrolled.)
COmparison of Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation for Prevention of Gastrointestinal Injury Evaluated by Ankon Magnetically Controlled Capsule Endoscopy [NCT03198741]	Phase 4	783 participants (Actual)	Interventional	2017-07-13	Completed
Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study) [NCT02829151]	Phase 4	390 participants (Anticipated)	Interventional	2017-02-21	Recruiting
Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled Trial [NCT04661709]	Phase 4	502 participants (Anticipated)	Interventional	2021-03-01	Not yet recruiting
A Randomized, Open-label, Single-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a Tablet Containing 75 mg of Clopidogrel and 100 mg of Aspirin and The Simultaneous Administration of The Separate Formulations of [NCT01388660]	Phase 1	60 participants (Anticipated)	Interventional	2011-06-30	Recruiting
Evaluation of Exercise Capacity as Measured by Peak Oxygen Uptake, Before and After Percutaneous Revascularization of Chronic Total Occlusion [NCT02499666]		15 participants (Actual)	Observational	2015-06-29	Terminated(stopped due to difficulty recruiting patients)
Effects of Clopidogrel and Clarithromycin on the Disposition of Sibutramine and Its Active Metabolites M1 and M2 in Relation to CYP2B6*6 Polymorphism [NCT01421706]	Phase 1	20 participants (Actual)	Interventional	2008-07-31	Completed
Clinical Assessment of Pidogrel® Versus Plavix® [NCT01431495]	Phase 4	219 participants (Actual)	Interventional	2010-04-30	Completed
Effect of Ticagrelor on Endothelial Function [NCT01805596]	Phase 3	45 participants (Anticipated)	Interventional	2013-04-30	Completed
PhaRmacodynamic Effects of Switching thErapy in paTients With High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose Versus Prasugrel RESET GENE Trial [NCT01465828]	Phase 3	30 participants (Actual)	Interventional	2011-10-31	Completed
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial [NCT03961334]	Phase 3	620 participants (Anticipated)	Interventional	2019-12-05	Recruiting
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism [NCT00915733]	Phase 4	80 participants (Actual)	Interventional	2009-05-31	Completed
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) [NCT05047172]	Phase 3	1,683 participants (Anticipated)	Interventional	2022-08-02	Recruiting
MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting [NCT05566301]		1,140 participants (Anticipated)	Observational	2021-09-02	Recruiting
ANTIPLATELET TREATMENT IN ACUTE CORONARY SYNDROMES. SAFETY AND EFFICACY OF ANTIPLATELET SWITCHING Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome [NCT04630288]		1,900 participants (Actual)	Observational	2019-07-02	Active, not recruiting
Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease [NCT03150667]	Phase 4	220 participants (Anticipated)	Interventional	2017-04-10	Recruiting
PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome [NCT00296803]	Phase 4	216 participants	Interventional	2005-11-30	Completed
[NCT02953405]		1,000 participants (Anticipated)	Observational	2015-12-31	Recruiting
Evaluation the Effect of Ticagrelor and Clopidogrel in Stable Coronary Syndrome A Randomized Clinical Trial [NCT05858918]		476 participants (Actual)	Interventional	2022-10-01	Completed
A Phase 1, Open-label, Randomized, Multiple-dose, Crossover Pharmacokinetic/Pharmacodynamic Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Phenotypes [NCT05162053]	Phase 1	128 participants (Actual)	Interventional	2021-12-09	Completed
Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Open-label, Randomized, Cross-over Evaluation: The AMPHORE Study [NCT01860105]	Phase 1	37 participants (Actual)	Interventional	2012-09-30	Completed
RE-DUAL PCI Real Life Registry Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI [NCT04688723]	Phase 4	1,000 participants (Anticipated)	Interventional	2020-12-23	Recruiting
A Single Center, Open-Label, Drug Interaction Study of MGL-3196 With Clopidogrel in Healthy Subjects [NCT04671069]	Phase 1	20 participants (Actual)	Interventional	2019-07-26	Completed
Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects [NCT00368238]	Phase 2	96 participants	Interventional	2005-10-31	Completed
CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction [NCT00372216]	Phase 3	337 participants (Actual)	Interventional	2006-10-31	Completed
Evaluation of the Effect of the H2 Haplotype and CYP3As Polymorphisms on the Antiplatelet Response to Clopidogrel Given Before Elective Percutaneous Coronary Intervention [NCT00433784]	Phase 4	120 participants	Interventional	2004-09-30	Completed
A Randomized Comparison of Platelet Inhibition Using a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Prior Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: [NCT03437044]	Phase 4	40 participants (Actual)	Interventional	2018-03-14	Completed
Anticoagulation in the Management of Grade I-III Blunt Cerebrovascular Injuries [NCT00494156]		0 participants (Actual)	Interventional	2003-07-31	Withdrawn(stopped due to Study halted prematurely prior to enrollment of first participant.)
A Prospective Trial to Evaluate the Effectiveness of Clopidogrel to Relieve Migraine With Right-to-left Shunt [NCT02938182]	Phase 4	50 participants (Anticipated)	Interventional	2016-10-31	Recruiting
[NCT02922465]	Phase 1	20 participants (Actual)	Interventional	2016-09-30	Completed
Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease [NCT04824911]	Phase 2	424 participants (Anticipated)	Interventional	2021-03-23	Recruiting
A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese [NCT01294462]	Phase 3	801 participants (Actual)	Interventional	2011-02-28	Completed
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease [NCT00557921]	Phase 3	5,000 participants (Anticipated)	Interventional	2007-12-31	Terminated(stopped due to Terminated by Sponsor)
PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Long Lesion Sub-trial [NCT01500434]	Phase 3	102 participants (Actual)	Interventional	2009-02-28	Completed
The Effect of Early Administration of Dapagliflozin in ST Elevation Myocardial Infarction Patients Presenting With Left Ventricular Systolic Dysfunction [NCT05045274]		300 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial [NCT00991029]	Phase 3	4,881 participants (Actual)	Interventional	2010-05-28	Terminated(stopped due to The trial was halted by the DSMB.)
[NCT00004564]		0 participants	Interventional		Recruiting
Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure [NCT01765400]	Phase 4	30 participants (Actual)	Interventional	2013-05-15	Completed
The Effects of Administering Clopidogrel on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers [NCT01469416]	Phase 1	10 participants (Actual)	Interventional	2012-03-31	Completed
Randomized, Open-label, Crossover Study to Evaluate the Effect of Genetic Polymorphism on Pharmacokinetic & Pharmacodynamic Interactions of Clopidogrel and Cilostazol in Korean Healthy Adult Volunteers [NCT01482117]		28 participants (Actual)	Interventional	2011-11-30	Completed
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation [NCT00243178]	Phase 3	6,706 participants (Actual)	Interventional	2003-07-31	Terminated
Which Early ST Elevation Myocardial Infarction Therapy? The WEST Study [NCT00121446]	Phase 2/Phase 3	300 participants	Interventional	2003-07-31	Completed
Impact of Chronic Kidney Disease (CKD) on Pharmacodynamic Profiles of the P2Y12 Receptor Inhibitor Clopidogrel in the Setting of Type 2 Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD) [NCT03774394]	Phase 4	61 participants (Actual)	Interventional	2019-08-22	Completed
Double-Blind Parallel Comparison Study of SR25990C Versus Standard Therapy in Japan(Ticlopidine) in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Who Are Planned for Percutaneous Coronary Intervention [NCT00325390]	Phase 3	800 participants	Interventional	2004-07-31	Completed
Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery [NCT00330772]	Phase 3	150 participants (Anticipated)	Interventional	2006-07-31	Completed
Switching From Standard of Care Dual Antiplatelet Treatment (DAPT) Regimens With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition (DPI) With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease: The Switching Anti-P [NCT04006288]	Phase 4	90 participants (Actual)	Interventional	2019-09-06	Completed
Effects of Clopidogrel vs Prasugel vs Ticagrelor on Endothelial Function, Inflammatory and Oxidative Stress Parameters and Platelet Function in Patients Undergoing Coronary Artery Stenting. A Randomised, Prospective Study. [NCT01700322]	Phase 4	126 participants (Actual)	Interventional	2012-08-31	Completed
A Single Center, Double-Blind, Randomized Trial to Evaluate the Effects of Aspirin 325 mg + Clopidogrel 75 mg v. Aspirin 325 mg + Placebo on Plasma Concentration of C-Reactive Protein: The CATER Trial Protocol [NCT00343876]	Phase 4	100 participants (Anticipated)	Interventional	2005-07-31	Completed
Impact of Pre-treatment With 600mg of Clopidogrel (Plavix) on the Incidence of Ischemic and Hemorrhagic Complications in Patients Undergoing Elective Percutaneous Coronary Revascularization.--Prospective Randomized Trial. [NCT00421252]	Phase 4	18 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Difficult to enroll patients; limited resources available)
A Double-Blind, Placebo-Controlled, Three Treatment Cross-Over Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension [NCT00105209]	Phase 2	20 participants	Interventional	2002-04-30	Completed
Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER) [NCT00109382]	Phase 2/Phase 3	500 participants (Anticipated)	Interventional	2003-05-31	Completed
Pilot Study of Personal Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes [NCT00404781]	Phase 4	305 participants (Actual)	Interventional	2006-06-30	Completed
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial [NCT02959606]	Phase 4	272 participants (Anticipated)	Interventional	2016-12-31	Recruiting
Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects. [NCT00152646]	Phase 4	36 participants (Anticipated)	Interventional	2005-03-31	Recruiting
Etude de la Reserve Vasomotrice Microcirculatoire cutanée [NCT00152724]		85 participants (Actual)	Observational	1996-01-31	Completed
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2) [NCT00140465]	Phase 4	60 participants (Actual)	Interventional	2004-10-31	Completed
Recombinant Human Prourokinase（rhPro-UK）for Injection Versus Standard Medical Treatment for Acute Mild Ischemic Stroke (NIHSS≤5) Within 4.5 Hours After Symptom Onset [NCT05507645]	Phase 3	1,446 participants (Anticipated)	Interventional	2022-10-21	Recruiting
Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack [NCT00363753]	Phase 1	0 participants (Actual)	Interventional	2006-08-31	Withdrawn
Radix/Rhizoma Notoginseng Extract (Sanchitongtshu) Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Placebo-controlled Study [NCT02975076]		120 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Effect of Antiplatelet Therapies in Patients With Depression and Coronary Disease [NCT05821062]		400 participants (Anticipated)	Observational	2022-04-14	Recruiting
Phase 4 Study of Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting [NCT01163604]	Phase 4	114 participants (Actual)	Interventional	2010-08-31	Completed
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes - the TC4 Comparative Effectiveness Study [NCT04057300]	Phase 4	1,038 participants (Actual)	Interventional	2018-10-01	Completed
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. [NCT00222261]	Phase 4	1,001 participants (Actual)	Interventional	2003-04-30	Completed
Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery [NCT00235248]	Phase 3	350 participants (Actual)	Interventional	2002-02-28	Completed
A Phase 1, Randomized, Open-Label, 2-Period, Crossover Design Study to Assess the Effects of Multiple Oral Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healt [NCT00942175]	Phase 1	160 participants (Actual)	Interventional	2009-12-31	Completed
Phase 4 Study of Clopidogrel in Patients With Stable Coronary Artery Disease to Determine Effects on Vascular Function, Biomarkers and Endothelial Progrenitor Cells [NCT01283282]	Phase 4	48 participants (Actual)	Interventional	2008-01-31	Completed
Clopidogrel Loading Dose for ad-Hoc Percutaneous Coronary Intervention Immediately Following Elective Coronary Angiography: Randomized Multicenter Trial Comparing Pre-Treatment > 6 Hours Before Every Angiography vs. Cath-Lab Administration After Angiograp [NCT00432120]	Phase 3	0 participants	Interventional	2006-03-31	Completed
Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS [NCT00444132]	Phase 3	50 participants (Anticipated)	Interventional	2005-03-31	Completed
Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events [NCT00484926]	Phase 4	2,000 participants (Actual)	Interventional	2007-03-31	Completed
Validation of the Clinical Applicability of Various Platelet Function Assessments in High-Risk Atherothrombotic Patients Undergoing Percutaneous Coronary Angioplasty: Phase 4 Study [NCT00513149]	Phase 4	150 participants (Anticipated)	Interventional	2006-07-31	Recruiting
A PhaseⅠ Study to Compare the Pharmacokinetic Characteristics and Safety After Oral Administration of G0041(75/100mg) With Those of Clopidogrel 75mg & Aspirin 100mg Coadministration in Healthy Male Volunteers [NCT01526122]	Phase 1	65 participants (Actual)	Interventional	2011-09-30	Completed
The ANTARCTIC Study - Assessment of a Normal Versus Tailored Dose of Prasugrel After Stenting in Patients Aged > 75 Years to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications [NCT01538446]	Phase 4	880 participants (Actual)	Interventional	2012-03-31	Completed
Comparison of Therapy With TICAGRELOR, Prasugrel and High Clopidogrel Dose in PCI Patients With High on Treatment Platelet Reactivity and Genotype Variation [NCT01543932]	Phase 3	81 participants (Actual)	Interventional	2012-07-31	Completed
Dose-Ranging Pharmacodynamic Assessment of Platelet Aggregation Inhibition With Clopidogrel in Children of Blalock-Taussig Shunt Age Categories (Neonates and Infants/Toddlers) [NCT00115375]	Phase 2	92 participants (Actual)	Interventional	2004-01-31	Completed
Evaluation the Effect of the Double Maintenance Dose of Clopidogrel Versus Single Dose in Patients With Coronary Artery Disease With a BMI ≥ 27 kg.m-2 [NCT01509365]	Phase 4	116 participants (Actual)	Interventional	2011-12-31	Completed
Open-label Randomized Control Trial to Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome [NCT05573958]	Phase 4	90 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
One Year Effects of Different Clopidogrel Maintaining Dosage on Patients With Acute Coronary Syndrome Undergoing Coronary Drug Eluting Stent Implantation [NCT00404053]	Phase 4	0 participants	Interventional	2004-12-31	Completed
Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding [NCT01806090]	Phase 4	216 participants (Actual)	Interventional	2012-02-29	Completed
Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients [NCT03823274]		1,011 participants (Actual)	Observational [Patient Registry]	2019-04-01	Completed
Development of a Risk Prediction Algorithm Through the Investigation of Genetic Risk Factors and the Complexity of Coronary Artery Disease to Estimate Future Risk of Cardiovascular Events: Angiographic (SYNTAX Score), Clinical and Pharmacogenetic Analysis [NCT03150680]		1,080 participants (Anticipated)	Observational [Patient Registry]	2017-09-01	Recruiting
A Prospective, Multi-center, Optical Coherence Tomography Guided Reperfusion Strategy in Patients With STEMI (EROSION II) [NCT03062826]		347 participants (Actual)	Observational	2017-01-11	Active, not recruiting
A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) [NCT00020189]	Phase 2	0 participants	Interventional	2000-06-30	Completed
A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low [NCT00050817]	Phase 3	15,603 participants (Actual)	Interventional	2002-10-31	Completed
Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study [NCT00163267]	Phase 2/Phase 3	80 participants (Actual)	Interventional	2005-09-30	Completed
Secondary Prevention of Small Subcortical Strokes (SPS3) Trial [NCT00059306]	Phase 3	3,020 participants (Actual)	Interventional	2003-02-28	Completed
Functional Mitral Regurgitation in STICH [NCT00224809]		250 participants (Anticipated)	Interventional	2002-09-30	Completed
Perioperative Risk Factors for the Development of Aspirin Low Response in Patients Undergoing Vascular Surgery. [NCT03587324]		176 participants (Actual)	Interventional	2013-02-28	Completed
PACT (Platelet Activity After Clopidogrel Termination) [NCT00619073]		15 participants (Actual)	Interventional	2008-04-30	Completed
The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization [NCT00644657]		27 participants (Actual)	Interventional	2007-03-31	Completed
A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease. [NCT01979445]	Phase 2	15 participants (Actual)	Interventional	2013-12-02	Completed
The Impact of Grapefruit Juice on the Response to a Loading Dose and Maintenance Dose of Clopidogrel in Healthy Volunteers [NCT00817999]	Phase 4	32 participants (Actual)	Interventional	2008-11-30	Completed
Coronary Artery Ectasia, Thrombotic Background and Efficacy of Various Anti Thrombotic Regimens. [NCT05718531]	Phase 3	200 participants (Anticipated)	Interventional	2023-02-01	Not yet recruiting
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX) [NCT01156571]	Phase 3	11,145 participants (Actual)	Interventional	2010-09-30	Completed
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI) [NCT05516784]	Phase 4	80 participants (Actual)	Interventional	2019-09-01	Completed
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study) [NCT01612884]	Phase 4	67 participants (Actual)	Interventional	2011-08-31	Terminated(stopped due to Slow enrollment)
Evaluation of Simplified Anti-Thrombotic Therapy for Coronary Fractional Flow Reserve [NCT02384070]		300 participants (Actual)	Interventional	2009-01-31	Completed
A Multicentre Study Comparing the Efficacy of Rosuvastatin With Atorvastatin When Given for a Period of 16 Wks to Subjects With Coronary Heart Disease & a Previously Performed Percutaneous Coronary Intervention [NCT00235950]	Phase 4	255 participants	Interventional	2004-01-31	Completed
Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel [NCT00262275]		0 participants	Interventional	2002-07-31	Completed
Cervical Artery Dissection in Stroke Study [NCT00238667]	Phase 3	250 participants (Actual)	Interventional	2005-11-30	Completed
A Sequence-randomized, Open-label, Single Dose, Crossover Study to Evaluate Pharmacokinetics and Safety After Oral Administration of Clopidogrel and Aspirin in Free Combination and Fixed-dose Combination as HCP0911 in Healthy Male Volunteers [NCT01448330]	Phase 1	64 participants (Actual)	Interventional	2011-07-31	Completed
A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI). [NCT00385138]	Phase 3	5,364 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Insufficient evidence of the clinical effectiveness of cangrelor)
A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers [NCT01603342]	Phase 1	18 participants (Actual)	Interventional	2007-12-31	Completed
Double-Blind, Double-Dummy, Randomized, Parallel Group Trial of SL650472 (Three Dose Regimens Versus Placebo and Cilostazol), for 24-Week Improvement of Walking Distance in Patients With Stage II Peripheral Arterial Disease Who Benefit From Optimal Preven [NCT00300339]	Phase 2	599 participants (Actual)	Interventional	2006-02-28	Completed
The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent in the Patients With Coronary Artery Disease (DATE Registry) [NCT00418860]		1,200 participants (Anticipated)	Interventional	2006-09-30	Completed
Comparison of Efficacy and Safety Between Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk [NCT02960126]	Phase 3	1,500 participants (Anticipated)	Interventional	2016-11-30	Not yet recruiting
A Randomized, Open-label, Three-period, Multiple Dosing Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacodynamics of Clopidogrel in Healthy Subjects [NCT06164834]	Phase 1	48 participants (Anticipated)	Interventional	2023-12-05	Not yet recruiting
Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy [NCT01495845]	Phase 1	48 participants (Actual)	Interventional	2011-12-31	Completed
Comparative Pharmacokinetics of Clopidogrel 75mg and Aspirin 100mg After Single Oral Administration as a Fixed Dose Combination Versus Separate Combination in Healthy Male Volunteers [NCT01496261]	Phase 1	60 participants (Actual)	Interventional	2011-08-31	Completed
Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions on the Pharmacokinetics/Pharmacodynamics of Clopidogrel in Healthy Volunteers [NCT01503658]	Phase 4	18 participants (Actual)	Interventional	2012-01-31	Completed
Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention [NCT01505790]	Phase 3	187 participants (Actual)	Interventional	2011-07-31	Completed
Randomized, Open-label, 2-Way Crossover, Bioequivalence Study of Clopidogrel 75 mg Tablet With Plavix® 75 mg In Healthy Subjects Under Fasting Conditions [NCT01506713]	Phase 1	53 participants (Actual)	Interventional	2006-09-30	Completed
Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? [NCT01621451]	Phase 4	400 participants (Anticipated)	Interventional	2012-06-30	Enrolling by invitation
An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Table [NCT01621750]	Phase 1	68 participants (Actual)	Interventional	2008-08-31	Completed
An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel 300 mg Tablets of Dr. Reddy's India and Plavix® 300 mg Tablets Under Fed Conditions [NCT01621763]	Phase 1	68 participants (Actual)	Interventional	2008-09-30	Completed
Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome. [NCT01626534]	Phase 3	125 participants (Actual)	Interventional	2012-03-31	Completed
Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. [NCT01627431]	Phase 4	410 participants (Anticipated)	Interventional	2012-07-31	Recruiting
An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Single-Dose Bioequivalence Study of Clopidogrel Tablets USP 75mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Plavix® (Clopidogrel Bisulfate Tablets) 75mg [NCT01630642]	Phase 1	0 participants	Interventional		Completed
An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Single-Dose Bioequivalence Study of Clopidogrel Tablets USP 75mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Plavix® (Clopidogrel Bisulfate Tablets) 75mg [NCT01630915]	Phase 1	0 participants	Interventional		Completed
Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment. [NCT01636180]	Phase 4	0 participants (Actual)	Interventional	2012-03-31	Withdrawn
Aspirin Versus Clopidogrel Effect on Uterine Perfusion in Women With Unexplained Recurrent Pregnancy Loss With Decreased Uterine Artery Pulsatility Index: A Randomized Controlled Trial [NCT01635426]	Phase 2/Phase 3	32 participants (Anticipated)	Interventional	2012-03-31	Recruiting
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel [NCT01643031]	Phase 4	500 participants (Anticipated)	Interventional	2012-08-31	Not yet recruiting
A Randomized, Open-label, Single Dose, 2-treatment, 2-period, 2-way Crossover Study to Assess the Pharmacokinetic Characteristics of YH14659, a Fixed Dose Combination Compared With Coadministration of Separate Constituents Under Fasted Conditions in Healt [NCT01657071]	Phase 1	60 participants (Actual)	Interventional	2012-03-31	Completed
Safety and Efficacy of Intensive Versus Guideline Antiplatelet Therapy in High Risk Patients With Recent Ischaemic Stroke or Transient Ischaemic Attack: a Randomised Controlled Trial [NCT01661322]	Phase 3	3,096 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Trial reached a definitive answer ahead of full recruitment.)
Comparative Pharmacokinetics of Clopidogrel 75mg and Aspirin 100mg After Single Oral Administration as a Fixed Dose Combination Versus Separate Combination in Healthy Male Volunteers [NCT01663038]	Phase 1	60 participants (Actual)	Interventional	2010-12-31	Completed
The Correlation Study Between Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis [NCT01665235]		200 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial [NCT04624854]	Phase 4	8,250 participants (Anticipated)	Interventional	2020-10-27	Recruiting
A Randomized Study With Loading Dose of Prasugrel Opposed to the Standard Dose of Clopidogrel in Type 2 Diabetic Patients in Acute Coronary Syndrome, Revascularized Through Drug-eluting Stent. [NCT01684813]	Phase 4	65 participants (Anticipated)	Interventional	2012-10-31	Completed
A Randomized Comparison of TAILOReD Anti-Platelet Therapy According to Platelet Reactivity Versus Uniform Clopidogrel Monotherapy Beyond 12 Months After Drug-eluting Stent Implantation in High-risk Patients: TAILOR-DAPT [NCT05936606]		3,434 participants (Anticipated)	Interventional	2023-08-16	Recruiting
Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE) [NCT01701453]		2,712 participants (Actual)	Interventional	2012-08-31	Active, not recruiting
A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease [NCT01706510]	Phase 4	28 participants (Actual)	Interventional	2012-12-31	Completed
Effects of Ticagrelor and Intracoronary Morphine on Myocardial Salvage in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [NCT01738100]	Phase 2	100 participants (Anticipated)	Interventional	2012-09-30	Recruiting
A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelia [NCT01743014]	Phase 4	60 participants (Anticipated)	Interventional	2012-07-31	Recruiting
A Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementatio [NCT01744288]	Phase 1	258 participants (Actual)	Interventional	2012-12-31	Completed
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine （SPRING）: a Multicenter, Random, Case Control Study [NCT04946734]	Phase 3	440 participants (Anticipated)	Interventional	2021-08-12	Recruiting
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events: BVS-LATE Trial [NCT02939872]	Phase 4	238 participants (Actual)	Interventional	2017-03-09	Active, not recruiting
Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients With Coronary Heart Disease: A Randomized, Open Label, Crossover Study [NCT01757262]	Phase 3	0 participants (Actual)	Interventional	2013-01-31	Withdrawn
Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin in Korean Patients With Coronary Artery Disease (a Single-center, Randomized, Open-label Clinical Trial) [NCT01763749]	Phase 4	91 participants (Actual)	Interventional	2012-10-31	Completed
Multi-center, Randomized, Open Study for Comparison of Efficacy and Safety of Plavix With Astrix and Closone in Patients With Post-Percutaneous Coronary Artery Intervention [NCT01765452]	Phase 4	285 participants (Actual)	Interventional	2012-10-31	Completed
Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome [NCT01774838]	Phase 3	49 participants (Actual)	Interventional	2014-10-31	Completed
Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions of Aspirin Co-administration on the PK/PD of Clopidogrel and PK of Digoxin in Healthy Volunteers [NCT01775839]	Phase 4	24 participants (Actual)	Interventional	2013-01-31	Completed
Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) [NCT01777503]	Phase 4	2,000 participants (Anticipated)	Interventional	2012-11-30	Recruiting
PhaRmacodynamic Effect of Antiplatelet Agents in Elderly Patients: Standard Clopidogrel Versus prasugrEl Low Dose Therapy. [NCT01778842]	Phase 3	68 participants (Anticipated)	Interventional	2013-03-31	Not yet recruiting
Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients. [NCT01779401]		1,078 participants (Actual)	Interventional	2012-09-30	Completed
A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack [NCT05476081]		1,067 participants (Anticipated)	Observational [Patient Registry]	2021-02-03	Recruiting
The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention [NCT01812330]	Phase 3	180 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis [NCT01823185]	Phase 4	1,500 participants (Anticipated)	Interventional	2013-03-31	Recruiting
Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During Percutaneous Coronary Intervention: an Optical Coherence Tomography Study [NCT01826175]	Phase 4	0 participants (Actual)	Interventional	2013-05-31	Withdrawn(stopped due to Study terminated mutually by sponsor & PI due to no enrollment)
Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy Volunteers [NCT01846559]	Phase 4	30 participants (Actual)	Interventional	2013-04-30	Completed
A Prospective Observational Cohort Study of Predictive Factors Related to Prognosis of In-hosiptal Patients With Ischemic Stroke Due to Large-artery Atherosclerosis [NCT04847752]		1,000 participants (Anticipated)	Observational	2021-03-01	Recruiting
Optimizing Therapy With Aspirin and Clopidogrel. The BOchum CLopidogrel and Aspirin Plan to Improve Dual Antiplatelet Therapy. [NCT01212302]		500 participants (Actual)	Interventional	2008-10-31	Completed
Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI) [NCT01742117]	Phase 4	5,276 participants (Actual)	Interventional	2013-05-31	Completed
Evaluation of Safety, Benefits and Complications of Long-term Dual Antiplatelet Therapy in Patients With Angioplasty [NCT02327741]		1,010 participants (Actual)	Interventional	2012-10-31	Completed
CLOpidogrel Versus TIcagreLor for Antiplatelet Maintenance in DIAbetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study [NCT02742987]	Phase 4	42 participants (Actual)	Interventional	2014-03-31	Completed
Comparison of Dual-Antiplatelet and Triple-Antiplatelet Preparation Using P2Y12 Assay in Patients With High On-Treatment Platelet Reactivity Undergoing Stent-Assisted Coil Embolization for An Unruptured Intracranial Aneurysm [NCT03581409]	Phase 4	198 participants (Actual)	Interventional	2018-10-24	Completed
A U.S. Post-Approval Study of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System [NCT01589978]	Phase 4	2,681 participants (Actual)	Interventional	2012-05-31	Completed
Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction [NCT02931045]	Phase 4	60 participants (Actual)	Interventional	2017-12-30	Completed
Randomized, Crossover Study of the Antithrombotic Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin When Administered With Bivalirudin [NCT01642238]	Phase 4	15 participants (Actual)	Interventional	2012-07-31	Completed
Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment (A Possible Mechanism of HOTPR:High On- Treatment Platelet Reactivity) [NCT03190005]		35 participants (Actual)	Observational	2017-01-01	Completed
A Phase IV, Randomised, Multi-Centre, Open Label Study, Comparing Ticagrelor Versus Clopidogrel in Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Patients Undergoing Percutaneous Coronary Intervention (PCI) With Bivalirudin [NCT02052635]	Phase 4	34 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to Patient recruitment challenges, low enrolment, and a forecasted inability to complete the study in an acceptable timeframe)
A Phase 2, Open Label, Pilot Study to Examine the Use of Rivaroxaban Plus Aspirin vs. Clopidogrel Plus Aspirin for the Prevention of Restenosis After Infrainguinal Percutaneous Transluminal Angioplasty for Critical Limb Ischemia [NCT02260622]	Phase 2	20 participants (Actual)	Interventional	2014-10-31	Completed
PHARMACOGENOMICS OF ANTI-PLATELET RESPONSE - I [NCT01815008]	Phase 4	19 participants (Actual)	Interventional	2012-10-31	Completed
Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients [NCT01823510]	Phase 4	20 participants (Actual)	Interventional	2013-07-31	Completed
Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery: A Prospective, Multicenter, Randomized Study Comparing Two Durations of Dual Antiplatelet Therapy [NCT06175377]		660 participants (Anticipated)	Interventional	2024-03-30	Not yet recruiting
Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients With Acute Myocardial Infarction: A Randomized, Placebo-controlled ACCEL-EPISODE Trial [NCT04407312]	Phase 4	60 participants (Actual)	Interventional	2016-01-01	Active, not recruiting
Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction: A Pilot Study [NCT02376283]	Phase 4	87 participants (Actual)	Interventional	2015-03-09	Completed
Tailoring Bleeding Reduction Approaches in Patients Undergoing Percutaneous Coronary Interventions: Comparative Pharmacodynamic Effects of Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy De-escalation [NCT05681702]	Phase 4	90 participants (Anticipated)	Interventional	2023-02-15	Recruiting
Bioavailability of Two Oral Formulations of Clopidogrel: A Randomized, Open Label, Single Dose, Two-Period, Crossover Comparison in Healthy Mexican Volunteers [NCT01447563]	Phase 1	32 participants (Actual)	Interventional	2008-05-31	Terminated
Observational Study on Predictive Value for Vascular Events of Residual Platelet Aggregation in Patients on Antiplatelet Therapy After Carotid Angioplasty With Stenting [NCT01449617]		272 participants (Anticipated)	Observational	2010-08-31	Recruiting
Low-dose Rivaroxaban Monotherapy Versus Guideline Determined Medication Therapy After Left Atrial Appendage Occlusion: a Randomized, Open-label, Multicentre, Superiority Trial [NCT05960721]		4,220 participants (Anticipated)	Interventional	2023-07-06	Recruiting
Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data [NCT04237935]		27,960 participants (Actual)	Observational	2019-09-22	Completed
Replication of the TRITON-TIMI Antiplatelet Trial in Healthcare Claims Data [NCT04237922]		43,864 participants (Actual)	Observational	2019-09-22	Completed
Randomized Controlled Trial to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent [NCT01341964]	Phase 4	302 participants (Actual)	Interventional	2011-05-31	Completed
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI) [NCT01463150]	Phase 4	27 participants (Actual)	Interventional	2011-10-31	Completed
A Multicentre, Open-label, Randomized, 6-week, Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel With Aspirin as Background Therapy in Chinese Patients With Non-ST or ST Elevation Acute Coronary [NCT01864005]	Phase 4	60 participants (Actual)	Interventional	2013-05-31	Completed
Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol [NCT04368377]	Phase 2	5 participants (Actual)	Interventional	2020-04-06	Completed
Efficacy and Safety of Different Ticagrelor Regimens Versus Clopidogrel in Patients With Coronary Artery Disease: a Retrospective Multicenter Study (SUPERIOR) [NCT03381742]	Phase 2/Phase 3	3,043 participants (Actual)	Interventional	2017-12-13	Completed
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry [NCT04822363]	Early Phase 1	125 participants (Anticipated)	Interventional	2021-08-20	Recruiting
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease. [NCT02983214]	Phase 4	826 participants (Actual)	Interventional	2016-11-30	Completed
Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV [NCT02559414]	Phase 2	55 participants (Actual)	Interventional	2015-02-28	Completed
Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study [NCT02548650]	Phase 4	66 participants (Actual)	Interventional	2016-03-25	Completed
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study [NCT02144831]	Phase 4	0 participants (Actual)	Interventional	2014-07-31	Withdrawn(stopped due to Could not get study started)
Aspirin and Plavix Following Coronary Artery Bypass Grafting (ASAP-CABG) [NCT01158703]	Phase 4	20 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to poor recruitment and reduction in CT surgery support)
Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion [NCT04502017]	Phase 4	360 participants (Anticipated)	Interventional	2020-08-05	Recruiting
Clopidogrel Pharmacogenomics Project [NCT01097343]	Phase 2	50 participants (Actual)	Interventional	2010-03-31	Completed
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design [NCT01924325]	Phase 2/Phase 3	10,000 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, P [NCT03430661]	Phase 1	77 participants (Actual)	Interventional	2018-01-24	Completed
Optimal Duration of Clopidogrel After Implantation of Second-Generation Drug-Eluting Stents (OPTIMA-C) [NCT03056118]	Phase 4	1,368 participants (Actual)	Interventional	2011-05-02	Completed
Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke: An Open-label, Blinded Endpoint, Randomized Controlled Trial [NCT05910125]	Phase 4	472 participants (Anticipated)	Interventional	2023-07-31	Not yet recruiting
Endovascular Stenting of Medically Refractory Intracranial Arterial Stenotic (ICAS) Disease (Clinical and Sonographic Study) [NCT04393025]	Phase 4	50 participants (Actual)	Interventional	2016-06-30	Completed
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry [NCT01515345]	Phase 3	1,008 participants (Actual)	Interventional	2011-07-31	Completed
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy [NCT01452152]	Phase 4	9 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Terminated by study sponsor.)
Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT [NCT03197298]		2,062 participants (Actual)	Observational [Patient Registry]	2012-12-21	Completed
TRIANA: A Randomized Trial to Compare the Efficay and Safety of Thrombolysis With Primary Angioplasty as Initial Reperfusion Therapy in Older Patients (>= 75 Years Old) With Acute Myocardial Infarction [NCT00257309]	Phase 4	266 participants (Actual)	Interventional	2005-04-30	Terminated(stopped due to Slow recruitment)
A Pilot Study of Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves: A Randomized Controlled Trial [NCT02696226]		3 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to Poor enrollment)
Comparison of Coronary Artery Bypass Graft Surgery Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel [NCT04431349]		1,097 participants (Actual)	Observational	2016-01-01	Completed
Effect of Cilostazol as an add-on Treatment to a Single Antiplatelet Agent (Acetylsalicylic Acid or Clopidogrel) on Platelet Function Testing and Bleeding Time in Healthy Volunteers [NCT02554721]	Phase 1	77 participants (Actual)	Interventional	2015-08-31	Completed
Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor [NCT03039205]	Phase 2	90 participants (Actual)	Interventional	2017-11-07	Completed
Modulation of the WNT/Beta-Catenin Pathway in Patients With Acute Myocardial Infarction [NCT05122741]		50 participants (Anticipated)	Observational [Patient Registry]	2021-12-01	Recruiting
Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV Clinical Trial [NCT01830491]	Phase 4	162 participants (Actual)	Interventional	2009-03-31	Completed
Escalated Single Platelet Inhibition for One Month Plus Direct Oral Anticoagulation in Patients With Atrial Fibrillation and acUte coRonary Syndrome Undergoing percutaneoUS Coronary Intervention [NCT04981041]	Phase 4	2,334 participants (Anticipated)	Interventional	2021-12-16	Recruiting
A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers [NCT01557335]	Phase 1	30 participants (Actual)	Interventional	2010-11-30	Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial) [NCT01559298]	Phase 4	178 participants (Actual)	Interventional	2012-03-31	Completed
Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary S [NCT01572129]	Phase 4	240 participants (Anticipated)	Interventional	2011-11-30	Recruiting
Efficacy of Two Different Pre-Intervention Therapeutic Strategies With Clopidogrel and Atorvastatin for the Prevention of Cerebral Damage During Carotid Artery Stenting. Armyda-Caro Randomized Trial. [NCT01572623]	Phase 4	150 participants (Anticipated)	Interventional	2011-07-31	Recruiting
The Effect Of Antiplatelets Therapy, Tirafiban, Prasugrel, And Aspirin On Saphenous Vein Coronary Artery Bypass Graft Patency [NCT01598337]	Phase 3	200 participants (Anticipated)	Interventional	2011-04-30	Recruiting
A Randomized, Pilot, Single-center Study, Investigator-Initiated Study to Look at an Aggressive Therapeutic Approach in Aspirin Resistant Patients Comparing to Standard for Patient Undergoing Percutaneous Coronary Intervention [NCT01103440]	Phase 2	36 participants (Actual)	Interventional	2007-04-30	Completed
Extended Antiplatelet Therapy With Clopidogrel Alone Versus Clopidogrel Plus Aspirin After Completion of 9- to 12-month Dual Antiplatelet Therapy for ACS Patients With Both High Bleeding and Ischemic Risk. [NCT03431142]	Phase 4	7,700 participants (Anticipated)	Interventional	2018-02-12	Recruiting
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes [NCT02556203]	Phase 3	1,653 participants (Actual)	Interventional	2015-12-16	Terminated(stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator)
A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom [NCT02293395]	Phase 2	3,037 participants (Actual)	Interventional	2015-04-20	Completed
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia [NCT02230527]	Phase 2/Phase 3	46 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Lack of enrollment)
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities [NCT02217501]	Phase 3	159 participants (Actual)	Interventional	2015-11-30	Completed
Stroke and Coated-Platelets - A Translational Research Initiative [NCT04698031]	Phase 4	152 participants (Anticipated)	Interventional	2022-03-30	Recruiting
Evaluation of Clopidogrel Use in Peri-Operative General Surgery Patients: A Prospective Study [NCT01960296]	Phase 2	48 participants (Actual)	Interventional	2012-01-31	Completed
Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial [NCT02206815]	Phase 4	296 participants (Actual)	Interventional	2014-09-19	Completed
Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions [NCT04744571]		200 participants (Anticipated)	Interventional	2021-02-28	Enrolling by invitation
"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization" [NCT02513004]	Phase 4	60 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Pharmacodynamic Evaluation of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease [NCT02287909]	Phase 4	87 participants (Actual)	Interventional	2014-12-31	Completed
Intravenous Thrombolysis With Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for Acute Non-large Vessel Occlusion in Extended Time Window--A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial [NCT05752916]	Phase 4	568 participants (Anticipated)	Interventional	2023-06-02	Recruiting
Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT03245489]	Phase 1	20 participants (Anticipated)	Interventional	2017-10-20	Recruiting
Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis. [NCT00360386]	Phase 2	110 participants	Interventional	2004-03-31	Completed
Left Atrial Appendage Occlusion Versus Novel Oral Anti-coagulation in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention: a Randomized, Multicentre, Open-label, Non-inferiority Trial [NCT05353140]		1,386 participants (Anticipated)	Interventional	2022-09-01	Recruiting
Randomized Clinical Trial Assessing the Value of Beta-Blockers and Antiplatelet Agents in Patients With Spontaneous Coronary Artery Dissection. (The BA-SCAD Randomized Clinical Trial) [NCT04850417]	Phase 4	600 participants (Anticipated)	Interventional	2021-04-30	Not yet recruiting
The Role of DLBS1033 in Evaluating Bleeding Profile and Clinical Outcome in Patients With Acute Ischemic Stroke: Comparison With Aspirin and Clopidogrel [NCT01790997]	Phase 3	126 participants (Actual)	Interventional	2012-05-31	Completed
A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting [NCT02330640]	Phase 4	137 participants (Actual)	Interventional	2016-01-31	Completed
Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Detection of Platelet Dysfunction Due to P2Y12 Antiplatelet Drugs [NCT03111420]		280 participants (Actual)	Interventional	2017-01-09	Completed
Incidence Des évènements cArdiovasculaires majeurS Chez Les Patients COronariens diabétiques Subissant Une angioPlastie Coronaire et traités Par Clopidogrel à la Dose 150 mg Versus 75 mg [NCT03329261]	Phase 4	167 participants (Actual)	Interventional	2017-12-07	Completed
Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial [NCT03078465]	Phase 3	0 participants (Actual)	Interventional	2017-06-20	Withdrawn(stopped due to Competitive studies were conducted at the same time, and enrollment was suspended.)
Reassessment of Long-Term Dual Anti-Platelet Therapy Using InDividualized Strategies - Using a Novel Combined Demographic and Pharmacogenomic Strategy: The RAPID EXTEND Pilot Study [NCT03224923]	Phase 4	5 participants (Actual)	Interventional	2017-08-18	Terminated(stopped due to Competing study to be started in November 2018)
Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention [NCT04999293]		1,505 participants (Actual)	Observational	2021-07-20	Completed
The Association Between Plasma or Platelet microRNAs and Clopidogrel Low Response and Its Mechanism [NCT02447809]	Phase 4	400 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients [NCT03054207]	Phase 1	21 participants (Actual)	Interventional	2015-06-30	Terminated(stopped due to difficulty to recruit)
An Open-label, Randomised, Three-way Crossover Study in Healthy Subjects to Assess the Bioequivalence of European Source Generic Clopidogrel Tablets and US and Japanese Source Branded Clopidogrel (Plavix®) Tablets. [NCT02185534]	Phase 1	144 participants (Actual)	Interventional	2014-08-31	Completed
Investigating the Changes of the Cognition in Asymptomatic Intracranial Stenosis Patients After 1-Year Standard Medical Treatment Without Stenting [NCT04850001]		40 participants (Anticipated)	Observational	2020-09-10	Recruiting
Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization [NCT02433587]	Phase 3	0 participants (Actual)	Interventional	2019-10-31	Withdrawn(stopped due to Never recruited any patients.)
Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With Non-ST-Elevation Acute Coronary Syndrome: A Randomized Clinical Trial [NCT02415803]	Phase 3	75 participants (Anticipated)	Interventional	2014-12-31	Recruiting
[NCT02411903]	Phase 4	160 participants (Anticipated)	Interventional	2015-03-31	Enrolling by invitation
Evaluation of the Safety and Efficacy of Clopidogrel sulfate50mg and Clopidogrel Sulfate 75mg for the Treatment of Cerebral Infarction [NCT00386191]	Phase 4	1,110 participants (Actual)	Interventional	2006-09-30	Completed
A Phase III Multi-centre Double-blind Placebo Controlled Study Analysing the Efficacy and Safety of Daily Administration of a P2Y12 Inhibitor (Clopidogrel) for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer [NCT02404363]	Phase 3	39 participants (Actual)	Interventional	2016-01-11	Terminated(stopped due to recruitment problem)
The Relationship Between Genotype and Platelet Reactivity in Patients Treated With Ticagrelor Versus Clopidogrel: PIANO Genotype Study [NCT02394145]	Phase 3	20 participants (Anticipated)	Interventional	2009-09-30	Recruiting
A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Followi [NCT03766581]	Phase 2	2,366 participants (Actual)	Interventional	2019-01-27	Completed
Effect of Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving Dual-antiplatelet Therapy Undergoing Dental Procedure. [NCT03103685]	Phase 4	428 participants (Anticipated)	Interventional	2017-05-01	Not yet recruiting
[NCT02391883]		356 participants (Actual)	Observational	2011-01-31	Completed
The Study of Berberine Affecting Metabolism, Inflammation Status, Endothelial Function and Thrombotic Events in Patients With Coronary Artery Disease by Remodeling Gut Microbiota [NCT04434365]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2019-06-21	Active, not recruiting
Early Initiation of Antiplatelet ThERapy In HeArt TranspLantation: AERIAL Trial [NCT04770012]	Phase 3	135 participants (Anticipated)	Interventional	2021-06-28	Recruiting
Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients [NCT03078257]	Phase 1	90 participants (Anticipated)	Interventional	2016-01-01	Recruiting
Effect of Aspirin and Clopidogrel in Prevention of Venous Obstruction After Implantation of Cardiac Pacemaker and Defibrillator [NCT02331511]		100 participants (Anticipated)	Interventional	2015-10-31	Recruiting
24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial [NCT04989257]		3,488 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI). [NCT00305162]	Phase 3	8,882 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to Insufficient evidence of the clinical effectiveness of cangrelor)
Multiphase Study to Determine if Platelet Function Analysis Results Correlate With Ischemic Events and Bleeding Complications [NCT01586975]	Phase 2/Phase 3	93 participants (Actual)	Interventional	2007-07-31	Completed
EndoTic - Endothelium and Ticagrelor: Pharmacological Effects Beyond Antiplatelet Therapy [NCT02244710]		109 participants (Actual)	Interventional	2015-03-31	Completed
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel in Patients With Coronary Atherosclerotic Heart Disease and Planned Percutaneous Coronary Intervention: a Multi-center, Randomized, Double-blind, Triple-dummy , Parallel-control [NCT03599284]	Phase 2	279 participants (Actual)	Interventional	2018-08-30	Completed
Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel [NCT01456546]	Phase 1	31 participants (Actual)	Interventional	2011-10-31	Completed
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance to Examine the Safety of Cessation of Dual Anti-Platelet Therapy in High Bleeding Risk Patients at One Month [NCT03606642]	Phase 2	50 participants (Actual)	Interventional	2018-11-19	Active, not recruiting
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation [NCT01813435]	Phase 3	15,991 participants (Actual)	Interventional	2013-07-01	Completed
"Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention (The ELIMIT Trial)" [NCT00687076]	Phase 4	102 participants (Actual)	Interventional	2004-04-30	Completed
The Randomized, Double-blind, Placebo-controlled Clinical Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent High-risk Ischemic Stroke Recurrence [NCT04142151]		60 participants (Anticipated)	Interventional	2019-09-01	Recruiting
Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction [NCT04369534]	Phase 4	120 participants (Actual)	Interventional	2015-12-01	Completed
Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study [NCT01896557]	Phase 4	92 participants (Actual)	Interventional	2011-10-31	Completed
Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. [NCT04333407]		320 participants (Actual)	Interventional	2020-04-03	Terminated(stopped due to Difficulty in recruiting eligible participants)
Body Weight Adjusted Clopidogrel Treatment in Patients With Coronary Artery Disease [NCT05657041]	Phase 2/Phase 3	80 participants (Anticipated)	Interventional	2023-04-26	Recruiting
Fasting, Comparative, Open-label, Randomized, Four-period, Two-sequence, Bioequivalence Study of Сlopidogrel Bisulfate Film-coated Tablets, 75 mg (JSC Farmak, Ukraine) vs Plavix® 75 mg Film-coated Tablets in Healthy Adult Subjects [NCT05125549]	Phase 1	48 participants (Actual)	Interventional	2018-07-12	Completed
Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling of Unruptured Intracranial Aneurysms: A Prospective Randomized Multicenter Trial [NCT05257824]	Phase 4	528 participants (Anticipated)	Interventional	2022-06-23	Recruiting
Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy [NCT03072121]	Phase 4	440 participants (Anticipated)	Interventional	2017-06-30	Not yet recruiting
Pharmacodynamic Effects of Different Ticagrelor Maintenance Dosing Regimens With and Without Aspirin in Patients With Diabetes Mellitus: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-7 Study [NCT04484259]	Phase 4	63 participants (Anticipated)	Interventional	2021-03-31	Recruiting
PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Pharmacokinetics Sub-trial [NCT01510327]	Phase 3	22 participants (Actual)	Interventional	2009-10-31	Completed
A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease [NCT03008083]	Phase 4	2,446 participants (Anticipated)	Interventional	2019-01-10	Recruiting
[NCT03006835]	Phase 4	120 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial [NCT05565976]	Phase 2/Phase 3	270 participants (Anticipated)	Interventional	2020-08-01	Recruiting
Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in Transcatheter Aortic Valve Implantation (TAVI) [NCT03001960]	Phase 3	200 participants (Anticipated)	Interventional	2017-03-31	Not yet recruiting
Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon [NCT05098704]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2022-06-22	Recruiting
A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke. [NCT02506140]	Phase 2/Phase 3	675 participants (Actual)	Interventional	2015-08-31	Completed
Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Trial [NCT02514642]	Phase 4	30 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes; Pharmacodynamics and Pharmacokinetics Study [NCT02319941]	Phase 2	65 participants (Actual)	Interventional	2015-05-20	Completed
Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation : STAMP-DES Trial [NCT02494284]	Phase 4	364 participants (Actual)	Interventional	2015-12-22	Terminated(stopped due to Slow enrollment)
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents (ADAPT AF-DES) [NCT04250116]	Phase 4	960 participants (Anticipated)	Interventional	2020-04-28	Recruiting
A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E [NCT02989558]	Phase 3	90 participants (Actual)	Interventional	2016-12-31	Completed
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin [NCT01768637]	Phase 1	48 participants (Actual)	Interventional	2013-01-31	Completed
An Open-label, Randomized, Controlled, Multicenter Study to Evaluate DUAL Antithrombotic Therapy With Rivaroxaban Plus Ticagrelor vs. Rivaroxaban Plus Clopidogrel in Patients With Atrial Fibrillation and Acute Coronary Syndrome [NCT04023630]	Phase 4	4,000 participants (Anticipated)	Interventional	2019-10-01	Not yet recruiting
Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous [NCT02320357]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2015-08-19	Completed
A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C [NCT02164864]	Phase 3	2,725 participants (Actual)	Interventional	2014-07-22	Completed
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study [NCT03679091]	Phase 4	36 participants (Actual)	Interventional	2018-08-29	Completed
Evaluation Of Human Urinary Kallidinogenase in Acute Stroke Patients: Magnetic Resonance Spectrum and CT Perfusion [NCT03431909]	Phase 4	80 participants (Actual)	Interventional	2014-01-01	Completed
Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease [NCT05122455]	Phase 2/Phase 3	70 participants (Anticipated)	Interventional	2021-09-14	Recruiting
Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses Of ISIS 681257 40 mg Subcutaneous Injections On The Pharmacokinetics And Pharmacodynamics Of Clopidogrel In Healthy Subjects [NCT03392051]	Phase 1	18 participants (Actual)	Interventional	2017-12-28	Completed
Two-center, Prospective, Randomized, Open-label, Controlled Clinical Trial With Endpoint Evaluation [NCT06102720]	Phase 4	200 participants (Anticipated)	Interventional	2023-01-12	Recruiting
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease [NCT01523366]	Phase 4	53 participants (Actual)	Interventional	2012-04-30	Completed
A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus [NCT03159559]	Phase 4	60 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke: a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study [NCT03661411]	Phase 4	760 participants (Actual)	Interventional	2018-10-17	Completed
Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion [NCT02398656]	Phase 3	1,274 participants (Anticipated)	Interventional	2015-04-30	Recruiting
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention [NCT01830543]	Phase 3	2,124 participants (Actual)	Interventional	2013-05-10	Completed
Pharmacodynamic Outcomes in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Treated With an Individualized Treatment STRATEGY [NCT05773989]	Phase 4	88 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products in Thai Healthy Volunteers [NCT02010632]	Phase 1	32 participants (Actual)	Interventional	2013-08-31	Completed
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention [NCT01802775]	Phase 2	203 participants (Actual)	Interventional	2013-02-06	Completed
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents [NCT03330223]		60 participants (Anticipated)	Observational	2017-11-10	Recruiting
The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease (SOS-moral): Study Protocol of a Prospective Multicenter Study [NCT03372785]		240 participants (Anticipated)	Observational [Patient Registry]	2018-04-10	Enrolling by invitation
Role of Anti-platelet in Treatment of Acute Ischemic Stroke [NCT03266731]		120 participants (Anticipated)	Interventional	2018-01-04	Not yet recruiting
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19 [NCT04505774]	Phase 4	880 participants (Actual)	Interventional	2020-09-04	Active, not recruiting
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction) [NCT02428374]	Phase 4	300 participants (Anticipated)	Interventional	2015-05-31	Recruiting
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease [NCT01732822]	Phase 3	13,885 participants (Actual)	Interventional	2012-12-04	Completed
Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia [NCT02224274]	Phase 4	57 participants (Actual)	Interventional	2014-08-31	Completed
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease [NCT01523392]	Phase 4	50 participants (Actual)	Interventional	2012-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00059215 (4) [back to overview]	Number of Participants With Major Adverse Cardiovascular Events (MACE)
NCT00059215 (4) [back to overview]	Number of Participants With Non-CABG TIMI Major or Minor Bleeding Plus MACE
NCT00059215 (4) [back to overview]	Number of Participants With Non-Coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding
NCT00059215 (4) [back to overview]	Number of Participants With Non-coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding Events
NCT00097591 (6) [back to overview]	Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke
NCT00097591 (6) [back to overview]	Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke
NCT00097591 (6) [back to overview]	Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events
NCT00097591 (6) [back to overview]	Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke
NCT00097591 (6) [back to overview]	Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)
NCT00097591 (6) [back to overview]	Number of Treated Subjects With Non-Coronary Artery Bypass Graft (CABG) Related Thrombolysis In Myocardial Infarction (TIMI) Study Group Major and Minor Bleeding Events
NCT00130039 (6) [back to overview]	Number of Patients With Ipsilateral Ischemic Stroke Rate
NCT00130039 (6) [back to overview]	Numbers of Fatal or Major Bleeding Complications
NCT00130039 (6) [back to overview]	Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI
NCT00130039 (6) [back to overview]	Number of Participants With Stroke Events
NCT00130039 (6) [back to overview]	Number of Participants With Progression of Symptomatic Intracranial Stenosis
NCT00130039 (6) [back to overview]	Number of Participants With Overall Cardiovascular Events
NCT00153062 (5) [back to overview]	Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)
NCT00153062 (5) [back to overview]	Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)
NCT00153062 (5) [back to overview]	Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)
NCT00153062 (5) [back to overview]	Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)
NCT00153062 (5) [back to overview]	Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)
NCT00228423 (4) [back to overview]	Vein Graft Intimal Area
NCT00228423 (4) [back to overview]	Vein Graft Angiographic Patency
NCT00228423 (4) [back to overview]	Incidence of Major Bleeding Events Within One Year Following Surgery
NCT00228423 (4) [back to overview]	Incidence of Major Adverse Coronary Events Within One Year Following Surgery
NCT00249873 (4) [back to overview]	Death From Any Cause (Cardiovascular and Noncardiovascular)
NCT00249873 (4) [back to overview]	Adjudicated Major Bleedings
NCT00249873 (4) [back to overview]	First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication
NCT00249873 (4) [back to overview]	Occurrence of Stroke
NCT00257309 (2) [back to overview]	Death/Reinfarction/Disabling Stroke at 30 Days
NCT00257309 (2) [back to overview]	Incidence of Death or Reinfarction or Disabling Stroke
NCT00263211 (5) [back to overview]	Mean Aspirin-Mediated Platelet Inhibition vs. Time Plotted for Plavix and Aspirin and Observation Groups
NCT00263211 (5) [back to overview]	Safety and Tolerability of Aspirin and Plavix Measured by the Number of Patients Who Discontinue the Study Drug
NCT00263211 (5) [back to overview]	Percentage of Patients With a Given Absolute Number of Circulating Tumor Cells (Broken Into Categories) Plotted Against Time
NCT00263211 (5) [back to overview]	Platelet Inhibition of Circulating Tumor Cells (CTCs) Measured by the Number of Patients With Detectable CTCs
NCT00263211 (5) [back to overview]	Clopidogrel-Mediated Percent of Platelet Inhibition vs. Time Plotted for Aspirin and Plavix and Observation Groups
NCT00305162 (17) [back to overview]	Incidence of ACUITY Major Bleeding (Without Hematoma >/= 5 cm)
NCT00305162 (17) [back to overview]	Incidence of All Cause Mortality
NCT00305162 (17) [back to overview]	Incidence of All-cause Mortality
NCT00305162 (17) [back to overview]	Incidence of All-cause Mortality and MI
NCT00305162 (17) [back to overview]	Incidence of All-cause Mortality or MI
NCT00305162 (17) [back to overview]	Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)
NCT00305162 (17) [back to overview]	Incidence of GUSTO Severe / Life-threatening Bleeding
NCT00305162 (17) [back to overview]	Incidence of IDR
NCT00305162 (17) [back to overview]	Incidence of MI
NCT00305162 (17) [back to overview]	Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding
NCT00305162 (17) [back to overview]	Incidence of All-cause Mortality, MI or IDR
NCT00305162 (17) [back to overview]	Individual Incidence of All-cause Mortality
NCT00305162 (17) [back to overview]	Incidence of ACUITY Major Bleeding
NCT00305162 (17) [back to overview]	Incidence of Stroke
NCT00305162 (17) [back to overview]	Incidence of Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, or Unsuccessful Procedure During the Index PCI
NCT00305162 (17) [back to overview]	Incidence of Stroke
NCT00305162 (17) [back to overview]	Individual Incidence of IDR
NCT00335452 (7) [back to overview]	First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level
NCT00335452 (7) [back to overview]	First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup
NCT00335452 (7) [back to overview]	Occurrence of Major Bleeding - ASA Dose Level Comparison
NCT00335452 (7) [back to overview]	Occurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison
NCT00335452 (7) [back to overview]	Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison
NCT00335452 (7) [back to overview]	First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison
NCT00335452 (7) [back to overview]	First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison
NCT00356135 (6) [back to overview]	Correlation Coefficent of Verify Now™ P2Y12 Assay Values to Maximum Platelet Aggregation (MPA) and Residual Platelet Aggregation (RPA) to 20 uM ADP at 1 Week
NCT00356135 (6) [back to overview]	Maximum Platelet Aggregation (MPA) (to 5 and 20 uM ADP) at 2 Hours, 24 Hours, 1 Week and 2 Weeks
NCT00356135 (6) [back to overview]	Number of Participants With Bleeding Events by Visit According to Thrombolysis in Myocardial Infarction Study Group (TIMI) Criteria
NCT00356135 (6) [back to overview]	Residual Platelet Aggregation (RPA) (to 5 and 20 uM ADP) at 2 Hours, 24 Hours, 1 Week and 2 Weeks
NCT00356135 (6) [back to overview]	Maximum Platelet Aggregation (MPA) to 20 Micromolar (uM) Adenosine Diphosphase (ADP)
NCT00356135 (6) [back to overview]	Maximum Platelet Aggregation (MPA) to 20 uM ADP According to Clopidogrel Use at Time of Qualifying Acute Coronary Syndrome (ACS) Event
NCT00357968 (18) [back to overview]	Number of Hyporesponsive Participants at the End of the Crossover Maintenance Dose Phase
NCT00357968 (18) [back to overview]	Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) 18 to 24 Hours After the Loading Dose
NCT00357968 (18) [back to overview]	Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) at 6 Hours After the Loading Dose
NCT00357968 (18) [back to overview]	Number of Hyporesponsive Participants at 6 Hours After the Loading Dose
NCT00357968 (18) [back to overview]	Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate After 14 Days of Maintenance Dose Treatment
NCT00357968 (18) [back to overview]	Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the First Maintenance Dose Phase
NCT00357968 (18) [back to overview]	Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate at 2 Hours After the Loading Dose
NCT00357968 (18) [back to overview]	Myonecrosis Measure: Cardiac Troponin 18 to 24 Hours After the Loading Dose
NCT00357968 (18) [back to overview]	Myonecrosis Measure: Cardiac Troponin at 6 Hours After the Loading Dose
NCT00357968 (18) [back to overview]	Number of Hyporesponsive Participants at the End of the First Maintenance Dose Phase
NCT00357968 (18) [back to overview]	Number of Participants With Major Adverse Cardiac Events (MACE) During the First Maintenance Dose Phase
NCT00357968 (18) [back to overview]	Number of Participants With Major Adverse Cardiac Events During the Crossover Maintenance Dose Phase
NCT00357968 (18) [back to overview]	Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the Crossover Maintenance Dose Phase
NCT00357968 (18) [back to overview]	Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) at 6 Hours After the Loading Dose
NCT00357968 (18) [back to overview]	Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) 18 to 24 Hours After the Loading Dose
NCT00357968 (18) [back to overview]	Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) After 14 Days of Maintenance Dose Treatment
NCT00357968 (18) [back to overview]	Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 2 Hours After the Loading Dose
NCT00357968 (18) [back to overview]	Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 6 Hours After the Loading Dose
NCT00385138 (20) [back to overview]	Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]
NCT00385138 (20) [back to overview]	Incidence of Stent Thrombosis
NCT00385138 (20) [back to overview]	Incidence of Stent Thrombosis
NCT00385138 (20) [back to overview]	Incidence of Stroke
NCT00385138 (20) [back to overview]	Incidence of Stroke
NCT00385138 (20) [back to overview]	Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major
NCT00385138 (20) [back to overview]	Incidence of All-cause Mortality or MI
NCT00385138 (20) [back to overview]	Incidence of All-cause Mortality, MI, or IDR
NCT00385138 (20) [back to overview]	Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)
NCT00385138 (20) [back to overview]	Incidence of GUSTO Severe / Life-threatening
NCT00385138 (20) [back to overview]	Incidence of All-cause Mortality
NCT00385138 (20) [back to overview]	Incidence of IDR
NCT00385138 (20) [back to overview]	Incidence of MI
NCT00385138 (20) [back to overview]	Incidence of All-cause Mortality
NCT00385138 (20) [back to overview]	Incidence of All-cause Mortality
NCT00385138 (20) [back to overview]	Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm
NCT00385138 (20) [back to overview]	Incidence of ACUITY Major Bleeding
NCT00385138 (20) [back to overview]	Incidence of IDR
NCT00385138 (20) [back to overview]	Incidence of All-cause Mortality or MI
NCT00385138 (20) [back to overview]	Incidence of MI
NCT00385944 (18) [back to overview]	Change in MPA to 20 μM ADP From Baseline to 6-18 Hrs Post Loading Dose (LD)
NCT00385944 (18) [back to overview]	Correlation of MPA to 20 μM ADP and PRU
NCT00385944 (18) [back to overview]	Inhibition of Residual Platelet Aggregation (IRPA) to 20 μM ADP
NCT00385944 (18) [back to overview]	Inhibition of Residual Platelet Aggregation (IRPA) to 5 μM ADP
NCT00385944 (18) [back to overview]	Inhibition Platelet Aggregation (IPA) to 20 μM ADP
NCT00385944 (18) [back to overview]	Inhibition Platelet Aggregation (IPA) to 5 μM ADP
NCT00385944 (18) [back to overview]	Maximum Platelet Aggregation (MPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP)
NCT00385944 (18) [back to overview]	Mean Residual Platelet Aggregation (RPA) to 20 µM ADP
NCT00385944 (18) [back to overview]	Mean Residual Platelet Aggregation (RPA) to 5 µM ADP
NCT00385944 (18) [back to overview]	MPA to 20 μM ADP at 14 Days After the First Maintenance Dose (MD)
NCT00385944 (18) [back to overview]	MPA to 20 μM ADP at 14 Days After the Second Maintenance Dose (MD)
NCT00385944 (18) [back to overview]	MPA to 5 μM ADP
NCT00385944 (18) [back to overview]	P2Y12 Reaction Units (PRU)
NCT00385944 (18) [back to overview]	Platelet Reactivity Index (PRI)
NCT00385944 (18) [back to overview]	Number of Participants With Bleeding Events According to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)
NCT00385944 (18) [back to overview]	Number of Participants With Bleeding Events According to Thrombolysis in Myocardial Infarction Study Group (TIMI) Criteria
NCT00385944 (18) [back to overview]	Poor Responder of MPA to 20 μM ADP Following Maintenance Dose (MD)
NCT00385944 (18) [back to overview]	Change in MPA to 20 μM ADP From 6-18 Hrs Post Loading Dose (LD) to 14 Days After the First Maintenance Dose (MD)
NCT00391872 (16) [back to overview]	Participants With Major or Minor Bleeding
NCT00391872 (16) [back to overview]	Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke
NCT00391872 (16) [back to overview]	Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.
NCT00391872 (16) [back to overview]	Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization
NCT00391872 (16) [back to overview]	Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke
NCT00391872 (16) [back to overview]	Participants With Any Major Bleeding Event
NCT00391872 (16) [back to overview]	Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding
NCT00391872 (16) [back to overview]	Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding
NCT00391872 (16) [back to overview]	Participants With Death From Any Cause
NCT00391872 (16) [back to overview]	Participants With Death From Vascular Causes
NCT00391872 (16) [back to overview]	Participants With MI Event
NCT00391872 (16) [back to overview]	Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding
NCT00391872 (16) [back to overview]	Participants With Non-procedural Major Bleeding
NCT00391872 (16) [back to overview]	Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization
NCT00391872 (16) [back to overview]	Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization
NCT00391872 (16) [back to overview]	Participants With Stroke
NCT00396877 (3) [back to overview]	Number of Participants With Bleeding Events
NCT00396877 (3) [back to overview]	Number of Participants According to Bleeding Type/Etiology
NCT00396877 (3) [back to overview]	Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose
NCT00528411 (45) [back to overview]	Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Post 6-week Treatment: FVC
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose
NCT00528411 (45) [back to overview]	Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: VT
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: VE
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: TLC
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: SpO2
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: RV
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: RR
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: FRC
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: EF
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Post 6-week Treatment: FEV1
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Tidal Volume (VT)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Residual Volume (RV)
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose
NCT00619073 (1) [back to overview]	Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention.
NCT00623623 (25) [back to overview]	Number of Patients With All Cause Death and Non-fatal Stroke
NCT00623623 (25) [back to overview]	Number of Patients With Total Non-disabling Stroke
NCT00623623 (25) [back to overview]	Number of Patients With Cardiac Mortality
NCT00623623 (25) [back to overview]	Number of Patients With Cardiogenic Shock
NCT00623623 (25) [back to overview]	Number of Patients With Congestive Heart Failure (CHF)
NCT00623623 (25) [back to overview]	Number of Patients With Intracranial Haemorrhage
NCT00623623 (25) [back to overview]	Number of Patients With Ischaemic Stroke
NCT00623623 (25) [back to overview]	Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions
NCT00623623 (25) [back to overview]	Number of Patients With Rehospitalisation for Cardiac Reasons
NCT00623623 (25) [back to overview]	Number of Patients With Rehospitalisation for Non-cardiac Reasons
NCT00623623 (25) [back to overview]	Number of Patients With Serious Repeat Target Vessel Revascularization
NCT00623623 (25) [back to overview]	Number of Patients With Serious Resuscitated Ventricular Fibrillation
NCT00623623 (25) [back to overview]	Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures
NCT00623623 (25) [back to overview]	Number of Patients With Minor Non-intracranial Bleeds
NCT00623623 (25) [back to overview]	Number of Patients With Recurrent Myocardial Infarction (Reinfarction)
NCT00623623 (25) [back to overview]	Number of Patients With Total Disabling Stroke
NCT00623623 (25) [back to overview]	Number of Patients With Total Stroke (All Types)
NCT00623623 (25) [back to overview]	Number of Patients With Total Non-intracranial Bleeds
NCT00623623 (25) [back to overview]	Number of Patients With Total Fatal Stroke
NCT00623623 (25) [back to overview]	Number of Patients With All Cause Death and Shock
NCT00623623 (25) [back to overview]	Number of Patients With All Cause Death and Shock and CHF
NCT00623623 (25) [back to overview]	Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke
NCT00623623 (25) [back to overview]	Number of Patients With All Cause Death and Shock and Reinfarction
NCT00623623 (25) [back to overview]	Number of Patients With All Cause Mortality
NCT00623623 (25) [back to overview]	Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.
NCT00642174 (5) [back to overview]	Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate
NCT00642174 (5) [back to overview]	Maximum Platelet Aggregation (MPA) as Assessed by Light Transmittance Aggregometry (LTA)
NCT00642174 (5) [back to overview]	Platelet Reactivity Index (PRI)
NCT00642174 (5) [back to overview]	Inhibition of Platelet Aggregation at 1- and 24-Hours After Loading Dose (LD) and 24-Hours After Last Maintenance Dose (LMD) Assessed by Accumetrics VerifyNow™ P2Y12 Assay
NCT00642174 (5) [back to overview]	Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay
NCT00642811 (6) [back to overview]	Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 28
NCT00642811 (6) [back to overview]	Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.
NCT00642811 (6) [back to overview]	Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.)
NCT00642811 (6) [back to overview]	Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 15
NCT00642811 (6) [back to overview]	Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 15
NCT00642811 (6) [back to overview]	Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 28
NCT00644657 (2) [back to overview]	The Percentage of Coated Platelets After Coronary Angiography and/or PCI
NCT00644657 (2) [back to overview]	The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty
NCT00684203 (15) [back to overview]	Mean CD40 Ligand Levels Among Participants Who Did Not Undergo PCI
NCT00684203 (15) [back to overview]	Number of Participants With Major, Minor, and Non-TIMI Bleeding Events Among Participants Who Did Not Undergo PCI
NCT00684203 (15) [back to overview]	Number of Participants Who Underwent PCI With Clinically Important Bleeding Events During Treatment and After Hospital Discharge
NCT00684203 (15) [back to overview]	Number of Participants Who Did Not Undergo PCI But Had Bleeding Events That Required Transfusion
NCT00684203 (15) [back to overview]	Number of Participants Who Did Not Undergo PCI But Had Bleeding Events That Required Subsequent Hospitalization
NCT00684203 (15) [back to overview]	Number of Participants Experiencing Non-Major Adverse Cardiac Events (MACE) Who Underwent PCI
NCT00684203 (15) [back to overview]	Median Hs-CRP Levels Among Participants Who Did Not Undergo PCI
NCT00684203 (15) [back to overview]	Median High-Sensitivity C-Reactive Protein (Hs-CRP) Levels Among Participants Who Underwent PCI By Study Visit
NCT00684203 (15) [back to overview]	Mean Membrane-Bound P-Selectin Levels Among Participants Who Underwent PCI
NCT00684203 (15) [back to overview]	Number of Participants Experiencing Non-MACE AEs Among Participants Who Did Not Undergo PCI
NCT00684203 (15) [back to overview]	Number of Participants Experiencing Adverse Events (AEs) Who Underwent Percutaneous Coronary Interventions (PCI)
NCT00684203 (15) [back to overview]	Number of Participants Who Underwent PCI With Inhibition of Platelet Aggregation By Study Visit
NCT00684203 (15) [back to overview]	Number of Participants With Major, Minor, and Non-Thrombolysis in Myocardial Infarction Cooperative Group (TIMI) Bleeding Events Among Participants Who Underwent PCI
NCT00684203 (15) [back to overview]	Number of Participants Who Did Not Undergo PCI That Had Clinically Important Bleeding Events
NCT00684203 (15) [back to overview]	Mean CD40 Ligand Levels Among Participants Who Underwent PCI
NCT00687076 (2) [back to overview]	Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic Resonance Imaging (MRI) to Examine the Femoral Artery for Progression of Atherosclerosis
NCT00687076 (2) [back to overview]	Change in Total Cholesterol (mg/dl) From Baseline to Month 12
NCT00699998 (10) [back to overview]	Platelet Aggregation Measures
NCT00699998 (10) [back to overview]	Summary of All Deaths
NCT00699998 (10) [back to overview]	Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke
NCT00699998 (10) [back to overview]	Percentage of Participants With a Composite Endpoint of CV Death and MI
NCT00699998 (10) [back to overview]	Percentage of Participants With a Composite Endpoint of CV Death, MI, Stroke, or Re-hospitalization for Recurrent Unstable Angina (UA)
NCT00699998 (10) [back to overview]	Genotyping Related to Drug Metabolism
NCT00699998 (10) [back to overview]	Percentage of Participants With a Composite Endpoint of All-cause Death, MI, or Stroke
NCT00699998 (10) [back to overview]	Biomarker Measurements of Inflammation/Hemodynamic Stress: C-Reactive Protein (CRP)
NCT00699998 (10) [back to overview]	Biomarker Measurements of Inflammation/Hemodynamic Stress: Brain Natriuretic Peptide (BNP)
NCT00699998 (10) [back to overview]	Economic and Quality of Life Outcomes
NCT00738894 (4) [back to overview]	Number of Subjects With Effective Closure in Test (Device) Arm
NCT00738894 (4) [back to overview]	Number of Subjects With Freedom From Recurrent Ischemic Stroke (Primary Outcome #1)
NCT00738894 (4) [back to overview]	Number of Subjects With New Brain Infarct or Recurrent Stroke (Primary Outcome #2)
NCT00738894 (4) [back to overview]	Number of Subjects With Study-related Serious Adverse Events
NCT00799396 (2) [back to overview]	Changes in Platelet Function in Response to Clopidogrel Plus Aspirin
NCT00799396 (2) [back to overview]	Changes in Platelet Function in Response to Clopidogrel
NCT00816166 (1) [back to overview]	Successful Outcome: No Stroke or Hard TIA in the Same Territory Within 12 Months
NCT00817999 (1) [back to overview]	% Platelet Inhibition
NCT00823212 (39) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
NCT00823212 (39) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
NCT00823212 (39) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
NCT00823212 (39) [back to overview]	Target Lesion Failure (TLF)
NCT00823212 (39) [back to overview]	Target Lesion Failure (TLF)
NCT00823212 (39) [back to overview]	Target Lesion Revascularization (TLR)
NCT00823212 (39) [back to overview]	Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)
NCT00823212 (39) [back to overview]	Target Lesion Revascularization (TLR)
NCT00823212 (39) [back to overview]	Target Vessel Failure (TVF)
NCT00823212 (39) [back to overview]	Target Vessel Failure (TVF)
NCT00823212 (39) [back to overview]	Target Vessel Failure (TVF)
NCT00823212 (39) [back to overview]	Target Vessel Revascularization (TVR)
NCT00823212 (39) [back to overview]	Target Vessel Revascularization (TVR)
NCT00823212 (39) [back to overview]	Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)
NCT00823212 (39) [back to overview]	Non-cardiac Death
NCT00823212 (39) [back to overview]	Myocardial Infarction (MI) Related to the Target Vessel
NCT00823212 (39) [back to overview]	Target Lesion Revascularization (TLR)
NCT00823212 (39) [back to overview]	Acute Technical Success
NCT00823212 (39) [back to overview]	All Cause Mortality
NCT00823212 (39) [back to overview]	All Cause Mortality
NCT00823212 (39) [back to overview]	Target Vessel Revascularization (TVR)
NCT00823212 (39) [back to overview]	All Cause Mortality
NCT00823212 (39) [back to overview]	All Death or Myocardial Infarction (MI)
NCT00823212 (39) [back to overview]	All Death or Myocardial Infarction (MI)
NCT00823212 (39) [back to overview]	All Death or Myocardial Infarction (MI)
NCT00823212 (39) [back to overview]	Cardiac Death or Myocardial Infarction (MI)
NCT00823212 (39) [back to overview]	Cardiac Death or Myocardial Infarction (MI)
NCT00823212 (39) [back to overview]	Cardiac Death or Myocardial Infarction (MI)
NCT00823212 (39) [back to overview]	Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)
NCT00823212 (39) [back to overview]	Cardiac Death Related to the Target Vessel
NCT00823212 (39) [back to overview]	Cardiac Death Related to the Target Vessel
NCT00823212 (39) [back to overview]	Cardiac Death Related to the Target Vessel
NCT00823212 (39) [back to overview]	Clinical Procedural Success
NCT00823212 (39) [back to overview]	Non-cardiac Death
NCT00823212 (39) [back to overview]	Non-cardiac Death
NCT00823212 (39) [back to overview]	Target Lesion Failure (TLF)
NCT00823212 (39) [back to overview]	Target Lesion Failure (TLF)
NCT00823212 (39) [back to overview]	Myocardial Infarction (MI) Related to the Target Vessel
NCT00823212 (39) [back to overview]	Myocardial Infarction (MI) Related to the Target Vessel
NCT00830960 (11) [back to overview]	Incidence of CABG-related TIMI Major or Minor Bleeding.
NCT00830960 (11) [back to overview]	Risk of All-cause Death in Primary Cohort and Low Weight/Elderly Cohort
NCT00830960 (11) [back to overview]	Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 30 Minutes, 2 and 4 Hours Post-Loading Dose (LD) in Primary (≥60 kg and <75 Years) and Low Weight/Elderly (<60 kg or ≥75 Years) Cohorts.
NCT00830960 (11) [back to overview]	Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at During Maintenance Dose (MD) Phase at 30 Days and 90 Days in Primary Cohort and Low Weight/Elderly Cohort
NCT00830960 (11) [back to overview]	Genetic Variation Related to Drug Metabolism and Transport Substudy Result Summary
NCT00830960 (11) [back to overview]	Incidence of Non-coronary Artery Bypass Graft (CABG) Related Thrombolysis in Myocardial Infarction (TIMI) Life-threatening (a Subset of Non-CABG-related TIMI Major Bleeding), Major, Minor, and Minimal Bleeding
NCT00830960 (11) [back to overview]	Percent Inhibition of Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) at 30 Minutes, 2 Hours, and 4 Hours Post-Loading Dose (LD) in Primary in Primary Cohort and Low Weight/Elderly Cohort
NCT00830960 (11) [back to overview]	Percent Inhibition of Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) During the Maintenance Dose (MD) Phase at 30 Days and 90 Days in Primary Cohort and Low Weight/Elderly Cohort
NCT00830960 (11) [back to overview]	Summary of Myocardial Infarction (MI), Stroke, Stent Thrombosis and Urgent Target Vessel Revascularization (UTVR) in Primary Cohort and Low Weight/Elderly Cohort
NCT00830960 (11) [back to overview]	Adenosine Diphosphate (ADP)-Induced P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 30 Days During Maintenance Dose (MD) Administration in Primary Cohort
NCT00830960 (11) [back to overview]	Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours Post-Loading Dose (LD) in Primary Cohort (≥60 kg and <75 Years)
NCT00833703 (3) [back to overview]	Number of Participants According to Bleeding Type/Etiology
NCT00833703 (3) [back to overview]	Number of Participants With Bleeding Events
NCT00833703 (3) [back to overview]	Number of Participants With Shunt Thrombosis Requiring Intervention or Deaths
NCT00910299 (3) [back to overview]	Number of Participants With Stent Thrombosis (ST)
NCT00910299 (3) [back to overview]	Number of Participants With Composite Endpoint of Cardiovascular Death or Myocardial Infarction (MI)
NCT00910299 (3) [back to overview]	Number of Participants With Composite Endpoint of All-Cause Death or Myocardial Infarction (MI)
NCT00942175 (5) [back to overview]	Pharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry).
NCT00942175 (5) [back to overview]	Pharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel's Active Metabolite.
NCT00942175 (5) [back to overview]	Pharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate.
NCT00942175 (5) [back to overview]	Pharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate.
NCT00942175 (5) [back to overview]	Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite.
NCT00954707 (13) [back to overview]	Rate of Major Adverse Cardiac Events (MACE)
NCT00954707 (13) [back to overview]	Rate of Non-cardiac Death
NCT00954707 (13) [back to overview]	Rate of Procedure Success
NCT00954707 (13) [back to overview]	Rate of Protocol Defined Major Bleeding Complications
NCT00954707 (13) [back to overview]	Rate of Protocol Defined Stent Thrombosis (ST)
NCT00954707 (13) [back to overview]	Rate of Target Vessel Failure (TVF)
NCT00954707 (13) [back to overview]	Phase I: the Rate of Target Lesion Failure (TLF)
NCT00954707 (13) [back to overview]	Rate of Academic Research Consortium (ARC) Defined Stent Thrombosis (ST)
NCT00954707 (13) [back to overview]	Rate of Cardiac Death
NCT00954707 (13) [back to overview]	Rate of Clinically Driven Target Vessel Revascularization (TVR)
NCT00954707 (13) [back to overview]	Rate of Clinically-driven Target Lesion Revascularization (TVR)
NCT00954707 (13) [back to overview]	Rate of Device Success
NCT00954707 (13) [back to overview]	Rate of Lesion Success
NCT00977938 (14) [back to overview]	Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
NCT00977938 (14) [back to overview]	Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
NCT00977938 (14) [back to overview]	Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT
NCT00977938 (14) [back to overview]	Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS
NCT00977938 (14) [back to overview]	Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT
NCT00977938 (14) [back to overview]	GUSTO Severe or Moderate Bleeding - Randomized DES ITT
NCT00977938 (14) [back to overview]	MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
NCT00977938 (14) [back to overview]	GUSTO Severe or Moderate Bleeding - Randomized DES ITT
NCT00977938 (14) [back to overview]	MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS
NCT00977938 (14) [back to overview]	MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
NCT00977938 (14) [back to overview]	MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT
NCT00977938 (14) [back to overview]	MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT
NCT00977938 (14) [back to overview]	GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
NCT00977938 (14) [back to overview]	GUSTO Severe or Moderate Bleeding - Randomized BMS ITT
NCT00991029 (13) [back to overview]	Minor Hemorrhage
NCT00991029 (13) [back to overview]	Ischemic Stroke
NCT00991029 (13) [back to overview]	Hemorrhagic Stroke
NCT00991029 (13) [back to overview]	Major Hemorrhage Other Than Intracranial Hemorrhage
NCT00991029 (13) [back to overview]	Death From Any Cause
NCT00991029 (13) [back to overview]	Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes
NCT00991029 (13) [back to overview]	Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage
NCT00991029 (13) [back to overview]	Major Hemorrhage
NCT00991029 (13) [back to overview]	Symptomatic Intracerebral Hemorrhage
NCT00991029 (13) [back to overview]	Ischemic or Hemorrhagic Stroke
NCT00991029 (13) [back to overview]	Myocardial Infarction
NCT00991029 (13) [back to overview]	Other Symptomatic Intracranial Hemorrhage
NCT00991029 (13) [back to overview]	Death From Ischemic Vascular Causes
NCT01012219 (1) [back to overview]	Cutaneous Bleeding Time (BT)
NCT01014624 (8) [back to overview]	Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on Primary Definition of Return to Baseline Using the Primary Population
NCT01014624 (8) [back to overview]	Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on Secondary Definition of Return to Baseline Using the Primary Population
NCT01014624 (8) [back to overview]	Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on the Secondary Definition of Return to Baseline Using the Responder Population
NCT01014624 (8) [back to overview]	The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition of Return to Baseline
NCT01014624 (8) [back to overview]	The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Secondary Definition of Return to Baseline
NCT01014624 (8) [back to overview]	Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on the Primary Definition of Return to Baseline Using the Responder Population
NCT01014624 (8) [back to overview]	Percentage of Inhibition of Platelet Aggregation on Washout Day 1
NCT01014624 (8) [back to overview]	Time to Return to Baseline PRU for the Primary Population Using the Primary Definition of Return to Baseline in Relation to the Inhibition of Platelet Aggregation 24 Hours Following the Last Maintenance Dose
NCT01097343 (1) [back to overview]	Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value >230
NCT01103440 (2) [back to overview]	Number of Participants With Elevation of Cardiac Enzyme
NCT01103440 (2) [back to overview]	Number of Participants With Major Adverse Cardiac Event (MACE)
NCT01107899 (8) [back to overview]	Effect of Initial Inhibition of Platelet Aggregation on the Day to Return to Baseline Platelet Function: VN-PRU
NCT01107899 (8) [back to overview]	Platelet Function by LTA at 5 and 20 μM ADP
NCT01107899 (8) [back to overview]	Platelet Function by Multiplate® ADP Test and ADP Test HS
NCT01107899 (8) [back to overview]	Percentage of Poor Pharmacodynamic Responders by Platelet Aggregation at 24 Hours Post-LD
NCT01107899 (8) [back to overview]	Platelet Function 24 Hours Post Loading Dose
NCT01107899 (8) [back to overview]	Extent of Initial Inhibition of Platelet Aggregation on the Return of Baseline Platelet Function: Light Transmission Aggregometry (LTA)
NCT01107899 (8) [back to overview]	Extent of Initial Inhibition of Platelet Aggregation to the Return of Baseline Platelet Function: Multiplate® ADP Test and ADP Test High Sensitivity (HS)
NCT01107899 (8) [back to overview]	Percentage of Participants Returning to Baseline Platelet Function
NCT01107912 (5) [back to overview]	Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA) From Baseline at Day 12 of Therapy
NCT01107912 (5) [back to overview]	Change in Maximum Platelet Aggregation (MPA) to 20 Micromoles (μM) Adenosine Diphosphate (ADP) as Measured by Light Transmission Aggregometry (LTA) From Baseline to 12 Days of Therapy in the First Treatment Period
NCT01107912 (5) [back to overview]	Change in Vasodilator-associated Stimulated Phosphoprotein (VASP) From Baseline to 12 Days of Therapy
NCT01107912 (5) [back to overview]	Change in VerifyNow P2Y12 Reaction Units (PRU) From Baseline to 12 Days of Therapy
NCT01107912 (5) [back to overview]	Active Metabolite Blood Levels to Drug Exposure as Measured by Pharmacokinetics (PK) Through 4 Hours After Dosing
NCT01107925 (5) [back to overview]	Pharmacokinetic (PK) Analysis of the Concentration-Time Curve (AUC)
NCT01107925 (5) [back to overview]	Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA) at Day 12 of Therapy
NCT01107925 (5) [back to overview]	Change From Baseline in Maximum Platelet Aggregation (MPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12 (Period 1)
NCT01107925 (5) [back to overview]	Change From Baseline in Vasodilator-Associated Stimulated Phosphoprotein (VASP) at Day 12 of Therapy
NCT01107925 (5) [back to overview]	Change From Baseline in VerifyNow® P2Y12 Reaction Units (PRU) at Day 12 of Therapy
NCT01115738 (9) [back to overview]	Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hemoglobin
NCT01115738 (9) [back to overview]	Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hematocrit
NCT01115738 (9) [back to overview]	Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation at Baseline, 2, 24 and 72 Hours After Prasugrel Loading Dose (LD)
NCT01115738 (9) [back to overview]	Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD)
NCT01115738 (9) [back to overview]	Percentage of Poor Responders
NCT01115738 (9) [back to overview]	Percentage of Inhibition of Platelet Aggregation
NCT01115738 (9) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT01115738 (9) [back to overview]	P2Y12 Reaction Units (PRU) of Clopidogrel Treated Participants at Baseline by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - CYP2C19 Extensive Metabolizers (EM) and Reduced Metabolizers (RM)
NCT01115738 (9) [back to overview]	P2Y12 Reaction Units (PRU) at 6 Hours Post-Prasugrel Loading Dose (LD) by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - Extensive Metabolizers (EM) and Reduced Metabolizers (RM)
NCT01118325 (11) [back to overview]	AZD6140 (Cmax) at Week 4
NCT01118325 (11) [back to overview]	AZD6140 (Tmax) at Week 4
NCT01118325 (11) [back to overview]	Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients
NCT01118325 (11) [back to overview]	IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients
NCT01118325 (11) [back to overview]	IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients
NCT01118325 (11) [back to overview]	IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients
NCT01118325 (11) [back to overview]	IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients
NCT01118325 (11) [back to overview]	AR-C124910XX (Tmax) at Week 4
NCT01118325 (11) [back to overview]	AR-C124910XX (AUC0-tau) at Week 4
NCT01118325 (11) [back to overview]	AR-C124910XX (Cmax) at Week 4
NCT01118325 (11) [back to overview]	AZD6140 (AUC0-tau) at Week 4
NCT01121224 (28) [back to overview]	In Patients Who Clinically Require Follow-up Angiography, Two Angiographic Endpoints Will be Assessed: (a) In-segment Binary Restenosis and (b) Angiographic Late In-segment Luminal Loss.
NCT01121224 (28) [back to overview]	Number of Participants With Target Lesion Revascularization (TLR)
NCT01121224 (28) [back to overview]	Procedural Success
NCT01121224 (28) [back to overview]	Patient-Oriented Composite Endpoint Will be Used as Secondary Outcome
NCT01121224 (28) [back to overview]	Number of Participants With Target Vessel Revascularization (TVR)
NCT01121224 (28) [back to overview]	Incremental Cost-effectiveness Ratios (ICERs) for Subgroups of Patients, Such as Those With Highest Risk of Restenosis, Tallies of Cost by Type, and a Cost-outcomes Analysis Such as Cost Per Restenosis Avoided.
NCT01121224 (28) [back to overview]	Device-oriented Composite Endpoint of Target Lesion Failure Will be Used as a Secondary Outcome
NCT01121224 (28) [back to overview]	Number of Participants With Target Vessel Myocardial Infarction
NCT01121224 (28) [back to overview]	Number of Participants With Stroke
NCT01121224 (28) [back to overview]	Number of Participants With Target Vessel Failure (TVF), Defined as the Target Vessel Revascularization
NCT01121224 (28) [back to overview]	Incremental Cost-effectiveness of DES Relative to BMS
NCT01121224 (28) [back to overview]	Procedural Complications (Post-procedural Myocardial Infarction and Post-procedural Bleeding)
NCT01121224 (28) [back to overview]	Quality Adjusted Life Years of DES Relative to BMS
NCT01121224 (28) [back to overview]	Number of Participants With Target Vessel Failure (TVF), Defined as the Target Vessel Myocardial Infarction
NCT01121224 (28) [back to overview]	Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death
NCT01121224 (28) [back to overview]	Number of Participants With Stroke
NCT01121224 (28) [back to overview]	Number of Participants With Any Revascularization
NCT01121224 (28) [back to overview]	Patient-oriented (for Target Lesion Failure) Composite Endpoints Will be Used as Secondary Outcomes as Proposed by Cutlip et al, and as Recommended in the Draft FDA Guidance for Industry Statement.
NCT01121224 (28) [back to overview]	Number of Participants With Non-Target Revascularization
NCT01121224 (28) [back to overview]	Number of Participants With Definite Stent Thrombosis as Defined Using the Academic Research Consortium (ARC) Definition
NCT01121224 (28) [back to overview]	Number of Participants With Myocardial Infarction (MI)
NCT01121224 (28) [back to overview]	Number of Participants With Non-Target Revascularization
NCT01121224 (28) [back to overview]	Number of Participants With Target Lesion Revascularization (TLR)
NCT01121224 (28) [back to overview]	Number of Participants With Definite or Probable Stent Thrombosis
NCT01121224 (28) [back to overview]	In Patients Who Clinically Require Follow-up Angiography, Two Angiographic Endpoints Will be Assessed: (a) In-segment Binary Restenosis and (b) Angiographic Late In-segment Luminal Loss.
NCT01121224 (28) [back to overview]	Device-oriented (for Target Lesion Failure) Composite Endpoints Will be Used as Secondary Outcomes as Proposed by Cutlip et al, and as Recommended in the Draft FDA Guidance for Industry Statement.
NCT01121224 (28) [back to overview]	Quality Adjusted Life Years for Subgroups of Patients
NCT01121224 (28) [back to overview]	Number of Participant Deaths (All Cause and Cardiac). All Deaths Will be Considered Cardiac Unless an Unequivocal Non-cardiac Cause Can be Established.
NCT01156571 (3) [back to overview]	Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)
NCT01156571 (3) [back to overview]	The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)
NCT01156571 (3) [back to overview]	Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild
NCT01158703 (6) [back to overview]	Incidence of More Than 50% Stenosis in Graft With Combination Therapy With Aspirin and Clopidogrel vs. Aspirin Alone
NCT01158703 (6) [back to overview]	Incidence of Bleeding Between the Two Treatment Arms
NCT01158703 (6) [back to overview]	Number of Angina Events
NCT01158703 (6) [back to overview]	Number of Major Adverse Cardiovascular Events With Combination Therapy
NCT01158703 (6) [back to overview]	Number of Myocardial Infarction Events
NCT01158703 (6) [back to overview]	Number of Thrombotic Events
NCT01163604 (1) [back to overview]	Number of Participants With Occlusion and Restenosis at One Year
NCT01212302 (1) [back to overview]	Number of Participants Who Were Responders or Low-Responders of Antiplatelet Therapy as a Result of Whole Blood Aggregometry Testing (See Outcome Measure Description)
NCT01235351 (2) [back to overview]	Comparisons of Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Platelet Reactivity Index (PRI)
NCT01235351 (2) [back to overview]	Comparisons of Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Platelet Reactivity Index (PRI)
NCT01260584 (7) [back to overview]	Assessment of P2Y12 Reaction Units (PRU) by Treatment and Smoking Status
NCT01260584 (7) [back to overview]	Assessment of Vasodilator Stimulated Phosphoprotein (VASP) by Treatment and Smoking Status
NCT01260584 (7) [back to overview]	Characterization of the Pharmacokinetics (PK) Area Under Curve (AUC)(0-Last) of the Active Metabolite of Prasugrel and the Active Metabolite of Clopidogrel in Smokers and Non-smokers
NCT01260584 (7) [back to overview]	Characterization of the Pharmacokinetics (PK) Cmax of the Active Metabolite of Prasugrel and the Active Metabolite of Clopidogrel in Smokers and Non-smokers
NCT01260584 (7) [back to overview]	Responder Rate by Treatment and Smoking Status Based on P2Y12 Reaction Units (PRU) <= 235
NCT01260584 (7) [back to overview]	Inhibition of Platelet Aggregation (IPA) in Prasugrel-treated and Clopidogrel-treated Smokers and Non-smokers Following 9 Days of Maintenance Therapy.
NCT01260584 (7) [back to overview]	Responder Rate by Treatment and Smoking Status Based on Platelet Reactivity Index (PRI) <= 50%
NCT01263093 (5) [back to overview]	Pharmacokinetics of R-130964, Time to Maximum Observed Drug Concentrations (Tmax)
NCT01263093 (5) [back to overview]	Percentage Inhibition of Platelet Aggregation
NCT01263093 (5) [back to overview]	Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)
NCT01263093 (5) [back to overview]	Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-tlast)
NCT01263093 (5) [back to overview]	Pharmacokinetics of R-130964, Maximum Observed Drug Concentrations (Cmax)
NCT01283282 (7) [back to overview]	Endothelial Progenitor Cells (EPCs)
NCT01283282 (7) [back to overview]	Oxidative Stress Markers
NCT01283282 (7) [back to overview]	Inflammatory Marker CD40 Ligand
NCT01283282 (7) [back to overview]	Flow-mediated Dilation (FMD)
NCT01283282 (7) [back to overview]	Inflammatory Marker High-sensitivity C-reactive Protein (hsCRP)
NCT01283282 (7) [back to overview]	Pulse Wave Velocity (PWV)
NCT01283282 (7) [back to overview]	Nitroglycerin-mediated Vasodilation
NCT01294462 (4) [back to overview]	Major Bleeding
NCT01294462 (4) [back to overview]	Major and Minor Bleeding
NCT01294462 (4) [back to overview]	Major Adverse Cardiac Events (MACE)
NCT01294462 (4) [back to overview]	Composite of All-cause Mortality, MI or Stroke
NCT01341600 (4) [back to overview]	Change in Platelet Aggregation Following Therapy With Clopidogrel and Omeprazole
NCT01341600 (4) [back to overview]	Level of Active Clopidogrel Metabolite
NCT01341600 (4) [back to overview]	Change in Platelet Aggregation Following Therapy With Clopidogrel
NCT01341600 (4) [back to overview]	Change in Platelet Aggregation Following Therapy With Clopidogrel
NCT01341964 (1) [back to overview]	Blood Concentration of the Active Metabolite of Clopidogrel
NCT01452152 (5) [back to overview]	Composite of All-cause Death, Myocardial Infarction (MI), Stroke and Repeat Revascularization
NCT01452152 (5) [back to overview]	Post-treatment Platelet Aggregation
NCT01452152 (5) [back to overview]	Occurrence of Post-randomization Cardiovascular Events
NCT01452152 (5) [back to overview]	Occurrence of Bleeding Events
NCT01452152 (5) [back to overview]	Occurrence of Adverse Events
NCT01500434 (26) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
NCT01500434 (26) [back to overview]	Target Vessel Failure (TVF)
NCT01500434 (26) [back to overview]	All Cause Death
NCT01500434 (26) [back to overview]	Target Vessel Revascularization (TVR)
NCT01500434 (26) [back to overview]	Target Vessel Revascularization (TVR)
NCT01500434 (26) [back to overview]	Target Vessel Revascularization (TVR)
NCT01500434 (26) [back to overview]	Acute Technical Success
NCT01500434 (26) [back to overview]	Target Vessel Failure (TVF)
NCT01500434 (26) [back to overview]	Target Vessel Failure (TVF)
NCT01500434 (26) [back to overview]	Target Lesion Revascularization (TLR)
NCT01500434 (26) [back to overview]	Target Lesion Revascularization (TLR)
NCT01500434 (26) [back to overview]	Target Lesion Failure (TLF)
NCT01500434 (26) [back to overview]	Target Lesion Failure (TLF)
NCT01500434 (26) [back to overview]	Cardiac Death Related to the Target Vessel
NCT01500434 (26) [back to overview]	All Cause Death
NCT01500434 (26) [back to overview]	Target Lesion Failure (TLF)
NCT01500434 (26) [back to overview]	Myocardial Infarction (MI) Related to the Target Vessel
NCT01500434 (26) [back to overview]	Myocardial Infarction (MI) Related to the Target Vessel
NCT01500434 (26) [back to overview]	Myocardial Infarction (MI) Related to the Target Vessel
NCT01500434 (26) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
NCT01500434 (26) [back to overview]	All Cause Death
NCT01500434 (26) [back to overview]	Cardiac Death Related to the Target Vessel
NCT01500434 (26) [back to overview]	Cardiac Death Related to the Target Vessel
NCT01500434 (26) [back to overview]	Target Lesion Revascularization (TLR)
NCT01500434 (26) [back to overview]	Clinical Procedural Success
NCT01500434 (26) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
NCT01510327 (14) [back to overview]	Area Under the Concentration Versus Time Curve (AUC 0-24), Everolimus
NCT01510327 (14) [back to overview]	All Death
NCT01510327 (14) [back to overview]	Area Under the Concentration Versus Time Curve (AUC 0-t) Everolimus
NCT01510327 (14) [back to overview]	Terminal Phase Half-life (t1/2) Everolimus
NCT01510327 (14) [back to overview]	Target Vessel Revascularization (TVR)
NCT01510327 (14) [back to overview]	Target Lesion Revascularization (TLR)
NCT01510327 (14) [back to overview]	Myocardial Infarction (MI) Related to the Target Vessel
NCT01510327 (14) [back to overview]	Maximum Observed Everolimus Blood Concentration (Cmax)
NCT01510327 (14) [back to overview]	Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition
NCT01510327 (14) [back to overview]	Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition
NCT01510327 (14) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
NCT01510327 (14) [back to overview]	Total Blood Clearance - Everolimus (CL)
NCT01510327 (14) [back to overview]	Time of Occurrence of Maximum Everolimus Concentration (Tmax)
NCT01510327 (14) [back to overview]	Area Under the Concentration Versus Time Curve (AUC 0-infinity) Everolimus
NCT01515345 (3) [back to overview]	Any Bleeding Event
NCT01515345 (3) [back to overview]	Definite Stent Thrombosis
NCT01515345 (3) [back to overview]	Probable Stent Thrombosis
NCT01523366 (5) [back to overview]	Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses
NCT01523366 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
NCT01523366 (5) [back to overview]	AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses
NCT01523366 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose
NCT01523366 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8
NCT01523392 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 Hour and 8 Hours After Loading Dose
NCT01523392 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
NCT01523392 (5) [back to overview]	Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses
NCT01523392 (5) [back to overview]	AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses
NCT01523392 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 Hours and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8
NCT01586975 (1) [back to overview]	PFA1
NCT01589978 (21) [back to overview]	Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients
NCT01589978 (21) [back to overview]	Cardiac Death or Myocardial Infarction (MI) Rate
NCT01589978 (21) [back to overview]	ARC ST Rate in PLATINUM-like Population.
NCT01589978 (21) [back to overview]	All Death Rate
NCT01589978 (21) [back to overview]	All Death or Myocardial Infarction Rate
NCT01589978 (21) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients
NCT01589978 (21) [back to overview]	Myocardial Infarction (MI) Rate
NCT01589978 (21) [back to overview]	Cardiac Death Rate
NCT01589978 (21) [back to overview]	Target Vessel Revascularization (TVR) Rate
NCT01589978 (21) [back to overview]	Target Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients
NCT01589978 (21) [back to overview]	Target Vessel Failure (TVF) Rate
NCT01589978 (21) [back to overview]	Rate of Target Vessel Revascularization (TVR) Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Target Vessel Failure (TVF) Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Myocardial Infarction (MI) Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Major Adverse Cardiac Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Longitudinal Stent Deformation
NCT01589978 (21) [back to overview]	Rate of Cardiac Death or Myocardial Infarction Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Cardiac Death Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Non-cardiac Death Rate
NCT01589978 (21) [back to overview]	Major Adverse Cardiac Event Rate (MACE)
NCT01589978 (21) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients
NCT01603082 (2) [back to overview]	Inhibition of the P2Y12 Receptor at 0.5 Hours, End of PCI, and 8 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by PRU From VerifyNow™
NCT01603082 (2) [back to overview]	Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™
NCT01612884 (2) [back to overview]	Number of Participants With Ischemic Events
NCT01612884 (2) [back to overview]	Thrombelastography (TEG) MA
NCT01642238 (8) [back to overview]	Platelet Reactivity
NCT01642238 (8) [back to overview]	Platelet-thrombus Formation in an ex Vivo Model of Thrombosis
NCT01642238 (8) [back to overview]	Platelet-thrombus Formation in an ex Vivo Model of Thrombosis
NCT01642238 (8) [back to overview]	Blood Thrombogenicity
NCT01642238 (8) [back to overview]	Blood Thrombogenicity
NCT01642238 (8) [back to overview]	Blood Thrombogenicity
NCT01642238 (8) [back to overview]	Platelet Reactivity
NCT01642238 (8) [back to overview]	Platelet Reactivity
NCT01732822 (24) [back to overview]	Changes in Fontaine Stage
NCT01732822 (24) [back to overview]	Any Amputation Caused by PAD
NCT01732822 (24) [back to overview]	All-cause Mortality
NCT01732822 (24) [back to overview]	ALI
NCT01732822 (24) [back to overview]	Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)
NCT01732822 (24) [back to overview]	Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)
NCT01732822 (24) [back to overview]	MI
NCT01732822 (24) [back to overview]	Major Amputation Caused by PAD
NCT01732822 (24) [back to overview]	Lower Extremity Revascularization
NCT01732822 (24) [back to overview]	Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke
NCT01732822 (24) [back to overview]	CV-related Hospitalization
NCT01732822 (24) [back to overview]	CV Death
NCT01732822 (24) [back to overview]	Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])
NCT01732822 (24) [back to overview]	Composite of CV Death, MI, Ischemic Stroke, and ALI
NCT01732822 (24) [back to overview]	Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)
NCT01732822 (24) [back to overview]	Change in ABI/TBI From Baseline
NCT01732822 (24) [back to overview]	TIMI Major or Minor Bleeding Events
NCT01732822 (24) [back to overview]	Changes in Rutherford Classification
NCT01732822 (24) [back to overview]	TIMI Major Bleeding Events
NCT01732822 (24) [back to overview]	Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event
NCT01732822 (24) [back to overview]	PLATO Major Bleeding Events
NCT01732822 (24) [back to overview]	Non-CV Death
NCT01732822 (24) [back to overview]	Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)
NCT01732822 (24) [back to overview]	Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)
NCT01742117 (4) [back to overview]	Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.
NCT01742117 (4) [back to overview]	Thrombolysis in Myocardial Infarction Major or Minor Bleeding
NCT01742117 (4) [back to overview]	Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.
NCT01742117 (4) [back to overview]	Occurrence of the a Major Adverse Cardiovascular Event
NCT01765400 (3) [back to overview]	The Change in Light Transmission Aggregometry (LTA)Between Baseline and Each Antiplatelet Medication
NCT01765400 (3) [back to overview]	The Change in Platelet Activation Assay (VASP)Between Baseline and Each Antiplatelet Medication
NCT01765400 (3) [back to overview]	The Change in Platelet Aggregation Measured by the Accumetrics (VerifyNow P2Y12) Assay Between Baseline and Each Antiplatelet Medication
NCT01768637 (3) [back to overview]	Whole Blood Platelet Aggregation to 20 µg/mL Adenosine Diphosphate
NCT01768637 (3) [back to overview]	Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid
NCT01768637 (3) [back to overview]	Whole Blood Platelet Aggregation to 2 µg/mL Collagen
NCT01789814 (1) [back to overview]	Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF.
NCT01802775 (6) [back to overview]	Percentage of Participants With Clinically Relevant Bleeding During Treatment
NCT01802775 (6) [back to overview]	Safety Assessments
NCT01802775 (6) [back to overview]	Percentage of Participants With First Re-stenosis / Re-occlusion
NCT01802775 (6) [back to overview]	Number of Participants With Amputations
NCT01802775 (6) [back to overview]	Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period
NCT01802775 (6) [back to overview]	Percentage of Participants With Major, Clinically Relevant Non-major (CRNM), and Minor Bleeding During Treatment
NCT01813435 (9) [back to overview]	Number of Participants With a Composite of All-cause Mortality, Stroke, or New Q-wave Myocardial Infarction
NCT01813435 (9) [back to overview]	Number of Participants With All-cause Mortality
NCT01813435 (9) [back to overview]	Number of Participants With Myocardial Infarction
NCT01813435 (9) [back to overview]	Number of Participants With New Q-wave Myocardial Infarction
NCT01813435 (9) [back to overview]	Number of Participants With a Stroke
NCT01813435 (9) [back to overview]	Number of Participants With a Bleeding Academic Research Consortium (BARC) 3 or 5 Bleeding
NCT01813435 (9) [back to overview]	Number of Participants With a Definite Stent Thrombosis
NCT01813435 (9) [back to overview]	Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI)
NCT01813435 (9) [back to overview]	Number of Participants With a Myocardial Revascularisation
NCT01815008 (4) [back to overview]	Difference in Arachidonic Acid-induced Platelet Aggregation
NCT01815008 (4) [back to overview]	Difference in ADP-induced Platelet Aggregation
NCT01815008 (4) [back to overview]	Changes in Platelet Transcriptome With Clopidogrel
NCT01815008 (4) [back to overview]	Difference in Collagen-induced Platelet Aggregation
NCT01823510 (4) [back to overview]	Thrombus Formation
NCT01823510 (4) [back to overview]	P2Y12 Reaction Unit (PRU)
NCT01823510 (4) [back to overview]	Platelet Reactivity Index (PRI)
NCT01823510 (4) [back to overview]	Platelet Reactivity
NCT01830543 (9) [back to overview]	Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding
NCT01830543 (9) [back to overview]	Percentage of Participants With Stroke
NCT01830543 (9) [back to overview]	Percentage of Participants With Stent Thrombosis
NCT01830543 (9) [back to overview]	Percentage of Participants With Myocardial Infarction
NCT01830543 (9) [back to overview]	Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding
NCT01830543 (9) [back to overview]	Percentage of Participants With Clinically Significant Bleeding
NCT01830543 (9) [back to overview]	Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)
NCT01830543 (9) [back to overview]	Percentage of Participants With Cardiovascular Death
NCT01830543 (9) [back to overview]	Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01896557 (4) [back to overview]	Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, After One Week of Randomized Treatment
NCT01896557 (4) [back to overview]	Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.
NCT01896557 (4) [back to overview]	Comparison of the Primary Outcome With Bioimpedance Aggregometry
NCT01896557 (4) [back to overview]	Comparison of the Primary Outcome With PFA-100 (Collagen/ADP Cartridge)
NCT01960296 (8) [back to overview]	Average Change in Hematocrit
NCT01960296 (8) [back to overview]	Average Length of Hospital Stay
NCT01960296 (8) [back to overview]	Bleeding-related Re-hospitalization
NCT01960296 (8) [back to overview]	Development of Myocardial Infarction or Thrombosis
NCT01960296 (8) [back to overview]	Perioperative Bleeding Complications
NCT01960296 (8) [back to overview]	Procedure Estimated Blood Loss
NCT01960296 (8) [back to overview]	Procedure Time
NCT01960296 (8) [back to overview]	Same Day Discharged
NCT01979445 (5) [back to overview]	Extent of Preservation of Platelet Inhibitory Effect of Cangrelor Treatment After Prasugrel or Clopidogrel Compared to Treatment With Cangrelor Alone Determined By VerifyNow P2Y12 Assay
NCT01979445 (5) [back to overview]	Bleeding Events In Accordance With GUSTO Scale
NCT01979445 (5) [back to overview]	Extent of Preservation Of Platelet Inhibitory Effect After Transition From Cangrelor To Prasugrel Or Clopidogrel Compared With Effect Observed With Prasugrel Or Clopidogrel Alone
NCT01979445 (5) [back to overview]	Extent of Preservation Of Platelet Inhibitory Effect After Transition From Cangrelor to Prasugrel Or Clopidogrel Compared With Effect Observed With Prasugrel Or Clopidogrel Alone Determined By VerifyNow P2Y12 Assay
NCT01979445 (5) [back to overview]	Extent Of Preservation Of Platelet Inhibitory Effect Of Cangrelor Treatment After Prasugrel Or Clopidogrel Compared To Treatment With Cangrelor Alone
NCT02010632 (1) [back to overview]	Pharmacodynamic Effect: The Platelet Inhibition Effect of Clopidogrel at the Various Times on Day 7 (0-24 Hours) (at Steady State)
NCT02052635 (2) [back to overview]	P2Y12 Reaction Units (PRU) Using VerifyNow™ at 0.5 Hours After Loading Dose
NCT02052635 (2) [back to overview]	P2Y12 Reaction Units (PRU) Using VerifyNow™ at 1 Hour After Loading Dose
NCT02164864 (13) [back to overview]	Time to First Adjudicated ST
NCT02164864 (13) [back to overview]	Time to First Adjudicated SE
NCT02164864 (13) [back to overview]	Time to First Adjudicated ISTH MBE or CRNMBE
NCT02164864 (13) [back to overview]	Time to Adjudicated All Cause Death
NCT02164864 (13) [back to overview]	Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG
NCT02164864 (13) [back to overview]	Time to Composite Endpoint of Death or First Thrombotic Event
NCT02164864 (13) [back to overview]	Time to First Adjudicated MI
NCT02164864 (13) [back to overview]	Time to Composite Endpoint of Death + MI + Stroke
NCT02164864 (13) [back to overview]	Time to Adjudicated Undetermined Cause of Death
NCT02164864 (13) [back to overview]	Time to Adjudicated CV
NCT02164864 (13) [back to overview]	Time to Adjudicated Non-CV
NCT02164864 (13) [back to overview]	Time to First Adjudicated Unplanned Revascularisation by PCI/CABG
NCT02164864 (13) [back to overview]	Time to First Adjudicated Stroke
NCT02185534 (3) [back to overview]	Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-last))
NCT02185534 (3) [back to overview]	Pharmacokinetics of Clopidogrel by Assessment of Observed Maximum Plasma Concentration (Cmax)
NCT02185534 (3) [back to overview]	Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))
NCT02217501 (2) [back to overview]	Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb, Ischemic Stroke, MI, or Death
NCT02217501 (2) [back to overview]	Number of Participants With First Occurrence of Bleeding
NCT02224274 (3) [back to overview]	VerifyNow P2Y12Test - Platelet Reactivity
NCT02224274 (3) [back to overview]	Multiplate ADP Test
NCT02224274 (3) [back to overview]	VerifyNow P2Y12Test - % Inhibition
NCT02230527 (1) [back to overview]	Absolute Change in TcPO2 From Baseline to Month 6
NCT02260622 (10) [back to overview]	TVR
NCT02260622 (10) [back to overview]	The Number of Patients Requiring Target Lesions Revascularization Between Day 1 and the Final Visit (TLR)
NCT02260622 (10) [back to overview]	Reintervention, Above Ankle Amputation and Restenosis (RAS)
NCT02260622 (10) [back to overview]	Peri-procedure Death
NCT02260622 (10) [back to overview]	Number of Participants With 2 Class Improvement on the Rutherford Scale
NCT02260622 (10) [back to overview]	Minor Bleeding
NCT02260622 (10) [back to overview]	Major Bleeding
NCT02260622 (10) [back to overview]	MACE
NCT02260622 (10) [back to overview]	Event-free Survival
NCT02260622 (10) [back to overview]	Overall Survival
NCT02287909 (1) [back to overview]	Platelet Reactivity Unit
NCT02293395 (1) [back to overview]	Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events
NCT02327741 (7) [back to overview]	Number of Patients With Central Vascular Accidents Proved by CT Scan
NCT02327741 (7) [back to overview]	Tolerability - the Number of Patients , Who Are Able to Take Plavix Concerning Compliance and Economic Issues
NCT02327741 (7) [back to overview]	Number of Patients With Minor Bleeding
NCT02327741 (7) [back to overview]	Revascularization - Need for Redo Bypass Surgery and Redo Angioplasty
NCT02327741 (7) [back to overview]	Number of Patients With Major Bleeding Need Transfusion
NCT02327741 (7) [back to overview]	Number of Patients With Death Due to Cardiac Causes
NCT02327741 (7) [back to overview]	Number of Patients With Myocardial Infarction Need Hospital Admission
NCT02376283 (3) [back to overview]	Pharmacokinetic Quantification of Plasma Concentration of Clopidogrel and Prasugrel Active Metabolite and Ticagrelor Parent Compound and Active Metabolite Assessed Using Liquid Chromatography in Tandem With Mass Spectrometry (LC-MS/MS) Expressed as ng/ml
NCT02376283 (3) [back to overview]	Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by VASP (Vasodilator Stimulated Phosphoprotein Phosphorylation) Flow Cytometry and Expressed as %PRI (Platelet Reactivity Index)
NCT02376283 (3) [back to overview]	Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU)
NCT02384070 (3) [back to overview]	Thrombotic Complications
NCT02384070 (3) [back to overview]	TIMI (Thrombolysis in Myocardial Infarction) Major and Minor Bleeding Scores
NCT02384070 (3) [back to overview]	Sub-clinical Ischemic Events Measured by Troponin Levels Post-procedure
NCT02486367 (8) [back to overview]	Change in D-Dimer Levels as Measured by Blood Test
NCT02486367 (8) [back to overview]	Change in Mono-CD62P as Measured by Blood Test
NCT02486367 (8) [back to overview]	Change in Mono-2b3a as Measured by Blood Test
NCT02486367 (8) [back to overview]	Change in IL-6 as Measured by Blood Test.
NCT02486367 (8) [back to overview]	Change in IL-8 as Measured by Blood Test
NCT02486367 (8) [back to overview]	Platelet Reactivity
NCT02486367 (8) [back to overview]	Inflammatory Monocyte Proportion
NCT02486367 (8) [back to overview]	Change in sCD14 as Measured by Blood Test.
NCT02548650 (2) [back to overview]	Maximal Platelet Aggregation in Non-DM
NCT02548650 (2) [back to overview]	Maximal Platelet Aggregation in DM
NCT02554721 (2) [back to overview]	Effects On Skin Bleeding Time (BT)
NCT02554721 (2) [back to overview]	Ex-vivo Inhibition Of Platelet Aggregation (IPA)
NCT02556203 (8) [back to overview]	Number of Participants With Primary Bleeding Event (PBE)
NCT02556203 (8) [back to overview]	Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds
NCT02556203 (8) [back to overview]	Number of Participants With Death or First Thromboembolic Event (DTE)
NCT02556203 (8) [back to overview]	Number of Participants With Cardiovascular Death or Thromboembolic Event
NCT02556203 (8) [back to overview]	Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds
NCT02556203 (8) [back to overview]	Number of Participants With Death or First Thromboembolic Event (DTE)
NCT02556203 (8) [back to overview]	Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds
NCT02556203 (8) [back to overview]	Number of Participants With Net-clinical Benefit
NCT02559414 (5) [back to overview]	Percentage Platelet Aggregation in PRP After Stimulation With ADP 5μM for 5 Min
NCT02559414 (5) [back to overview]	Percentage Monocyte-Platelet Aggregates
NCT02559414 (5) [back to overview]	Percentage Monocyte-Platelet Aggregates
NCT02559414 (5) [back to overview]	Percentage Leukocyte-Platelet Aggregate
NCT02559414 (5) [back to overview]	Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min
NCT02578706 (23) [back to overview]	Change in Spontaneous Platelet Aggregometry From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in sCD14 From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in sCD40L From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in Platelet Aggregometry in Response to ADP 20µM From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in Maximum Clot Firmness (MCF) From Baseline to 24 Weeks
NCT02578706 (23) [back to overview]	Change in Intermediate Monocyte Subsets From Baseline to Week 24.
NCT02578706 (23) [back to overview]	Change in IL-6 From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in D-dimer From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in Coagulation Time (CT) From Baseline to 24 Weeks
NCT02578706 (23) [back to overview]	Change in Clot Formation Time (CFT) From Baseline to 24 Weeks
NCT02578706 (23) [back to overview]	Change in sTNFR I From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in sTNFR II From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in Classical Monocyte Subsets From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in Alpha Angle From Baseline to 24 Weeks
NCT02578706 (23) [back to overview]	Change in Thrombus Formation (High Shear) From Baseline to 24 Weeks
NCT02578706 (23) [back to overview]	Change in Thrombus Formation (Low Shear) From Baseline to 24 Weeks
NCT02578706 (23) [back to overview]	Number of Subjects With at Least One Grade 3 or Higher Sign/Symptom or Laboratory Abnormality
NCT02578706 (23) [back to overview]	Change in Monocyte Activation sCD163 From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in Monocyte Platelet Aggregates From Baseline to 24 Weeks
NCT02578706 (23) [back to overview]	Change in Non-classical Monocyte Subsets From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in Platelet Aggregometry in Response to Arachidonic Acid 1500µM From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in Platelet Aggregometry in Response to Collagen 2µg/mL From Baseline to Week 24
NCT02578706 (23) [back to overview]	Change in Platelet Aggregometry in Response to Epi 5µM From Baseline to Week 24
NCT02742987 (1) [back to overview]	Flow-mediated Dilation of the Brachial Artery
NCT02833948 (10) [back to overview]	Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.
NCT02833948 (10) [back to overview]	Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.
NCT02833948 (10) [back to overview]	The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan
NCT02833948 (10) [back to overview]	Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.
NCT02833948 (10) [back to overview]	Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.
NCT02833948 (10) [back to overview]	Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan
NCT02833948 (10) [back to overview]	Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.
NCT02833948 (10) [back to overview]	Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.
NCT02833948 (10) [back to overview]	The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan
NCT02833948 (10) [back to overview]	The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan
NCT02866175 (7) [back to overview]	Number of Participants With Main Efficacy Endpoints For the Overall Study Period Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Adjudicated Major, Clinically Relevant Non-major and Minor Bleeding (All Events) Defined by International Society on Thrombosis and Haemostasis Following Edoxaban-based Regimen Compared With Vitamin K Antagonist-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Adjudicated Major, Minor, and Minimal Bleeding by Thrombolysis in Myocardial Infarction (TIMI) Definition Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Bleeding Academic Research Consortium (BARC) Type 1, 2, 3, and 5 Bleeding According to the BARC Definitions Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Study Drug-related Treatment-emergent Adverse Events (TEAEs) Experienced by 2 or More Participants Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding As First Event Defined by International Society on Thrombosis and Haemostasis Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02925923 (12) [back to overview]	Number of Patients With Minor Bleeding Complications
NCT02925923 (12) [back to overview]	A Change in Hematocrit Levels
NCT02925923 (12) [back to overview]	Heparin Dose, Unit/Kg
NCT02925923 (12) [back to overview]	Activated Clotting Time (ACT), Seconds
NCT02925923 (12) [back to overview]	Platelet Aggregation Levels
NCT02925923 (12) [back to overview]	Number of Patients With Negative Clinical Outcomes
NCT02925923 (12) [back to overview]	Number of Participants With a Change in high-on Treatment Platelet Reactivity (HPR)
NCT02925923 (12) [back to overview]	Change in Hemoglobin Levels (g/dL)
NCT02925923 (12) [back to overview]	Number of Patients With Minor Bleeding Complications
NCT02925923 (12) [back to overview]	Number of Patients With Major Bleeding Complications
NCT02925923 (12) [back to overview]	Number of Patients With Major Bleeding Complications
NCT02925923 (12) [back to overview]	Number of Participants With a Periprocedural Myocardial Infarction and Injury (PMI)
NCT02931045 (1) [back to overview]	Concentration of Platelet Extracellular Vesicles/ml
NCT03188705 (2) [back to overview]	Changes in Platelet Function in Response to Clopidogrel Plus Aspirin
NCT03188705 (2) [back to overview]	Changes in Platelet Function in Response to Clopidogrel
NCT03190005 (1) [back to overview]	PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication
NCT03207451 (3) [back to overview]	Effects of Vorapaxar on Von Willebrand Factor (vWF).
NCT03207451 (3) [back to overview]	Effects of Vorapaxar on Thrombin Induced Platelet-fibrin Clot Strength (TIP-FCS)
NCT03207451 (3) [back to overview]	Effects of Vorapaxar on 15 μmol/L SFLLRN (PAR-1 Activating Peptide) Induced Platelet Aggregation
NCT03381742 (2) [back to overview]	ADP-induced Platelet-fibrin Clot Strength (MA)
NCT03381742 (2) [back to overview]	ADP-induced Inhibition of Platelet Aggregation
NCT03437044 (2) [back to overview]	Platelet Reactivity Index (PRI)
NCT03437044 (2) [back to overview]	P2Y12 Reaction Units (PRU)
NCT03649711 (2) [back to overview]	ADP Induced Platelet Aggregation
NCT03649711 (2) [back to overview]	Platelet Surface P-selectin Expression
NCT03766581 (23) [back to overview]	Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI
NCT03766581 (23) [back to overview]	Number of Participants With Bleeding Based on BARC Types 1-5
NCT03766581 (23) [back to overview]	Number of Participants With Bleeding Based on ISTH-Defined Criteria
NCT03766581 (23) [back to overview]	Number of Participants With Bleeding Based on PLATO-Defined Criteria
NCT03766581 (23) [back to overview]	Number of Participants With Clinically Significant Laboratory Abnormalities - Liver
NCT03766581 (23) [back to overview]	Percent of Participants With Ischemic Stroke Events
NCT03766581 (23) [back to overview]	Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death
NCT03766581 (23) [back to overview]	Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
NCT03766581 (23) [back to overview]	Pharmacokinetic Parameter - Estimated Clearance (CL)
NCT03766581 (23) [back to overview]	Pharmacokinetic Parameter - Volume of the Central Compartment (VC)
NCT03766581 (23) [back to overview]	Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI
NCT03766581 (23) [back to overview]	Digit Symbol Substitution Test (DSST)
NCT03766581 (23) [back to overview]	Modified Rankin Scale (mRS)
NCT03766581 (23) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT03766581 (23) [back to overview]	Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90
NCT03766581 (23) [back to overview]	Percent of Participants With Major Bleeding According to BARC Type 3 and 5
NCT03766581 (23) [back to overview]	National Institutes of Health Stroke Scale (NIHSS)
NCT03766581 (23) [back to overview]	Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90
NCT03766581 (23) [back to overview]	Percent Change From Baseline in Factor XI Clotting Activity
NCT03766581 (23) [back to overview]	Percent Change From Baseline in aPTT Activity
NCT03766581 (23) [back to overview]	Number of Participants With Clinically Significant Vital Sign Abnormalities
NCT03766581 (23) [back to overview]	Number of Participants With Clinically Significant Physical Examination Abnormalities
NCT03766581 (23) [back to overview]	Montreal Cognitive Assessment (MoCA)
NCT03774394 (4) [back to overview]	Clopidogrel Active Metabolite Concentration
NCT03774394 (4) [back to overview]	P2Y12 Reaction Units (PRU) Assessed by VerifyNow. The Cutoff for High Platelet Reactivity is >208.
NCT03774394 (4) [back to overview]	Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50%
NCT03774394 (4) [back to overview]	Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50%
NCT04006288 (1) [back to overview]	Maximal Platelet Aggregation (MPA%) by Light Transmittance Aggregometry (LTA)

Number of Participants With Major Adverse Cardiovascular Events (MACE)

Number of participants with any of the following: death, nonfatal myocardial infarction, stroke, total or subtotal occlusion of the target vessel, urgent target vessel revascularization, recurrent ischemia requiring hospitalization. (NCT00059215)
Timeframe: randomization though 30 days after percutaneous coronary intervention (PCI)

Intervention	participants (Number)
Prasugrel (CS-747) 40-mg LD/7.5-mg MD	15
Prasugrel (CS-747) 60-mg LD/10-mg MD	15
Prasugrel (CS-747) 60-mg LD/15-mg MD	17
Clopidogrel	24
Prasugrel (CS-747) Combined	47

Intervention	Participants (Number)
	UA/NSTEMI (n=5044, n=5030)	STEMI (n=1769, n=1765)	All ACS (n=6813, n=6795)
Clopidogrel	565	216	781
Prasugrel	469	174	643

Intervention	Participants (Number)
	All ACS (Through 30 days)	All ACS (Through 90 days)
Clopidogrel	502	573
Prasugrel	389	462

Intervention	Participants (Number)
	TIMI Major or Minor Bleeding	TIMI Major Bleeding	TIMI Major Bleeding - Life-threatening (LT)	LT - Fatal	LT - Symptomatic intracranial hemorrage (ICH)	LT - Requiring inotropes	LT - Requiring surgical intervention	LT - Requiring transfusion (>=4 units)	TIMI Minor Bleeding
Clopidogrel	231	111	56	5	17	8	19	30	125
Prasugrel	303	146	85	21	19	21	19	45	164

Intervention	participants (Number)
	All components	- Myocardial Infarction (fatal or not)	- Stroke (fatal or not)	- Non-CNS systemic embolism	- Vascular death
Clopidogrel + ASA	832	84	285	50	413
Placebo + ASA	924	105	391	48	380

Intervention	Aspirin Reaction Units (Mean)
	Baseline Aspirin Reaction UnitsARU	2 weeks ARU	1 month ARU
Observation Only	579.81	578.35	593.58
Plavix and Aspirin	610.39	435.33	455.44

Intervention	participants (Number)
	Bleeding (possibly related)	Back pain (unlikely related)
Observation Only	0	0
Plavix and Aspirin	1	1

Intervention	percentage of participants (Number)
	Baseline 0 CTCs	2 week 0 CTCs	1 month 0 CTCs	Baseline 1-5 CTCs	2 weeks 1-5 CTCs	1 month 1-5 CTCs	Baseline >=5 CTS	2 weeks >=5 CTCs	1 month >=5 CTCs
Observation Only	22.73	40.00	35.00	63.64	45.00	55.00	13.64	15.00	10.00
Plavix and Aspirin	40.00	45.00	41.18	45.00	31.58	52.94	15.00	21.05	5.88

Intervention	percentage of platelet inhibition (Mean)
	Baseline	2 weeks	1 month
Observation Only	13.00	9.05	7.05
Plavix and Aspirin	9.85	37.35	35.56

Intervention	participants (Number)
	primary hemorrhagic	infarction with hemorrhagic conversion	cerebral infarction	uncertain type
Cangrelor Arm	1	0	5	0
Clopidogrel Arm	0	0	7	0

Intervention	participants (Number)
Clopidogrel 300/75/75 mg + ASA Low Dose	267
Clopidogrel 300/75/75 mg + ASA High Dose	290
Clopidogrel 600/150/75 mg + ASA Low Dose	282
Clopidogrel 600/150/75 mg + ASA High Dose	240

Intervention	participants (Number)
	CV death/MI/Stroke	- CV death	- MI (fatal or not)	- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA	392	132	225	35
Clopidogrel 600/150/75 mg + ASA	330	130	172	28

Intervention	participants (Number)
	Major bleeding	- Severe bleeding	- Major but not severe bleeding
Clopidogrel + ASA High Dose	282	216	73
Clopidogrel + ASA Low Dose	285	215	74

Intervention	participants (Number)
	Stent trombosis	- Definite	- Probable
Clopidogrel 300/75/75 mg + ASA	200	111	89
Clopidogrel 600/150/75 mg + ASA	135	58	77

Intervention	correlation coefficient (Number)
	MPA (20 uM ADP) at 1 week	RPA (20 uM ADP) at 1 week
Clopidogrel 75/75 mg	0.426	0.425
Prasugrel 10/10 mg	0.564	0.640
Prasugrel 60/10 mg	0.439	0.547

Intervention	percent maximum platelet aggregation (%) (Mean)
	2 Hour (20 uM ADP)	24 Hour (20 uM ADP)	1 Week (20 uM ADP)	2 Week (20 uM ADP)	2 Hour (5 uM ADP)	24 Hour (5 uM ADP)	1 Week (5 uM ADP)	2 Week (5 uM ADP)
Clopidogrel 75/75 mg	48.07	53.80	53.80	52.25	37.25	40.88	41.94	41.05
Prasugrel 10/10 mg	49.46	52.29	42.95	40.84	37.87	38.84	32.44	30.18
Prasugrel 60/10 mg	26.65	27.36	40.64	38.61	19.97	20.94	31.45	28.64

Intervention	Participants (Number)
	Any Bleeding at Any Time During Randomized Period	Baseline: Any Bleeding	Baseline: Insignificant Bleeding	Baseline: Minor Bleeding	Baseline: Major Bleeding	Hour 24: Any Bleeding	Hour 24: Insignificant Bleeding	Hour 24: Minor Bleeding	Hour 24: Major Bleeding	Day 7: Any Bleeding	Day 7: Insignificant Bleeding	Day 7: Minor Bleeding	Day 7: Major Bleeding	Day 14: Any Bleeding	Day 14: Insignificant Bleeding	Day 14: Minor Bleeding	Day 14: Major Bleeding
Clopidogrel 75/75 mg	6	3	3	0	0	0	0	0	0	2	2	0	0	4	4	0	0
Prasugrel 10/10 mg	4	0	0	0	0	0	0	0	0	2	2	0	0	2	2	0	0
Prasugrel 60/10 mg	6	1	1	0	0	1	1	0	0	3	3	0	0	2	2	0	0

Intervention	percent maximum platelet aggregation (%) (Least Squares Mean)
Prasugrel 10/10 mg	41.1
Clopidogrel 75/75 mg	55.0
Prasugrel 60/10 mg	41.0

Intervention	Participants (Number)
	Severe or life-threatening	Moderate	Minor
Clopidogrel	0	0	2
Prasugrel	0	0	3

Intervention	participants (Number)
	Any bleeding event	- Serious	- Serious with an outcome of death	- Leading to permanent treatment discontinuation
Clopidogrel 0.2 mg/kg/Day	87	30	1	9
Placebo	88	32	1	9

Intervention	participants (Number)
	Spontaneous	Post-traumatic	Puncture (vascular access site)	Surgical
Clopidogrel 0.2 mg/kg/Day	56	11	9	17
Placebo	60	6	19	10

clopidogrel

Description

Cross-References

Synonyms (127)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (3)

Pathways (2)

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (97)

Molecular Functions (48)

Ceullar Components (22)

Bioassays (202)

Research

Studies (9,793)

Study Types

Clinical Trials (707)

Trial Overview

Trial Outcomes

Number of Participants With Major Adverse Cardiovascular Events (MACE)

Number of Participants With Non-CABG TIMI Major or Minor Bleeding Plus MACE

Number of Participants With Non-Coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding

Number of Participants With Non-coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding Events

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)

Number of Treated Subjects With Non-Coronary Artery Bypass Graft (CABG) Related Thrombolysis In Myocardial Infarction (TIMI) Study Group Major and Minor Bleeding Events

Number of Patients With Ipsilateral Ischemic Stroke Rate

Numbers of Fatal or Major Bleeding Complications

Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI

Number of Participants With Stroke Events

Number of Participants With Progression of Symptomatic Intracranial Stenosis

Number of Participants With Overall Cardiovascular Events

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Vein Graft Intimal Area

Vein Graft Angiographic Patency

Incidence of Major Bleeding Events Within One Year Following Surgery

Incidence of Major Adverse Coronary Events Within One Year Following Surgery

Death From Any Cause (Cardiovascular and Noncardiovascular)

Adjudicated Major Bleedings

First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

Occurrence of Stroke

Death/Reinfarction/Disabling Stroke at 30 Days

Incidence of Death or Reinfarction or Disabling Stroke

Mean Aspirin-Mediated Platelet Inhibition vs. Time Plotted for Plavix and Aspirin and Observation Groups

Safety and Tolerability of Aspirin and Plavix Measured by the Number of Patients Who Discontinue the Study Drug

Percentage of Patients With a Given Absolute Number of Circulating Tumor Cells (Broken Into Categories) Plotted Against Time

Platelet Inhibition of Circulating Tumor Cells (CTCs) Measured by the Number of Patients With Detectable CTCs

Clopidogrel-Mediated Percent of Platelet Inhibition vs. Time Plotted for Aspirin and Plavix and Observation Groups

Incidence of ACUITY Major Bleeding (Without Hematoma >/= 5 cm)

Incidence of All Cause Mortality

Incidence of All-cause Mortality

Incidence of All-cause Mortality and MI

Incidence of All-cause Mortality or MI

Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)

Incidence of GUSTO Severe / Life-threatening Bleeding

Incidence of IDR

Incidence of MI

Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding

Incidence of All-cause Mortality, MI or IDR

Individual Incidence of All-cause Mortality

Incidence of ACUITY Major Bleeding

Incidence of Stroke

Incidence of Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, or Unsuccessful Procedure During the Index PCI

Incidence of Stroke

Individual Incidence of IDR

Intervention	participants (Number)
	Death / Shunt Thrombosis / Cardiac Procedure	- Death	- Shunt thrombosis	- Cardiac procedure <120 days of thrombotic nature
Clopidogrel 0.2 mg/kg/Day	89	51	26	12
Placebo	90	60	21	9

Intervention	millimeters (mm) (Least Squares Mean)
	Baseline	1 Hour After Loading Dose	4 Hours After Loading Dose	24 Hours After Loading Dose	24 Hours After Last Maintenance Dose
Clopidogrel	58.1	54.8	48.1	49.2	46.8
Prasugrel	56.8	38.5	24.2	29.3	44.2

Intervention	percent platelet aggregation (Least Squares Mean)
	Baseline (5 μM ADP)	1 Hour After Loading Dose (5 μM ADP)	4 Hours After Loading Dose (5 μM ADP)	24 Hours After Loading Dose (5 μM ADP)	24 Hours After Last Maintenance Dose (5 μM ADP)	Baseline (20 μM ADP)	1 Hour After Loading Dose (20 μM ADP)	4 Hours After Loading Dose (20 μM ADP)	24 Hours After Loading Dose (20 μM ADP)	24 Hours After Last Maintenance Dose (20 μM ADP)
Clopidogrel	65.7	56.7	44.6	45.6	38.3	76.9	69.8	57.5	58.4	50.7
Prasugrel	64.9	33.7	18.0	22.3	29.6	77.1	44.7	22.4	27.4	38.3

Intervention	ng/mL (Mean)
	Baseline	Time of Hospital Discharge
Placebo/Placebo Non-PCI	11.1	12.9
Vorapaxar 20 mg Loading Dose Non-PCI	8.4	10.1
Vorapaxar 40 mg Loading Dose Non-PCI	4.6	7.1

Intervention	Participants (Number)
	Major TIMI Events	Minor TIMI Events	Non-TIMI Bleeding Events
Placebo/Placebo Non-PCI	0	0	1
Vorapaxar 20 mg Loading Dose Non-PCI	1	0	1
Vorapaxar 40 mg Loading Dose Non-PCI	2	0	8

Intervention	Participants (Number)
	Treatment Phase	Post-Hospital Discharge
Placebo/Placebo PCI	0	0
Vorapaxar 20 mg/1 mg PCI	3	1
Vorapaxar 20 mg/2.5 mg PCI	0	0
Vorapaxar 40 mg/1 mg PCI	2	2
Vorapaxar 40 mg/2.5 mg PCI	0	0

Intervention	mg/L (Median)
	Baseline (n=37, 34, 21)	Day 30 (n=35, 34, 21)	Day 60 (n=30, 25, 13)
Placebo/Placebo PCI	1.78	2.99	1.27
Vorapaxar 1 mg Maintenance Dose PCI	1.30	1.28	1.20
Vorapaxar 2.5 mg Maintenance Dose PCI	2.00	1.01	0.79

Intervention	Arbitrary Units (Mean)
	Baseline (n=4, 4, 3)	Day 30 (n=3, 4, 3)	Day 60 (n=2, 3, 1)
Placebo/Placebo PCI	15.9	18.8	19.4
Vorapaxar 1 mg Maintenance Dose PCI	24.8	20.6	25.0
Vorapaxar 2.5 mg Maintenance Dose PCI	16.5	16.4	14.9

Intervention	Participants (Number)
Vorapaxar 20 mg Loading Dose PCI	40
Vorapaxar 40 mg Loading Dose PCI	30
Placebo/Placebo PCI	21

Intervention	Participants (Number)
	Baseline	Day 30	Day 60	Day 74 (follow-up period)	Day 90 (follow-up period)	Day 121 (follow-up period)
Placebo/Placebo PCI	3	3	1	3	3	3
Vorapaxar 1 mg Maintenance Dose PCI	5	5	3	5	5	5
Vorapaxar 2.5 mg Maintenance Dose PCI	4	4	3	4	4	4